{"7597af14544ede9a1dc53ccaa8a29dbac7dbd590": [["Severe acute respiratory failure from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) coronavirus disease has challenged intensivists worldwide with both increased severity of illness and quantity of patients.", [["respiratory", "ANATOMY", 13, 24], ["acute respiratory failure", "DISEASE", 7, 32], ["acute respiratory syndrome coronavirus", "DISEASE", 49, 87], ["coronavirus disease", "DISEASE", 103, 122], ["SARS-CoV-2", "ORGANISM", 91, 101], ["coronavirus", "ORGANISM", 103, 114], ["patients", "ORGANISM", 217, 225], ["patients", "SPECIES", 217, 225], ["severe acute respiratory syndrome coronavirus", "SPECIES", 42, 87], ["SARS-CoV-2) coronavirus", "SPECIES", 91, 114], ["Severe acute respiratory failure", "PROBLEM", 0, 32], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 38, 87], ["SARS", "PROBLEM", 91, 95], ["coronavirus disease", "PROBLEM", 103, 122], ["illness", "PROBLEM", 193, 200], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["respiratory failure", "OBSERVATION", 13, 32], ["severe", "OBSERVATION_MODIFIER", 42, 48], ["acute", "OBSERVATION_MODIFIER", 49, 54], ["respiratory syndrome coronavirus", "OBSERVATION", 55, 87], ["coronavirus disease", "OBSERVATION", 103, 122]]], ["An extraordinary amount has been published about presentation, treatment, and outcomes of these patients in both medical journals and social media.", [["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104], ["treatment", "TREATMENT", 63, 72], ["extraordinary", "OBSERVATION_MODIFIER", 3, 16], ["amount", "OBSERVATION_MODIFIER", 17, 23]]], ["Less than 6 months since the first reported case, a search for COVID-19 in PubMed finds more than 5,000 publications.", [["COVID-19", "DNA", 63, 71], ["COVID", "TEST", 63, 68]]], ["Unfortunately, most of these reports are anecdotal, with few comparative, scientific studies among them.", [["scientific studies", "TEST", 74, 92]]], ["Similarly, Twitter and other social media platforms have been abuzz with anecdotes and \"expert\" advice as to how to care for these patients.", [["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 131, 139]]], ["Many of those pieces of advice have represented small-sample clinical experience or uncontrolled experiments, often without consent or regulatory oversight, with offlabel uses of already-approved medications aimed at treating some mechanistic pathway or presumed pathophysiology extrapolated from a limited number of these patients.", [["patients", "ORGANISM", 323, 331], ["patients", "SPECIES", 323, 331], ["uncontrolled experiments", "PROBLEM", 84, 108], ["medications", "TREATMENT", 196, 207], ["small", "OBSERVATION_MODIFIER", 48, 53]]], ["For example, on the basis of a case series of 21 patients published in a Chinese preprint (1), off-label use of the interleukin-6 receptor antagonist tocilizumab has been proposed to treat the \"cytokine storm\" that many have postulated causes the multisystem organ dysfunction seen with critically ill patients with COVID-19.", [["organ", "ANATOMY", 259, 264], ["tocilizumab", "CHEMICAL", 150, 161], ["multisystem organ dysfunction", "DISEASE", 247, 276], ["critically ill", "DISEASE", 287, 301], ["COVID-19", "CHEMICAL", 316, 324], ["patients", "ORGANISM", 49, 57], ["interleukin-6 receptor antagonist", "SIMPLE_CHEMICAL", 116, 149], ["tocilizumab", "SIMPLE_CHEMICAL", 150, 161], ["organ", "ORGAN", 259, 264], ["patients", "ORGANISM", 302, 310], ["interleukin-6 receptor", "PROTEIN", 116, 138], ["cytokine", "PROTEIN", 194, 202], ["patients", "SPECIES", 49, 57], ["patients", "SPECIES", 302, 310], ["a case series", "TEST", 29, 42], ["the interleukin-6 receptor antagonist tocilizumab", "TREATMENT", 112, 161], ["the \"cytokine storm", "PROBLEM", 189, 208], ["the multisystem organ dysfunction", "PROBLEM", 243, 276], ["COVID", "TEST", 316, 321], ["multisystem organ dysfunction", "OBSERVATION", 247, 276]]], ["Recently, off-label use of inhaled nitric oxide to prevent intubation and empiric anticoagulation or thrombolysis to treat the microthromboses seen in the lungs on autopsy (2) has also been proposed.", [["lungs", "ANATOMY", 155, 160], ["nitric oxide", "CHEMICAL", 35, 47], ["microthromboses", "DISEASE", 127, 142], ["nitric oxide", "CHEMICAL", 35, 47], ["nitric oxide", "SIMPLE_CHEMICAL", 35, 47], ["lungs", "ORGAN", 155, 160], ["inhaled nitric oxide", "TREATMENT", 27, 47], ["intubation", "TREATMENT", 59, 69], ["empiric anticoagulation", "TREATMENT", 74, 97], ["thrombolysis", "TREATMENT", 101, 113], ["the microthromboses", "PROBLEM", 123, 142], ["autopsy", "TEST", 164, 171], ["microthromboses", "OBSERVATION", 127, 142], ["lungs", "ANATOMY", 155, 160]]], ["Although many effective treatments start with similar postulates, these modalities can only demonstrate effectiveness, and thus become evidencebased treatments, in well-designed, placebocontrolled randomized trials.", [["many effective treatments", "TREATMENT", 9, 34], ["evidencebased treatments", "TREATMENT", 135, 159], ["placebocontrolled randomized trials", "TREATMENT", 179, 214], ["effective", "OBSERVATION_MODIFIER", 14, 23]]], ["All too often in critical care, hypotheses based on mechanism and observation failed the test of the randomized trial.", [["the test", "TEST", 85, 93], ["the randomized trial", "TREATMENT", 97, 117]]]], "PMC6235841": [["IntroductionCancer-causing sexually transmitted infections (STI), such as human papillomavirus (HPV), human immunodeficiency virus (HIV), and herpes simplex virus (HSV), are common worldwide.", [["Cancer", "ANATOMY", 12, 18], ["Cancer-causing sexually transmitted infections", "DISEASE", 12, 58], ["STI", "DISEASE", 60, 63], ["human papillomavirus (HPV), human immunodeficiency virus (HIV)", "DISEASE", 74, 136], ["herpes simplex virus (HSV)", "DISEASE", 142, 168], ["Cancer", "CANCER", 12, 18], ["human papillomavirus", "ORGANISM", 74, 94], ["HPV", "ORGANISM", 96, 99], ["human immunodeficiency virus", "ORGANISM", 102, 130], ["HIV", "ORGANISM", 132, 135], ["herpes simplex virus", "ORGANISM", 142, 162], ["HSV", "ORGANISM", 164, 167], ["human", "SPECIES", 74, 79], ["papillomavirus", "SPECIES", 80, 94], ["human immunodeficiency virus", "SPECIES", 102, 130], ["(HIV", "SPECIES", 131, 135], ["herpes simplex virus", "SPECIES", 142, 162], ["human papillomavirus", "SPECIES", 74, 94], ["HPV", "SPECIES", 96, 99], ["human immunodeficiency virus", "SPECIES", 102, 130], ["HIV", "SPECIES", 132, 135], ["herpes simplex virus", "SPECIES", 142, 162], ["HSV", "SPECIES", 164, 167], ["IntroductionCancer", "PROBLEM", 0, 18], ["sexually transmitted infections (STI)", "PROBLEM", 27, 64], ["human papillomavirus (HPV)", "PROBLEM", 74, 100], ["human immunodeficiency virus", "PROBLEM", 102, 130], ["HIV)", "PROBLEM", 132, 136], ["herpes simplex virus (HSV", "PROBLEM", 142, 167], ["Cancer", "OBSERVATION", 12, 18], ["infections", "OBSERVATION", 48, 58]]], ["HPV infections cause cervical and head and neck cancers, while HIV infections cause Kaposi\u2019s sarcoma1.", [["cervical", "ANATOMY", 21, 29], ["head and neck cancers", "ANATOMY", 34, 55], ["HPV infections", "DISEASE", 0, 14], ["cervical and head and neck cancers", "DISEASE", 21, 55], ["HIV infections", "DISEASE", 63, 77], ["Kaposi\u2019s sarcoma1", "DISEASE", 84, 101], ["HPV", "ORGANISM", 0, 3], ["cervical", "ORGANISM_SUBDIVISION", 21, 29], ["head and neck cancers", "CANCER", 34, 55], ["HIV", "ORGANISM", 63, 66], ["Kaposi\u2019s sarcoma1", "ORGANISM", 84, 101], ["HIV", "SPECIES", 63, 66], ["HPV", "SPECIES", 0, 3], ["HIV", "SPECIES", 63, 66], ["HPV infections", "PROBLEM", 0, 14], ["cervical and head and neck cancers", "PROBLEM", 21, 55], ["HIV infections", "PROBLEM", 63, 77], ["Kaposi\u2019s sarcoma1", "PROBLEM", 84, 101], ["infections", "OBSERVATION", 4, 14], ["cervical", "ANATOMY", 21, 29], ["head", "ANATOMY", 34, 38], ["neck", "ANATOMY", 43, 47], ["cancers", "OBSERVATION", 48, 55]]], ["The prostate gland is an organ that is easily exposed to infections of the urogenital tract.", [["prostate gland", "ANATOMY", 4, 18], ["organ", "ANATOMY", 25, 30], ["urogenital tract", "ANATOMY", 75, 91], ["prostate gland", "DISEASE", 4, 18], ["infections of the urogenital tract", "DISEASE", 57, 91], ["prostate gland", "ORGAN", 4, 18], ["organ", "ORGAN", 25, 30], ["urogenital tract", "ORGANISM_SUBDIVISION", 75, 91], ["infections of the urogenital tract", "PROBLEM", 57, 91], ["prostate gland", "ANATOMY", 4, 18], ["organ", "ANATOMY", 25, 30], ["infections", "OBSERVATION", 57, 67], ["urogenital tract", "ANATOMY", 75, 91]]], ["The innate immune response of the urogenital epithelium provides the first line of defense against pathogens and may protect against urogenital cancers.", [["urogenital epithelium", "ANATOMY", 34, 55], ["urogenital cancers", "ANATOMY", 133, 151], ["urogenital cancers", "DISEASE", 133, 151], ["urogenital epithelium", "TISSUE", 34, 55], ["urogenital cancers", "CANCER", 133, 151], ["the urogenital epithelium", "PROBLEM", 30, 55], ["pathogens", "PROBLEM", 99, 108], ["urogenital cancers", "PROBLEM", 133, 151], ["urogenital epithelium", "ANATOMY", 34, 55], ["cancers", "OBSERVATION", 144, 151]]], ["Accordingly, studies have reported an association between prostate cancer risk and mutations or genetic variants in innate immune response genes2,3.", [["prostate cancer", "ANATOMY", 58, 73], ["prostate cancer", "DISEASE", 58, 73], ["prostate cancer", "CANCER", 58, 73], ["innate immune response genes2,3", "DNA", 116, 147], ["studies", "TEST", 13, 20], ["prostate cancer risk", "PROBLEM", 58, 78], ["mutations", "PROBLEM", 83, 92], ["genetic variants", "PROBLEM", 96, 112], ["prostate", "ANATOMY", 58, 66], ["cancer", "OBSERVATION", 67, 73]]], ["However, the evidence for an association between STI and prostate cancer remains inconclusive.", [["prostate cancer", "ANATOMY", 57, 72], ["STI", "DISEASE", 49, 52], ["prostate cancer", "DISEASE", 57, 72], ["prostate cancer", "CANCER", 57, 72], ["an association between STI and prostate cancer", "PROBLEM", 26, 72], ["prostate", "ANATOMY", 57, 65], ["cancer", "OBSERVATION", 66, 72]]], ["Multiple epidemiological studies have evaluated the association between lifetime number of sexual partners, as a proxy for STI, and prostate cancer risk and reported both positive4\u201311 and null associations12\u201315.", [["prostate cancer", "ANATOMY", 132, 147], ["prostate cancer", "DISEASE", 132, 147], ["prostate cancer", "CANCER", 132, 147], ["\u201311", "GENE_OR_GENE_PRODUCT", 180, 183], ["Multiple epidemiological studies", "TEST", 0, 32], ["STI", "PROBLEM", 123, 126], ["prostate cancer risk", "PROBLEM", 132, 152], ["null associations", "TEST", 188, 205], ["prostate", "ANATOMY", 132, 140], ["cancer", "OBSERVATION", 141, 147]]], ["Therefore, we hypothesized that discordance in these observations could be due to residual confounding by unknown host factors modifying the relationship between STI and prostate cancer.IntroductionOne of the host factors of importance for innate immune response to STI could be a germline dinucleotide polymorphism, rs368234815 (TT or \u0394G alleles), in the IFNL4 gene that encodes IFN-\u03bb4, a type-III interferon16,17.", [["prostate cancer", "ANATOMY", 170, 185], ["prostate cancer", "DISEASE", 170, 185], ["prostate cancer", "CANCER", 170, 185], ["rs368234815 (TT or \u0394G alleles", "GENE_OR_GENE_PRODUCT", 317, 346], ["IFNL4", "GENE_OR_GENE_PRODUCT", 356, 361], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 380, 386], ["type-III interferon16,17", "GENE_OR_GENE_PRODUCT", 390, 414], ["germline", "DNA", 281, 289], ["TT", "DNA", 330, 332], ["IFNL4 gene", "DNA", 356, 366], ["IFN", "PROTEIN", 380, 383], ["\u03bb4", "PROTEIN", 384, 386], ["residual confounding", "PROBLEM", 82, 102], ["STI and prostate cancer", "PROBLEM", 162, 185], ["STI", "PROBLEM", 266, 269], ["a germline dinucleotide polymorphism", "PROBLEM", 279, 315], ["TT", "TEST", 330, 332], ["IFN", "TEST", 380, 383], ["a type-III interferon", "TREATMENT", 388, 409], ["prostate", "ANATOMY", 170, 178], ["cancer", "OBSERVATION", 179, 185]]], ["The \u0394G allele creates an open reading frame for IFN-\u03bb4, thus this interferon can only be produced in carriers of the \u0394G allele.", [["\u0394G", "GENE_OR_GENE_PRODUCT", 4, 6], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 48, 54], ["interferon", "GENE_OR_GENE_PRODUCT", 66, 76], ["\u0394G", "GENE_OR_GENE_PRODUCT", 117, 119], ["\u0394G allele", "DNA", 4, 13], ["open reading frame", "DNA", 25, 43], ["IFN", "PROTEIN", 48, 51], ["\u03bb4", "PROTEIN", 52, 54], ["interferon", "PROTEIN", 66, 76], ["\u0394G allele", "DNA", 117, 126], ["The \u0394G allele", "PROBLEM", 0, 13], ["IFN", "TEST", 48, 51]]], ["Paradoxically, although IFN-\u03bb4 is an antiviral cytokine and a potent inducer of the JAK-STAT pathway, individuals carrying the IFNL4-\u0394G allele have impaired ability to clear certain viral infections such as hepatitis C virus (HCV)16,18,19, cytomegalovirus20,21, coronavirus22,23, and possibly HIV24.", [["viral infections", "DISEASE", 182, 198], ["hepatitis C", "DISEASE", 207, 218], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 24, 30], ["JAK", "GENE_OR_GENE_PRODUCT", 84, 87], ["STAT", "GENE_OR_GENE_PRODUCT", 88, 92], ["IFNL4", "GENE_OR_GENE_PRODUCT", 127, 132], ["\u0394G", "GENE_OR_GENE_PRODUCT", 133, 135], ["hepatitis C virus (HCV)16,18,19", "ORGANISM", 207, 238], ["cytomegalovirus20,21", "ORGANISM", 240, 260], ["coronavirus22,23", "ORGANISM", 262, 278], ["IFN", "PROTEIN", 24, 27], ["\u03bb4", "PROTEIN", 28, 30], ["antiviral cytokine", "PROTEIN", 37, 55], ["JAK", "PROTEIN", 84, 87], ["STAT", "PROTEIN", 88, 92], ["IFNL4-\u0394G allele", "DNA", 127, 142], ["hepatitis C virus", "SPECIES", 207, 224], ["hepatitis C virus", "SPECIES", 207, 224], ["HCV", "SPECIES", 226, 229], ["IFN", "TEST", 24, 27], ["an antiviral cytokine", "TREATMENT", 34, 55], ["the IFNL4", "TEST", 123, 132], ["impaired ability", "PROBLEM", 148, 164], ["certain viral infections", "PROBLEM", 174, 198], ["hepatitis C virus", "PROBLEM", 207, 224], ["HCV", "TEST", 226, 229], ["cytomegalovirus", "TEST", 240, 255], ["coronavirus", "TEST", 262, 273]]], ["This effect has been attributed to increased induction of negative regulators of interferon signaling by IFN-\u03bb4 that could affect the function of other interferons16,17.", [["interferon", "GENE_OR_GENE_PRODUCT", 81, 91], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 105, 111], ["interferon", "PROTEIN", 81, 91], ["IFN", "PROTEIN", 105, 108], ["\u03bb4", "PROTEIN", 109, 111], ["interferons16,17", "PROTEIN", 152, 168], ["interferon signaling", "PROBLEM", 81, 101], ["IFN", "TEST", 105, 108], ["attributed to", "UNCERTAINTY", 21, 34], ["increased", "OBSERVATION_MODIFIER", 35, 44]]], ["We recently showed that IFNL4-\u0394G is closely associated with the occurrence of an interferon signature, termed Interferon-related DNA Damage Resistance Signature (IRDS), in prostate tumors of African-American patients with decreased overall survival in this patient group25.", [["prostate tumors", "ANATOMY", 172, 187], ["prostate tumors", "DISEASE", 172, 187], ["IFNL4-\u0394G", "GENE_OR_GENE_PRODUCT", 24, 32], ["DNA", "CELLULAR_COMPONENT", 129, 132], ["prostate tumors", "CANCER", 172, 187], ["patients", "ORGANISM", 208, 216], ["patient", "ORGANISM", 257, 264], ["IFNL4", "PROTEIN", 24, 29], ["\u0394G", "DNA", 30, 32], ["interferon", "PROTEIN", 81, 91], ["Interferon", "PROTEIN", 110, 120], ["patients", "SPECIES", 208, 216], ["patient", "SPECIES", 257, 264], ["an interferon signature", "PROBLEM", 78, 101], ["termed Interferon", "TREATMENT", 103, 120], ["DNA Damage Resistance Signature (IRDS)", "PROBLEM", 129, 167], ["interferon", "OBSERVATION", 81, 91], ["Damage Resistance", "OBSERVATION", 133, 150], ["prostate", "ANATOMY", 172, 180], ["tumors", "OBSERVATION", 181, 187]]], ["Thus, IFNL4-\u0394G may have a significant function in prostate cancer biology.IntroductionIn the present study, we identified a gene\u2013environment interaction between IFNL4-\u0394G and an increased likelihood of exposure to STI resulting in the development of aggressive prostate cancer, suggesting a yet unidentified relationship between an infectious agent and prostate cancer in men with IFNL4-\u0394G.Clinical and demographic characteristics of participants ::: ResultsCharacteristics of the participants in the NCI-Maryland Prostate Cancer Case-Control Study have been previously described26.", [["prostate cancer", "ANATOMY", 50, 65], ["prostate cancer", "ANATOMY", 260, 275], ["prostate cancer", "ANATOMY", 352, 367], ["Prostate Cancer", "ANATOMY", 513, 528], ["prostate cancer", "DISEASE", 50, 65], ["STI", "DISEASE", 213, 216], ["prostate cancer", "DISEASE", 260, 275], ["prostate cancer", "DISEASE", 352, 367], ["Prostate Cancer", "DISEASE", 513, 528], ["IFNL4-\u0394G", "GENE_OR_GENE_PRODUCT", 6, 14], ["prostate cancer", "CANCER", 50, 65], ["IFNL4", "GENE_OR_GENE_PRODUCT", 161, 166], ["prostate cancer", "CANCER", 260, 275], ["prostate cancer", "CANCER", 352, 367], ["men", "ORGANISM", 371, 374], ["IFNL4", "GENE_OR_GENE_PRODUCT", 380, 385], ["Prostate Cancer", "CANCER", 513, 528], ["IFNL4", "PROTEIN", 6, 11], ["\u0394G", "PROTEIN", 12, 14], ["IFNL4", "PROTEIN", 161, 166], ["men", "SPECIES", 371, 374], ["participants", "SPECIES", 433, 445], ["participants", "SPECIES", 480, 492], ["a significant function in prostate cancer", "PROBLEM", 24, 65], ["the present study", "TEST", 89, 106], ["a gene\u2013environment interaction", "PROBLEM", 122, 152], ["IFNL4", "TREATMENT", 161, 166], ["STI", "PROBLEM", 213, 216], ["aggressive prostate cancer", "PROBLEM", 249, 275], ["an infectious agent", "PROBLEM", 328, 347], ["prostate cancer", "PROBLEM", 352, 367], ["significant", "OBSERVATION_MODIFIER", 26, 37], ["function", "OBSERVATION", 38, 46], ["prostate", "ANATOMY", 50, 58], ["cancer", "OBSERVATION", 59, 65], ["increased", "OBSERVATION_MODIFIER", 177, 186], ["aggressive", "OBSERVATION_MODIFIER", 249, 259], ["prostate", "ANATOMY", 260, 268], ["cancer", "OBSERVATION", 269, 275], ["infectious", "OBSERVATION", 331, 341], ["prostate", "ANATOMY", 352, 360], ["cancer", "OBSERVATION", 361, 367], ["Prostate", "ANATOMY", 513, 521], ["Cancer", "OBSERVATION", 522, 528]]], ["The study enrolled 976 cases (489 African-American [AA] and 487 European-American [EA]) and 1034 population controls (486 AA and 548 EA) (Table 1) who were asked about their sexual history (Supplementary Table 1).", [["The study", "TEST", 0, 9], ["AA", "TEST", 52, 54], ["population controls", "TEST", 97, 116], ["AA", "TEST", 122, 124]]], ["Cases and controls had similar age and BMI distributions.", [["BMI distributions", "OBSERVATION", 39, 56]]], ["More cases, compared to controls, had a first degree family history of prostate cancer (11% vs. 7%, P = 0.003, Chi-square test), whereas fewer cases than controls had a college or graduate-level degree (32% vs. 50%, P < 0.001, Chi-square test).", [["prostate cancer", "ANATOMY", 71, 86], ["prostate cancer", "DISEASE", 71, 86], ["prostate cancer", "CANCER", 71, 86], ["prostate cancer", "PROBLEM", 71, 86], ["P", "TEST", 100, 101], ["Chi-square test", "TEST", 111, 126], ["P", "TEST", 216, 217], ["Chi-square test", "TEST", 227, 242], ["prostate", "ANATOMY", 71, 79], ["cancer", "OBSERVATION", 80, 86]]], ["Additionally, more cases were current smokers than controls (25% vs. 15%, P < 0.001, Chi-square test).", [["Chi-square test", "TEST", 85, 100]]], ["Among the 976 cases, 138 men (14%) had advanced disease (stage 3 or 4 prostate cancer).", [["prostate cancer", "ANATOMY", 70, 85], ["prostate cancer", "DISEASE", 70, 85], ["men", "ORGANISM", 25, 28], ["prostate cancer", "CANCER", 70, 85], ["men", "SPECIES", 25, 28], ["advanced disease (stage 3 or 4 prostate cancer", "PROBLEM", 39, 85], ["advanced", "OBSERVATION_MODIFIER", 39, 47], ["disease", "OBSERVATION", 48, 55], ["stage 3", "OBSERVATION_MODIFIER", 57, 64], ["prostate", "ANATOMY", 70, 78], ["cancer", "OBSERVATION", 79, 85]]], ["High Gleason score (>7) was reported in 167 patients (17%).", [["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["High Gleason score", "TEST", 0, 18]]], ["Both AA and EA men had similar Gleason score distribution, but AA men tended to have higher blood PSA levels at diagnosis.", [["blood", "ANATOMY", 92, 97], ["AA", "CHEMICAL", 5, 7], ["men", "ORGANISM", 15, 18], ["men", "ORGANISM", 66, 69], ["blood", "ORGANISM_SUBSTANCE", 92, 97], ["PSA", "GENE_OR_GENE_PRODUCT", 98, 101], ["PSA", "PROTEIN", 98, 101], ["men", "SPECIES", 15, 18], ["men", "SPECIES", 66, 69], ["higher blood PSA levels", "PROBLEM", 85, 108], ["Gleason", "OBSERVATION", 31, 38]]], ["A greater proportion of EA (16%) men, compared with AA men (13%), presented with an advanced disease in this cohort.", [["EA", "CANCER", 24, 26], ["men", "ORGANISM", 33, 36], ["men", "ORGANISM", 55, 58], ["men", "SPECIES", 33, 36], ["men", "SPECIES", 55, 58], ["an advanced disease", "PROBLEM", 81, 100], ["greater", "OBSERVATION_MODIFIER", 2, 9], ["advanced", "OBSERVATION_MODIFIER", 84, 92], ["disease", "OBSERVATION", 93, 100]]], ["Based on the combination of low/high-grade and localized/advanced disease (see Methods), 732 and 244 cases were assigned into groups of nonaggressive and aggressive prostate cancer, respectively.Number of sexual partners as proxy to assess exposure to STI ::: ResultsTo establish the validity of our surrogate variable (see Methods), we tested if the number of self-reported sexual partners can be used to infer exposure to gonorrhea, an established STI.", [["prostate cancer", "ANATOMY", 165, 180], ["prostate cancer", "DISEASE", 165, 180], ["gonorrhea", "DISEASE", 424, 433], ["STI", "DISEASE", 450, 453], ["high-grade", "CANCER", 32, 42], ["prostate cancer", "CANCER", 165, 180], ["low/high-grade and localized/advanced disease", "PROBLEM", 28, 73], ["nonaggressive and aggressive prostate cancer", "PROBLEM", 136, 180], ["gonorrhea", "PROBLEM", 424, 433], ["low", "OBSERVATION_MODIFIER", 28, 31], ["high-grade", "OBSERVATION_MODIFIER", 32, 42], ["advanced", "OBSERVATION_MODIFIER", 57, 65], ["disease", "OBSERVATION", 66, 73], ["nonaggressive", "OBSERVATION_MODIFIER", 136, 149], ["aggressive", "OBSERVATION_MODIFIER", 154, 164], ["prostate", "ANATOMY", 165, 173], ["cancer", "OBSERVATION", 174, 180]]], ["As shown in Supplementary Table 2, men with 10 or more sexual partners in their teens to 30s were about 3- to 5-fold more likely to have had a gonorrhea infection than men that had only 0\u20131 sexual partners, while men with 2\u20139 partners had a 2- to 3-fold increased odds of this infection.", [["gonorrhea infection", "DISEASE", 143, 162], ["infection", "DISEASE", 277, 286], ["men", "ORGANISM", 35, 38], ["men", "ORGANISM", 168, 171], ["men", "ORGANISM", 213, 216], ["men", "SPECIES", 35, 38], ["men", "SPECIES", 168, 171], ["men", "SPECIES", 213, 216], ["a gonorrhea infection", "PROBLEM", 141, 162], ["this infection", "PROBLEM", 272, 286], ["infection", "OBSERVATION", 153, 162], ["infection", "OBSERVATION", 277, 286]]], ["These relationships were statistically significant in an analysis of all men combined or when we stratified into controls and cases.", [["men", "ORGANISM", 73, 76], ["men", "SPECIES", 73, 76], ["an analysis", "TEST", 54, 65], ["significant", "OBSERVATION_MODIFIER", 39, 50]]], ["The lifetime number of sexual partners also correlated with the likelihood of contracting gonorrhea in an exposure-dependent manner (Supplementary Table 2), and the likelihood of contracting gonorrhea was increased with a higher lifetime number of sexual partners (Ptrend < 0.001), further validating the utility of this proxy variable to infer likelihood of exposure to STI.Number of sexual partners and prostate cancer risk ::: ResultsAs the youngest age at diagnosis in our cohort was 42 years, and 24 of our participants had a prostate cancer diagnosis in their 40s and therefore could not report any sexual partners in their 50s and beyond, we decided to only look at exposures during their teens, 20, and 30s.", [["prostate cancer", "ANATOMY", 405, 420], ["prostate cancer", "ANATOMY", 531, 546], ["gonorrhea", "DISEASE", 90, 99], ["gonorrhea", "DISEASE", 191, 200], ["STI", "DISEASE", 371, 374], ["prostate cancer", "DISEASE", 405, 420], ["prostate cancer", "DISEASE", 531, 546], ["prostate cancer", "CANCER", 405, 420], ["participants", "ORGANISM", 512, 524], ["prostate cancer", "CANCER", 531, 546], ["participants", "SPECIES", 512, 524], ["contracting gonorrhea", "PROBLEM", 78, 99], ["contracting gonorrhea", "PROBLEM", 179, 200], ["STI", "PROBLEM", 371, 374], ["a prostate cancer", "PROBLEM", 529, 546], ["gonorrhea", "OBSERVATION", 90, 99], ["gonorrhea", "OBSERVATION", 191, 200], ["prostate", "ANATOMY", 405, 413], ["cancer", "OBSERVATION", 414, 420], ["prostate", "ANATOMY", 531, 539], ["cancer", "OBSERVATION", 540, 546]]], ["Table 2 presents the associations of sexual activity during early adulthood (up to age 39) and throughout lifetime with prostate cancer.", [["prostate cancer", "ANATOMY", 120, 135], ["prostate cancer", "DISEASE", 120, 135], ["prostate cancer", "CANCER", 120, 135], ["prostate cancer", "PROBLEM", 120, 135], ["prostate", "ANATOMY", 120, 128], ["cancer", "OBSERVATION", 129, 135]]], ["We did not observe a significant association between the number of sexual partners when the men were teens and their risk of developing prostate cancer later in life, according to the multivariable model, although a trend towards an increased risk was observed in the univariate analysis.", [["prostate cancer", "ANATOMY", 136, 151], ["prostate cancer", "DISEASE", 136, 151], ["men", "ORGANISM", 92, 95], ["prostate cancer", "CANCER", 136, 151], ["men", "SPECIES", 92, 95], ["developing prostate cancer", "PROBLEM", 125, 151], ["an increased risk", "PROBLEM", 230, 247], ["the univariate analysis", "TEST", 264, 287], ["prostate", "ANATOMY", 136, 144], ["cancer", "OBSERVATION", 145, 151]]], ["On the other hand, when considering the number of sexual partners during an individual\u2019s 20s and 30s, individuals who had 10 or more sexual partners had a 41% and 59% increased odd of prostate cancer, respectively, compared with men who had 0\u20131 partners.", [["prostate cancer", "ANATOMY", 184, 199], ["prostate cancer", "DISEASE", 184, 199], ["prostate cancer", "CANCER", 184, 199], ["men", "ORGANISM", 229, 232], ["men", "SPECIES", 229, 232], ["prostate cancer", "PROBLEM", 184, 199], ["prostate", "ANATOMY", 184, 192], ["cancer", "OBSERVATION", 193, 199]]], ["Similarly, when considering the total number of sexual partners through the life course, men who had 20 or more sexual partners had a 47% increased odd of prostate cancer.", [["prostate cancer", "ANATOMY", 155, 170], ["prostate cancer", "DISEASE", 155, 170], ["men", "ORGANISM", 89, 92], ["prostate cancer", "CANCER", 155, 170], ["men", "SPECIES", 89, 92], ["prostate cancer", "PROBLEM", 155, 170], ["prostate", "ANATOMY", 155, 163], ["cancer", "OBSERVATION", 164, 170]]], ["These associations were significant in the multivariable model and were also dose-dependent.", [["significant", "OBSERVATION_MODIFIER", 24, 35]]], ["For example, men who had 10 or more sexual partners had more risk than those who had 2\u20139 sexual partners during their 20s (Ptrend = 0.029) and 30s (Ptrend = 0.001).", [["men", "ORGANISM", 13, 16], ["men", "SPECIES", 13, 16]]], ["Our findings indicate that increased exposure to STI during early adulthood elevates individuals\u2019 risk of developing prostate cancer later in life, suggesting that STI may play a role in the etiology of prostate cancer.", [["prostate cancer", "ANATOMY", 117, 132], ["prostate cancer", "ANATOMY", 203, 218], ["STI", "DISEASE", 49, 52], ["prostate cancer", "DISEASE", 117, 132], ["prostate cancer", "DISEASE", 203, 218], ["prostate cancer", "CANCER", 117, 132], ["prostate cancer", "CANCER", 203, 218], ["increased exposure", "PROBLEM", 27, 45], ["STI", "PROBLEM", 49, 52], ["developing prostate cancer", "PROBLEM", 106, 132], ["STI", "PROBLEM", 164, 167], ["prostate cancer", "PROBLEM", 203, 218], ["increased", "OBSERVATION_MODIFIER", 27, 36], ["exposure", "OBSERVATION", 37, 45], ["prostate", "ANATOMY", 117, 125], ["cancer", "OBSERVATION", 126, 132], ["prostate", "ANATOMY", 203, 211], ["cancer", "OBSERVATION", 212, 218]]], ["These findings were observed in both EA and AA men.", [["men", "ORGANISM", 47, 50], ["men", "SPECIES", 47, 50]]], ["However, we noted a more robust risk association among the AA men (Table 2).IFNL4-\u0394G modifies sexual activity-associated cancer risk ::: ResultsIFNL4 rs368234815 genotypes were determined for 828 cases and 953 controls with available germline DNA.", [["cancer", "ANATOMY", 121, 127], ["cancer", "DISEASE", 121, 127], ["men", "ORGANISM", 62, 65], ["IFNL4", "GENE_OR_GENE_PRODUCT", 76, 81], ["\u0394G", "GENE_OR_GENE_PRODUCT", 82, 84], ["cancer", "CANCER", 121, 127], ["ResultsIFNL4", "GENE_OR_GENE_PRODUCT", 137, 149], ["DNA", "CELLULAR_COMPONENT", 243, 246], ["IFNL4", "PROTEIN", 76, 81], ["\u0394G", "DNA", 82, 84], ["germline DNA", "DNA", 234, 246], ["men", "SPECIES", 62, 65], ["genotypes", "TEST", 162, 171], ["available germline DNA", "PROBLEM", 224, 246], ["cancer", "OBSERVATION", 121, 127]]], ["As expected16, the \u0394G allele was more common among AA (61.7%) than EA (33.7%) men (Supplementary Table 3).", [["\u0394G", "GENE_OR_GENE_PRODUCT", 19, 21], ["men", "ORGANISM", 78, 81], ["\u0394G allele", "DNA", 19, 28], ["men", "SPECIES", 78, 81], ["the \u0394G allele", "PROBLEM", 15, 28], ["AA", "TEST", 51, 53], ["EA", "TEST", 67, 69]]], ["To investigate whether IFNL4-\u0394G modifies the association between likelihood of exposure to STI and prostate cancer risk, we stratified the participants into those with one or two \u0394G alleles vs. none.", [["prostate cancer", "ANATOMY", 99, 114], ["STI", "DISEASE", 91, 94], ["prostate cancer", "DISEASE", 99, 114], ["IFNL4-\u0394G", "GENE_OR_GENE_PRODUCT", 23, 31], ["prostate cancer", "CANCER", 99, 114], ["IFNL4", "PROTEIN", 23, 28], ["\u0394G", "DNA", 29, 31], ["\u0394G alleles", "DNA", 179, 189], ["participants", "SPECIES", 139, 151], ["STI and prostate cancer risk", "PROBLEM", 91, 119], ["prostate", "ANATOMY", 99, 107], ["cancer", "OBSERVATION", 108, 114]]], ["As shown in Fig. 1 and Table 3, the adjusted logistic regression analysis revealed that the increased risk of prostate cancer associated with sexual activity was restricted to carriers of at least one \u0394G allele.", [["prostate cancer", "ANATOMY", 110, 125], ["prostate cancer", "DISEASE", 110, 125], ["prostate cancer", "CANCER", 110, 125], ["\u0394G", "GENE_OR_GENE_PRODUCT", 201, 203], ["\u0394G allele", "DNA", 201, 210], ["the adjusted logistic regression analysis", "TEST", 32, 73], ["prostate cancer", "PROBLEM", 110, 125], ["increased", "OBSERVATION_MODIFIER", 92, 101], ["prostate", "ANATOMY", 110, 118], ["cancer", "OBSERVATION", 119, 125]]], ["For instance, among individuals that had 10 or more sexual partners in their 20s, the odds of diagnosis with prostate cancer for men with at least one \u0394G allele vs. none was 1.68-fold (95% CI: 1.16, 2.43) vs. 1.05-fold (95% CI: 0.59, 1.87), respectively.", [["prostate cancer", "ANATOMY", 109, 124], ["prostate cancer", "DISEASE", 109, 124], ["prostate cancer", "CANCER", 109, 124], ["men", "ORGANISM", 129, 132], ["\u0394G allele", "DNA", 151, 160], ["men", "SPECIES", 129, 132], ["prostate cancer", "PROBLEM", 109, 124], ["CI", "TEST", 189, 191], ["CI", "TEST", 224, 226], ["prostate", "ANATOMY", 109, 117], ["cancer", "OBSERVATION", 118, 124]]], ["The effect of the \u0394G allele remained statistically significant after adjusting for race/ethnicity or applying a Bonferroni-adjusted significance threshold of P < 0.00625.IFNL4-\u0394G modifies sexual activity-associated cancer risk ::: ResultsWe reasoned that among men who had multiple sexual partners during early adulthood, carriers of two copies of \u0394G allele (\u0394G/\u0394G genotype) would be expected to have a higher prostate cancer risk than those with one copy (\u0394G/TT genotype).", [["cancer", "ANATOMY", 215, 221], ["prostate cancer", "ANATOMY", 410, 425], ["cancer", "DISEASE", 215, 221], ["prostate cancer", "DISEASE", 410, 425], ["\u0394G", "GENE_OR_GENE_PRODUCT", 18, 20], ["IFNL4", "GENE_OR_GENE_PRODUCT", 170, 175], ["\u0394G", "GENE_OR_GENE_PRODUCT", 176, 178], ["cancer", "CANCER", 215, 221], ["men", "ORGANISM", 261, 264], ["\u0394G", "GENE_OR_GENE_PRODUCT", 348, 350], ["prostate cancer", "CANCER", 410, 425], ["\u0394G allele", "DNA", 18, 27], ["IFNL4", "PROTEIN", 170, 175], ["\u0394G", "DNA", 176, 178], ["\u0394G allele", "DNA", 348, 357], ["men", "SPECIES", 261, 264], ["the \u0394G allele", "PROBLEM", 14, 27], ["a Bonferroni", "TREATMENT", 110, 122], ["\u0394G allele (\u0394G/\u0394G genotype", "TREATMENT", 348, 373], ["a higher prostate cancer risk", "PROBLEM", 401, 430], ["\u0394G/TT genotype)", "TREATMENT", 457, 472], ["cancer", "OBSERVATION", 215, 221], ["prostate", "ANATOMY", 410, 418], ["cancer", "OBSERVATION", 419, 425]]], ["As shown in Supplementary Table 4, among those with an increased likelihood of exposure to STI in their 20s, 30s, or during their lifetime, the odds of diagnosis with prostate cancer were higher in carriers of \u0394G/\u0394G than of \u0394G/TT or TT/TT genotypes.", [["prostate cancer", "ANATOMY", 167, 182], ["STI", "DISEASE", 91, 94], ["prostate cancer", "DISEASE", 167, 182], ["prostate cancer", "CANCER", 167, 182], ["\u0394G/TT", "GENE_OR_GENE_PRODUCT", 224, 229], ["STI", "PROBLEM", 91, 94], ["prostate cancer", "PROBLEM", 167, 182], ["\u0394G/TT", "TREATMENT", 224, 229], ["TT/TT genotypes", "PROBLEM", 233, 248], ["prostate", "ANATOMY", 167, 175], ["cancer", "OBSERVATION", 176, 182]]], ["Again, there was no significant relationship between the number of sexual partners and prostate cancer risk among TT/TT carriers.", [["prostate cancer", "ANATOMY", 87, 102], ["prostate cancer", "DISEASE", 87, 102], ["prostate cancer", "CANCER", 87, 102], ["prostate cancer risk", "PROBLEM", 87, 107], ["TT/TT carriers", "TREATMENT", 114, 128], ["no", "UNCERTAINTY", 17, 19], ["significant", "OBSERVATION_MODIFIER", 20, 31], ["prostate", "ANATOMY", 87, 95], ["cancer", "OBSERVATION", 96, 102]]], ["However, \u0394G/\u0394G carriers who had two or more sexual partners in their 20s and 30s, or had 20 or more sexual partners during their lifetime, had increased risk.", [["\u0394G/\u0394G", "GENE_OR_GENE_PRODUCT", 9, 14], ["increased risk", "PROBLEM", 143, 157]]], ["For instance, for men with two or more sexual partners vs. none during their 30s, the odds ratios increased from 1.05 (95% CI: 0.79, 1.57) to 1.62 (95% CI: 1.16, 2.27) to 1.86 (95% CI: 1.17, 2.95) if their IFNL4 genotypes were TT/TT, \u0394G/TT, or \u0394G/\u0394G, respectively.", [["men", "ORGANISM", 18, 21], ["IFNL4", "GENE_OR_GENE_PRODUCT", 206, 211], ["men", "SPECIES", 18, 21], ["the odds ratios", "TEST", 82, 97], ["CI", "TEST", 123, 125], ["CI", "TEST", 152, 154], ["CI", "TEST", 181, 183], ["genotypes", "TEST", 212, 221], ["TT", "TEST", 227, 229], ["TT", "TEST", 230, 232], ["\u0394G", "TEST", 234, 236], ["TT", "TEST", 237, 239], ["\u0394G/\u0394G", "TREATMENT", 244, 249]]], ["Similarly, among men who had 20 or more sexual partners vs. <5 partners in their lifetime, the odds ratios increased from 1.00 (95% CI: 0.59, 1.68) to 1.64 (95% CI: 1.06, 2.53) to 1.97 (95% CI: 1.10, 3.51) if their IFNL4 genotypes were TT/TT, \u0394G/TT, or \u0394G/\u0394G, respectively.IFNL4-\u0394G modifies sexual activity-associated cancer risk ::: ResultsTo further examine this observation, we tested for statistical significance of an interaction term between IFNL4-\u0394G and likelihood of exposure to STI during early adulthood, using the number of sexual partners as the surrogate measurement for STI likelihood.", [["cancer", "ANATOMY", 318, 324], ["cancer", "DISEASE", 318, 324], ["men", "ORGANISM", 17, 20], ["IFNL4", "GENE_OR_GENE_PRODUCT", 215, 220], ["IFNL4", "GENE_OR_GENE_PRODUCT", 273, 278], ["\u0394G", "GENE_OR_GENE_PRODUCT", 279, 281], ["cancer", "CANCER", 318, 324], ["IFNL4", "GENE_OR_GENE_PRODUCT", 448, 453], ["IFNL4", "PROTEIN", 273, 278], ["\u0394G", "DNA", 279, 281], ["IFNL4", "PROTEIN", 448, 453], ["men", "SPECIES", 17, 20], ["the odds ratios", "TEST", 91, 106], ["CI", "TEST", 132, 134], ["CI", "TEST", 161, 163], ["CI", "TEST", 190, 192], ["genotypes", "TEST", 221, 230], ["TT", "TEST", 236, 238], ["TT", "TEST", 239, 241], ["\u0394G", "TEST", 243, 245], ["TT", "TEST", 246, 248], ["\u0394G/\u0394G", "TREATMENT", 253, 258], ["this observation", "TEST", 360, 376], ["an interaction term", "PROBLEM", 420, 439], ["STI", "PROBLEM", 487, 490], ["the surrogate measurement", "TEST", 554, 579], ["STI likelihood", "PROBLEM", 584, 598], ["cancer", "OBSERVATION", 318, 324]]], ["This analysis was performed for all prostate cancer cases and then stratified into nonaggressive and aggressive disease.", [["prostate cancer", "ANATOMY", 36, 51], ["prostate cancer", "DISEASE", 36, 51], ["prostate cancer", "CANCER", 36, 51], ["This analysis", "TEST", 0, 13], ["all prostate cancer cases", "PROBLEM", 32, 57], ["nonaggressive and aggressive disease", "PROBLEM", 83, 119], ["prostate", "ANATOMY", 36, 44], ["cancer", "OBSERVATION", 45, 51], ["aggressive", "OBSERVATION_MODIFIER", 101, 111], ["disease", "OBSERVATION", 112, 119]]], ["Notably, the strongest evidence for a gene\u2013environment interaction revealed an association of this interaction with the odds of developing the aggressive disease (Table 4), where both IFNL4-\u0394G and multiple lifetime sexual partners synergistically increased the odds for aggressive prostate cancer (P interaction = 0.004).", [["prostate cancer", "ANATOMY", 281, 296], ["aggressive disease", "DISEASE", 143, 161], ["aggressive prostate cancer", "DISEASE", 270, 296], ["IFNL4", "GENE_OR_GENE_PRODUCT", 184, 189], ["prostate cancer", "CANCER", 281, 296], ["IFNL4", "PROTEIN", 184, 189], ["a gene\u2013environment interaction", "PROBLEM", 36, 66], ["the aggressive disease", "PROBLEM", 139, 161], ["aggressive prostate cancer", "PROBLEM", 270, 296], ["aggressive", "OBSERVATION_MODIFIER", 143, 153], ["prostate", "ANATOMY", 281, 289], ["cancer", "OBSERVATION", 290, 296]]], ["This association remained significant when a Bonferroni-adjusted significance threshold of P < 0.00625 was applied.", [["a Bonferroni", "TREATMENT", 43, 55], ["significant", "OBSERVATION_MODIFIER", 26, 37]]], ["We made similar observations when we examined the association between number of sexual partners and disease risk among IFNL4-\u0394G carriers in strata of aggressive and nonaggressive prostate cancer.", [["prostate cancer", "ANATOMY", 179, 194], ["prostate cancer", "DISEASE", 179, 194], ["IFNL4-\u0394G", "CANCER", 119, 127], ["nonaggressive prostate cancer", "CANCER", 165, 194], ["nonaggressive prostate cancer", "PROBLEM", 165, 194], ["nonaggressive", "OBSERVATION_MODIFIER", 165, 178], ["prostate", "ANATOMY", 179, 187], ["cancer", "OBSERVATION", 188, 194]]], ["As shown in Fig. 1 and Table 5, IFNL4-\u0394G carriers who had 10 or more sexual partners in their 20s and 30s (or 20 or more lifetime partners), tended to have higher odds of being diagnosed with an aggressive than a nonaggressive disease.IFNL4-\u0394G modifies sexual activity-associated cancer risk ::: ResultsIFNL4-\u0394G has very divergent allelic frequencies across populations\u2014<10% in Asians, ~30% in Europeans, and up to 78% in Africans16\u2014which can lead to a wide range of population attributable risks associated with this genetic variant.", [["cancer", "ANATOMY", 280, 286], ["cancer", "DISEASE", 280, 286], ["IFNL4-\u0394G", "GENE_OR_GENE_PRODUCT", 32, 40], ["IFNL4", "GENE_OR_GENE_PRODUCT", 235, 240], ["\u0394G", "GENE_OR_GENE_PRODUCT", 241, 243], ["cancer", "CANCER", 280, 286], ["ResultsIFNL4", "GENE_OR_GENE_PRODUCT", 296, 308], ["\u0394G", "GENE_OR_GENE_PRODUCT", 309, 311], ["IFNL4", "PROTEIN", 32, 37], ["IFNL4", "PROTEIN", 235, 240], ["\u0394G", "DNA", 241, 243], ["ResultsIFNL4", "PROTEIN", 296, 308], ["\u0394G", "DNA", 309, 311], ["a nonaggressive disease", "PROBLEM", 211, 234], ["very divergent allelic frequencies across populations", "PROBLEM", 316, 369], ["Asians", "TEST", 378, 384], ["Africans", "TEST", 422, 430], ["this genetic variant", "PROBLEM", 513, 533], ["nonaggressive", "OBSERVATION_MODIFIER", 213, 226], ["disease", "OBSERVATION", 227, 234], ["cancer", "OBSERVATION", 280, 286]]], ["Given that the allele frequency is higher in AA, we stratified our analysis by race/ethnicity.", [["allele", "DNA", 15, 21], ["the allele frequency", "PROBLEM", 11, 31], ["higher", "OBSERVATION_MODIFIER", 35, 41]]], ["We found that the odds of being diagnosed with aggressive prostate cancer in men who had 10 or more sexual partners in their 20s or 30s (or 20 or more lifetime partners) was higher among AA men than EA men (Table 6), consistent with the increased frequency of the IFNL4-\u0394G risk allele in AA compared to any other racial group.", [["prostate cancer", "ANATOMY", 58, 73], ["prostate cancer", "DISEASE", 58, 73], ["AA", "CHEMICAL", 288, 290], ["prostate cancer", "CANCER", 58, 73], ["men", "ORGANISM", 77, 80], ["men", "ORGANISM", 190, 193], ["IFNL4", "GENE_OR_GENE_PRODUCT", 264, 269], ["\u0394G", "GENE_OR_GENE_PRODUCT", 270, 272], ["IFNL4-\u0394G risk allele", "DNA", 264, 284], ["men", "SPECIES", 77, 80], ["men", "SPECIES", 190, 193], ["men", "SPECIES", 202, 205], ["aggressive prostate cancer", "PROBLEM", 47, 73], ["allele in AA", "PROBLEM", 278, 290], ["aggressive", "OBSERVATION_MODIFIER", 47, 57], ["prostate", "ANATOMY", 58, 66], ["cancer", "OBSERVATION", 67, 73]]], ["For AA men, having multiple sexual partners (10 or more) in their 30s, increased their odds of diagnosis with aggressive prostate cancer by 207% vs. only by 43% for nonaggressive prostate cancer (Table 6).", [["prostate cancer", "ANATOMY", 121, 136], ["prostate cancer", "ANATOMY", 179, 194], ["AA", "CHEMICAL", 4, 6], ["aggressive prostate cancer", "DISEASE", 110, 136], ["prostate cancer", "DISEASE", 179, 194], ["men", "ORGANISM", 7, 10], ["prostate cancer", "CANCER", 121, 136], ["prostate cancer", "CANCER", 179, 194], ["men", "SPECIES", 7, 10], ["aggressive prostate cancer", "PROBLEM", 110, 136], ["nonaggressive prostate cancer", "PROBLEM", 165, 194], ["aggressive", "OBSERVATION_MODIFIER", 110, 120], ["prostate", "ANATOMY", 121, 129], ["cancer", "OBSERVATION", 130, 136], ["prostate", "ANATOMY", 179, 187], ["cancer", "OBSERVATION", 188, 194]]], ["Similarly, in men with at least one copy of the \u0394G allele, having multiple sexual partners in their 30s was associated with 182% increased odds of a diagnosis with aggressive prostate cancer vs. only 56% for nonaggressive prostate cancer (Table 5).", [["prostate cancer", "ANATOMY", 175, 190], ["prostate cancer", "ANATOMY", 222, 237], ["prostate cancer", "DISEASE", 175, 190], ["prostate cancer", "DISEASE", 222, 237], ["men", "ORGANISM", 14, 17], ["\u0394G", "GENE_OR_GENE_PRODUCT", 48, 50], ["prostate cancer", "CANCER", 175, 190], ["nonaggressive prostate cancer", "CANCER", 208, 237], ["\u0394G allele", "DNA", 48, 57], ["men", "SPECIES", 14, 17], ["aggressive prostate cancer", "PROBLEM", 164, 190], ["nonaggressive prostate cancer", "PROBLEM", 208, 237], ["prostate", "ANATOMY", 175, 183], ["cancer", "OBSERVATION", 184, 190], ["prostate", "ANATOMY", 222, 230], ["cancer", "OBSERVATION", 231, 237]]], ["In EA men, however, these relationships were either non-significant, or borderline significant, again suggesting that the higher prevalence of the \u0394G allele in AA men could contribute to their increased risk for aggressive prostate cancer.Endogenous IFN-\u03bb4 is induced by viral infection in PC3 cells ::: ResultsBecause the exact viral pathogens causing STI in the prostate gland are unknown, we infected human prostate cancer cell lines with Sendai virus (SeV), which is a murine RNA virus that infects diverse human cell types and induces a robust antiviral response, including IFN-\u03bb4 expression in primary human hepatocytes17.", [["prostate cancer", "ANATOMY", 223, 238], ["PC3 cells", "ANATOMY", 290, 299], ["prostate gland", "ANATOMY", 364, 378], ["prostate cancer cell lines", "ANATOMY", 410, 436], ["cell", "ANATOMY", 517, 521], ["hepatocytes", "ANATOMY", 614, 625], ["AA", "CHEMICAL", 160, 162], ["prostate cancer", "DISEASE", 223, 238], ["viral infection", "DISEASE", 271, 286], ["STI in the prostate gland", "DISEASE", 353, 378], ["prostate cancer", "DISEASE", 410, 425], ["men", "ORGANISM", 6, 9], ["\u0394G", "GENE_OR_GENE_PRODUCT", 147, 149], ["men", "ORGANISM", 163, 166], ["prostate cancer", "CANCER", 223, 238], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 250, 256], ["PC3 cells", "CELL", 290, 299], ["prostate gland", "ORGAN", 364, 378], ["human", "ORGANISM", 404, 409], ["prostate cancer cell lines", "CELL", 410, 436], ["Sendai virus", "ORGANISM", 442, 454], ["SeV", "ORGANISM", 456, 459], ["murine", "ORGANISM", 473, 479], ["human", "ORGANISM", 511, 516], ["cell types", "CELL", 517, 527], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 579, 585], ["human", "ORGANISM", 608, 613], ["hepatocytes17", "CELL", 614, 627], ["\u0394G allele", "DNA", 147, 156], ["IFN", "PROTEIN", 250, 253], ["\u03bb4", "PROTEIN", 254, 256], ["PC3 cells", "CELL_LINE", 290, 299], ["human prostate cancer cell lines", "CELL_LINE", 404, 436], ["human cell types", "CELL_TYPE", 511, 527], ["IFN", "PROTEIN", 579, 582], ["\u03bb4", "PROTEIN", 583, 585], ["primary human hepatocytes17", "CELL_LINE", 600, 627], ["men", "SPECIES", 6, 9], ["men", "SPECIES", 163, 166], ["human", "SPECIES", 404, 409], ["Sendai virus", "SPECIES", 442, 454], ["murine", "SPECIES", 473, 479], ["human", "SPECIES", 511, 516], ["human", "SPECIES", 608, 613], ["human", "SPECIES", 404, 409], ["Sendai virus", "SPECIES", 442, 454], ["SeV", "SPECIES", 456, 459], ["human", "SPECIES", 511, 516], ["human", "SPECIES", 608, 613], ["aggressive prostate cancer", "PROBLEM", 212, 238], ["Endogenous IFN", "TEST", 239, 253], ["viral infection in PC3 cells", "PROBLEM", 271, 299], ["the exact viral pathogens", "PROBLEM", 319, 344], ["STI in the prostate gland", "PROBLEM", 353, 378], ["infected human prostate cancer cell lines", "PROBLEM", 395, 436], ["Sendai virus", "PROBLEM", 442, 454], ["a murine RNA virus", "PROBLEM", 471, 489], ["a robust antiviral response", "PROBLEM", 540, 567], ["IFN", "TEST", 579, 582], ["aggressive", "OBSERVATION_MODIFIER", 212, 222], ["prostate", "ANATOMY", 223, 231], ["cancer", "OBSERVATION", 232, 238], ["viral", "OBSERVATION_MODIFIER", 271, 276], ["infection", "OBSERVATION", 277, 286], ["PC3 cells", "OBSERVATION", 290, 299], ["viral pathogens", "OBSERVATION", 329, 344], ["prostate gland", "ANATOMY", 364, 378], ["prostate", "ANATOMY", 410, 418], ["cancer cell lines", "OBSERVATION", 419, 436], ["Sendai virus", "OBSERVATION", 442, 454], ["murine RNA virus", "OBSERVATION", 473, 489], ["human cell types", "OBSERVATION", 511, 527], ["robust", "OBSERVATION_MODIFIER", 542, 548], ["antiviral response", "OBSERVATION", 549, 567], ["hepatocytes", "ANATOMY", 614, 625]]], ["In SeV-infected human prostate cancer cell lines, PC3 and DU145, we observed a robust induction of the transcripts in the IFNL4 region (Supplementary Figure 1, Supplementary Table 5).", [["prostate cancer cell lines", "ANATOMY", 22, 48], ["PC3", "ANATOMY", 50, 53], ["DU145", "ANATOMY", 58, 63], ["IFNL4 region", "ANATOMY", 122, 134], ["prostate cancer", "DISEASE", 22, 37], ["SeV", "ORGANISM", 3, 6], ["human", "ORGANISM", 16, 21], ["prostate cancer cell lines", "CELL", 22, 48], ["PC3", "CELL", 50, 53], ["DU145", "CELL", 58, 63], ["SeV-infected human prostate cancer cell lines", "CELL_LINE", 3, 48], ["PC3", "CELL_LINE", 50, 53], ["DU145", "CELL_LINE", 58, 63], ["IFNL4 region", "DNA", 122, 134], ["human", "SPECIES", 16, 21], ["human", "SPECIES", 16, 21], ["SeV-infected human prostate cancer cell lines", "TREATMENT", 3, 48], ["PC3", "PROBLEM", 50, 53], ["DU145", "TREATMENT", 58, 63], ["the transcripts in the IFNL4 region", "TREATMENT", 99, 134], ["SeV", "OBSERVATION_MODIFIER", 3, 6], ["infected", "OBSERVATION_MODIFIER", 7, 15], ["human prostate", "ANATOMY", 16, 30], ["cancer cell lines", "OBSERVATION", 31, 48]]], ["Of note, mRNA induction is not allele-specific and can be detected in cells with the TT/TT genotype, although expression is generally lower with the TT/TT genotype due to nonsense-mediated decay of prematurely terminated out-of-frame transcripts16.", [["cells", "ANATOMY", 70, 75], ["cells", "CELL", 70, 75], ["mRNA induction", "TEST", 9, 23], ["the TT/TT genotype", "TEST", 81, 99], ["the TT/TT genotype", "TREATMENT", 145, 163], ["nonsense-mediated decay", "PROBLEM", 171, 194]]], ["However, IFN-\u03bb4 protein can be produced only in the presence of the \u0394G allele.", [["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 9, 15], ["\u0394G", "GENE_OR_GENE_PRODUCT", 68, 70], ["IFN", "PROTEIN", 9, 12], ["\u03bb4 protein", "PROTEIN", 13, 23], ["\u0394G allele", "DNA", 68, 77], ["IFN", "TEST", 9, 12]]], ["Indeed, our Western blot analysis showed that IFN-\u03bb4 was strongly induced in the SeV-infected PC3 cells that have the \u0394G/\u0394G genotype but not in DU145 cells that have the TT/TT genotype (Fig. 2, Supplementary Figure 2).DiscussionAs a key finding, our study revealed a gene\u2013environment interaction in prostate cancer etiology between increased exposure to STI due to sexual activity and a germline genetic variant, IFNL4-\u0394G, that regulates the innate immune response to infections in epithelial cells.", [["PC3 cells", "ANATOMY", 94, 103], ["DU145 cells", "ANATOMY", 144, 155], ["prostate cancer", "ANATOMY", 299, 314], ["epithelial cells", "ANATOMY", 482, 498], ["prostate cancer", "DISEASE", 299, 314], ["STI", "DISEASE", 354, 357], ["infections", "DISEASE", 468, 478], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 46, 52], ["SeV", "ORGANISM", 81, 84], ["PC3 cells", "CELL", 94, 103], ["DU145 cells", "CELL", 144, 155], ["prostate cancer", "CANCER", 299, 314], ["IFNL4-\u0394G", "GENE_OR_GENE_PRODUCT", 413, 421], ["epithelial cells", "CELL", 482, 498], ["IFN", "PROTEIN", 46, 49], ["\u03bb4", "PROTEIN", 50, 52], ["SeV-infected PC3 cells", "CELL_LINE", 81, 103], ["DU145 cells", "CELL_LINE", 144, 155], ["IFNL4", "PROTEIN", 413, 418], ["\u0394G", "DNA", 419, 421], ["epithelial cells", "CELL_TYPE", 482, 498], ["our Western blot analysis", "TEST", 8, 33], ["IFN", "TEST", 46, 49], ["infected PC3 cells", "PROBLEM", 85, 103], ["the \u0394G/\u0394G genotype", "PROBLEM", 114, 132], ["DU145 cells", "PROBLEM", 144, 155], ["the TT/TT genotype (Fig", "PROBLEM", 166, 189], ["our study", "TEST", 246, 255], ["a gene\u2013environment interaction", "PROBLEM", 265, 295], ["prostate cancer", "PROBLEM", 299, 314], ["increased exposure", "PROBLEM", 332, 350], ["STI", "PROBLEM", 354, 357], ["sexual activity", "PROBLEM", 365, 380], ["a germline genetic variant", "PROBLEM", 385, 411], ["IFNL4-\u0394G", "PROBLEM", 413, 421], ["infections in epithelial cells", "PROBLEM", 468, 498], ["infected PC3 cells", "OBSERVATION", 85, 103], ["prostate", "ANATOMY", 299, 307], ["cancer", "OBSERVATION", 308, 314], ["germline genetic variant", "OBSERVATION", 387, 411], ["epithelial cells", "OBSERVATION", 482, 498]]], ["Our observations were consistent across age group and IFNL4 genotype strata.", [["Our observations", "TEST", 0, 16]]], ["Furthermore, the odds of developing prostate cancer, particularly of an aggressive type, increased with the number of sexual partners in men carrying the IFNL4-\u0394G allele.", [["prostate cancer", "ANATOMY", 36, 51], ["prostate cancer", "DISEASE", 36, 51], ["prostate cancer", "CANCER", 36, 51], ["men", "ORGANISM", 137, 140], ["IFNL4", "GENE_OR_GENE_PRODUCT", 154, 159], ["\u0394G", "GENE_OR_GENE_PRODUCT", 160, 162], ["IFNL4-\u0394G allele", "DNA", 154, 169], ["men", "SPECIES", 137, 140], ["developing prostate cancer", "PROBLEM", 25, 51], ["prostate", "ANATOMY", 36, 44], ["cancer", "OBSERVATION", 45, 51], ["aggressive", "OBSERVATION_MODIFIER", 72, 82], ["increased", "OBSERVATION_MODIFIER", 89, 98]]], ["As AA are more likely than EA men to carry the \u0394G allele, the effect was more pronounced in the former population.", [["AA", "CHEMICAL", 3, 5], ["men", "ORGANISM", 30, 33], ["\u0394G", "GENE_OR_GENE_PRODUCT", 47, 49], ["\u0394G allele", "DNA", 47, 56], ["men", "SPECIES", 30, 33], ["more pronounced", "OBSERVATION_MODIFIER", 73, 88]]], ["The identification of this novel gene\u2013environment interaction suggests an association between a yet unidentified infectious agent and prostate cancer risk in men with IFNL4-\u0394G.", [["prostate cancer", "ANATOMY", 134, 149], ["prostate cancer", "DISEASE", 134, 149], ["prostate cancer", "CANCER", 134, 149], ["men", "ORGANISM", 158, 161], ["IFNL4", "GENE_OR_GENE_PRODUCT", 167, 172], ["IFNL4", "PROTEIN", 167, 172], ["men", "SPECIES", 158, 161], ["a yet unidentified infectious agent", "PROBLEM", 94, 129], ["prostate cancer risk", "PROBLEM", 134, 154], ["IFNL4", "TEST", 167, 172], ["infectious", "OBSERVATION", 113, 123], ["prostate", "ANATOMY", 134, 142], ["cancer", "OBSERVATION", 143, 149]]], ["Efforts are warranted to identify this etiologic agent.DiscussionSince the first documented implication of STI as a possible etiologic agent for prostate cancer in the early 1950s27, multiple epidemiologic studies have subsequently explored this relationship.", [["prostate cancer", "ANATOMY", 145, 160], ["prostate cancer", "DISEASE", 145, 160], ["prostate cancer", "CANCER", 145, 160], ["STI", "PROBLEM", 107, 110], ["prostate cancer", "PROBLEM", 145, 160], ["multiple epidemiologic studies", "TEST", 183, 213], ["prostate", "ANATOMY", 145, 153], ["cancer", "OBSERVATION", 154, 160]]], ["Yet, epidemiologic evidence for the association of STI with prostate cancer is still not firmly established.", [["prostate cancer", "ANATOMY", 60, 75], ["STI", "DISEASE", 51, 54], ["prostate cancer", "DISEASE", 60, 75], ["prostate cancer", "CANCER", 60, 75], ["STI", "PROBLEM", 51, 54], ["prostate cancer", "PROBLEM", 60, 75], ["prostate", "ANATOMY", 60, 68], ["cancer", "OBSERVATION", 69, 75]]], ["Multiple studies with self-reported exposure to any STI or to the most common, symptomatic STI (i.e. gonorrhea) have reported a positive association4,6,8,9,11,14,28\u201331, resembling the epidemiologic literature for cervical cancer before the discovery of HPV as the etiologic agent.", [["cervical cancer", "ANATOMY", 213, 228], ["STI", "DISEASE", 91, 94], ["gonorrhea", "DISEASE", 101, 110], ["cervical cancer", "DISEASE", 213, 228], ["cervical cancer", "CANCER", 213, 228], ["HPV", "ORGANISM", 253, 256], ["HPV", "SPECIES", 253, 256], ["Multiple studies", "TEST", 0, 16], ["any STI", "PROBLEM", 48, 55], ["symptomatic STI", "PROBLEM", 79, 94], ["gonorrhea", "PROBLEM", 101, 110], ["cervical cancer", "PROBLEM", 213, 228], ["HPV", "PROBLEM", 253, 256], ["cervical", "ANATOMY", 213, 221], ["cancer", "OBSERVATION", 222, 228]]], ["In our study, we observed that self-reported exposure to gonorrhea increased the odds of diagnosis with prostate cancer by about 30% (Supplementary Table 6), which is in concordance with the 200532 and the 201533 meta-analysis data that reported a 35% and 31% increase in risk, respectively.", [["prostate cancer", "ANATOMY", 104, 119], ["gonorrhea", "DISEASE", 57, 66], ["prostate cancer", "DISEASE", 104, 119], ["prostate cancer", "CANCER", 104, 119], ["our study", "TEST", 3, 12], ["gonorrhea", "PROBLEM", 57, 66], ["prostate cancer", "PROBLEM", 104, 119], ["meta-analysis data", "TEST", 213, 231], ["gonorrhea", "OBSERVATION", 57, 66], ["prostate", "ANATOMY", 104, 112], ["cancer", "OBSERVATION", 113, 119], ["increase", "OBSERVATION_MODIFIER", 260, 268]]], ["The search for prostate cancer etiologic agents also encompassed sero-epidemiologic evaluations of the association between prostate cancer risk and infection with human herpesvirus 8, herpes simplex type 2, HPV, Chlamydia trachomatis, and Trichomonas vaginalis, but the reported findings are far from conclusive34\u201345.", [["prostate cancer", "ANATOMY", 15, 30], ["prostate cancer", "ANATOMY", 123, 138], ["prostate cancer", "DISEASE", 15, 30], ["prostate cancer", "DISEASE", 123, 138], ["infection", "DISEASE", 148, 157], ["herpes simplex type 2", "DISEASE", 184, 205], ["Chlamydia trachomatis", "DISEASE", 212, 233], ["Trichomonas vaginalis", "DISEASE", 239, 260], ["prostate cancer", "CANCER", 15, 30], ["prostate cancer", "CANCER", 123, 138], ["human herpesvirus 8", "ORGANISM", 163, 182], ["herpes simplex type 2", "ORGANISM", 184, 205], ["HPV", "ORGANISM", 207, 210], ["Chlamydia trachomatis", "ORGANISM", 212, 233], ["Trichomonas vaginalis", "ORGANISM", 239, 260], ["human", "SPECIES", 163, 168], ["herpes simplex", "SPECIES", 184, 198], ["Chlamydia trachomatis", "SPECIES", 212, 233], ["Trichomonas vaginalis", "SPECIES", 239, 260], ["human herpesvirus 8", "SPECIES", 163, 182], ["HPV", "SPECIES", 207, 210], ["Chlamydia trachomatis", "SPECIES", 212, 233], ["Trichomonas vaginalis", "SPECIES", 239, 260], ["prostate cancer", "PROBLEM", 15, 30], ["sero-epidemiologic evaluations", "TEST", 65, 95], ["prostate cancer risk", "PROBLEM", 123, 143], ["infection", "PROBLEM", 148, 157], ["human herpesvirus", "PROBLEM", 163, 180], ["herpes simplex type 2", "PROBLEM", 184, 205], ["HPV", "PROBLEM", 207, 210], ["Chlamydia trachomatis", "PROBLEM", 212, 233], ["Trichomonas vaginalis", "PROBLEM", 239, 260], ["prostate", "ANATOMY", 15, 23], ["cancer", "OBSERVATION", 24, 30], ["prostate", "ANATOMY", 123, 131], ["cancer", "OBSERVATION", 132, 138], ["infection", "OBSERVATION", 148, 157], ["Chlamydia trachomatis", "OBSERVATION", 212, 233], ["Trichomonas vaginalis", "OBSERVATION", 239, 260]]], ["Although our observations of a gene\u2013environment interaction related to a STI do not implicate a specific STI, they suggest that exposure to some sexually transmitted etiologic agent(s) may lead to prostate cancer, but only in genetically susceptible individuals.DiscussionIn our NCI-Maryland case-control study, we observed that men who had multiple sexual partners, and hence may have had an increased likelihood of exposures to STI during early adulthood, had higher odds of diagnosis with aggressive prostate cancer later in life.", [["prostate cancer", "ANATOMY", 197, 212], ["prostate cancer", "ANATOMY", 503, 518], ["prostate cancer", "DISEASE", 197, 212], ["STI", "DISEASE", 430, 433], ["prostate cancer", "DISEASE", 503, 518], ["prostate cancer", "CANCER", 197, 212], ["men", "ORGANISM", 329, 332], ["prostate cancer", "CANCER", 503, 518], ["men", "SPECIES", 329, 332], ["a gene\u2013environment interaction", "PROBLEM", 29, 59], ["a STI", "PROBLEM", 71, 76], ["a specific STI", "PROBLEM", 94, 108], ["prostate cancer", "PROBLEM", 197, 212], ["aggressive prostate cancer", "PROBLEM", 492, 518], ["prostate", "ANATOMY", 197, 205], ["cancer", "OBSERVATION", 206, 212], ["aggressive", "OBSERVATION_MODIFIER", 492, 502], ["prostate", "ANATOMY", 503, 511], ["cancer", "OBSERVATION", 512, 518]]], ["Consistent with the increased prevalence of the \u0394G allele among individuals of African ancestry, this association was stronger in AA than EA men.", [["AA", "CHEMICAL", 130, 132], ["\u0394G", "GENE_OR_GENE_PRODUCT", 48, 50], ["men", "ORGANISM", 141, 144], ["\u0394G allele", "DNA", 48, 57], ["men", "SPECIES", 141, 144], ["increased", "OBSERVATION_MODIFIER", 20, 29]]], ["In vitro infection of prostate cancer cell lines with SeV, a model for a wide range of RNA viruses, showed induction of IFN-\u03bb4 in a cell line homozygote for the \u0394G allele (PC3) but not in a cell line without this allele (DU145), supporting the hypothesis for a viral origin of IFN-\u03bb4 expression in prostate tissue.", [["prostate cancer cell lines", "ANATOMY", 22, 48], ["cell line", "ANATOMY", 132, 141], ["PC3", "ANATOMY", 172, 175], ["cell line", "ANATOMY", 190, 199], ["DU145", "ANATOMY", 221, 226], ["prostate tissue", "ANATOMY", 298, 313], ["infection", "DISEASE", 9, 18], ["prostate cancer", "DISEASE", 22, 37], ["prostate cancer cell lines", "CELL", 22, 48], ["SeV", "ORGANISM", 54, 57], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 120, 126], ["cell line", "CELL", 132, 141], ["\u0394G", "GENE_OR_GENE_PRODUCT", 161, 163], ["PC3", "CELL", 172, 175], ["cell line", "CELL", 190, 199], ["DU145", "CELL", 221, 226], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 277, 283], ["prostate tissue", "TISSUE", 298, 313], ["prostate cancer cell lines", "CELL_LINE", 22, 48], ["IFN", "PROTEIN", 120, 123], ["\u03bb4", "PROTEIN", 124, 126], ["cell line homozygote", "CELL_LINE", 132, 152], ["\u0394G allele", "DNA", 161, 170], ["PC3", "CELL_LINE", 172, 175], ["allele", "DNA", 213, 219], ["DU145", "CELL_LINE", 221, 226], ["IFN", "PROTEIN", 277, 280], ["\u03bb4", "PROTEIN", 281, 283], ["prostate cancer", "PROBLEM", 22, 37], ["cell lines", "TREATMENT", 38, 48], ["a wide range of RNA viruses", "PROBLEM", 71, 98], ["IFN", "TEST", 120, 123], ["a cell line homozygote", "TREATMENT", 130, 152], ["the \u0394G allele (PC3", "PROBLEM", 157, 175], ["a cell line", "TREATMENT", 188, 199], ["the hypothesis", "PROBLEM", 240, 254], ["IFN", "PROBLEM", 277, 280], ["expression in prostate tissue", "PROBLEM", 284, 313], ["infection", "OBSERVATION", 9, 18], ["prostate", "ANATOMY", 22, 30], ["cancer cell lines", "OBSERVATION", 31, 48], ["RNA viruses", "OBSERVATION", 87, 98], ["cell line", "OBSERVATION", 190, 199], ["viral origin", "OBSERVATION_MODIFIER", 261, 273], ["prostate tissue", "ANATOMY", 298, 313]]], ["Until now, a detectable induction of endogenous IFN-\u03bb4 protein was only shown for hepatic cells16,17.", [["hepatic cells", "ANATOMY", 82, 95], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 48, 54], ["hepatic cells", "CELL", 82, 95], ["IFN", "PROTEIN", 48, 51], ["\u03bb4 protein", "PROTEIN", 52, 62], ["hepatic cells", "CELL_TYPE", 82, 95], ["endogenous IFN", "TEST", 37, 51], ["hepatic cells", "PROBLEM", 82, 95], ["hepatic", "ANATOMY", 82, 89]]], ["Once induced, IFN-\u03bb4 protein may enhance negative regulation of IFN signaling, leading to impaired viral clearance and a distinct tumor biology in carriers of IFNL4-\u0394G allele, as previously reported16,17,25.", [["tumor", "ANATOMY", 130, 135], ["impaired viral clearance", "DISEASE", 90, 114], ["tumor", "DISEASE", 130, 135], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 14, 20], ["IFN", "GENE_OR_GENE_PRODUCT", 64, 67], ["tumor", "CANCER", 130, 135], ["IFNL4", "GENE_OR_GENE_PRODUCT", 159, 164], ["\u0394G", "GENE_OR_GENE_PRODUCT", 165, 167], ["IFN", "PROTEIN", 14, 17], ["\u03bb4 protein", "PROTEIN", 18, 28], ["IFN", "PROTEIN", 64, 67], ["IFNL4-\u0394G allele", "DNA", 159, 174], ["IFN", "TEST", 14, 17], ["IFN signaling", "PROBLEM", 64, 77], ["impaired viral clearance", "PROBLEM", 90, 114], ["distinct", "OBSERVATION_MODIFIER", 121, 129], ["tumor", "OBSERVATION", 130, 135]]], ["An impaired IFN signaling may also affect innate immune response to non-viral pathogens.DiscussionIFNL4-\u0394G is more common in individuals of African ancestry (up to 78%), compared with those of European ancestry (~30%)16, and we observed a comparable distribution in our case-control study, with 61.7% and 33.7% IFNL4-\u0394G allele frequencies among AA and EA men, respectively (Supplementary Table 3).", [["IFN", "GENE_OR_GENE_PRODUCT", 12, 15], ["IFNL4-\u0394G", "GENE_OR_GENE_PRODUCT", 311, 319], ["men", "ORGANISM", 355, 358], ["IFN", "PROTEIN", 12, 15], ["DiscussionIFNL4", "PROTEIN", 88, 103], ["\u0394G", "DNA", 104, 106], ["men", "SPECIES", 355, 358], ["An impaired IFN signaling", "PROBLEM", 0, 25], ["non-viral pathogens", "PROBLEM", 68, 87], ["European ancestry", "TEST", 193, 210], ["control study", "TEST", 275, 288], ["IFNL4", "TEST", 311, 316], ["impaired", "OBSERVATION", 3, 11], ["more common", "OBSERVATION_MODIFIER", 110, 121]]], ["This is in line with the health disparity in prostate cancer that manifests as a more aggressive and deadly disease in AA compared to other racial groups.", [["prostate cancer", "ANATOMY", 45, 60], ["prostate cancer", "DISEASE", 45, 60], ["AA", "CHEMICAL", 119, 121], ["prostate cancer", "CANCER", 45, 60], ["prostate cancer", "PROBLEM", 45, 60], ["a more aggressive and deadly disease in AA", "PROBLEM", 79, 121], ["line", "OBSERVATION_MODIFIER", 11, 15], ["prostate", "ANATOMY", 45, 53], ["cancer", "OBSERVATION", 54, 60]]], ["Moreover, the findings of this study are also consistent with our previous work where we observed a distinct interferon signature that was more prevalent in tumors from AA than EA men25,46.", [["tumors", "ANATOMY", 157, 163], ["tumors", "DISEASE", 157, 163], ["tumors", "CANCER", 157, 163], ["interferon", "PROTEIN", 109, 119], ["this study", "TEST", 26, 36], ["a distinct interferon signature", "PROBLEM", 98, 129], ["tumors", "PROBLEM", 157, 163], ["consistent with", "UNCERTAINTY", 46, 61], ["distinct", "OBSERVATION_MODIFIER", 100, 108], ["interferon", "OBSERVATION", 109, 119], ["tumors", "OBSERVATION", 157, 163]]], ["A role of the interferon-inducible system in the pathogenesis of an aggressive form of prostate cancer is further suggested by germline mutations in RNASEL, a gene involved in the interferon antiviral pathway, that were found to predispose men to familial prostate cancer2,47.DiscussionCarriers of the IFNL4-\u0394G allele who had multiple sexual partners during early adulthood had about a 3-fold increase in their odds of being diagnosed with an aggressive prostate cancer later in life.", [["prostate cancer", "ANATOMY", 87, 102], ["prostate cancer", "ANATOMY", 256, 271], ["prostate cancer", "ANATOMY", 454, 469], ["prostate cancer", "DISEASE", 87, 102], ["prostate cancer", "DISEASE", 256, 271], ["prostate cancer", "DISEASE", 454, 469], ["interferon", "GENE_OR_GENE_PRODUCT", 14, 24], ["prostate cancer", "CANCER", 87, 102], ["RNASEL", "GENE_OR_GENE_PRODUCT", 149, 155], ["interferon", "GENE_OR_GENE_PRODUCT", 180, 190], ["men", "ORGANISM", 240, 243], ["prostate cancer", "CANCER", 256, 271], ["IFNL4", "GENE_OR_GENE_PRODUCT", 302, 307], ["\u0394G", "GENE_OR_GENE_PRODUCT", 308, 310], ["prostate cancer", "CANCER", 454, 469], ["interferon", "PROTEIN", 14, 24], ["RNASEL", "DNA", 149, 155], ["interferon", "PROTEIN", 180, 190], ["IFNL4-\u0394G allele", "DNA", 302, 317], ["men", "SPECIES", 240, 243], ["the interferon-inducible system", "TREATMENT", 10, 41], ["prostate cancer", "PROBLEM", 87, 102], ["germline mutations", "PROBLEM", 127, 145], ["the interferon antiviral pathway", "TREATMENT", 176, 208], ["familial prostate cancer", "PROBLEM", 247, 271], ["an aggressive prostate cancer", "PROBLEM", 440, 469], ["interferon", "OBSERVATION", 14, 24], ["aggressive", "OBSERVATION_MODIFIER", 68, 78], ["prostate", "ANATOMY", 87, 95], ["cancer", "OBSERVATION", 96, 102], ["prostate", "ANATOMY", 256, 264], ["cancer", "OBSERVATION", 265, 271], ["aggressive", "OBSERVATION_MODIFIER", 443, 453], ["prostate", "ANATOMY", 454, 462], ["cancer", "OBSERVATION", 463, 469]]], ["On the contrary, men with the IFNL4-TT variant did not bear a similar STI-associated prostate cancer risk even if they had as many partners.", [["prostate cancer", "ANATOMY", 85, 100], ["prostate cancer", "DISEASE", 85, 100], ["men", "ORGANISM", 17, 20], ["IFNL4", "GENE_OR_GENE_PRODUCT", 30, 35], ["prostate cancer", "CANCER", 85, 100], ["IFNL4", "PROTEIN", 30, 35], ["men", "SPECIES", 17, 20], ["prostate cancer risk", "PROBLEM", 85, 105], ["prostate", "ANATOMY", 85, 93], ["cancer", "OBSERVATION", 94, 100]]], ["However, IFNL4-\u0394G may not predispose to prostate cancer in the context of all STI.", [["prostate cancer", "ANATOMY", 40, 55], ["prostate cancer", "DISEASE", 40, 55], ["STI", "DISEASE", 78, 81], ["IFNL4-\u0394G", "GENE_OR_GENE_PRODUCT", 9, 17], ["prostate cancer", "CANCER", 40, 55], ["IFNL4", "PROTEIN", 9, 14], ["\u0394G", "PROTEIN", 15, 17], ["prostate cancer", "PROBLEM", 40, 55], ["all STI", "PROBLEM", 74, 81], ["prostate", "ANATOMY", 40, 48], ["cancer", "OBSERVATION", 49, 55]]], ["For example, it has been shown that a herpesvirus infection and its latency confer protection from bacterial infections48.", [["herpesvirus infection", "DISEASE", 38, 59], ["bacterial infections", "DISEASE", 99, 119], ["herpesvirus", "ORGANISM", 38, 49], ["a herpesvirus infection", "PROBLEM", 36, 59], ["bacterial infections", "PROBLEM", 99, 119], ["herpesvirus", "OBSERVATION_MODIFIER", 38, 49], ["infection", "OBSERVATION", 50, 59], ["bacterial", "OBSERVATION_MODIFIER", 99, 108], ["infections", "OBSERVATION", 109, 119]]], ["Thus, chronic viral infection in carriers of IFNL4-\u0394G may lead to a decreased risk for a bacterial infection.", [["viral infection", "DISEASE", 14, 29], ["bacterial infection", "DISEASE", 89, 108], ["IFNL4-\u0394G", "GENE_OR_GENE_PRODUCT", 45, 53], ["IFNL4", "PROTEIN", 45, 50], ["chronic viral infection", "PROBLEM", 6, 29], ["IFNL4-\u0394G", "PROBLEM", 45, 53], ["a bacterial infection", "PROBLEM", 87, 108], ["chronic", "OBSERVATION_MODIFIER", 6, 13], ["viral", "OBSERVATION_MODIFIER", 14, 19], ["infection", "OBSERVATION", 20, 29], ["bacterial", "OBSERVATION_MODIFIER", 89, 98], ["infection", "OBSERVATION", 99, 108]]], ["Accordingly, we found that the association of gonorrhea with prostate cancer was stronger for IFNL4-TT/TT than IFNL4-\u0394G carriers (Supplementary Table 6), arguing that the overall unfavorable association of IFNL4-\u0394G with prostate cancer, as shown in our study, is more likely related to an infectious agent of viral origin.", [["prostate cancer", "ANATOMY", 61, 76], ["prostate cancer", "ANATOMY", 220, 235], ["gonorrhea", "DISEASE", 46, 55], ["prostate cancer", "DISEASE", 61, 76], ["prostate cancer", "DISEASE", 220, 235], ["prostate cancer", "CANCER", 61, 76], ["IFNL4", "GENE_OR_GENE_PRODUCT", 94, 99], ["IFNL4-\u0394G", "GENE_OR_GENE_PRODUCT", 111, 119], ["IFNL4-\u0394G", "GENE_OR_GENE_PRODUCT", 206, 214], ["prostate cancer", "CANCER", 220, 235], ["IFNL4", "PROTEIN", 94, 99], ["IFNL4", "PROTEIN", 206, 211], ["gonorrhea", "PROBLEM", 46, 55], ["prostate cancer", "PROBLEM", 61, 76], ["IFNL4", "TEST", 94, 99], ["prostate cancer", "PROBLEM", 220, 235], ["our study", "TEST", 249, 258], ["gonorrhea", "OBSERVATION", 46, 55], ["prostate", "ANATOMY", 61, 69], ["cancer", "OBSERVATION", 70, 76], ["prostate", "ANATOMY", 220, 228], ["cancer", "OBSERVATION", 229, 235], ["more likely related to", "UNCERTAINTY", 263, 285], ["infectious", "OBSERVATION", 289, 299], ["viral origin", "OBSERVATION", 309, 321]]], ["Additional studies are needed to identify this microbial agent.DiscussionOur study has several limitations that should be considered.", [["Additional studies", "TEST", 0, 18], ["this microbial agent", "TREATMENT", 42, 62], ["DiscussionOur study", "TEST", 63, 82]]], ["Our study should not be affected by interviewer bias since sexual history information was acquired through a self-administered questionnaire filled in privacy.", [["Our study", "TEST", 0, 9]]], ["In our view, it is unlikely that the general population is aware of the infectious hypothesis in the context of prostate cancer, arguing against a recall bias.", [["prostate cancer", "ANATOMY", 112, 127], ["prostate cancer", "DISEASE", 112, 127], ["prostate cancer", "CANCER", 112, 127], ["the infectious hypothesis", "PROBLEM", 68, 93], ["prostate cancer", "PROBLEM", 112, 127], ["is unlikely", "UNCERTAINTY", 16, 27], ["infectious", "OBSERVATION", 72, 82], ["prostate", "ANATOMY", 112, 120], ["cancer", "OBSERVATION", 121, 127]]], ["Additionally, the fact that the self-reported number of sexual partners could be used to infer exposure to gonorrhea in both cases and controls in a similar manner suggests that the case-control status did not influence self-reported sexual history (Supplementary Table 2).", [["gonorrhea", "DISEASE", 107, 116], ["gonorrhea", "PROBLEM", 107, 116]]], ["Likewise, the fact that we observed STI-associated prostate cancer risks exclusively in men with at least one copy of the \u0394G allele, whereas not in men with the TT/TT genotype, albeit both groups having reported multiple sexual partners, makes it rather unlikely that a recall bias contributed to these findings.", [["prostate cancer", "ANATOMY", 51, 66], ["prostate cancer", "DISEASE", 51, 66], ["prostate cancer", "CANCER", 51, 66], ["men", "ORGANISM", 88, 91], ["\u0394G", "GENE_OR_GENE_PRODUCT", 122, 124], ["men", "ORGANISM", 148, 151], ["\u0394G allele", "DNA", 122, 131], ["men", "SPECIES", 88, 91], ["men", "SPECIES", 148, 151], ["STI-associated prostate cancer", "PROBLEM", 36, 66], ["the TT/TT genotype", "TREATMENT", 157, 175], ["prostate", "ANATOMY", 51, 59], ["cancer", "OBSERVATION", 60, 66]]], ["As we report an association of IFNL4-\u0394G with disease risk in the context of sexual activity, there could only be confounding/bias in this observation if the men knew their IFNL4 genotype, which they certainly did not, and then reported sexual activity biased by this knowledge.", [["IFNL4", "GENE_OR_GENE_PRODUCT", 31, 36], ["men", "ORGANISM", 157, 160], ["IFNL4", "GENE_OR_GENE_PRODUCT", 172, 177], ["IFNL4", "PROTEIN", 31, 36], ["men", "SPECIES", 157, 160], ["disease risk", "PROBLEM", 45, 57]]], ["To further buttress the validity of our observations, we also found a significant relationship between a gonorrhea infection history and prostate cancer in a very consistent manner with recent meta-analyses32,33.", [["prostate cancer", "ANATOMY", 137, 152], ["gonorrhea infection", "DISEASE", 105, 124], ["prostate cancer", "DISEASE", 137, 152], ["prostate cancer", "CANCER", 137, 152], ["a gonorrhea infection history", "PROBLEM", 103, 132], ["prostate cancer", "PROBLEM", 137, 152], ["recent meta-analyses", "TEST", 186, 206], ["gonorrhea", "OBSERVATION_MODIFIER", 105, 114], ["infection", "OBSERVATION", 115, 124], ["prostate", "ANATOMY", 137, 145], ["cancer", "OBSERVATION", 146, 152]]], ["Our study population is rather unique having AA subjects, an in-depth survey about sexual activity, and germline DNA for genotyping, making it difficult to replicate our findings without the requirement for additional recruitment.", [["DNA", "CELLULAR_COMPONENT", 113, 116], ["germline DNA", "DNA", 104, 116], ["Our study", "TEST", 0, 9], ["germline DNA", "PROBLEM", 104, 116], ["additional recruitment", "TREATMENT", 207, 229]]], ["Nevertheless, the fact that we observed a dose response relationship that fits a biologically plausible mechanism suggests that the associations we observed warrant further investigations, including prospective cohorts.DiscussionIn conclusion, an increased likelihood of exposure to STI among men with genetically impaired clearance of viral infections was found to be positively associated with the risk of prostate cancer.", [["prostate cancer", "ANATOMY", 408, 423], ["STI", "DISEASE", 283, 286], ["viral infections", "DISEASE", 336, 352], ["prostate cancer", "DISEASE", 408, 423], ["men", "ORGANISM", 293, 296], ["prostate cancer", "CANCER", 408, 423], ["men", "SPECIES", 293, 296], ["further investigations", "TEST", 165, 187], ["prospective cohorts", "TREATMENT", 199, 218], ["STI", "PROBLEM", 283, 286], ["viral infections", "PROBLEM", 336, 352], ["prostate cancer", "PROBLEM", 408, 423], ["viral infections", "OBSERVATION", 336, 352], ["prostate", "ANATOMY", 408, 416], ["cancer", "OBSERVATION", 417, 423]]], ["Although our findings do not implicate a specific STI, they strongly argue for an infection as an etiologic agent for prostate cancer in a substantial subset of patients.", [["prostate cancer", "ANATOMY", 118, 133], ["infection", "DISEASE", 82, 91], ["prostate cancer", "DISEASE", 118, 133], ["prostate cancer", "CANCER", 118, 133], ["patients", "ORGANISM", 161, 169], ["patients", "SPECIES", 161, 169], ["a specific STI", "PROBLEM", 39, 53], ["an infection", "PROBLEM", 79, 91], ["prostate cancer", "PROBLEM", 118, 133], ["infection", "OBSERVATION", 82, 91], ["prostate", "ANATOMY", 118, 126], ["cancer", "OBSERVATION", 127, 133]]], ["Whether the observed association is due to carcinogenic effects of a putative etiologic infectious agent or rather due to the host\u2019s response to the infectious agent needs to be examined in future work.", [["a putative etiologic infectious agent", "PROBLEM", 67, 104], ["the infectious agent", "PROBLEM", 145, 165], ["infectious", "OBSERVATION", 149, 159]]], ["Our data suggest that the etiology of prostate cancer may vary in population groups due to the ancestry-related genetic variation in resolution or progression of an infection following exposure.", [["prostate cancer", "ANATOMY", 38, 53], ["prostate cancer", "DISEASE", 38, 53], ["infection", "DISEASE", 165, 174], ["prostate cancer", "CANCER", 38, 53], ["Our data", "TEST", 0, 8], ["prostate cancer", "PROBLEM", 38, 53], ["an infection", "PROBLEM", 162, 174], ["prostate", "ANATOMY", 38, 46], ["cancer", "OBSERVATION", 47, 53], ["resolution", "OBSERVATION_MODIFIER", 133, 143], ["progression", "OBSERVATION_MODIFIER", 147, 158], ["infection", "OBSERVATION", 165, 174]]], ["The proposed synergistic mechanism of prostate cancer pathophysiology is relevant for all populations but could disproportionally affect men of African ancestry.", [["prostate cancer", "ANATOMY", 38, 53], ["prostate cancer", "DISEASE", 38, 53], ["prostate cancer", "CANCER", 38, 53], ["men", "ORGANISM", 137, 140], ["men", "SPECIES", 137, 140], ["prostate cancer", "PROBLEM", 38, 53], ["synergistic", "OBSERVATION_MODIFIER", 13, 24], ["prostate", "ANATOMY", 38, 46], ["cancer", "OBSERVATION", 47, 53]]], ["As such, these findings may shed light on the prostate cancer health disparity.NCI-Maryland prostate cancer case-control study ::: MethodsThis case-control study has been previously described26.", [["prostate cancer", "ANATOMY", 46, 61], ["prostate cancer", "ANATOMY", 92, 107], ["prostate cancer", "DISEASE", 46, 61], ["prostate cancer", "DISEASE", 92, 107], ["prostate cancer", "CANCER", 46, 61], ["NCI-Maryland prostate cancer", "CANCER", 79, 107], ["the prostate cancer health disparity", "PROBLEM", 42, 78], ["Methods", "TREATMENT", 131, 138], ["This case-control study", "TEST", 138, 161], ["prostate", "ANATOMY", 46, 54], ["cancer", "OBSERVATION", 55, 61], ["prostate", "ANATOMY", 92, 100], ["cancer", "OBSERVATION", 101, 107]]], ["The study was initiated to test the primary hypothesis that environmental exposures and ancestry-related factors contribute to the excessive prostate cancer burden among AA men.", [["prostate cancer", "ANATOMY", 141, 156], ["prostate cancer", "DISEASE", 141, 156], ["prostate cancer", "CANCER", 141, 156], ["men", "ORGANISM", 173, 176], ["men", "SPECIES", 173, 176], ["The study", "TEST", 0, 9], ["the excessive prostate cancer burden", "PROBLEM", 127, 163], ["excessive", "OBSERVATION_MODIFIER", 131, 140], ["prostate", "ANATOMY", 141, 149], ["cancer", "OBSERVATION", 150, 156]]], ["All study forms and procedures were approved by the NCI (protocol # 05-C-N021) and the University of Maryland (protocol #0298229) Institutional Review Boards.", [["All study", "TEST", 0, 9]]], ["Cases were recruited at the Baltimore Veterans Affairs Medical Center and the University of Maryland Medical Center.NCI-Maryland prostate cancer case-control study ::: MethodsEligibility criteria included the following: diagnosis with prostate cancer within two years prior to enrollment, residence in Maryland or adjacent counties in Pennsylvania, Delaware, Virginia, or District of Columbia, 40 to 90 years old at the time of enrollment, born in the United States, either African-American (AA) or European-American (EA) by self-report, can be interviewed in English, had a working home phone number, physically and mentally fit to be interviewed, not severely ill, and not residing in an institution such as prison, nursing home, or shelter.", [["prostate cancer", "ANATOMY", 129, 144], ["prostate cancer", "ANATOMY", 235, 250], ["prostate cancer", "DISEASE", 129, 144], ["prostate cancer", "DISEASE", 235, 250], ["NCI-Maryland prostate cancer", "CANCER", 116, 144], ["prostate cancer", "CANCER", 235, 250], ["prostate cancer", "PROBLEM", 235, 250], ["prostate", "ANATOMY", 129, 137], ["cancer", "OBSERVATION", 138, 144], ["prostate", "ANATOMY", 235, 243], ["cancer", "OBSERVATION", 244, 250]]], ["A total of 976 cases (489 AA and 487 EA men) were recruited into the study between 2005 and 2015.NCI-Maryland prostate cancer case-control study ::: MethodsControls were identified through the Maryland Department of Motor Vehicle Administration database and were frequency-matched to cases on age and race.", [["prostate cancer", "ANATOMY", 110, 125], ["prostate cancer", "DISEASE", 110, 125], ["men", "ORGANISM", 40, 43], ["NCI-Maryland prostate cancer", "CANCER", 97, 125], ["men", "SPECIES", 40, 43], ["AA", "TEST", 26, 28], ["the study", "TEST", 65, 74], ["MethodsControls", "TREATMENT", 149, 164], ["prostate", "ANATOMY", 110, 118], ["cancer", "OBSERVATION", 119, 125]]], ["The controls also had the same eligibility criteria as cases with the exception that they could not have a personal history of cancer (other than non-melanoma skin cancer), radiation therapy, or chemotherapy.", [["cancer", "ANATOMY", 127, 133], ["non-melanoma skin cancer", "ANATOMY", 146, 170], ["cancer", "DISEASE", 127, 133], ["non-melanoma skin cancer", "DISEASE", 146, 170], ["cancer", "CANCER", 127, 133], ["non-melanoma skin cancer", "CANCER", 146, 170], ["cancer", "PROBLEM", 127, 133], ["non-melanoma skin cancer", "PROBLEM", 146, 170], ["radiation therapy", "TREATMENT", 173, 190], ["chemotherapy", "TREATMENT", 195, 207], ["cancer", "OBSERVATION", 127, 133], ["skin", "ANATOMY", 159, 163], ["cancer", "OBSERVATION", 164, 170]]], ["A total of 1034 population controls were recruited (486 AA and 548 EA men).", [["men", "ORGANISM", 70, 73], ["men", "SPECIES", 70, 73]]], ["At the time of enrollment, both cases and controls were administered a survey by a trained interviewer and a blood sample or mouthwash rinse/buccal cells was collected.", [["blood sample", "ANATOMY", 109, 121], ["buccal cells", "ANATOMY", 141, 153], ["blood", "ORGANISM_SUBSTANCE", 109, 114], ["buccal cells", "CELL", 141, 153], ["buccal cells", "CELL_TYPE", 141, 153], ["a blood sample", "TEST", 107, 121], ["mouthwash rinse", "TREATMENT", 125, 140], ["buccal cells", "PROBLEM", 141, 153], ["buccal cells", "ANATOMY", 141, 153]]], ["The survey asked about their demographics, tobacco use, nutrition, medical history, family history of cancer, prostatitis, or benign prostatic hypertrophy, occupational history, socioeconomic status, anthropometry, and sexual history.", [["cancer", "ANATOMY", 102, 108], ["benign prostatic", "ANATOMY", 126, 142], ["cancer", "DISEASE", 102, 108], ["prostatitis", "DISEASE", 110, 121], ["prostatic hypertrophy", "DISEASE", 133, 154], ["tobacco", "ORGANISM", 43, 50], ["cancer", "CANCER", 102, 108], ["prostatic", "ORGAN", 133, 142], ["tobacco", "SPECIES", 43, 50], ["cancer", "PROBLEM", 102, 108], ["prostatitis", "PROBLEM", 110, 121], ["benign prostatic hypertrophy", "PROBLEM", 126, 154], ["cancer", "OBSERVATION", 102, 108], ["prostatitis", "OBSERVATION", 110, 121], ["benign", "OBSERVATION_MODIFIER", 126, 132], ["prostatic", "ANATOMY", 133, 142], ["hypertrophy", "OBSERVATION", 143, 154]]], ["The participants were given 20 min of privacy to complete the sexual history section of the survey.Assessment of sexual history ::: MethodsThe sexual history section of the survey assessed the participants\u2019 number of sexual partners using the following questions: (1) Throughout your life, what is the total number of partners with whom you have had sexual intercourse\u2014fewer than 5, 5 to 9, 10 to 19, 20 to 30, 40 or more; (2) when you were (in your teens, in your 20s, in your 30s, in your 40s, in your 50s, in your 60s, or in your 70s) with how many different partners did you have intercourse\u20140, 1, 2, 3\u20134, 5\u20139, 10\u201319, 20\u201339, 40 or more.", [["participants", "ORGANISM", 4, 16], ["participants", "SPECIES", 4, 16], ["participants", "SPECIES", 193, 205], ["Methods", "TREATMENT", 132, 139]]], ["More than 90% of the participants (92%, 97%, 97%, and 99% of the cases and 94%, 97%, 97%, and 98% of the controls) reported the number of sexual partners they had in their teens, 20s, 30s, and throughout their life, respectively; the remainder either declined to answer or provided incomplete information (Supplementary Table 1).", [["participants", "ORGANISM", 21, 33], ["participants", "SPECIES", 21, 33]]], ["Similarly, for the number of sexual partners that the men had during their different age decades (teens, 20s, 30s, 40s, 50s, 60s, 70s), we collapsed the categories to three groups: a reference group (0\u20131 sexual partners) with presumed no or low chance of contracting a STI, a medium risk group (2\u20139 sexual partners) with intermediate likelihood of contracting a STI, and a higher risk group (10 or more sexual partners) with the highest likelihood of contracting a STI.", [["STI", "DISEASE", 269, 272], ["STI", "DISEASE", 362, 365], ["STI", "DISEASE", 465, 468], ["men", "ORGANISM", 54, 57], ["men", "SPECIES", 54, 57], ["a STI", "PROBLEM", 360, 365]]], ["The sexual history section also asked about the history of condom use using the following question: do you usually use condoms (rubbers)\u2014no, yes.Assessment of history of sexually transmitted disease ::: MethodsThe medical history section of the questionnaire asked about the participants\u2019 history of two sexually transmitted diseases using the following questions: (1) Did a doctor ever tell you that you had gonorrhea\u2014no, yes; (2) Did a doctor ever tell you that you had syphilis\u2014no, yes; if the participants answered \u201cyes\u201d to either of the two questions, they were asked the follow-up questions: \u201cHow old were you when you were first diagnosed?\u201d and \u201cHow many times altogether have you had the disease?\u201d", [["sexually transmitted disease", "DISEASE", 170, 198], ["sexually transmitted diseases", "DISEASE", 304, 333], ["participants", "SPECIES", 275, 287], ["participants", "SPECIES", 497, 509], ["Methods", "TREATMENT", 203, 210], ["the disease", "PROBLEM", 692, 703]]], ["History of syphilis infection was not analyzed in detail because it was reported by only few participants (31 cases and 26 controls).", [["syphilis infection", "DISEASE", 11, 29], ["participants", "SPECIES", 93, 105], ["syphilis infection", "PROBLEM", 11, 29], ["syphilis", "OBSERVATION_MODIFIER", 11, 19], ["infection", "OBSERVATION", 20, 29]]], ["Infection with gonorrhea was more common (226 cases and 172 controls) and this information was used for analysis.Prostate cancer classification ::: MethodsGleason grading system was used to classify prostate tumors into low-grade (Gleason score \u2264 7) or high-grade (Gleason score > 7).", [["Prostate cancer", "ANATOMY", 113, 128], ["prostate tumors", "ANATOMY", 199, 214], ["gonorrhea", "DISEASE", 15, 24], ["Prostate cancer", "DISEASE", 113, 128], ["prostate tumors", "DISEASE", 199, 214], ["Prostate cancer", "CANCER", 113, 128], ["prostate tumors", "CANCER", 199, 214], ["low-grade", "CANCER", 220, 229], ["high-grade", "CANCER", 253, 263], ["Infection", "PROBLEM", 0, 9], ["gonorrhea", "PROBLEM", 15, 24], ["analysis", "TEST", 104, 112], ["Prostate cancer", "PROBLEM", 113, 128], ["prostate tumors", "PROBLEM", 199, 214], ["Gleason score", "TEST", 231, 244], ["Gleason score", "TEST", 265, 278], ["gonorrhea", "OBSERVATION", 15, 24], ["cancer", "OBSERVATION", 122, 128], ["prostate", "ANATOMY", 199, 207], ["tumors", "OBSERVATION", 208, 214], ["low-grade", "OBSERVATION_MODIFIER", 220, 229]]], ["Tumor stage at diagnosis was obtained from medical records, stage 1 or 2 was defined as localized and stage 3 or 4 as advanced disease.", [["Tumor", "ANATOMY", 0, 5], ["Tumor", "CANCER", 0, 5], ["Tumor stage", "PROBLEM", 0, 11], ["stage 3 or 4 as advanced disease", "PROBLEM", 102, 134], ["stage 3", "OBSERVATION_MODIFIER", 102, 109]]], ["Cases with a combination of low-grade tumors and localized disease were defined as nonaggressive prostate cancer, while cases with either high-grade tumors or advanced disease were defined as aggressive prostate cancer.Genotyping of IFNL4 rs368234815 ::: MethodsGenomic DNA was isolated from buffy coats, when available, and from cell lines using the DNeasy Blood & Tissue Kit (Qiagen).", [["low-grade tumors", "ANATOMY", 28, 44], ["prostate cancer", "ANATOMY", 97, 112], ["high-grade tumors", "ANATOMY", 138, 155], ["prostate cancer", "ANATOMY", 203, 218], ["buffy coats", "ANATOMY", 292, 303], ["cell lines", "ANATOMY", 330, 340], ["low-grade tumors", "DISEASE", 28, 44], ["prostate cancer", "DISEASE", 97, 112], ["tumors", "DISEASE", 149, 155], ["prostate cancer", "DISEASE", 203, 218], ["low-grade tumors", "CANCER", 28, 44], ["prostate cancer", "CANCER", 97, 112], ["high-grade tumors", "CANCER", 138, 155], ["prostate cancer", "CANCER", 203, 218], ["IFNL4", "GENE_OR_GENE_PRODUCT", 233, 238], ["DNA", "CELLULAR_COMPONENT", 270, 273], ["buffy coats", "ORGANISM_SUBSTANCE", 292, 303], ["cell lines", "CELL", 330, 340], ["Tissue Kit", "ORGANISM_SUBSTANCE", 366, 376], ["Qiagen", "ORGANISM_SUBSTANCE", 378, 384], ["IFNL4 rs368234815", "DNA", 233, 250], ["MethodsGenomic DNA", "DNA", 255, 273], ["cell lines", "CELL_LINE", 330, 340], ["low-grade tumors", "PROBLEM", 28, 44], ["localized disease", "PROBLEM", 49, 66], ["nonaggressive prostate cancer", "PROBLEM", 83, 112], ["high-grade tumors", "PROBLEM", 138, 155], ["advanced disease", "PROBLEM", 159, 175], ["aggressive prostate cancer", "PROBLEM", 192, 218], ["MethodsGenomic DNA", "PROBLEM", 255, 273], ["buffy coats", "TREATMENT", 292, 303], ["cell lines", "TREATMENT", 330, 340], ["the DNeasy Blood & Tissue Kit (Qiagen)", "TREATMENT", 347, 385], ["tumors", "OBSERVATION", 38, 44], ["localized", "OBSERVATION_MODIFIER", 49, 58], ["disease", "OBSERVATION", 59, 66], ["nonaggressive", "OBSERVATION_MODIFIER", 83, 96], ["prostate", "ANATOMY", 97, 105], ["cancer", "OBSERVATION", 106, 112], ["tumors", "OBSERVATION", 149, 155], ["advanced", "OBSERVATION_MODIFIER", 159, 167], ["disease", "OBSERVATION", 168, 175], ["aggressive", "OBSERVATION_MODIFIER", 192, 202], ["prostate", "ANATOMY", 203, 211], ["cancer", "OBSERVATION", 212, 218], ["buffy coats", "OBSERVATION", 292, 303], ["cell lines", "OBSERVATION", 330, 340]]], ["For a subset of men (100 cases and 112 controls), genomic DNA was obtained from a mouthwash sample using the Gentra Puregene Buccal Cell Kit (Qiagen).", [["sample", "ANATOMY", 92, 98], ["men", "ORGANISM", 16, 19], ["DNA", "CELLULAR_COMPONENT", 58, 61], ["genomic DNA", "DNA", 50, 61], ["men", "SPECIES", 16, 19], ["genomic DNA", "PROBLEM", 50, 61], ["a mouthwash sample", "TREATMENT", 80, 98], ["the Gentra Puregene Buccal Cell Kit", "TREATMENT", 105, 140]]], ["In total, genomic DNA was available for 828 cases (84.8% of study participants) and 953 controls (92.2%).", [["DNA", "CELLULAR_COMPONENT", 18, 21], ["genomic DNA", "DNA", 10, 21], ["participants", "SPECIES", 66, 78], ["genomic DNA", "TEST", 10, 21]]], ["Genotyping of rs368234815 was done as previously described16 with a custom-designed assay purchased from Thermo Fisher.", [["rs368234815", "GENE_OR_GENE_PRODUCT", 14, 25], ["rs368234815", "DNA", 14, 25], ["Genotyping", "TEST", 0, 10]]], ["The genotyping was performed using ABI 7900 (Applied Biosystems) according to the standard protocol.", [["ABI 7900", "CHEMICAL", 35, 43], ["The genotyping", "TEST", 0, 14], ["ABI", "TEST", 35, 38]]], ["Genotype concordance among duplicates was 97%.", [["Genotype concordance", "TEST", 0, 20]]], ["There was no deviation from the Hardy\u2013Weinberg equilibrium in controls.", [["deviation", "PROBLEM", 13, 22], ["no", "UNCERTAINTY", 10, 12], ["deviation", "OBSERVATION", 13, 22]]], ["Genotyping success rate was 98.6%.", [["Genotyping success rate", "TEST", 0, 23]]], ["The genotyping failure rate was similar (1.4%) for DNA extracted from blood and mouthwash samples.", [["blood", "ANATOMY", 70, 75], ["samples", "ANATOMY", 90, 97], ["DNA", "CELLULAR_COMPONENT", 51, 54], ["blood", "ORGANISM_SUBSTANCE", 70, 75], ["mouthwash samples", "ORGANISM_SUBSTANCE", 80, 97], ["The genotyping failure rate", "TEST", 0, 27], ["DNA", "PROBLEM", 51, 54], ["blood and mouthwash samples", "TEST", 70, 97]]], ["The genotype along with the clinical information for the 976 cases and 1034 controls is presented in Supplementary Data 1.SeV infection and expression analysis ::: MethodsHuman prostate cancer cell lines, PC3 (IFNL4 rs368234815-\u0394G/\u0394G genotype) and DU145 (TT/TT genotype), were obtained from the American Type Culture Collection (Manassas, VA); the cells have been regularly authenticated using a short tandem repeat analysis with GenePrint10 and tested for Mycoplasma contamination.", [["MethodsHuman prostate cancer cell lines", "ANATOMY", 164, 203], ["PC3", "ANATOMY", 205, 208], ["DU145", "ANATOMY", 248, 253], ["cells", "ANATOMY", 348, 353], ["SeV infection", "DISEASE", 122, 135], ["prostate cancer", "DISEASE", 177, 192], ["Mycoplasma contamination", "DISEASE", 457, 481], ["SeV", "ORGANISM", 122, 125], ["MethodsHuman prostate cancer cell lines", "CELL", 164, 203], ["PC3", "CELL", 205, 208], ["IFNL4 rs368234815", "CELL", 210, 227], ["DU145", "CELL", 248, 253], ["cells", "CELL", 348, 353], ["Mycoplasma", "ORGANISM", 457, 467], ["MethodsHuman prostate cancer cell lines", "CELL_LINE", 164, 203], ["PC3", "CELL_LINE", 205, 208], ["DU145", "CELL_LINE", 248, 253], ["SeV", "SPECIES", 122, 125], ["SeV infection", "PROBLEM", 122, 135], ["MethodsHuman prostate cancer", "PROBLEM", 164, 192], ["cell lines", "TEST", 193, 203], ["PC3", "TEST", 205, 208], ["IFNL4", "TEST", 210, 215], ["\u0394G", "TEST", 228, 230], ["genotype", "TEST", 234, 242], ["DU145 (TT/TT genotype", "TREATMENT", 248, 269], ["a short tandem repeat analysis", "TEST", 394, 424], ["GenePrint10", "TREATMENT", 430, 441], ["Mycoplasma contamination", "PROBLEM", 457, 481], ["infection", "OBSERVATION", 126, 135], ["prostate", "ANATOMY", 177, 185], ["cancer", "OBSERVATION", 186, 192], ["cell lines", "OBSERVATION", 193, 203]]], ["Both cell lines are not commonly misidentified per the register of misidentified cell lines curated by ICLAC (International Cell Line Authentication Committee).", [["cell lines", "ANATOMY", 5, 15], ["cell lines", "ANATOMY", 81, 91], ["cell lines", "CELL", 5, 15], ["cell lines", "CELL", 81, 91], ["cell lines", "CELL_LINE", 5, 15], ["misidentified cell lines", "CELL_LINE", 67, 91], ["cell lines", "OBSERVATION", 5, 15], ["misidentified cell lines", "OBSERVATION", 67, 91], ["Cell Line", "OBSERVATION", 124, 133]]], ["PC3 cells were cultured in F-12K Medium (ATCC, Manassas, VA) with 10% FBS, and DU145 were cultured in Eagle\u2019s Minimum Essential Medium (ATCC) with 10% FBS.", [["PC3 cells", "ANATOMY", 0, 9], ["Manassas", "ANATOMY", 47, 55], ["FBS", "ANATOMY", 70, 73], ["DU145", "ANATOMY", 79, 84], ["FBS", "ANATOMY", 151, 154], ["DU145", "CHEMICAL", 79, 84], ["PC3 cells", "CELL", 0, 9], ["F-12K Medium", "CELL", 27, 39], ["ATCC", "CELL", 41, 45], ["FBS", "ORGANISM_SUBSTANCE", 70, 73], ["DU145", "CELL", 79, 84], ["FBS", "ORGANISM_SUBSTANCE", 151, 154], ["PC3 cells", "CELL_LINE", 0, 9], ["DU145", "CELL_LINE", 79, 84], ["PC3 cells", "TEST", 0, 9], ["ATCC", "TEST", 41, 45], ["10% FBS", "TEST", 66, 73], ["10% FBS", "TREATMENT", 147, 154]]], ["SeV infection was done as described17.", [["SeV infection", "DISEASE", 0, 13], ["SeV", "ORGANISM", 0, 3], ["SeV", "SPECIES", 0, 3], ["SeV infection", "PROBLEM", 0, 13], ["infection", "OBSERVATION", 4, 13]]], ["For IFN-\u03bb4 protein expression analysis, the cells were seeded overnight at a density of 0.3 \u00d7 106 cells in six-well plates and infected in triplicates with SeV Cantell strain (Charles River Laboratories) or mock (control) for 24 h, harvested, lysed with 100 \u00b5l of RIPA (Sigma) supplemented with protease inhibitor (Promega) and pulse sonicated for 30s, with 10s burst-cooling cycles, at 4 \u00b0C. Lysates were centrifuged at 10,000 \u00d7 g for 5 min, supernatant was boiled in reducing sample buffer for 5 min at 100 \u00b0C, resolved on 4\u201312% Bis-Tris Bolt gels, and transferred using an iBlot 2 (Thermo Fisher).", [["cells", "ANATOMY", 44, 49], ["cells", "ANATOMY", 98, 103], ["Lysates", "ANATOMY", 393, 400], ["supernatant", "ANATOMY", 443, 454], ["Bis-Tris", "CHEMICAL", 531, 539], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 4, 10], ["cells", "CELL", 44, 49], ["cells", "CELL", 98, 103], ["SeV", "ORGANISM", 156, 159], ["Charles River Laboratories", "ORGANISM", 176, 202], ["Lysates", "ORGANISM_SUBSTANCE", 393, 400], ["Bis-Tris Bolt gels", "SIMPLE_CHEMICAL", 531, 549], ["IFN", "PROTEIN", 4, 7], ["\u03bb4", "PROTEIN", 8, 10], ["IFN", "TEST", 4, 7], ["protein expression analysis", "TEST", 11, 38], ["the cells", "PROBLEM", 40, 49], ["RIPA (Sigma)", "TREATMENT", 264, 276], ["protease inhibitor", "TREATMENT", 295, 313], ["10s burst-cooling cycles", "TREATMENT", 358, 382], ["Lysates", "TEST", 393, 400], ["4\u201312% Bis-Tris Bolt gels", "TREATMENT", 525, 549], ["infected", "OBSERVATION", 127, 135]]], ["The blot was blocked with 2% milk for 1 h and then incubated with rabbit anti-IFN-\u03bb4 (1:500, ab196984; Abcam) and developed with secondary HRP-linked goat anti-rabbit antibody (1:5000, #7074; Cell Signaling Technology) and SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Fisher).", [["milk", "ANATOMY", 29, 33], ["milk", "ORGANISM_SUBSTANCE", 29, 33], ["rabbit", "ORGANISM", 66, 72], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 78, 84], ["Abcam", "GENE_OR_GENE_PRODUCT", 103, 108], ["HRP", "SIMPLE_CHEMICAL", 139, 142], ["goat", "ORGANISM", 150, 154], ["Cell", "CELL", 192, 196], ["IFN", "PROTEIN", 78, 81], ["\u03bb4", "PROTEIN", 82, 84], ["1:500, ab196984; Abcam", "PROTEIN", 86, 108], ["secondary HRP", "PROTEIN", 129, 142], ["goat anti-rabbit antibody", "PROTEIN", 150, 175], ["rabbit", "SPECIES", 66, 72], ["goat", "SPECIES", 150, 154], ["anti-rabbit", "SPECIES", 155, 166], ["rabbit", "SPECIES", 66, 72], ["goat", "SPECIES", 150, 154], ["2% milk", "TREATMENT", 26, 33], ["rabbit anti-IFN", "TREATMENT", 66, 81], ["secondary HRP", "PROBLEM", 129, 142], ["goat anti-rabbit antibody", "TEST", 150, 175]]], ["For gene expression, cells were infected with SeV, as described above, but for 10 h.", [["cells", "ANATOMY", 21, 26], ["cells", "CELL", 21, 26], ["SeV", "ORGANISM", 46, 49], ["SeV", "SPECIES", 46, 49], ["gene expression", "PROBLEM", 4, 19], ["cells", "PROBLEM", 21, 26], ["SeV", "TREATMENT", 46, 49]]], ["Total RNA was extracted using an RNeasy Kit with on-column DNase I digestion (Qiagen). cDNA was generated from 500 ng of total RNA with the RT2 First Strand Kit (Qiagen) with an additional DNA removal step.", [["DNase I", "GENE_OR_GENE_PRODUCT", 59, 66], ["DNA", "CELLULAR_COMPONENT", 189, 192], ["DNase I", "PROTEIN", 59, 66], ["cDNA", "DNA", 87, 91], ["Total RNA", "TREATMENT", 0, 9], ["an RNeasy Kit", "TEST", 30, 43], ["column DNase I digestion", "TREATMENT", 52, 76], ["total RNA", "TREATMENT", 121, 130], ["an additional DNA removal step", "TREATMENT", 175, 205]]], ["Total RNA input was 2.5 ng per reaction.", [["Total RNA input", "TEST", 0, 15]]], ["Expression was measured in technical quadruplicates\u2014of IFNL4, ISG15, and endogenous controls, GAPDH and ACTB, using TaqMan expression assays.", [["IFNL4", "GENE_OR_GENE_PRODUCT", 55, 60], ["ISG15", "GENE_OR_GENE_PRODUCT", 62, 67], ["GAPDH", "GENE_OR_GENE_PRODUCT", 94, 99], ["ACTB", "GENE_OR_GENE_PRODUCT", 104, 108], ["IFNL4", "PROTEIN", 55, 60], ["ISG15", "PROTEIN", 62, 67], ["GAPDH", "PROTEIN", 94, 99], ["ACTB", "PROTEIN", 104, 108], ["ISG15", "TREATMENT", 62, 67], ["GAPDH and ACTB", "TREATMENT", 94, 108], ["TaqMan expression assays", "TEST", 116, 140]]], ["SeV loads were measured with a SYBR Green expression assay for SeV defective-interfering RNA, as previously described17.", [["SeV", "ORGANISM", 0, 3], ["SeV", "ORGANISM", 63, 66], ["SeV defective-interfering RNA", "RNA", 63, 92], ["SeV loads", "TEST", 0, 9], ["SeV defective-interfering RNA", "PROBLEM", 63, 92], ["interfering RNA", "OBSERVATION", 77, 92]]], ["QuantStudio 7 (Thermo Fisher) was used for the expression analysis.Statistical analysis ::: MethodsAll statistical analyses were performed using Stata/SE 14.0 statistical software package (Stata Corp).", [["QuantStudio 7 (Thermo Fisher)", "TREATMENT", 0, 29], ["the expression analysis", "TEST", 43, 66], ["Methods", "TREATMENT", 92, 99], ["All statistical analyses", "TEST", 99, 123]]], ["All statistical tests were two-sided and P < 0.05 was considered statistically significant.", [["All statistical tests", "TEST", 0, 21]]], ["We used the Bonferroni\u2019s method for multiple comparison correction based on the number of survey questions in the main analyses (n = 4) and for additional subgroups in the stratified analyses.", [["the Bonferroni\u2019s method", "TREATMENT", 8, 31]]], ["For the main analysis, we evaluated whether the sexual history variables were associated with prostate cancer and then stratified by race/ethnicity (AA vs. EA) and IFNL4 rs368234815 (\u0394G/\u0394G or \u0394G/TT vs. TT/TT) for all cases or cases with aggressive vs. nonaggressive disease.", [["prostate cancer", "ANATOMY", 94, 109], ["prostate cancer", "DISEASE", 94, 109], ["nonaggressive disease", "DISEASE", 252, 273], ["prostate cancer", "CANCER", 94, 109], ["IFNL4 rs368234815", "GENE_OR_GENE_PRODUCT", 164, 181], ["the main analysis", "TEST", 4, 21], ["prostate cancer", "PROBLEM", 94, 109], ["IFNL4", "TEST", 164, 169], ["\u0394G", "TEST", 183, 185], ["\u0394G", "TEST", 186, 188], ["\u0394G", "TEST", 192, 194], ["TT vs", "TEST", 195, 200], ["nonaggressive disease", "PROBLEM", 252, 273], ["prostate", "ANATOMY", 94, 102], ["cancer", "OBSERVATION", 103, 109], ["disease", "OBSERVATION", 266, 273]]], ["Unconditional logistic regression was used to compute the odds ratios (OR) and 95% confidence intervals (CI) to assess the association of sexual history and medical history parameters (number of sexual partners during the different age decades, total number of sexual partners, or history of gonorrhea) with prostate cancer.", [["prostate cancer", "ANATOMY", 308, 323], ["gonorrhea", "DISEASE", 292, 301], ["prostate cancer", "DISEASE", 308, 323], ["prostate cancer", "CANCER", 308, 323], ["Unconditional logistic regression", "PROBLEM", 0, 33], ["CI", "TEST", 105, 107], ["gonorrhea", "PROBLEM", 292, 301], ["prostate cancer", "PROBLEM", 308, 323], ["prostate", "ANATOMY", 308, 316], ["cancer", "OBSERVATION", 317, 323]]], ["We adjusted for potential confounding factors: body mass index at study enrollment (BMI, kg m\u22122), age at enrollment, education (high school or less, some college, college, professional school), family history of prostate cancer (first degree relatives, yes/no), smoking history (never, former, current), condom use (usually use, yes/no), aspirin use (regular user, yes/no), IFNL4 rs368234815 (\u0394G/\u0394G or \u0394G/TT vs. TT/TT), and race/ethnicity as applicable.Statistical analysis ::: MethodsTo test for a gene\u2013environment interaction between IFNL4-\u0394G and the number of sexual partners as a proxy for likelihood of exposure to STI, we examined for departure from additivity49.", [["body", "ANATOMY", 47, 51], ["prostate cancer", "ANATOMY", 212, 227], ["prostate cancer", "DISEASE", 212, 227], ["aspirin", "CHEMICAL", 338, 345], ["STI", "DISEASE", 620, 623], ["aspirin", "CHEMICAL", 338, 345], ["body", "ORGANISM_SUBDIVISION", 47, 51], ["prostate cancer", "CANCER", 212, 227], ["aspirin", "SIMPLE_CHEMICAL", 338, 345], ["IFNL4 rs368234815", "GENE_OR_GENE_PRODUCT", 374, 391], ["IFNL4", "GENE_OR_GENE_PRODUCT", 536, 541], ["TT", "PROTEIN", 405, 407], ["TT", "PROTEIN", 412, 414], ["IFNL4", "PROTEIN", 536, 541], ["\u0394G", "PROTEIN", 542, 544], ["potential confounding factors", "PROBLEM", 16, 45], ["body mass index", "PROBLEM", 47, 62], ["prostate cancer", "PROBLEM", 212, 227], ["\u0394G", "TEST", 393, 395], ["\u0394G", "TEST", 396, 398], ["\u0394G", "TEST", 402, 404], ["TT", "TEST", 405, 407], ["TT/TT", "TEST", 412, 417], ["Methods", "TREATMENT", 478, 485], ["STI", "PROBLEM", 620, 623], ["mass", "OBSERVATION", 52, 56], ["prostate", "ANATOMY", 212, 220], ["cancer", "OBSERVATION", 221, 227]]], ["We applied the multivariable model with and without the interaction term and examined significance with the likelihood ratio test.", [["the likelihood ratio test", "TEST", 104, 129]]], ["The results were adjusted for potential confounding factors listed above.", [["potential confounding factors", "PROBLEM", 30, 59]]], ["A P < 0.05 was considered as statistical evidence for effect modification.", [["effect modification", "PROBLEM", 54, 73]]]], "fb78819a380a608503588b81e1f25d3b82141b8a": [["IntroductionThe Corona Virus Disease 2019 (COVID-19) pandemic goes along with strongly increased respiratory disease mortality.", [["respiratory", "ANATOMY", 97, 108], ["Corona Virus Disease", "DISEASE", 16, 36], ["COVID-19", "CHEMICAL", 43, 51], ["respiratory disease", "DISEASE", 97, 116], ["Corona Virus", "ORGANISM", 16, 28], ["COVID-19", "ORGANISM", 43, 51], ["Corona Virus Disease 2019 (COVID-19", "SPECIES", 16, 51], ["The Corona Virus Disease", "PROBLEM", 12, 36], ["COVID", "TEST", 43, 48], ["pandemic", "PROBLEM", 53, 61], ["strongly increased respiratory disease mortality", "PROBLEM", 78, 126], ["Corona Virus", "ANATOMY", 16, 28], ["increased", "OBSERVATION_MODIFIER", 87, 96], ["respiratory disease", "OBSERVATION", 97, 116]]], ["It has been suggested that vitamin D 3 supplementation could be a potentially promising and safe approach to reduce risk of COVID-19 infections and deaths [1] .", [["vitamin D", "CHEMICAL", 27, 36], ["COVID", "DISEASE", 124, 129], ["infections", "DISEASE", 133, 143], ["deaths", "DISEASE", 148, 154], ["vitamin D 3", "CHEMICAL", 27, 38], ["vitamin D 3", "SIMPLE_CHEMICAL", 27, 38], ["vitamin D 3 supplementation", "TREATMENT", 27, 54], ["safe approach", "TREATMENT", 92, 105], ["COVID-19 infections", "PROBLEM", 124, 143]]], ["Meta-analyses of randomized clinical trials (RCTs) have shown that vitamin D 3 supplementation reduces the risk of acute respiratory tract infections [2] .", [["respiratory tract", "ANATOMY", 121, 138], ["vitamin D", "CHEMICAL", 67, 76], ["acute respiratory tract infections", "DISEASE", 115, 149], ["vitamin D 3", "CHEMICAL", 67, 78], ["vitamin D 3", "SIMPLE_CHEMICAL", 67, 78], ["tract", "ORGANISM_SUBDIVISION", 133, 138], ["randomized clinical trials (RCTs", "TREATMENT", 17, 49], ["vitamin D 3 supplementation", "TREATMENT", 67, 94], ["acute respiratory tract infections", "PROBLEM", 115, 149], ["acute", "OBSERVATION_MODIFIER", 115, 120], ["respiratory tract", "ANATOMY", 121, 138]]], ["Risk reduction with regular (daily or weekly) supplementation of physiological doses of vitamin D was especially strong (by 70%) among people with vitamin D deficiency, but significant risk reduction (by 25%) was also found among people with higher vitamin D levels.", [["vitamin D", "CHEMICAL", 88, 97], ["vitamin D", "CHEMICAL", 147, 156], ["vitamin D", "CHEMICAL", 249, 258], ["vitamin D", "CHEMICAL", 88, 97], ["vitamin D", "CHEMICAL", 147, 156], ["vitamin D", "CHEMICAL", 249, 258], ["vitamin D", "SIMPLE_CHEMICAL", 88, 97], ["people", "ORGANISM", 135, 141], ["vitamin D", "SIMPLE_CHEMICAL", 147, 156], ["people", "ORGANISM", 230, 236], ["vitamin D", "SIMPLE_CHEMICAL", 249, 258], ["people", "SPECIES", 135, 141], ["people", "SPECIES", 230, 236], ["Risk reduction", "TREATMENT", 0, 14], ["regular (daily or weekly) supplementation of physiological doses of vitamin D", "TREATMENT", 20, 97], ["vitamin D deficiency", "PROBLEM", 147, 167], ["significant risk reduction", "PROBLEM", 173, 199], ["higher vitamin D levels", "TEST", 242, 265]]], ["Meta-analyses of clinical trials have demonstrated that vitamin D 3 supplementation has the potential to also reduce cancer mortality by approximately 13% [3] .IntroductionPeople with pre-existing major diseases, such as diabetes or cancer, are at increased risk of dying from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.", [["cancer", "ANATOMY", 117, 123], ["cancer", "ANATOMY", 233, 239], ["vitamin D", "CHEMICAL", 56, 65], ["cancer", "DISEASE", 117, 123], ["major diseases", "DISEASE", 197, 211], ["diabetes or cancer", "DISEASE", 221, 239], ["acute respiratory syndrome coronavirus", "DISEASE", 284, 322], ["infections", "DISEASE", 338, 348], ["vitamin D 3", "CHEMICAL", 56, 67], ["vitamin D 3", "SIMPLE_CHEMICAL", 56, 67], ["cancer", "CANCER", 117, 123], ["People", "ORGANISM", 172, 178], ["cancer", "CANCER", 233, 239], ["SARS-CoV-2", "ORGANISM", 326, 336], ["People", "SPECIES", 172, 178], ["severe acute respiratory syndrome coronavirus", "SPECIES", 277, 322], ["SARS-CoV-2", "SPECIES", 326, 336], ["vitamin D 3 supplementation", "TREATMENT", 56, 83], ["cancer mortality", "PROBLEM", 117, 133], ["pre-existing major diseases", "PROBLEM", 184, 211], ["diabetes", "PROBLEM", 221, 229], ["cancer", "PROBLEM", 233, 239], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 277, 322], ["SARS", "PROBLEM", 326, 330], ["infections", "PROBLEM", 338, 348], ["major", "OBSERVATION_MODIFIER", 197, 202], ["diseases", "OBSERVATION", 203, 211], ["cancer", "OBSERVATION", 233, 239], ["severe", "OBSERVATION_MODIFIER", 277, 283], ["acute", "OBSERVATION_MODIFIER", 284, 289], ["respiratory syndrome", "OBSERVATION", 290, 310]]], ["At the same time, prevention of and care for these diseases have been and keep being strongly compromised by current measures to limit the COVID-19 pandemic.", [["these diseases", "PROBLEM", 45, 59], ["the COVID", "TEST", 135, 144], ["pandemic", "PROBLEM", 148, 156]]], ["We previously assessed the prevalence of vitamin D insufficiency and deficiency and their association with all-cause mortality and mortality from cardiovascular, cancer and respiratory diseases during a mean follow-up of 9.5 years in a cohort of 9548 adults aged 50-75 years from Saarland, Germany [4] [5] [6] [7] [8] .", [["cardiovascular", "ANATOMY", 146, 160], ["cancer", "ANATOMY", 162, 168], ["respiratory", "ANATOMY", 173, 184], ["vitamin D", "CHEMICAL", 41, 50], ["cardiovascular, cancer", "DISEASE", 146, 168], ["respiratory diseases", "DISEASE", 173, 193], ["vitamin D", "CHEMICAL", 41, 50], ["vitamin D", "SIMPLE_CHEMICAL", 41, 50], ["cancer", "CANCER", 162, 168], ["[4] [5] [6] [7] [8]", "SIMPLE_CHEMICAL", 298, 317], ["vitamin D insufficiency", "PROBLEM", 41, 64], ["deficiency", "PROBLEM", 69, 79], ["cardiovascular, cancer", "PROBLEM", 146, 168], ["respiratory diseases", "PROBLEM", 173, 193], ["cancer", "OBSERVATION", 162, 168], ["respiratory diseases", "OBSERVATION", 173, 193]]], ["In our previous analysis, the number of deaths from respiratory disease had still been rather small (n = 55).", [["respiratory", "ANATOMY", 52, 63], ["deaths", "DISEASE", 40, 46], ["respiratory disease", "DISEASE", 52, 71], ["respiratory disease", "PROBLEM", 52, 71], ["respiratory disease", "OBSERVATION", 52, 71], ["small", "OBSERVATION_MODIFIER", 94, 99]]], ["We aim to present considerably updated and sex-specific follow-up data of 15 years here and to calculate the proportion of respiratory disease mortality that is attributable to vitamin D insufficiency and deficiency.", [["respiratory", "ANATOMY", 123, 134], ["respiratory disease", "DISEASE", 123, 142], ["vitamin D", "CHEMICAL", 177, 186], ["vitamin D", "CHEMICAL", 177, 186], ["vitamin D", "SIMPLE_CHEMICAL", 177, 186], ["respiratory disease mortality", "PROBLEM", 123, 152], ["vitamin D insufficiency", "PROBLEM", 177, 200], ["deficiency", "PROBLEM", 205, 215], ["respiratory disease", "OBSERVATION", 123, 142]]], ["Furthermore, we discuss potential implications for prevention in the context of the ongoing COVID-19 pandemic.Study DesignThis investigation is based on the ESTHER study (German name: Epidemiologische Studie der Verh\u00fctung, Fr\u00fcherkennung und optimierten Therapie chronischer Erkrankungen in der \u00e4lteren Bev\u00f6lkerung), an ongoing statewide cohort study from Saarland, Germany, details of which have been reported elsewhere [4] [5] [6] [7] [8] [9] .", [["[4] [5] [6] [7] [8] [9]", "SIMPLE_CHEMICAL", 420, 443], ["prevention", "TREATMENT", 51, 61], ["the ongoing COVID", "TEST", 80, 97], ["pandemic", "PROBLEM", 101, 109], ["Study DesignThis investigation", "TEST", 110, 140], ["the ESTHER study", "TEST", 153, 169]]], ["Briefly, 9940 men and women, aged 50-75 years at baseline, were recruited by their general practitioners during a routine health check-up between 2000 and 2002.", [["men", "ORGANISM", 14, 17], ["women", "ORGANISM", 22, 27], ["men", "SPECIES", 14, 17], ["women", "SPECIES", 22, 27], ["a routine health check", "TEST", 112, 134]]], ["Blood samples were taken at baseline at the general practitioners' offices.", [["Blood samples", "ANATOMY", 0, 13], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["Blood samples", "TEST", 0, 13]]], ["Information on socio-demographic and lifestyle characteristics and medical history were obtained by questionnaires from participants and their general practitioners, and the distribution of those characteristics was similar to the distribution in the respective age categories in the German National Health Survey conducted in a representative sample of the German population in 1998 [9] .", [["participants", "SPECIES", 120, 132]]], ["The ESTHER study was approved by the ethics committees of the University of Heidelberg and the state medical board of Saarland, Germany.", [["The ESTHER study", "TEST", 0, 16]]], ["Written informed consent was issued by all participants.Variable AssessmentInformation on socio-demographic characteristics, lifestyle and diet were obtained by a comprehensive self-administered questionnaire from the study participants at baseline.", [["participants", "SPECIES", 43, 55], ["participants", "SPECIES", 224, 236], ["the study", "TEST", 214, 223]]], ["Skin colour, race or ethnicity were not individually recorded.", [["Skin", "ANATOMY", 0, 4], ["Skin", "ORGAN", 0, 4], ["Skin colour", "TEST", 0, 11], ["colour", "OBSERVATION_MODIFIER", 5, 11]]], ["However, we assume that close to 100% of this German cohort of adults aged 50 years and older has white skin colour since 99% gave the information that they were born in Germany (94%) or another European country (5%).", [["skin", "ANATOMY", 104, 108], ["adults", "ORGANISM", 63, 69], ["skin", "ORGAN", 104, 108], ["white skin colour", "PROBLEM", 98, 115], ["skin", "ANATOMY", 104, 108]]], ["Height and weight were assessed and documented on a standardized form by the general practitioners during the health check-up.", [["Height", "TEST", 0, 6], ["weight", "TEST", 11, 17], ["the health check", "TEST", 106, 122]]], ["Furthermore, blood and urine samples were taken during the health check-up, centrifuged, sent to the study center and stored at \u221280 \u2022 C until analysis.Variable AssessmentThe most abundant and stable vitamin D metabolite in blood samples, 25-hydroxyvitamin D (25(OH)D) levels, was measured from stored serum samples taken at recruitment.", [["blood", "ANATOMY", 13, 18], ["urine samples", "ANATOMY", 23, 36], ["blood samples", "ANATOMY", 223, 236], ["serum samples", "ANATOMY", 301, 314], ["vitamin D", "CHEMICAL", 199, 208], ["25-hydroxyvitamin D", "CHEMICAL", 238, 257], ["25(OH)D", "CHEMICAL", 259, 266], ["vitamin D", "CHEMICAL", 199, 208], ["25-hydroxyvitamin D", "CHEMICAL", 238, 257], ["25(OH)D", "CHEMICAL", 259, 266], ["blood", "ORGANISM_SUBSTANCE", 13, 18], ["urine samples", "ORGANISM_SUBSTANCE", 23, 36], ["vitamin D", "SIMPLE_CHEMICAL", 199, 208], ["blood samples", "ORGANISM_SUBSTANCE", 223, 236], ["25-hydroxyvitamin D", "SIMPLE_CHEMICAL", 238, 257], ["25(OH)D", "SIMPLE_CHEMICAL", 259, 266], ["serum samples", "ORGANISM_SUBSTANCE", 301, 314], ["blood and urine samples", "TEST", 13, 36], ["the health check", "TEST", 55, 71], ["analysis", "TEST", 142, 150], ["Variable Assessment", "TEST", 151, 170], ["vitamin D metabolite in blood samples", "TEST", 199, 236], ["hydroxyvitamin D (25(OH)D) levels", "TEST", 241, 274], ["serum samples", "TEST", 301, 314]]], ["In brief, 25(OH)D levels in women were measured with the Diasorin-Liaison analyzer (Diasorin Inc., Stillwater, OK, USA).", [["OH)D", "CHEMICAL", 13, 17], ["25(OH)D", "CHEMICAL", 10, 17], ["25(OH)D", "SIMPLE_CHEMICAL", 10, 17], ["women", "ORGANISM", 28, 33], ["women", "SPECIES", 28, 33], ["OH)D levels", "TEST", 13, 24], ["the Diasorin", "TREATMENT", 53, 65]]], ["Analyses in men were conducted in the context of a separate research project several years later (when the Diasorin measurements were no longer offered) with IDS-iSYS (Immunodiagnostic Systems GmbH, Frankfurt Main, Germany).", [["men", "ORGANISM", 12, 15], ["men", "SPECIES", 12, 15], ["the Diasorin measurements", "TEST", 103, 128]]], ["Both immunoassays were standardized retrospectively to the gold standard method liquid chromatography tandem-mass-spectrometry.Variable AssessmentDeaths until end of 2016 were identified by inquiry at the residents' registration offices and death certificates of deceased study participants were provided by local health authorities.", [["death", "DISEASE", 241, 246], ["participants", "SPECIES", 278, 290], ["Both immunoassays", "TEST", 0, 17]]], ["The leading cause of death with an ICD-10 code was available for 98.9% of deceased study participants and was coded with ICD-10 codes R98-R99 \"unknown cause of death\" for 4.4% of deceased participants.", [["death", "DISEASE", 21, 26], ["death", "DISEASE", 160, 165], ["participants", "SPECIES", 89, 101], ["participants", "SPECIES", 188, 200], ["death", "PROBLEM", 21, 26], ["an ICD", "TREATMENT", 32, 38], ["deceased study", "TEST", 74, 88], ["ICD", "TREATMENT", 121, 124], ["death", "PROBLEM", 160, 165], ["ICD", "OBSERVATION", 35, 38]]], ["These individuals were not excluded and censored at the time of death for cause-specific mortality outcomes.Statistical MethodsParticipants of the ESTHER baseline examination (n = 9940) were excluded from this investigation if no blood sample was available or 25(OH)D could not be measured (n = 368) or if they could not be followed-up for mortality (n = 24), which resulted in a total sample size of n = 9548 subjects for this analysis.Statistical MethodsWe used the Institute of Medicine's cut-offs to define adequate vitamin D status (>50 nmol/L), vitamin D insufficiency (30-50 nmol/L) and vitamin D deficiency (<30 nmol/L) [10] .", [["blood sample", "ANATOMY", 230, 242], ["death", "DISEASE", 64, 69], ["vitamin D", "CHEMICAL", 520, 529], ["vitamin D", "CHEMICAL", 551, 560], ["vitamin D", "CHEMICAL", 594, 603], ["25(OH)D", "CHEMICAL", 260, 267], ["vitamin D", "CHEMICAL", 520, 529], ["vitamin D", "CHEMICAL", 551, 560], ["vitamin D", "CHEMICAL", 594, 603], ["individuals", "ORGANISM", 6, 17], ["blood", "ORGANISM_SUBSTANCE", 230, 235], ["25(OH)D", "SIMPLE_CHEMICAL", 260, 267], ["vitamin D", "SIMPLE_CHEMICAL", 520, 529], ["vitamin D", "SIMPLE_CHEMICAL", 551, 560], ["vitamin D", "SIMPLE_CHEMICAL", 594, 603], ["the ESTHER baseline examination", "TEST", 143, 174], ["this investigation", "TEST", 205, 223], ["blood sample", "TEST", 230, 242], ["this analysis", "TEST", 423, 436], ["adequate vitamin D status", "TEST", 511, 536], ["vitamin D insufficiency", "PROBLEM", 551, 574], ["vitamin D deficiency", "PROBLEM", 594, 614], ["not excluded", "UNCERTAINTY", 23, 35]]], ["We assessed prevalence of vitamin D insufficiency and deficiency and the distribution (median, interquartile range) of 25(OH)D values in the total study population and according to age, sex, lifestyle factors and major diseases.", [["vitamin D", "CHEMICAL", 26, 35], ["vitamin D", "CHEMICAL", 26, 35], ["25(OH)D", "CHEMICAL", 119, 126], ["vitamin D", "SIMPLE_CHEMICAL", 26, 35], ["OH)D", "SIMPLE_CHEMICAL", 122, 126], ["vitamin D insufficiency", "PROBLEM", 26, 49], ["deficiency", "PROBLEM", 54, 64], ["the total study", "TEST", 137, 152], ["major diseases", "PROBLEM", 213, 227], ["vitamin D", "OBSERVATION_MODIFIER", 26, 35], ["insufficiency", "OBSERVATION", 36, 49]]], ["We provide Kaplan-Meier curves for mortality from respiratory diseases among participants with sufficient vitamin D status, vitamin D insufficiency and deficiency and conducted log-rank tests with comparison to the reference group \"sufficient vitamin D status.\"", [["respiratory", "ANATOMY", 50, 61], ["respiratory diseases", "DISEASE", 50, 70], ["vitamin D", "CHEMICAL", 106, 115], ["vitamin D", "CHEMICAL", 124, 133], ["vitamin D", "CHEMICAL", 243, 252], ["vitamin D", "CHEMICAL", 106, 115], ["vitamin D", "CHEMICAL", 124, 133], ["vitamin D", "CHEMICAL", 243, 252], ["vitamin D", "SIMPLE_CHEMICAL", 106, 115], ["vitamin D", "SIMPLE_CHEMICAL", 124, 133], ["vitamin D", "SIMPLE_CHEMICAL", 243, 252], ["participants", "SPECIES", 77, 89], ["respiratory diseases", "PROBLEM", 50, 70], ["vitamin D insufficiency", "PROBLEM", 124, 147], ["deficiency", "PROBLEM", 152, 162], ["rank tests", "TEST", 181, 191], ["respiratory diseases", "OBSERVATION", 50, 70]]], ["In addition, dose-response relationships between 25(OH)D levels and respiratory disease mortality were estimated by restricted cubic splines [11] .Statistical MethodsFurthermore, we compared all-cause, cardiovascular disease, cancer, and respiratory disease mortality between subjects with vitamin D insufficiency or deficiency and subjects with adequate 25(OH)D levels and estimated hazard ratios (HR) with 95% confidence intervals (95% CI) by multivariable Cox proportional hazards models.", [["respiratory", "ANATOMY", 68, 79], ["cardiovascular", "ANATOMY", 202, 216], ["cancer", "ANATOMY", 226, 232], ["respiratory", "ANATOMY", 238, 249], ["25(OH)D", "CHEMICAL", 49, 56], ["respiratory disease", "DISEASE", 68, 87], ["cardiovascular disease", "DISEASE", 202, 224], ["cancer", "DISEASE", 226, 232], ["respiratory disease", "DISEASE", 238, 257], ["vitamin D", "CHEMICAL", 290, 299], ["insufficiency", "DISEASE", 300, 313], ["25(OH)D", "CHEMICAL", 49, 56], ["vitamin D", "CHEMICAL", 290, 299], ["25(OH)D", "CHEMICAL", 355, 362], ["25(OH)D", "SIMPLE_CHEMICAL", 49, 56], ["cardiovascular", "ANATOMICAL_SYSTEM", 202, 216], ["cancer", "CANCER", 226, 232], ["vitamin D", "SIMPLE_CHEMICAL", 290, 299], ["25(OH)D", "SIMPLE_CHEMICAL", 355, 362], ["OH)D levels", "TEST", 52, 63], ["respiratory disease mortality", "PROBLEM", 68, 97], ["cardiovascular disease", "PROBLEM", 202, 224], ["cancer", "PROBLEM", 226, 232], ["respiratory disease mortality", "PROBLEM", 238, 267], ["vitamin D insufficiency", "PROBLEM", 290, 313], ["deficiency", "PROBLEM", 317, 327], ["OH)D levels", "TEST", 358, 369], ["estimated hazard ratios", "PROBLEM", 374, 397], ["HR", "TEST", 399, 401], ["multivariable Cox proportional hazards models", "PROBLEM", 445, 490], ["respiratory disease", "OBSERVATION", 68, 87], ["cardiovascular", "ANATOMY", 202, 216], ["disease", "OBSERVATION", 217, 224], ["cancer", "OBSERVATION", 226, 232], ["respiratory disease", "OBSERVATION", 238, 257]]], ["Missing values for covariates ranged from 0% to 5.8% (for fish consumption).", [["fish", "ORGANISM_SUBDIVISION", 58, 62], ["Missing values", "TEST", 0, 14], ["covariates", "TEST", 19, 29]]], ["Missing covariate values were imputed with multiple imputation using the Markov Chain Monte Carlo (MCMC) method with 200 burn-in iterations.", [["Missing covariate values", "PROBLEM", 0, 24], ["multiple imputation", "TREATMENT", 43, 62], ["the Markov Chain Monte Carlo (MCMC) method", "TREATMENT", 69, 111]]], ["Twenty data sets were generated.", [["Twenty data sets", "TEST", 0, 16]]], ["The imputation model consisted of all variables of the full model (modelled as used in the full model) but not the outcome data, and the imputation was carried out stratified by sex.Statistical MethodsWe used an age, sex and season adjusted model and a full model that was adjusted for potential confounders, which are listed in Table 1 .", [["The imputation model", "TEST", 0, 20], ["the imputation", "TEST", 133, 147]]], ["Additional adjustment for potential intermediates (cardiovascular disease, history of cancer, diabetes mellitus, hypertension, asthma, total serum cholesterol and serum C-reactive protein levels) did not lead to substantially different results (data not shown).", [["cardiovascular", "ANATOMY", 51, 65], ["cancer", "ANATOMY", 86, 92], ["serum", "ANATOMY", 141, 146], ["serum", "ANATOMY", 163, 168], ["cardiovascular disease", "DISEASE", 51, 73], ["cancer", "DISEASE", 86, 92], ["diabetes mellitus", "DISEASE", 94, 111], ["hypertension", "DISEASE", 113, 125], ["asthma", "DISEASE", 127, 133], ["cholesterol", "CHEMICAL", 147, 158], ["cholesterol", "CHEMICAL", 147, 158], ["cancer", "CANCER", 86, 92], ["serum", "ORGANISM_SUBSTANCE", 141, 146], ["cholesterol", "SIMPLE_CHEMICAL", 147, 158], ["serum", "ORGANISM_SUBSTANCE", 163, 168], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 169, 187], ["serum C-reactive protein", "PROTEIN", 163, 187], ["potential intermediates (cardiovascular disease", "PROBLEM", 26, 73], ["cancer", "PROBLEM", 86, 92], ["diabetes mellitus", "PROBLEM", 94, 111], ["hypertension", "PROBLEM", 113, 125], ["asthma", "PROBLEM", 127, 133], ["total serum cholesterol", "TEST", 135, 158], ["serum C", "TEST", 163, 170], ["reactive protein levels", "TEST", 171, 194], ["cancer", "OBSERVATION", 86, 92]]], ["Age and body mass index (BMI) were modelled as continuous variables and all other variables were modelled with the categories shown in Table 1 .Statistical MethodsFurthermore, sex-specific analyses were performed and statistical tests on interaction were carried out.", [["body", "ANATOMY", 8, 12], ["body", "ORGANISM_SUBDIVISION", 8, 12], ["Age and body mass index", "PROBLEM", 0, 23], ["sex-specific analyses", "TEST", 176, 197], ["statistical tests", "TEST", 217, 234], ["body", "ANATOMY", 8, 12], ["mass", "OBSERVATION", 13, 17]]], ["Finally, we estimated the population attributable fraction (PAF) of respiratory disease mortality from the prevalence of vitamin D insufficiency and deficiency and their associations with respiratory disease mortality, as derived from the full model.", [["respiratory", "ANATOMY", 188, 199], ["respiratory disease", "DISEASE", 68, 87], ["vitamin D", "CHEMICAL", 121, 130], ["respiratory disease", "DISEASE", 188, 207], ["vitamin D", "CHEMICAL", 121, 130], ["vitamin D", "SIMPLE_CHEMICAL", 121, 130], ["PAF", "PROBLEM", 60, 63], ["respiratory disease mortality", "PROBLEM", 68, 97], ["vitamin D insufficiency", "PROBLEM", 121, 144], ["deficiency", "PROBLEM", 149, 159], ["respiratory disease mortality", "PROBLEM", 188, 217], ["respiratory disease", "OBSERVATION", 68, 87], ["respiratory disease", "OBSERVATION", 188, 207]]], ["The PAF of mortality is the share of mortality in a population that is statistically attributable to a risk factor and that could be avoided by entirely eliminating that risk factor (here: vitamin D insufficiency or deficiency) [12] .Statistical MethodsAll statistical tests were two-sided, and the alpha level of significance was set to 0.05, with no adjustment for multiple testing.", [["PAF", "CHEMICAL", 4, 7], ["vitamin D", "CHEMICAL", 189, 198], ["vitamin D", "CHEMICAL", 189, 198], ["vitamin D", "SIMPLE_CHEMICAL", 189, 198], ["PAF", "PROTEIN", 4, 7], ["The PAF of mortality", "PROBLEM", 0, 20], ["a risk factor", "PROBLEM", 101, 114], ["vitamin D insufficiency", "PROBLEM", 189, 212], ["deficiency)", "PROBLEM", 216, 227], ["All statistical tests", "TEST", 253, 274], ["the alpha level", "TEST", 295, 310], ["multiple testing", "TEST", 367, 383], ["PAF", "OBSERVATION", 4, 7]]], ["All statistical analyses were conducted with the software package SAS, Version 9.4 (Cary, NC, USA).ResultsThe study population included 43.8% men, mean age was 62.ResultsThe study population included 43.8% men, mean age was 62.1 years.", [["men", "ORGANISM", 142, 145], ["men", "ORGANISM", 206, 209], ["men", "SPECIES", 142, 145], ["men", "SPECIES", 206, 209], ["All statistical analyses", "TEST", 0, 24], ["Version", "TEST", 71, 78], ["The study population", "TEST", 106, 126], ["mean age", "TEST", 147, 155], ["The study population", "TEST", 170, 190]]], ["Among the 9548 participants included in the study, 4186 (43.8%) had vitamin D insufficiency (25(OH)D levels of 30-<50 nmol/L) and 1438 (15.1%) had vitamin D deficiency (25(OH)D levels <30 nmol/L) ( Figure 1 ).", [["vitamin D", "CHEMICAL", 68, 77], ["insufficiency", "DISEASE", 78, 91], ["OH)D", "CHEMICAL", 96, 100], ["vitamin D", "CHEMICAL", 147, 156], ["OH)D", "CHEMICAL", 172, 176], ["vitamin D", "CHEMICAL", 68, 77], ["25(OH)D", "CHEMICAL", 93, 100], ["vitamin D", "CHEMICAL", 147, 156], ["25(OH)D", "CHEMICAL", 169, 176], ["vitamin D", "SIMPLE_CHEMICAL", 68, 77], ["25(OH)D", "SIMPLE_CHEMICAL", 93, 100], ["vitamin D", "SIMPLE_CHEMICAL", 147, 156], ["25(OH)D", "SIMPLE_CHEMICAL", 169, 176], ["participants", "SPECIES", 15, 27], ["the study", "TEST", 40, 49], ["vitamin D insufficiency", "PROBLEM", 68, 91], ["D levels", "TEST", 99, 107], ["vitamin D deficiency", "PROBLEM", 147, 167], ["D levels", "TEST", 175, 183]]], ["Furthermore, 13 (0.1%) had too high 25(OH)D levels >200 nmol/L. Table 1 provides a description of the characteristics of the study population at baseline as well as prevalence of vitamin D insufficiency and deficiency and median 25(OH)D levels according to those characteristics.", [["vitamin D", "CHEMICAL", 179, 188], ["25(OH)D", "CHEMICAL", 36, 43], ["vitamin D", "CHEMICAL", 179, 188], ["25(OH)D", "CHEMICAL", 229, 236], ["25(OH)D", "SIMPLE_CHEMICAL", 36, 43], ["vitamin D", "SIMPLE_CHEMICAL", 179, 188], ["25(OH)D", "SIMPLE_CHEMICAL", 229, 236], ["Furthermore", "TEST", 0, 11], ["D levels", "TEST", 42, 50], ["the study population", "TEST", 121, 141], ["vitamin D insufficiency", "PROBLEM", 179, 202], ["deficiency", "PROBLEM", 207, 217], ["median 25(OH)D levels", "TEST", 222, 243]]], ["Both vitamin D insufficiency and deficiency were more frequent among females with higher age and BMI.", [["vitamin D", "CHEMICAL", 5, 14], ["vitamin D", "CHEMICAL", 5, 14], ["vitamin D", "SIMPLE_CHEMICAL", 5, 14], ["Both vitamin D insufficiency", "PROBLEM", 0, 28], ["deficiency", "PROBLEM", 33, 43], ["BMI", "PROBLEM", 97, 100], ["vitamin D insufficiency", "OBSERVATION", 5, 28]]], ["In subjects with low physical activity and those who consumed fish less than once per week, median 25(OH)D levels were correspondingly lower.", [["low physical activity", "DISEASE", 17, 38], ["25(OH)D", "CHEMICAL", 99, 106], ["25(OH)D", "SIMPLE_CHEMICAL", 99, 106], ["median 25(OH)D levels", "TEST", 92, 113], ["lower", "OBSERVATION_MODIFIER", 135, 140]]], ["A seasonal variation with lower 25(OH)D levels in winter than in summer months was also observed.", [["OH)D", "CHEMICAL", 35, 39], ["25(OH)D", "CHEMICAL", 32, 39], ["25(OH)D", "SIMPLE_CHEMICAL", 32, 39], ["A seasonal variation", "PROBLEM", 0, 20], ["seasonal variation", "OBSERVATION", 2, 20]]], ["Moreover, 25(OH)D levels were particularly low among subjects with low education and current smokers.", [["OH)D", "CHEMICAL", 13, 17], ["25(OH)D", "CHEMICAL", 10, 17], ["25(OH)D", "SIMPLE_CHEMICAL", 10, 17], ["OH)D levels", "TEST", 13, 24]]], ["Table 1 provides a description of the characteristics of the study population at baseline as well as prevalence of vitamin D insufficiency and deficiency and median 25(OH)D levels according to those characteristics.", [["vitamin D", "CHEMICAL", 115, 124], ["vitamin D", "CHEMICAL", 115, 124], ["25(OH)D", "CHEMICAL", 165, 172], ["vitamin D", "SIMPLE_CHEMICAL", 115, 124], ["25(OH)D", "SIMPLE_CHEMICAL", 165, 172], ["the study population", "TEST", 57, 77], ["vitamin D insufficiency", "PROBLEM", 115, 138], ["deficiency", "PROBLEM", 143, 153], ["median 25(OH)D levels", "TEST", 158, 179]]], ["Both vitamin D insufficiency and deficiency were more frequent among females with higher age and BMI.", [["vitamin D", "CHEMICAL", 5, 14], ["vitamin D", "CHEMICAL", 5, 14], ["vitamin D", "SIMPLE_CHEMICAL", 5, 14], ["Both vitamin D insufficiency", "PROBLEM", 0, 28], ["deficiency", "PROBLEM", 33, 43], ["BMI", "PROBLEM", 97, 100], ["vitamin D insufficiency", "OBSERVATION", 5, 28]]], ["In subjects with low physical activity and those who consumed fish less than once per week, median 25(OH)D levels were correspondingly lower.", [["low physical activity", "DISEASE", 17, 38], ["25(OH)D", "CHEMICAL", 99, 106], ["25(OH)D", "SIMPLE_CHEMICAL", 99, 106], ["median 25(OH)D levels", "TEST", 92, 113], ["lower", "OBSERVATION_MODIFIER", 135, 140]]], ["A seasonal variation with lower 25(OH)D levels in winter than in summer months was also observed.", [["OH)D", "CHEMICAL", 35, 39], ["25(OH)D", "CHEMICAL", 32, 39], ["25(OH)D", "SIMPLE_CHEMICAL", 32, 39], ["A seasonal variation", "PROBLEM", 0, 20], ["seasonal variation", "OBSERVATION", 2, 20]]], ["Moreover, 25(OH)D levels were particularly low among subjects with low education and current smokers.", [["OH)D", "CHEMICAL", 13, 17], ["25(OH)D", "CHEMICAL", 10, 17], ["25(OH)D", "SIMPLE_CHEMICAL", 10, 17], ["OH)D levels", "TEST", 13, 24]]], ["Overall, 2363 (24.7%) study participants died during a median of 15.3 years of follow-up, of whom 815, 825 and 123 died from cardiovascular disease (CVD), cancer and respiratory disease, respectively.", [["cardiovascular", "ANATOMY", 125, 139], ["cancer", "ANATOMY", 155, 161], ["respiratory", "ANATOMY", 166, 177], ["cardiovascular disease", "DISEASE", 125, 147], ["CVD", "DISEASE", 149, 152], ["cancer", "DISEASE", 155, 161], ["respiratory disease", "DISEASE", 166, 185], ["participants", "ORGANISM", 28, 40], ["cancer", "CANCER", 155, 161], ["participants", "SPECIES", 28, 40], ["cardiovascular disease (CVD)", "PROBLEM", 125, 153], ["cancer", "PROBLEM", 155, 161], ["respiratory disease", "PROBLEM", 166, 185], ["cardiovascular", "ANATOMY", 125, 139], ["disease", "OBSERVATION", 140, 147], ["cancer", "OBSERVATION", 155, 161], ["respiratory disease", "OBSERVATION", 166, 185]]], ["Figure 2 shows the Kaplan-Meier curves for deaths from respiratory disease according to vitamin D status.", [["respiratory", "ANATOMY", 55, 66], ["deaths", "DISEASE", 43, 49], ["respiratory disease", "DISEASE", 55, 74], ["vitamin D", "CHEMICAL", 88, 97], ["vitamin D", "CHEMICAL", 88, 97], ["vitamin D", "SIMPLE_CHEMICAL", 88, 97], ["deaths", "PROBLEM", 43, 49], ["respiratory disease", "PROBLEM", 55, 74], ["vitamin D status", "TEST", 88, 104], ["respiratory disease", "OBSERVATION", 55, 74]]], ["Mortality from respiratory diseases was consistently highest among participants with vitamin D deficiency and consistently lowest among those with sufficient vitamin D levels throughout up to 16.5 years of follow-up.", [["respiratory", "ANATOMY", 15, 26], ["respiratory diseases", "DISEASE", 15, 35], ["vitamin D", "CHEMICAL", 85, 94], ["vitamin D", "CHEMICAL", 158, 167], ["vitamin D", "CHEMICAL", 85, 94], ["vitamin D", "CHEMICAL", 158, 167], ["vitamin D", "SIMPLE_CHEMICAL", 85, 94], ["vitamin D", "SIMPLE_CHEMICAL", 158, 167], ["participants", "SPECIES", 67, 79], ["respiratory diseases", "PROBLEM", 15, 35], ["vitamin D deficiency", "PROBLEM", 85, 105], ["sufficient vitamin D levels", "PROBLEM", 147, 174], ["respiratory diseases", "OBSERVATION", 15, 35]]], ["The log-rank test indicated statistically significant survival differences with respect to respiratory disease mortality between the groups with vitamin D deficiency and sufficient vitamin D (p < 0.0001), as well as for the comparison of subjects with vitamin D insufficiency and sufficient vitamin D (p = 0.023).", [["respiratory", "ANATOMY", 91, 102], ["respiratory disease", "DISEASE", 91, 110], ["vitamin D", "CHEMICAL", 145, 154], ["vitamin D", "CHEMICAL", 181, 190], ["vitamin D", "CHEMICAL", 252, 261], ["vitamin D", "CHEMICAL", 291, 300], ["vitamin D", "CHEMICAL", 145, 154], ["vitamin D", "CHEMICAL", 181, 190], ["vitamin D", "CHEMICAL", 252, 261], ["vitamin D", "CHEMICAL", 291, 300], ["vitamin D", "SIMPLE_CHEMICAL", 145, 154], ["vitamin D", "SIMPLE_CHEMICAL", 181, 190], ["vitamin D", "SIMPLE_CHEMICAL", 252, 261], ["vitamin D", "SIMPLE_CHEMICAL", 291, 300], ["The log-rank test", "TEST", 0, 17], ["significant survival differences", "PROBLEM", 42, 74], ["respiratory disease mortality", "PROBLEM", 91, 120], ["vitamin D deficiency", "TREATMENT", 145, 165], ["sufficient vitamin D", "TREATMENT", 170, 190], ["vitamin D insufficiency", "TREATMENT", 252, 275], ["sufficient vitamin D", "TREATMENT", 280, 300], ["significant", "OBSERVATION_MODIFIER", 42, 53], ["survival", "OBSERVATION", 54, 62], ["respiratory disease", "OBSERVATION", 91, 110]]], ["It is not statistically significant that 25(OH)D levels >75 nmol/L are associated with further decreasing respiratory disease mortality because the confidence interval is large and includes the null effect value of HR = 1.ResultsCurves were assessed by using restricted cubic splines with knots at 25-hydroxyvitamin D concentrations of 30, 60, 90 and 120 nmol/L, and a 25-hydroxyvitamin D concentration of 75 nmol/L was used as the reference.", [["respiratory", "ANATOMY", 106, 117], ["OH)D", "CHEMICAL", 44, 48], ["respiratory disease", "DISEASE", 106, 125], ["25-hydroxyvitamin D", "CHEMICAL", 298, 317], ["25-hydroxyvitamin D", "CHEMICAL", 369, 388], ["25(OH)D", "CHEMICAL", 41, 48], ["25-hydroxyvitamin D", "CHEMICAL", 298, 317], ["25-hydroxyvitamin D", "CHEMICAL", 369, 388], ["25(OH)D", "SIMPLE_CHEMICAL", 41, 48], ["25-hydroxyvitamin D", "SIMPLE_CHEMICAL", 298, 317], ["25-hydroxyvitamin D", "SIMPLE_CHEMICAL", 369, 388], ["OH)D levels", "TEST", 44, 55], ["further decreasing respiratory disease mortality", "PROBLEM", 87, 135], ["HR", "TEST", 215, 217], ["restricted cubic splines", "TREATMENT", 259, 283], ["knots", "TEST", 289, 294], ["hydroxyvitamin D concentrations", "TEST", 301, 332], ["a 25-hydroxyvitamin D concentration", "TREATMENT", 367, 402], ["not", "UNCERTAINTY", 6, 9], ["statistically", "OBSERVATION_MODIFIER", 10, 23], ["significant", "OBSERVATION_MODIFIER", 24, 35], ["decreasing", "OBSERVATION_MODIFIER", 95, 105], ["respiratory disease", "OBSERVATION", 106, 125], ["large", "OBSERVATION_MODIFIER", 171, 176]]], ["The Cox proportional hazards regression model was adjusted for sex, age, season of blood draw, school education, smoking, BMI, physical activity, and fish consumption.", [["blood", "ANATOMY", 83, 88], ["blood", "ORGANISM_SUBSTANCE", 83, 88], ["fish", "ORGANISM_SUBDIVISION", 150, 154], ["The Cox proportional hazards regression model", "TREATMENT", 0, 45]]], ["Table 2 shows the associations of vitamin D status with all-cause, CVD, cancer and respiratory disease mortality after adjustment for multiple potential confounders.", [["cancer", "ANATOMY", 72, 78], ["respiratory", "ANATOMY", 83, 94], ["vitamin D", "CHEMICAL", 34, 43], ["CVD", "DISEASE", 67, 70], ["cancer", "DISEASE", 72, 78], ["respiratory disease", "DISEASE", 83, 102], ["vitamin D", "CHEMICAL", 34, 43], ["vitamin D", "SIMPLE_CHEMICAL", 34, 43], ["cancer", "CANCER", 72, 78], ["vitamin D status", "TREATMENT", 34, 50], ["CVD", "PROBLEM", 67, 70], ["cancer", "PROBLEM", 72, 78], ["respiratory disease mortality", "PROBLEM", 83, 112], ["cancer", "OBSERVATION", 72, 78], ["respiratory disease", "OBSERVATION", 83, 102]]], ["Vitamin D insufficiency and Nutrients 2020, 12, 2488 6 of 11 deficiency were associated with significantly increased all-cause mortality compared to sufficient vitamin D status (full model HRs (95%CI): 1.2 (1.1-1.3) and 1.7 (1.5-1.9), respectively) ( Table 2) .", [["Vitamin D", "CHEMICAL", 0, 9], ["vitamin D", "CHEMICAL", 160, 169], ["Vitamin D", "CHEMICAL", 0, 9], ["vitamin D", "CHEMICAL", 160, 169], ["Vitamin D", "SIMPLE_CHEMICAL", 0, 9], ["vitamin D", "SIMPLE_CHEMICAL", 160, 169], ["Vitamin D insufficiency", "PROBLEM", 0, 23], ["vitamin D status", "TEST", 160, 176], ["CI", "TEST", 197, 199], ["insufficiency", "OBSERVATION", 10, 23]]], ["Vitamin D deficiency was also associated with significant increases in CVD and cancer mortality by 52% and 38%, respectively (full model results).", [["cancer", "ANATOMY", 79, 85], ["Vitamin D", "CHEMICAL", 0, 9], ["CVD", "DISEASE", 71, 74], ["cancer", "DISEASE", 79, 85], ["Vitamin D", "CHEMICAL", 0, 9], ["Vitamin D", "SIMPLE_CHEMICAL", 0, 9], ["cancer", "CANCER", 79, 85], ["Vitamin D deficiency", "PROBLEM", 0, 20], ["CVD", "PROBLEM", 71, 74], ["cancer mortality", "PROBLEM", 79, 95], ["associated with", "UNCERTAINTY", 30, 45], ["significant", "OBSERVATION_MODIFIER", 46, 57], ["increases", "OBSERVATION_MODIFIER", 58, 67], ["cancer", "OBSERVATION", 79, 85]]], ["However, vitamin D insufficiency and deficiency were particularly strongly associated with respiratory disease mortality with full model HRs of 2.1 (95%CI: 1.3-3.2) and 3.0 (95%CI: 1.8-5.2), respectively.", [["respiratory", "ANATOMY", 91, 102], ["vitamin D", "CHEMICAL", 9, 18], ["respiratory disease", "DISEASE", 91, 110], ["vitamin D", "CHEMICAL", 9, 18], ["vitamin D", "SIMPLE_CHEMICAL", 9, 18], ["vitamin D insufficiency", "PROBLEM", 9, 32], ["deficiency", "PROBLEM", 37, 47], ["respiratory disease mortality", "PROBLEM", 91, 120], ["full model HRs", "TEST", 126, 140], ["CI", "TEST", 152, 154], ["CI", "TEST", 177, 179], ["insufficiency", "OBSERVATION", 19, 32]]], ["Overall, 41% (95%CI: 20-58%]) of all deaths from respiratory diseases were statistically attributable to 25(OH)D levels <50 nmol/L. Figure 3 presents results on the adjusted dose-response relationship between 25(OH)D levels and respiratory disease mortality.", [["respiratory", "ANATOMY", 49, 60], ["respiratory", "ANATOMY", 228, 239], ["deaths", "DISEASE", 37, 43], ["respiratory diseases", "DISEASE", 49, 69], ["25(OH)D", "CHEMICAL", 209, 216], ["respiratory disease", "DISEASE", 228, 247], ["25(OH)D", "CHEMICAL", 105, 112], ["25(OH)D", "CHEMICAL", 209, 216], ["25(OH)D", "SIMPLE_CHEMICAL", 105, 112], ["25(OH)D", "SIMPLE_CHEMICAL", 209, 216], ["Overall", "TEST", 0, 7], ["CI", "TEST", 17, 19], ["all deaths", "PROBLEM", 33, 43], ["respiratory diseases", "PROBLEM", 49, 69], ["OH)D levels", "TEST", 108, 119], ["response relationship", "TEST", 179, 200], ["OH)D levels", "TEST", 212, 223], ["respiratory disease mortality", "PROBLEM", 228, 257], ["respiratory", "ANATOMY", 49, 60], ["diseases", "OBSERVATION", 61, 69], ["respiratory", "ANATOMY", 228, 239], ["disease", "OBSERVATION", 240, 247]]], ["Mortality strongly increased with decreasing 25(OH)D levels below 50 nmol/L and even more so below 30 nmol/L, i.e., in the vitamin D insufficiency and deficiency range.", [["vitamin D", "CHEMICAL", 123, 132], ["insufficiency", "DISEASE", 133, 146], ["25(OH)D", "CHEMICAL", 45, 52], ["vitamin D", "CHEMICAL", 123, 132], ["25(OH)D", "SIMPLE_CHEMICAL", 45, 52], ["vitamin D", "SIMPLE_CHEMICAL", 123, 132], ["OH)D levels", "TEST", 48, 59], ["the vitamin D insufficiency", "PROBLEM", 119, 146], ["deficiency range", "PROBLEM", 151, 167], ["increased", "OBSERVATION_MODIFIER", 19, 28], ["insufficiency", "OBSERVATION", 133, 146]]], ["It is not statistically significant that 25(OH)D levels >75 nmol/L are associated with further decreasing respiratory disease mortality because the confidence interval is large and includes the null effect value of HR = 1.", [["respiratory", "ANATOMY", 106, 117], ["OH)D", "CHEMICAL", 44, 48], ["respiratory disease", "DISEASE", 106, 125], ["25(OH)D", "CHEMICAL", 41, 48], ["25(OH)D", "SIMPLE_CHEMICAL", 41, 48], ["OH)D levels", "TEST", 44, 55], ["further decreasing respiratory disease mortality", "PROBLEM", 87, 135], ["HR", "TEST", 215, 217], ["not", "UNCERTAINTY", 6, 9], ["statistically", "OBSERVATION_MODIFIER", 10, 23], ["significant", "OBSERVATION_MODIFIER", 24, 35], ["decreasing", "OBSERVATION_MODIFIER", 95, 105], ["respiratory disease", "OBSERVATION", 106, 125], ["large", "OBSERVATION_MODIFIER", 171, 176]]], ["For all-cause, cardiovascular disease and cancer mortality, only modest, statistically non-significant differences were seen between women and men.", [["cardiovascular", "ANATOMY", 15, 29], ["cancer", "ANATOMY", 42, 48], ["cardiovascular disease", "DISEASE", 15, 37], ["cancer", "DISEASE", 42, 48], ["cancer", "CANCER", 42, 48], ["women", "ORGANISM", 133, 138], ["men", "ORGANISM", 143, 146], ["women", "SPECIES", 133, 138], ["men", "SPECIES", 143, 146], ["cardiovascular disease", "PROBLEM", 15, 37], ["cancer mortality", "PROBLEM", 42, 58], ["cardiovascular", "ANATOMY", 15, 29], ["disease", "OBSERVATION", 30, 37], ["cancer", "OBSERVATION", 42, 48]]], ["Although significant increases were seen for respiratory disease mortality in both women and men, they were much stronger among women, with 8.5 (95% CI 2.4-30.1) and 2.3 (95% CI 1.1-4.4)-fold increase of respiratory disease mortality in the case of vitamin D deficiency among women and men, respectively.", [["respiratory", "ANATOMY", 45, 56], ["respiratory", "ANATOMY", 204, 215], ["respiratory disease", "DISEASE", 45, 64], ["respiratory disease", "DISEASE", 204, 223], ["vitamin D", "CHEMICAL", 249, 258], ["vitamin D", "CHEMICAL", 249, 258], ["women", "ORGANISM", 83, 88], ["men", "ORGANISM", 93, 96], ["women", "ORGANISM", 128, 133], ["vitamin D", "SIMPLE_CHEMICAL", 249, 258], ["women", "ORGANISM", 276, 281], ["men", "ORGANISM", 286, 289], ["women", "SPECIES", 83, 88], ["men", "SPECIES", 93, 96], ["women", "SPECIES", 128, 133], ["women", "SPECIES", 276, 281], ["men", "SPECIES", 286, 289], ["respiratory disease mortality", "PROBLEM", 45, 74], ["CI", "TEST", 149, 151], ["CI", "TEST", 175, 177], ["respiratory disease mortality", "PROBLEM", 204, 233], ["vitamin D deficiency", "PROBLEM", 249, 269], ["significant", "OBSERVATION_MODIFIER", 9, 20], ["increases", "OBSERVATION_MODIFIER", 21, 30], ["respiratory disease", "OBSERVATION", 204, 223]]], ["However, the number of respiratory deaths among women was small (n = 42 overall), especially in the reference groups of those with 25(OH)D > 50 nmol/L (n = 3), which resulted in very wide confidence intervals of the estimated hazard ratios.DiscussionIn this large population-based cohort study from Saarland, Germany, the majority of participants aged 50-75 years at baseline had vitamin D insufficiency or deficiency, and these conditions were associated with increased mortality.", [["respiratory deaths", "DISEASE", 23, 41], ["vitamin D", "CHEMICAL", 380, 389], ["25(OH)D", "CHEMICAL", 131, 138], ["vitamin D", "CHEMICAL", 380, 389], ["women", "ORGANISM", 48, 53], ["25(OH)D", "SIMPLE_CHEMICAL", 131, 138], ["participants", "ORGANISM", 334, 346], ["vitamin D", "SIMPLE_CHEMICAL", 380, 389], ["women", "SPECIES", 48, 53], ["participants", "SPECIES", 334, 346], ["respiratory deaths", "PROBLEM", 23, 41], ["D", "TEST", 137, 138], ["the estimated hazard ratios", "PROBLEM", 212, 239], ["cohort study", "TEST", 281, 293], ["vitamin D insufficiency", "PROBLEM", 380, 403], ["deficiency", "PROBLEM", 407, 417], ["increased mortality", "PROBLEM", 461, 480], ["number", "OBSERVATION_MODIFIER", 13, 19], ["respiratory deaths", "OBSERVATION", 23, 41], ["small", "OBSERVATION_MODIFIER", 58, 63], ["large", "OBSERVATION_MODIFIER", 258, 263], ["insufficiency", "OBSERVATION", 390, 403]]], ["In particular, mortality from respiratory diseases was increased by 2.1-and 3.0-fold in subjects with vitamin D insufficiency or deficiency, respectively, compared to participants with sufficient vitamin D status.", [["respiratory", "ANATOMY", 30, 41], ["respiratory diseases", "DISEASE", 30, 50], ["vitamin D", "CHEMICAL", 102, 111], ["insufficiency", "DISEASE", 112, 125], ["vitamin D", "CHEMICAL", 196, 205], ["vitamin D", "CHEMICAL", 102, 111], ["vitamin D", "CHEMICAL", 196, 205], ["vitamin D", "SIMPLE_CHEMICAL", 102, 111], ["vitamin D", "SIMPLE_CHEMICAL", 196, 205], ["participants", "SPECIES", 167, 179], ["respiratory diseases", "PROBLEM", 30, 50], ["vitamin D insufficiency", "PROBLEM", 102, 125], ["deficiency", "PROBLEM", 129, 139], ["respiratory diseases", "OBSERVATION", 30, 50], ["insufficiency", "OBSERVATION", 112, 125]]], ["Significant associations with respiratory disease mortality were seen among both women and men, but they were particularly strong for women.", [["respiratory", "ANATOMY", 30, 41], ["respiratory disease", "DISEASE", 30, 49], ["women", "ORGANISM", 81, 86], ["men", "ORGANISM", 91, 94], ["women", "ORGANISM", 134, 139], ["women", "SPECIES", 81, 86], ["men", "SPECIES", 91, 94], ["women", "SPECIES", 134, 139], ["respiratory disease mortality", "PROBLEM", 30, 59], ["respiratory disease", "OBSERVATION", 30, 49]]], ["Overall, 41% of deaths from respiratory diseases were statistically attributable to vitamin D insufficiency or deficiency and could possibly be avoided by overcoming these conditions, assuming causality of the association.DiscussionThe assumption of causality of vitamin D 3 effects on mortality obviously requires most careful discussion.", [["respiratory", "ANATOMY", 28, 39], ["deaths", "DISEASE", 16, 22], ["respiratory diseases", "DISEASE", 28, 48], ["vitamin D", "CHEMICAL", 84, 93], ["insufficiency", "DISEASE", 94, 107], ["vitamin D", "CHEMICAL", 263, 272], ["vitamin D", "CHEMICAL", 84, 93], ["vitamin D 3", "CHEMICAL", 263, 274], ["vitamin D", "SIMPLE_CHEMICAL", 84, 93], ["vitamin D 3", "SIMPLE_CHEMICAL", 263, 274], ["respiratory diseases", "PROBLEM", 28, 48], ["vitamin D insufficiency", "PROBLEM", 84, 107], ["deficiency", "PROBLEM", 111, 121], ["vitamin D", "TREATMENT", 263, 272], ["respiratory diseases", "OBSERVATION", 28, 48]]], ["Although we made the best attempts to adjust potential confounding factors, we cannot exclude the possibility of residual confounding by imperfect measurement of confounding variables, such as smoking or physical activity, or omission of unknown confounders.", [["residual confounding", "PROBLEM", 113, 133], ["confounding variables", "PROBLEM", 162, 183], ["physical activity", "PROBLEM", 204, 221]]], ["As addressed in detail elsewhere [6] , interpretation of the evidence is further complicated by the fact that vitamin D deficiency could be considered both a consequence of poor health as well as a risk factor for increased vulnerability to acute disease and poor outcomes of chronic diseases among people with poor health.", [["vitamin D", "CHEMICAL", 110, 119], ["chronic diseases", "DISEASE", 276, 292], ["vitamin D", "CHEMICAL", 110, 119], ["vitamin D", "SIMPLE_CHEMICAL", 110, 119], ["people", "ORGANISM", 299, 305], ["people", "SPECIES", 299, 305], ["vitamin D deficiency", "PROBLEM", 110, 130], ["increased vulnerability", "PROBLEM", 214, 237], ["acute disease", "PROBLEM", 241, 254], ["chronic diseases", "PROBLEM", 276, 292], ["acute", "OBSERVATION_MODIFIER", 241, 246], ["disease", "OBSERVATION", 247, 254], ["chronic", "OBSERVATION_MODIFIER", 276, 283], ["diseases", "OBSERVATION", 284, 292]]], ["Our findings therefore require critical discussion in the light of additional criteria and evidence, such as biological mechanisms and plausibility, and, in particular, in the light of data from RCTs providing vitamin D 3 supplementation.DiscussionDeaths from respiratory disease are mostly deaths from lower respiratory infections [13] .", [["respiratory", "ANATOMY", 260, 271], ["respiratory", "ANATOMY", 309, 320], ["vitamin D", "CHEMICAL", 210, 219], ["respiratory disease", "DISEASE", 260, 279], ["deaths", "DISEASE", 291, 297], ["lower respiratory infections", "DISEASE", 303, 331], ["vitamin D 3", "CHEMICAL", 210, 221], ["vitamin D 3", "SIMPLE_CHEMICAL", 210, 221], ["RCTs", "TREATMENT", 195, 199], ["vitamin D 3 supplementation", "TREATMENT", 210, 237], ["respiratory disease", "PROBLEM", 260, 279], ["lower respiratory infections", "PROBLEM", 303, 331], ["respiratory disease", "OBSERVATION", 260, 279], ["lower", "ANATOMY_MODIFIER", 303, 308], ["respiratory", "ANATOMY", 309, 320], ["infections", "OBSERVATION", 321, 331]]], ["Vitamin D 3 is thought to protect from occurrence and poor outcomes of respiratory infections by several mechanisms, including enhanced physical barriers (maintenance of junction integrity), cellular innate immunity, and adaptive immunity [1] .DiscussionInnate and adaptive immunity are being influenced by sex hormones [14] , which may explain the observed interaction of sex and 25(OH)D levels with respiratory disease mortality.", [["respiratory", "ANATOMY", 71, 82], ["junction", "ANATOMY", 170, 178], ["cellular", "ANATOMY", 191, 199], ["respiratory", "ANATOMY", 401, 412], ["Vitamin D", "CHEMICAL", 0, 9], ["respiratory infections", "DISEASE", 71, 93], ["OH)D", "CHEMICAL", 384, 388], ["respiratory disease", "DISEASE", 401, 420], ["Vitamin D 3", "CHEMICAL", 0, 11], ["25(OH)D", "CHEMICAL", 381, 388], ["Vitamin D 3", "GENE_OR_GENE_PRODUCT", 0, 11], ["cellular", "CELL", 191, 199], ["25(OH)D", "SIMPLE_CHEMICAL", 381, 388], ["Vitamin D", "TREATMENT", 0, 9], ["respiratory infections", "PROBLEM", 71, 93], ["enhanced physical barriers", "TREATMENT", 127, 153], ["respiratory disease mortality", "PROBLEM", 401, 430], ["respiratory infections", "OBSERVATION", 71, 93], ["respiratory", "ANATOMY", 401, 412], ["disease", "OBSERVATION", 413, 420]]], ["According to data from the US-American National Health and Nutrition Survey, women have a higher inflammation burden than men (the age range was 40-90+ years [15] ).", [["inflammation", "DISEASE", 97, 109], ["women", "ORGANISM", 77, 82], ["men", "ORGANISM", 122, 125], ["women", "SPECIES", 77, 82], ["men", "SPECIES", 122, 125], ["a higher inflammation burden", "PROBLEM", 88, 116], ["higher", "OBSERVATION_MODIFIER", 90, 96], ["inflammation", "OBSERVATION", 97, 109]]], ["Especially postmenopausal women, like those included in the ESTHER study, have a high inflammatory burden because a decline in estrogen levels during menopause is associated with an increased expression of pro-inflammatory cytokines, including interleukin 6 and tumor necrosis factor (TNF) \u03b1 [14, 16, 17] .DiscussionA cytokine storm as an adverse immune response to a SARS-CoV-2 infection is currently a major hypothesis for the underlying cause of a large proportion of COVID-19 deaths [18] .", [["estrogen", "CHEMICAL", 127, 135], ["necrosis", "DISEASE", 268, 276], ["SARS", "DISEASE", 368, 372], ["infection", "DISEASE", 379, 388], ["COVID", "DISEASE", 471, 476], ["deaths", "DISEASE", 480, 486], ["estrogen", "CHEMICAL", 127, 135], ["women", "ORGANISM", 26, 31], ["estrogen", "SIMPLE_CHEMICAL", 127, 135], ["interleukin 6", "GENE_OR_GENE_PRODUCT", 244, 257], ["tumor necrosis factor (TNF) \u03b1", "GENE_OR_GENE_PRODUCT", 262, 291], ["SARS-CoV-2", "ORGANISM", 368, 378], ["pro-inflammatory cytokines", "PROTEIN", 206, 232], ["interleukin 6", "PROTEIN", 244, 257], ["tumor necrosis factor", "PROTEIN", 262, 283], ["TNF", "PROTEIN", 285, 288], ["cytokine", "PROTEIN", 318, 326], ["women", "SPECIES", 26, 31], ["SARS-CoV-2", "SPECIES", 368, 378], ["the ESTHER study", "TEST", 56, 72], ["a high inflammatory burden", "PROBLEM", 79, 105], ["a decline in estrogen levels", "PROBLEM", 114, 142], ["pro-inflammatory cytokines", "PROBLEM", 206, 232], ["interleukin 6", "PROBLEM", 244, 257], ["tumor necrosis factor", "PROBLEM", 262, 283], ["an adverse immune response", "PROBLEM", 336, 362], ["a SARS", "PROBLEM", 366, 372], ["CoV-2 infection", "PROBLEM", 373, 388], ["high", "OBSERVATION_MODIFIER", 81, 85], ["inflammatory", "OBSERVATION_MODIFIER", 86, 98], ["increased", "OBSERVATION_MODIFIER", 182, 191], ["pro-inflammatory cytokines", "OBSERVATION", 206, 232], ["tumor", "OBSERVATION_MODIFIER", 262, 267], ["necrosis", "OBSERVATION", 268, 276], ["large", "OBSERVATION_MODIFIER", 451, 456]]], ["Sufficient 25(OH)D levels are suggested to contribute to prevention of the cytokine storm [1, 19, 20] .", [["25(OH)D", "CHEMICAL", 11, 18], ["25(OH)D", "CHEMICAL", 11, 18], ["25(OH)D", "SIMPLE_CHEMICAL", 11, 18], ["cytokine", "PROTEIN", 75, 83], ["OH)D levels", "TEST", 14, 25]]], ["Vitamin D is known to interact with the angiotensin-converting enzyme 2 (ACE2), which is both used by SARS-CoV-2 as an entry receptor and is an important protein on an anti-inflammatory pathway [21] .", [["Vitamin D", "CHEMICAL", 0, 9], ["angiotensin", "CHEMICAL", 40, 51], ["Vitamin D", "CHEMICAL", 0, 9], ["Vitamin D", "SIMPLE_CHEMICAL", 0, 9], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 40, 71], ["ACE2", "GENE_OR_GENE_PRODUCT", 73, 77], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 102, 112], ["angiotensin-converting enzyme 2", "PROTEIN", 40, 71], ["ACE2", "PROTEIN", 73, 77], ["Vitamin D", "TREATMENT", 0, 9], ["the angiotensin-converting enzyme", "TREATMENT", 36, 69], ["an anti-inflammatory pathway", "TREATMENT", 165, 193]]], ["While SARS-CoV-2 downregulates the expression of ACE2, vitamin D upregulates it.DiscussionIn a meta-analysis of individual participant data of 25 RCTs that included 11,321 participants aged 0-95 years, vitamin D 3 supplementation was shown to reduce the risk of acute respiratory tract infection (OR 0.88, 95% CI 0.81-0.96) [2] .", [["respiratory tract", "ANATOMY", 268, 285], ["vitamin D", "CHEMICAL", 55, 64], ["vitamin D", "CHEMICAL", 202, 211], ["acute respiratory tract infection", "DISEASE", 262, 295], ["vitamin D", "CHEMICAL", 55, 64], ["vitamin D 3", "CHEMICAL", 202, 213], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 6, 16], ["ACE2", "GENE_OR_GENE_PRODUCT", 49, 53], ["vitamin D", "SIMPLE_CHEMICAL", 55, 64], ["vitamin D 3", "SIMPLE_CHEMICAL", 202, 213], ["respiratory tract", "ORGANISM_SUBDIVISION", 268, 285], ["ACE2", "PROTEIN", 49, 53], ["vitamin D", "PROTEIN", 55, 64], ["participants", "SPECIES", 172, 184], ["SARS-CoV", "SPECIES", 6, 14], ["SARS", "TEST", 6, 10], ["CoV", "TEST", 11, 14], ["ACE2", "TREATMENT", 49, 53], ["vitamin D upregulates", "TREATMENT", 55, 76], ["vitamin D 3 supplementation", "TREATMENT", 202, 229], ["acute respiratory tract infection", "PROBLEM", 262, 295], ["CI", "TEST", 310, 312], ["acute", "OBSERVATION_MODIFIER", 262, 267], ["respiratory tract", "ANATOMY", 268, 285], ["infection", "OBSERVATION", 286, 295]]], ["The best effects were shown for daily or weekly vitamin D 3 supplementation without additional bolus doses (OR 0.81, 95% CI 0.72 to 0.91).", [["vitamin D", "CHEMICAL", 48, 57], ["vitamin D 3", "CHEMICAL", 48, 59], ["vitamin D 3", "SIMPLE_CHEMICAL", 48, 59], ["weekly vitamin D 3 supplementation", "TREATMENT", 41, 75], ["additional bolus doses", "TREATMENT", 84, 106], ["CI", "TEST", 121, 123]]], ["The protective effects were particularly strong in those with baseline 25-hydroxyvitamin D levels <25 nmol/L (OR 0.30, 95% CI 0.17-0.53).", [["25-hydroxyvitamin D", "CHEMICAL", 71, 90], ["25-hydroxyvitamin D", "CHEMICAL", 71, 90], ["25-hydroxyvitamin D", "SIMPLE_CHEMICAL", 71, 90], ["hydroxyvitamin D levels", "TEST", 74, 97], ["CI", "TEST", 123, 125]]], ["In a recent meta-analysis of RCTs on vitamin D 3 supplementation for patients with chronic obstructive pulmonary disease (COPD), the risk of acute exacerbations was estimated to be reduced by 61% (95% CI 36-77%) [22] .", [["pulmonary", "ANATOMY", 103, 112], ["vitamin D", "CHEMICAL", 37, 46], ["chronic obstructive pulmonary disease", "DISEASE", 83, 120], ["COPD", "DISEASE", 122, 126], ["vitamin D 3", "CHEMICAL", 37, 48], ["vitamin D 3", "SIMPLE_CHEMICAL", 37, 48], ["patients", "ORGANISM", 69, 77], ["pulmonary", "ORGAN", 103, 112], ["patients", "SPECIES", 69, 77], ["RCTs", "TREATMENT", 29, 33], ["vitamin D 3 supplementation", "TREATMENT", 37, 64], ["chronic obstructive pulmonary disease", "PROBLEM", 83, 120], ["COPD", "PROBLEM", 122, 126], ["acute exacerbations", "PROBLEM", 141, 160], ["CI", "TEST", 201, 203], ["chronic", "OBSERVATION_MODIFIER", 83, 90], ["obstructive", "OBSERVATION_MODIFIER", 91, 102], ["pulmonary", "ANATOMY", 103, 112], ["disease", "OBSERVATION", 113, 120], ["COPD", "OBSERVATION", 122, 126], ["acute", "OBSERVATION_MODIFIER", 141, 146], ["exacerbations", "OBSERVATION", 147, 160]]], ["In remarkable consistency with our results, these meta-analyses of RCTs provide strong evidence for the preventive potential of vitamin D 3 supplementation against acute respiratory infections and COPD exacerbations in particular.DiscussionIt appears plausible to assume that the anti-inflammatory mechanisms of vitamin D would be relevant for SARS-CoV-2 infections in a similar manner as for other severe viral respiratory diseases, such as influenza.", [["respiratory", "ANATOMY", 170, 181], ["respiratory", "ANATOMY", 412, 423], ["vitamin D", "CHEMICAL", 128, 137], ["acute respiratory infections", "DISEASE", 164, 192], ["COPD", "DISEASE", 197, 201], ["vitamin D", "CHEMICAL", 312, 321], ["SARS-CoV-2 infections", "DISEASE", 344, 365], ["viral respiratory diseases", "DISEASE", 406, 432], ["influenza", "DISEASE", 442, 451], ["vitamin D 3", "CHEMICAL", 128, 139], ["vitamin D", "CHEMICAL", 312, 321], ["vitamin D 3", "SIMPLE_CHEMICAL", 128, 139], ["vitamin D", "SIMPLE_CHEMICAL", 312, 321], ["SARS-CoV-2", "ORGANISM", 344, 354], ["SARS-CoV", "SPECIES", 344, 352], ["RCTs", "TREATMENT", 67, 71], ["vitamin D 3 supplementation", "TREATMENT", 128, 155], ["acute respiratory infections", "PROBLEM", 164, 192], ["COPD exacerbations", "PROBLEM", 197, 215], ["vitamin D", "TREATMENT", 312, 321], ["SARS", "PROBLEM", 344, 348], ["CoV", "PROBLEM", 349, 352], ["2 infections", "PROBLEM", 353, 365], ["other severe viral respiratory diseases", "PROBLEM", 393, 432], ["influenza", "PROBLEM", 442, 451], ["respiratory", "ANATOMY", 170, 181], ["infections", "OBSERVATION", 182, 192], ["COPD", "OBSERVATION", 197, 201], ["severe", "OBSERVATION_MODIFIER", 399, 405], ["viral", "OBSERVATION_MODIFIER", 406, 411], ["respiratory diseases", "OBSERVATION", 412, 432]]], ["A first study posted on a pre-print server on 13 May 2020 suggests that the protective effects of vitamin D 3 on other acute respiratory tract infections may be translated to COVID-19 infections [23] .", [["respiratory tract", "ANATOMY", 125, 142], ["vitamin D", "CHEMICAL", 98, 107], ["respiratory tract infections", "DISEASE", 125, 153], ["infections", "DISEASE", 184, 194], ["vitamin D 3", "CHEMICAL", 98, 109], ["vitamin D 3", "SIMPLE_CHEMICAL", 98, 109], ["tract", "ORGANISM_SUBDIVISION", 137, 142], ["A first study", "TEST", 0, 13], ["vitamin D", "TREATMENT", 98, 107], ["other acute respiratory tract infections", "PROBLEM", 113, 153], ["COVID", "TEST", 175, 180], ["respiratory tract", "ANATOMY", 125, 142]]], ["Vitamin D deficiency and vitamin D 3 treatment data were available for 499 COVID-19 patients from Chicago for the year prior COVID-19 testing.", [["Vitamin D", "CHEMICAL", 0, 9], ["vitamin D", "CHEMICAL", 25, 34], ["Vitamin D", "CHEMICAL", 0, 9], ["vitamin D 3", "CHEMICAL", 25, 36], ["Vitamin D", "SIMPLE_CHEMICAL", 0, 9], ["vitamin D 3", "SIMPLE_CHEMICAL", 25, 36], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["Vitamin D deficiency", "PROBLEM", 0, 20], ["vitamin D 3 treatment data", "TREATMENT", 25, 51], ["COVID", "TEST", 75, 80], ["COVID", "TEST", 125, 130]]], ["Being likely vitamin D deficient (defined as being vitamin D deficient at last available time point without increase of vitamin D treatment) at the time of COVID-19 testing was associated with a 1.8-fold increased risk of being tested positive for COVID-19 (p < 0.02) as compared to likely vitamin D sufficient.DiscussionIt is worth noting that beneficial effects of vitamin D 3 supplementation against manifestation or exacerbation of acute respiratory infection during an epidemic would be expected to go beyond individual protection of those using supplementation, as limiting such manifestation and exacerbation would also be expected to reduce the potential of spread of the disease to other persons and relieve the overload of the medical system by the epidemic.DiscussionTo our knowledge, no previous vitamin D 3 supplementation RCTs have addressed mortality from respiratory disease as the primary endpoint, and no meta-analysis of results for this specific endpoint have been reported, which most likely reflects the relatively small share of deaths from respiratory diseases among all deaths.", [["respiratory", "ANATOMY", 442, 453], ["respiratory", "ANATOMY", 871, 882], ["respiratory", "ANATOMY", 1064, 1075], ["vitamin D", "CHEMICAL", 13, 22], ["vitamin D", "CHEMICAL", 51, 60], ["vitamin D", "CHEMICAL", 120, 129], ["vitamin D", "CHEMICAL", 290, 299], ["vitamin D", "CHEMICAL", 367, 376], ["acute respiratory infection", "DISEASE", 436, 463], ["vitamin D", "CHEMICAL", 808, 817], ["respiratory disease", "DISEASE", 871, 890], ["deaths", "DISEASE", 1052, 1058], ["respiratory diseases", "DISEASE", 1064, 1084], ["deaths", "DISEASE", 1095, 1101], ["vitamin D", "CHEMICAL", 13, 22], ["vitamin D", "CHEMICAL", 51, 60], ["vitamin D", "CHEMICAL", 120, 129], ["COVID-19", "CHEMICAL", 248, 256], ["vitamin D", "CHEMICAL", 290, 299], ["vitamin D 3", "CHEMICAL", 367, 378], ["vitamin D 3", "CHEMICAL", 808, 819], ["vitamin D", "SIMPLE_CHEMICAL", 13, 22], ["vitamin D", "SIMPLE_CHEMICAL", 51, 60], ["vitamin D", "SIMPLE_CHEMICAL", 120, 129], ["vitamin D", "SIMPLE_CHEMICAL", 290, 299], ["vitamin D 3", "SIMPLE_CHEMICAL", 367, 378], ["persons", "ORGANISM", 697, 704], ["vitamin D 3", "SIMPLE_CHEMICAL", 808, 819], ["persons", "SPECIES", 697, 704], ["vitamin D deficient", "PROBLEM", 13, 32], ["vitamin D deficient", "TREATMENT", 51, 70], ["vitamin D treatment", "TREATMENT", 120, 139], ["COVID", "TEST", 156, 161], ["a 1.8-fold increased risk", "PROBLEM", 193, 218], ["COVID", "TEST", 248, 253], ["vitamin D sufficient", "PROBLEM", 290, 310], ["vitamin D 3 supplementation", "TREATMENT", 367, 394], ["exacerbation", "PROBLEM", 420, 432], ["acute respiratory infection", "PROBLEM", 436, 463], ["supplementation", "TREATMENT", 551, 566], ["exacerbation", "PROBLEM", 603, 615], ["the disease", "PROBLEM", 676, 687], ["the overload of the medical system", "PROBLEM", 717, 751], ["previous vitamin D 3 supplementation RCTs", "TREATMENT", 799, 840], ["respiratory disease", "PROBLEM", 871, 890], ["respiratory diseases", "PROBLEM", 1064, 1084], ["likely", "UNCERTAINTY", 6, 12], ["vitamin D deficient", "OBSERVATION_MODIFIER", 13, 32], ["acute", "OBSERVATION_MODIFIER", 436, 441], ["respiratory", "ANATOMY", 442, 453], ["infection", "OBSERVATION", 454, 463], ["overload", "OBSERVATION", 721, 729], ["respiratory disease", "OBSERVATION", 871, 890], ["small", "OBSERVATION_MODIFIER", 1037, 1042], ["respiratory diseases", "OBSERVATION", 1064, 1084]]], ["In our cohort of older adults, these deaths accounted for 5.2% of all deaths.", [["deaths", "DISEASE", 37, 43], ["deaths", "DISEASE", 70, 76]]], ["Even though this proportion is expected to be higher during the COVID-19 pandemic, the majority of deaths still occur from other diseases, and the summary effect, benefit-harm ratio and cost-effectiveness with respect to all relevant outcomes therefore deserve most careful attention for any general prevention efforts.DiscussionIn that respect, vitamin D 3 supplementation appears to be a particularly promising approach, especially for population groups with high prevalence of vitamin D insufficiency or deficiency, such as the elderly and those with severe comorbidities (which essentially coincide with population groups at highest risk of severe course and death from SARS-CoV-2 infection [24] ).", [["deaths", "DISEASE", 99, 105], ["vitamin D", "CHEMICAL", 346, 355], ["vitamin D", "CHEMICAL", 480, 489], ["death", "DISEASE", 663, 668], ["SARS-CoV-2 infection", "DISEASE", 674, 694], ["vitamin D 3", "CHEMICAL", 346, 357], ["vitamin D", "CHEMICAL", 480, 489], ["vitamin D 3", "SIMPLE_CHEMICAL", 346, 357], ["vitamin D", "SIMPLE_CHEMICAL", 480, 489], ["SARS-CoV-2", "ORGANISM", 674, 684], ["COVID-19", "SPECIES", 64, 72], ["the COVID", "TEST", 60, 69], ["other diseases", "PROBLEM", 123, 137], ["cost-effectiveness", "TREATMENT", 186, 204], ["any general prevention efforts", "TREATMENT", 288, 318], ["vitamin D 3 supplementation", "TREATMENT", 346, 373], ["vitamin D insufficiency", "PROBLEM", 480, 503], ["deficiency", "PROBLEM", 507, 517], ["severe comorbidities", "PROBLEM", 554, 574], ["severe course", "PROBLEM", 645, 658], ["death", "PROBLEM", 663, 668], ["SARS", "PROBLEM", 674, 678], ["CoV-2 infection", "PROBLEM", 679, 694], ["higher", "OBSERVATION_MODIFIER", 46, 52], ["severe", "OBSERVATION_MODIFIER", 645, 651]]], ["The personal, health care and societal costs of the vitamin D 3 intervention are negligibly low compared to the very high costs of currently employed \"general population measures,\" such as extensive testing for the infection and the lockdown of large proportions of economic and social life, including the delay or omission of much of routine medical care for other relevant diseases.", [["vitamin D", "CHEMICAL", 52, 61], ["infection", "DISEASE", 215, 224], ["vitamin D 3", "CHEMICAL", 52, 63], ["vitamin D 3", "GENE_OR_GENE_PRODUCT", 52, 63], ["the vitamin D 3 intervention", "TREATMENT", 48, 76], ["negligibly low", "PROBLEM", 81, 95], ["general population measures", "TREATMENT", 151, 178], ["extensive testing", "TEST", 189, 206], ["the infection", "PROBLEM", 211, 224], ["routine medical care", "TREATMENT", 335, 355], ["other relevant diseases", "PROBLEM", 360, 383], ["infection", "OBSERVATION", 215, 224]]], ["In fact, some of these measures are expected to severely aggravate vitamin D insufficiency or deficiency, especially in high risk groups, such as restrictions of spending time outdoors for the total population (as practiced, for example, in France and Spain) or certain high risk groups, such as nursing home residents (as practiced in many countries, including Germany).", [["vitamin D", "CHEMICAL", 67, 76], ["vitamin D", "CHEMICAL", 67, 76], ["vitamin D", "SIMPLE_CHEMICAL", 67, 76], ["severely aggravate vitamin D insufficiency", "PROBLEM", 48, 90], ["deficiency", "PROBLEM", 94, 104]]], ["Such restrictions dramatically reduce opportunities to maintain adequate vitamin D levels through endogenous synthesis by relevant sun exposure.", [["vitamin D", "CHEMICAL", 73, 82], ["vitamin D", "CHEMICAL", 73, 82], ["vitamin D", "SIMPLE_CHEMICAL", 73, 82], ["sun", "ORGANISM_SUBDIVISION", 131, 134], ["endogenous synthesis", "TREATMENT", 98, 118]]], ["Avoidance of sun exposure has been shown to be associated with increased mortality in epidemiological studies [25] .DiscussionVitamin D 3 supplementation has been demonstrated to be safe in numerous large-scale studies, and the risk of harm seems to be negligible compared to the risk of harmful side effects of the aforementioned and other general population measures, such as delayed diagnosis and treatment of cancer, myocardial infarction or stroke, withheld or deferred delivery of surgical or other medical services, or health risks related to unemployment and loneliness [26] [27] [28] [29] .", [["cancer", "ANATOMY", 413, 419], ["myocardial", "ANATOMY", 421, 431], ["Vitamin D", "CHEMICAL", 126, 135], ["cancer", "DISEASE", 413, 419], ["myocardial infarction", "DISEASE", 421, 442], ["stroke", "DISEASE", 446, 452], ["loneliness", "DISEASE", 567, 577], ["Vitamin D 3", "CHEMICAL", 126, 137], ["Vitamin D 3", "SIMPLE_CHEMICAL", 126, 137], ["cancer", "CANCER", 413, 419], ["myocardial", "MULTI-TISSUE_STRUCTURE", 421, 431], ["[26] [27] [28", "SIMPLE_CHEMICAL", 578, 591], ["increased mortality", "PROBLEM", 63, 82], ["epidemiological studies", "TEST", 86, 109], ["Vitamin D 3 supplementation", "TREATMENT", 126, 153], ["harm", "PROBLEM", 236, 240], ["harmful side effects", "PROBLEM", 288, 308], ["general population measures", "TREATMENT", 341, 368], ["cancer", "PROBLEM", 413, 419], ["myocardial infarction", "PROBLEM", 421, 442], ["stroke", "PROBLEM", 446, 452], ["cancer", "OBSERVATION", 413, 419], ["myocardial", "ANATOMY", 421, 431], ["infarction", "OBSERVATION", 432, 442]]], ["On the contrary, one expected \"side effect\" would be reducing total cancer mortality by 13%, as suggested by a recent meta-analysis of RCTs [3] .", [["cancer", "ANATOMY", 68, 74], ["cancer", "DISEASE", 68, 74], ["cancer", "CANCER", 68, 74], ["total cancer mortality", "PROBLEM", 62, 84]]], ["For Germany, with currently approximately 230,000 deaths from cancer per year [30] , this would translate in prevention of approximately 30,000 cancer deaths each year, suggesting substantial additional benefit besides lowering the COVID-19 burden during the COVID-19 pandemic and beyond.ConclusionsIn conclusion, our results, along with evidence from meta-analyses from RCTs regarding results of vitamin D 3 supplementation on various outcomes, suggest that vitamin D 3 supplementation could contribute to lowering mortality from respiratory and other diseases during and beyond the COVID-19 pandemic, in particular among women.", [["cancer", "ANATOMY", 62, 68], ["cancer", "ANATOMY", 144, 150], ["respiratory", "ANATOMY", 531, 542], ["deaths", "DISEASE", 50, 56], ["cancer", "DISEASE", 62, 68], ["cancer", "DISEASE", 144, 150], ["deaths", "DISEASE", 151, 157], ["vitamin D", "CHEMICAL", 397, 406], ["vitamin D", "CHEMICAL", 459, 468], ["respiratory and other diseases", "DISEASE", 531, 561], ["vitamin D 3", "CHEMICAL", 397, 408], ["vitamin D 3", "CHEMICAL", 459, 470], ["cancer", "CANCER", 62, 68], ["cancer", "CANCER", 144, 150], ["vitamin D 3", "SIMPLE_CHEMICAL", 397, 408], ["vitamin D 3", "SIMPLE_CHEMICAL", 459, 470], ["women", "ORGANISM", 623, 628], ["women", "SPECIES", 623, 628], ["the COVID", "TEST", 228, 237], ["the COVID", "TEST", 255, 264], ["meta-analyses", "TEST", 352, 365], ["RCTs", "TREATMENT", 371, 375], ["vitamin D 3 supplementation", "TREATMENT", 397, 424], ["vitamin D 3 supplementation", "TREATMENT", 459, 486], ["lowering mortality", "PROBLEM", 507, 525], ["respiratory and other diseases", "PROBLEM", 531, 561], ["the COVID", "TEST", 580, 589], ["cancer", "OBSERVATION", 62, 68], ["cancer", "OBSERVATION", 144, 150], ["substantial", "OBSERVATION_MODIFIER", 180, 191]]], ["The Endocrine Society recommends 1500-2000 IU vitamin D 3 /day for adults of any age at high risk for vitamin D deficiency [31] .", [["vitamin D", "CHEMICAL", 46, 55], ["vitamin D", "CHEMICAL", 102, 111], ["vitamin D 3", "CHEMICAL", 46, 57], ["vitamin D", "CHEMICAL", 102, 111], ["vitamin D", "SIMPLE_CHEMICAL", 102, 111], ["vitamin D", "TREATMENT", 46, 55], ["vitamin D deficiency", "PROBLEM", 102, 122]]], ["The costs for such supplementation are in the order of 30 \u20ac per person per year, or even half that amount when sufficient vitamin D supply is ensured by carefully dosed sun exposure during the summer months.", [["vitamin D", "CHEMICAL", 122, 131], ["vitamin D", "CHEMICAL", 122, 131], ["vitamin D", "SIMPLE_CHEMICAL", 122, 131], ["person", "SPECIES", 64, 70], ["such supplementation", "TREATMENT", 14, 34], ["vitamin D supply", "TREATMENT", 122, 138]]], ["Along with expected savings from prevented respiratory and other diseases, this would make vitamin D 3 supplementation a particularly cost-effective and most likely cost-saving measure, whose currently still widely neglected potential should receive increased attention in the debate on how to fight against the COVID-19 pandemic.ConclusionsAuthor Contributions: H.B. designed the research and drafted the manuscript, B.S. conducted statistical analyses, and B.H. critically read and commented the manuscript and added aspects to the discussion.", [["respiratory and other diseases", "DISEASE", 43, 73], ["vitamin D", "CHEMICAL", 91, 100], ["vitamin D 3", "CHEMICAL", 91, 102], ["vitamin D 3", "SIMPLE_CHEMICAL", 91, 102], ["COVID-19", "ORGANISM", 312, 320], ["respiratory and other diseases", "PROBLEM", 43, 73], ["vitamin D 3 supplementation", "TREATMENT", 91, 118], ["the COVID", "TEST", 308, 317], ["pandemic", "PROBLEM", 321, 329], ["respiratory", "ANATOMY", 43, 54], ["diseases", "OBSERVATION", 65, 73]]]], "95c7adefa9d3a947bdcdea866d54392c18086527": [["IntroductionThe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in a global pandemic.", [["acute respiratory syndrome coronavirus", "DISEASE", 23, 61], ["SARS-CoV-2", "CHEMICAL", 65, 75], ["SARS-CoV-2", "ORGANISM", 65, 75], ["severe acute respiratory syndrome coronavirus", "SPECIES", 16, 61], ["SARS-CoV-2", "SPECIES", 65, 75], ["The severe acute respiratory syndrome coronavirus", "PROBLEM", 12, 61], ["SARS-CoV", "TEST", 65, 73], ["a global pandemic", "PROBLEM", 93, 110], ["severe", "OBSERVATION_MODIFIER", 16, 22], ["acute", "OBSERVATION_MODIFIER", 23, 28], ["respiratory syndrome", "OBSERVATION", 29, 49], ["global", "OBSERVATION_MODIFIER", 95, 101], ["pandemic", "OBSERVATION", 102, 110]]], ["1,2 SARS-CoV-2, which is responsible for coronavirus disease 2019 (COVID- 19) , can cause pneumonia and acute respiratory distress syndrome (ARDS) as well as several extrapulmonary manifestations.", [["respiratory", "ANATOMY", 110, 121], ["extrapulmonary", "ANATOMY", 166, 180], ["coronavirus disease", "DISEASE", 41, 60], ["COVID- 19", "CHEMICAL", 67, 76], ["pneumonia", "DISEASE", 90, 99], ["acute respiratory distress syndrome", "DISEASE", 104, 139], ["ARDS", "DISEASE", 141, 145], ["SARS-CoV-2", "ORGANISM", 4, 14], ["coronavirus disease", "PROBLEM", 41, 60], ["COVID", "TEST", 67, 72], ["pneumonia", "PROBLEM", 90, 99], ["acute respiratory distress syndrome", "PROBLEM", 104, 139], ["ARDS", "PROBLEM", 141, 145], ["several extrapulmonary manifestations", "PROBLEM", 158, 195], ["responsible for", "UNCERTAINTY", 25, 40], ["coronavirus disease", "OBSERVATION", 41, 60], ["pneumonia", "OBSERVATION", 90, 99], ["acute", "OBSERVATION_MODIFIER", 104, 109], ["respiratory distress", "OBSERVATION", 110, 130], ["ARDS", "OBSERVATION", 141, 145], ["several", "OBSERVATION_MODIFIER", 158, 165], ["extrapulmonary", "ANATOMY", 166, 180], ["manifestations", "OBSERVATION", 181, 195]]], ["These include cardiovascular, hematologic, and thrombotic sequelae due to direct and indirect effects of the viral illness.", [["cardiovascular", "ANATOMY", 14, 28], ["cardiovascular, hematologic, and thrombotic sequelae", "DISEASE", 14, 66], ["viral illness", "DISEASE", 109, 122], ["cardiovascular", "ANATOMICAL_SYSTEM", 14, 28], ["cardiovascular, hematologic", "PROBLEM", 14, 41], ["thrombotic sequelae", "PROBLEM", 47, 66], ["the viral illness", "PROBLEM", 105, 122], ["thrombotic", "OBSERVATION", 47, 57], ["viral illness", "OBSERVATION", 109, 122]]], ["[3] [4] [5] Indeed, the limited data available on thrombotic complications in patients with COVID-19 suggest that rates of venous thromboembolic events may be as high as 25 to 30%, particularly in critically ill, mechanically ventilated patients.", [["venous", "ANATOMY", 123, 129], ["thrombotic complications", "DISEASE", 50, 74], ["venous thromboembolic", "DISEASE", 123, 144], ["critically ill", "DISEASE", 197, 211], ["patients", "ORGANISM", 78, 86], ["venous", "MULTI-TISSUE_STRUCTURE", 123, 129], ["patients", "ORGANISM", 237, 245], ["patients", "SPECIES", 78, 86], ["patients", "SPECIES", 237, 245], ["thrombotic complications", "PROBLEM", 50, 74], ["COVID", "TEST", 92, 97], ["venous thromboembolic events", "PROBLEM", 123, 151], ["venous", "ANATOMY", 123, 129], ["thromboembolic", "OBSERVATION", 130, 144], ["critically ill", "OBSERVATION_MODIFIER", 197, 211]]], ["[6] [7] [8] Thrombotic complications also include stroke, acute limb ischemia, and acute coronary syndromes.", [["limb", "ANATOMY", 64, 68], ["coronary", "ANATOMY", 89, 97], ["Thrombotic complications", "DISEASE", 12, 36], ["stroke", "DISEASE", 50, 56], ["acute limb ischemia", "DISEASE", 58, 77], ["acute coronary syndromes", "DISEASE", 83, 107], ["limb", "ORGANISM_SUBDIVISION", 64, 68], ["Thrombotic complications", "PROBLEM", 12, 36], ["stroke", "PROBLEM", 50, 56], ["acute limb ischemia", "PROBLEM", 58, 77], ["acute coronary syndromes", "PROBLEM", 83, 107], ["stroke", "OBSERVATION", 50, 56], ["acute", "OBSERVATION_MODIFIER", 58, 63], ["limb", "ANATOMY", 64, 68], ["ischemia", "OBSERVATION", 69, 77], ["acute", "OBSERVATION_MODIFIER", 83, 88], ["coronary", "ANATOMY", 89, 97], ["syndromes", "OBSERVATION", 98, 107]]], ["[9] [10] [11] Limited data are available to determine the antithrombotic therapy to improve outcomes in patients with COVID-19 who do not have confirmed evidence of thrombosis.", [["thrombosis", "DISEASE", 165, 175], ["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112], ["the antithrombotic therapy", "TREATMENT", 54, 80], ["COVID", "TEST", 118, 123], ["thrombosis", "PROBLEM", 165, 175], ["evidence of", "UNCERTAINTY", 153, 164], ["thrombosis", "OBSERVATION", 165, 175]]], ["The optimal dose and agent for thromboprophylaxis remain unknown.", [["agent", "TREATMENT", 21, 26], ["thromboprophylaxis", "TREATMENT", 31, 49]]], ["Conservative management has merit based on historical data pertaining to critically ill medical patients 12 as well as for COVID-19-specific escalation of treatment.", [["critically ill", "DISEASE", 73, 87], ["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104], ["Conservative management", "TREATMENT", 0, 23], ["historical data", "TEST", 43, 58], ["COVID", "TEST", 123, 128], ["treatment", "TREATMENT", 155, 164]]], ["13 For interim decision-making, consensus-based guidance has been provided by some groups, 14-18 including the Global COVID-19 Thrombosis Collaborative Group 5 (\u25baTable 1).", [["Thrombosis", "DISEASE", 127, 137], ["the Global COVID", "TEST", 107, 123], ["Thrombosis", "OBSERVATION", 127, 137]]], ["However, unlike other extensively studied illnesses such as sepsis, 19 a comprehensive assessment of potential options for prevention of thrombosis in various subgroups of patients with COVID-19 has not to date been proposed.IntroductionIn this article, prepared by the Global COVID-19 Thrombosis Collaborative Group, we summarize potential therapeutic options for prevention of thrombosis in COVID-19 patients in the absence of confirmed thrombotic events.", [["sepsis", "DISEASE", 60, 66], ["thrombosis", "DISEASE", 137, 147], ["COVID-19", "CHEMICAL", 186, 194], ["Thrombosis", "DISEASE", 286, 296], ["thrombosis", "DISEASE", 379, 389], ["thrombotic", "DISEASE", 439, 449], ["COVID-19", "CHEMICAL", 186, 194], ["patients", "ORGANISM", 172, 180], ["patients", "ORGANISM", 402, 410], ["patients", "SPECIES", 172, 180], ["patients", "SPECIES", 402, 410], ["sepsis", "PROBLEM", 60, 66], ["a comprehensive assessment", "TEST", 71, 97], ["thrombosis", "PROBLEM", 137, 147], ["COVID", "TEST", 186, 191], ["therapeutic options", "TREATMENT", 341, 360], ["thrombosis", "PROBLEM", 379, 389], ["COVID", "TEST", 393, 398], ["thrombotic events", "PROBLEM", 439, 456], ["sepsis", "OBSERVATION", 60, 66], ["thrombosis", "OBSERVATION", 137, 147], ["Thrombosis", "OBSERVATION", 286, 296], ["thrombosis", "OBSERVATION", 379, 389], ["thrombotic", "OBSERVATION", 439, 449]]], ["Our focus is on novel approaches to dosing commonly used antithrombotic agents (heparin-based regimens and direct oral anticoagulants [DOACs]), considerations for empiric use of less widely used antithrombotic drugs such as danaparoid, and the potential applications of antiplatelet agents.", [["oral", "ANATOMY", 114, 118], ["antiplatelet", "ANATOMY", 270, 282], ["heparin", "CHEMICAL", 80, 87], ["DOACs", "CHEMICAL", 135, 140], ["danaparoid", "CHEMICAL", 224, 234], ["danaparoid", "CHEMICAL", 224, 234], ["heparin", "SIMPLE_CHEMICAL", 80, 87], ["oral", "ORGANISM_SUBDIVISION", 114, 118], ["anticoagulants", "SIMPLE_CHEMICAL", 119, 133], ["DOACs", "SIMPLE_CHEMICAL", 135, 140], ["danaparoid", "SIMPLE_CHEMICAL", 224, 234], ["antiplatelet agents", "SIMPLE_CHEMICAL", 270, 289], ["antithrombotic agents", "TREATMENT", 57, 78], ["heparin-based regimens", "TREATMENT", 80, 102], ["direct oral anticoagulants", "TREATMENT", 107, 133], ["DOACs", "TREATMENT", 135, 140], ["antithrombotic drugs", "TREATMENT", 195, 215], ["danaparoid", "TREATMENT", 224, 234], ["antiplatelet agents", "TREATMENT", 270, 289]]], ["In addition to the direct antithrombotic effects, other mechanisms of action-including anti-inflammatory or antiviral effects-have been postulated.", [["the direct antithrombotic effects", "TREATMENT", 15, 48], ["anti-inflammatory", "TREATMENT", 87, 104], ["antiviral effects", "TREATMENT", 108, 125]]], ["20, 21 Finally, we discuss other therapies, such as immunomodulators, that may have antithrombotic properties.", [["other therapies", "TREATMENT", 27, 42], ["immunomodulators", "TREATMENT", 52, 68], ["antithrombotic properties", "TREATMENT", 84, 109]]], ["The goal is not to provide immediately actionable management recommendations (as high-quality data to reliably inform such guidance in patients with COVID-19 are lacking), but rather to summarize potential treatment options and their advantages and limitations for ongoing and future investigations.", [["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 135, 143], ["treatment options", "TREATMENT", 206, 223], ["future investigations", "TEST", 277, 298]]], ["We outline research priorities for these agents across the relevant clinical subgroups.Methodological ConsiderationsTo provide a thorough assessment for the rationale and potential advantages and limitations of various antithrombotic agents, subcommittees from the collaborative drafted the sections focused on specific agents, and these sections were then reviewed and revised by the entire group.", [["sections", "ANATOMY", 291, 299], ["sections", "ANATOMY", 338, 346], ["these agents", "TREATMENT", 35, 47], ["a thorough assessment", "TEST", 127, 148], ["various antithrombotic agents", "TREATMENT", 211, 240], ["these sections", "TEST", 332, 346]]], ["The colead authors searched MEDLINE (with PubMed interface) to ensure that no other high-quality clinical study was missed (date of last search: May 5, 2020) .Methodological ConsiderationsFor research priority setting, a survey was sent to the group of coauthors who were asked to rate the overall priority for investigating each of the discussed agents and to identify the care setting wherein the investigation was most reasonable (outpatients with COVID-19, inpatients on the wards, critically ill patients in the intensive care unit [ICU] , or patients posthospital discharge).Investigational Strategies Targeting Thromboinflammation in COVID-19In the subsequent sections, we describe various investigational strategies for anticoagulants, antiplatelet agents, hemostatic modulating agents, and immunomodulators that may have potential for further investigation for patients with COVID-19 (\u25baTable 2; \u25baFig. 1).", [["sections", "ANATOMY", 667, 675], ["critically ill", "DISEASE", 486, 500], ["patients", "ORGANISM", 501, 509], ["patients", "ORGANISM", 548, 556], ["anticoagulants", "SIMPLE_CHEMICAL", 728, 742], ["antiplatelet agents", "SIMPLE_CHEMICAL", 744, 763], ["patients", "ORGANISM", 870, 878], ["patients", "SPECIES", 501, 509], ["patients", "SPECIES", 548, 556], ["patients", "SPECIES", 870, 878], ["a survey", "TEST", 219, 227], ["Thromboinflammation", "TEST", 618, 637], ["COVID", "TEST", 641, 646], ["anticoagulants", "TREATMENT", 728, 742], ["antiplatelet agents", "TREATMENT", 744, 763], ["hemostatic modulating agents", "TREATMENT", 765, 793], ["immunomodulators", "TREATMENT", 799, 815], ["further investigation", "TEST", 844, 865], ["COVID", "TEST", 884, 889]]], ["In addition, a summary of the survey results for research priorities with these agents is provided in \u25baTable 3 and \u25baFigs.", [["these agents", "TREATMENT", 74, 86]]], ["2 and 3.Unfractionated Heparin and Low-Molecular-Weight HeparinsUnfractionated heparin and low-molecular-weight heparins (LMWHs) are the most frequently administered parenteral anticoagulants.", [["parenteral", "ANATOMY", 166, 176], ["Heparin", "CHEMICAL", 23, 30], ["heparin", "CHEMICAL", 79, 86], ["LMWHs", "CHEMICAL", 122, 127], ["Heparin", "SIMPLE_CHEMICAL", 23, 30], ["heparin", "SIMPLE_CHEMICAL", 79, 86], ["low-molecular-weight heparins", "SIMPLE_CHEMICAL", 91, 120], ["LMWHs", "SIMPLE_CHEMICAL", 122, 127], ["Unfractionated Heparin", "TREATMENT", 8, 30], ["Low-Molecular", "TREATMENT", 35, 48], ["Weight HeparinsUnfractionated heparin", "TREATMENT", 49, 86], ["low-molecular-weight heparins (LMWHs", "TREATMENT", 91, 127], ["parenteral anticoagulants", "TREATMENT", 166, 191]]], ["22 In addition to their antithrombotic activity, they have postulated anti-inflammatory and antiviral Table 1 Suggested considerations for prevention and management of thrombosis among hospitalized patients with COVID-19 a Risk stratification for VTE should be performed for all inpatients with COVID-19.", [["thrombosis", "DISEASE", 168, 178], ["VTE", "DISEASE", 247, 250], ["COVID-19", "CHEMICAL", 295, 303], ["patients", "ORGANISM", 198, 206], ["patients", "SPECIES", 198, 206], ["their antithrombotic activity", "TREATMENT", 18, 47], ["anti-inflammatory and antiviral Table", "TREATMENT", 70, 107], ["management", "TREATMENT", 154, 164], ["thrombosis", "PROBLEM", 168, 178], ["COVID", "TEST", 212, 217], ["VTE", "PROBLEM", 247, 250], ["COVID", "TEST", 295, 300], ["anti-inflammatory", "OBSERVATION_MODIFIER", 70, 87], ["thrombosis", "OBSERVATION", 168, 178]]], ["In the absence of contraindications, the vast majority of inpatients, including all patients with severe COVID-19 who are critically ill should receive prophylactic anticoagulationUnfractionated Heparin and Low-Molecular-Weight HeparinsThe optimal intensity of anticoagulation in patients with COVID-19 remains unknown.", [["critically ill", "DISEASE", 122, 136], ["Heparin", "CHEMICAL", 195, 202], ["COVID-19", "CHEMICAL", 294, 302], ["COVID-19", "CHEMICAL", 294, 302], ["inpatients", "ORGANISM", 58, 68], ["patients", "ORGANISM", 84, 92], ["Heparin", "SIMPLE_CHEMICAL", 195, 202], ["patients", "ORGANISM", 280, 288], ["patients", "SPECIES", 84, 92], ["patients", "SPECIES", 280, 288], ["severe COVID", "PROBLEM", 98, 110], ["critically ill", "PROBLEM", 122, 136], ["prophylactic anticoagulation", "TREATMENT", 152, 180], ["Unfractionated Heparin", "TREATMENT", 180, 202], ["Low-Molecular-Weight Heparins", "TREATMENT", 207, 236], ["anticoagulation", "TREATMENT", 261, 276], ["COVID", "TEST", 294, 299]]], ["Although prophylactic dosing is most widely used, higher intensity of anticoagulation (including intermediate-dose and full-therapeutic anticoagulation) is being used by many clinicians/institutions.", [["prophylactic dosing", "TREATMENT", 9, 28], ["anticoagulation", "TREATMENT", 70, 85], ["full-therapeutic anticoagulation", "TREATMENT", 119, 151]]], ["Additional studies are required to identify the optimal regimen in various patient groups with COVID-19Unfractionated Heparin and Low-Molecular-Weight HeparinsFor hospitalized patients with COVID-19 who require therapeutic anticoagulation (for prior indications including AF, VTE, mechanical valves, or new incident events such as new VTE or type I myocardial infarction), presence or absence of DIC, and hepatic and renal function should be considered when determining the appropriate choice of anticoagulant agent and dose a Hemostatic derangements, including elevated D-dimer levels, are common among inpatients with COVID-19.", [["myocardial", "ANATOMY", 349, 359], ["hepatic", "ANATOMY", 405, 412], ["renal", "ANATOMY", 417, 422], ["AF", "DISEASE", 272, 274], ["VTE", "DISEASE", 276, 279], ["VTE", "DISEASE", 335, 338], ["type I myocardial infarction", "DISEASE", 342, 370], ["DIC", "DISEASE", 396, 399], ["hepatic and renal function", "DISEASE", 405, 431], ["COVID-19", "CHEMICAL", 620, 628], ["patient", "ORGANISM", 75, 82], ["COVID-19Unfractionated Heparin", "SIMPLE_CHEMICAL", 95, 125], ["Low-Molecular-Weight Heparins", "SIMPLE_CHEMICAL", 130, 159], ["patients", "ORGANISM", 176, 184], ["myocardial", "MULTI-TISSUE_STRUCTURE", 349, 359], ["hepatic", "MULTI-TISSUE_STRUCTURE", 405, 412], ["renal", "ORGAN", 417, 422], ["D-dimer", "GENE_OR_GENE_PRODUCT", 571, 578], ["patient", "SPECIES", 75, 82], ["patients", "SPECIES", 176, 184], ["Additional studies", "TEST", 0, 18], ["COVID", "TREATMENT", 95, 100], ["Heparin", "TREATMENT", 118, 125], ["Low-Molecular-Weight Heparins", "TREATMENT", 130, 159], ["COVID", "TREATMENT", 190, 195], ["therapeutic anticoagulation", "TREATMENT", 211, 238], ["prior indications", "TREATMENT", 244, 261], ["AF", "PROBLEM", 272, 274], ["VTE", "PROBLEM", 276, 279], ["mechanical valves", "TREATMENT", 281, 298], ["new incident events", "PROBLEM", 303, 322], ["new VTE", "PROBLEM", 331, 338], ["type I myocardial infarction", "PROBLEM", 342, 370], ["DIC", "PROBLEM", 396, 399], ["hepatic and renal function", "PROBLEM", 405, 431], ["anticoagulant agent", "TREATMENT", 496, 515], ["a Hemostatic derangements", "PROBLEM", 525, 550], ["elevated D-dimer levels", "PROBLEM", 562, 585], ["COVID", "TEST", 620, 625], ["mechanical valves", "OBSERVATION", 281, 298], ["myocardial", "ANATOMY", 349, 359], ["infarction", "OBSERVATION", 360, 370], ["hepatic", "ANATOMY", 405, 412], ["renal", "ANATOMY", 417, 422]]], ["The majority of a consensus panel did not find sufficient evidence for routine screening for VTE (e.g., bilateral lower extremity ultrasound, or computed tomography pulmonary angiography) for hospitalized patients with COVID- 19 Therapeutic Targets for COVID-19-Associated Thrombosis Bikdeli et al. properties.", [["lower extremity", "ANATOMY", 114, 129], ["pulmonary", "ANATOMY", 165, 174], ["VTE", "DISEASE", 93, 96], ["Thrombosis", "DISEASE", 273, 283], ["pulmonary", "ORGAN", 165, 174], ["patients", "ORGANISM", 205, 213], ["patients", "SPECIES", 205, 213], ["a consensus panel", "TEST", 16, 33], ["routine screening", "TEST", 71, 88], ["VTE", "PROBLEM", 93, 96], ["bilateral lower extremity ultrasound", "TEST", 104, 140], ["computed tomography pulmonary angiography", "TEST", 145, 186], ["COVID", "TEST", 219, 224], ["COVID", "TEST", 253, 258], ["Thrombosis Bikdeli", "PROBLEM", 273, 291], ["bilateral", "ANATOMY_MODIFIER", 104, 113], ["lower extremity", "ANATOMY", 114, 129], ["pulmonary", "ANATOMY", 165, 174], ["Thrombosis", "OBSERVATION", 273, 283]]], ["Their anti-inflammatory properties may occur through selectin blockade, inhibition of bradykinin and thrombin generation, and binding of inflammatory cytokines.", [["bradykinin", "CHEMICAL", 86, 96], ["bradykinin", "CHEMICAL", 86, 96], ["selectin", "GENE_OR_GENE_PRODUCT", 53, 61], ["bradykinin", "SIMPLE_CHEMICAL", 86, 96], ["thrombin", "GENE_OR_GENE_PRODUCT", 101, 109], ["selectin", "PROTEIN", 53, 61], ["thrombin", "PROTEIN", 101, 109], ["inflammatory cytokines", "PROTEIN", 137, 159], ["Their anti-inflammatory properties", "TREATMENT", 0, 34], ["selectin blockade", "TREATMENT", 53, 70], ["bradykinin", "PROBLEM", 86, 96], ["thrombin generation", "TREATMENT", 101, 120], ["inflammatory cytokines", "PROBLEM", 137, 159], ["thrombin generation", "OBSERVATION", 101, 120], ["inflammatory cytokines", "OBSERVATION", 137, 159]]], ["23, 24 Heparins may also possess antiviral properties.", [["Heparins", "GENE_OR_GENE_PRODUCT", 7, 15], ["Heparins", "TREATMENT", 7, 15], ["antiviral properties", "TREATMENT", 33, 53], ["antiviral properties", "OBSERVATION", 33, 53]]], ["For example, heparin may attenuate viral interaction with the angiotensin-converting enzyme 2 (ACE2) receptor by binding SARS-CoV-2 spike protein.", [["heparin", "CHEMICAL", 13, 20], ["angiotensin", "CHEMICAL", 62, 73], ["heparin", "SIMPLE_CHEMICAL", 13, 20], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 62, 93], ["ACE2", "GENE_OR_GENE_PRODUCT", 95, 99], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 121, 131], ["angiotensin-converting enzyme 2 (ACE2) receptor", "PROTEIN", 62, 109], ["SARS-CoV-2 spike protein", "PROTEIN", 121, 145], ["heparin", "TREATMENT", 13, 20], ["viral interaction", "PROBLEM", 35, 52], ["the angiotensin-converting enzyme 2 (ACE2) receptor", "TREATMENT", 58, 109], ["binding SARS", "TEST", 113, 125], ["CoV", "TEST", 126, 129]]], ["25 The use of empiric heparin anticoagulation in patients with H1N1 ARDS was associated with reduced risk of thrombotic events without an increase in bleeding complications.", [["heparin", "CHEMICAL", 22, 29], ["ARDS", "DISEASE", 68, 72], ["thrombotic", "DISEASE", 109, 119], ["bleeding", "DISEASE", 150, 158], ["heparin", "SIMPLE_CHEMICAL", 22, 29], ["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["empiric heparin anticoagulation", "TREATMENT", 14, 45], ["H1N1 ARDS", "PROBLEM", 63, 72], ["thrombotic events", "PROBLEM", 109, 126], ["an increase in bleeding complications", "PROBLEM", 135, 172], ["ARDS", "OBSERVATION", 68, 72], ["thrombotic", "OBSERVATION", 109, 119], ["increase", "OBSERVATION_MODIFIER", 138, 146], ["bleeding", "OBSERVATION", 150, 158]]], ["26 With this consideration and the concern for breakthrough rates of thrombotic events despite prophylactic anticoagulation, 7 several randomized trials evaluating varying intensities of heparin-based anticoagulation, ranging from prophylactic, or weight-adjusted prophylactic dose treatment to intermediate to full-dose therapy are underway (NCT04345848, NCT04344756, NCT04373707, NCT04359277, NCT04367831, NCT04362085, NCT04377997).", [["thrombotic", "DISEASE", 69, 79], ["heparin", "CHEMICAL", 187, 194], ["NCT04345848", "CHEMICAL", 343, 354], ["heparin", "SIMPLE_CHEMICAL", 187, 194], ["breakthrough rates", "PROBLEM", 47, 65], ["thrombotic events", "PROBLEM", 69, 86], ["prophylactic anticoagulation", "TREATMENT", 95, 123], ["heparin", "TREATMENT", 187, 194], ["anticoagulation", "TREATMENT", 201, 216], ["prophylactic", "TREATMENT", 231, 243], ["weight", "TEST", 248, 254], ["prophylactic dose treatment", "TREATMENT", 264, 291], ["full-dose therapy", "TREATMENT", 311, 328], ["thrombotic", "OBSERVATION", 69, 79]]], ["Additionally, several institutions have implemented protocols to initiate therapeutic anti-coagulation empirically, utilizing risk stratification based on an individual's thrombotic and bleeding risk.", [["thrombotic", "DISEASE", 171, 181], ["bleeding", "DISEASE", 186, 194], ["therapeutic anti-coagulation", "TREATMENT", 74, 102], ["risk stratification", "TEST", 126, 145], ["an individual's thrombotic and bleeding risk", "PROBLEM", 155, 199], ["thrombotic", "OBSERVATION", 171, 181]]], ["27, 28 Future prospective studies are needed to evaluate the use of these strategies on thrombotic and bleeding complications.Unfractionated Heparin and Low-Molecular-Weight HeparinsOne potential challenge in the use of unfractionated heparin is the utility of the activated partial thromboplastin time (aPTT) for monitoring heparin.", [["thrombotic", "DISEASE", 88, 98], ["bleeding", "DISEASE", 103, 111], ["Heparin", "CHEMICAL", 141, 148], ["heparin", "CHEMICAL", 235, 242], ["heparin", "CHEMICAL", 325, 332], ["Heparin", "SIMPLE_CHEMICAL", 141, 148], ["heparin", "SIMPLE_CHEMICAL", 235, 242], ["thromboplastin", "GENE_OR_GENE_PRODUCT", 283, 297], ["heparin", "SIMPLE_CHEMICAL", 325, 332], ["Future prospective studies", "TEST", 7, 33], ["these strategies", "TREATMENT", 68, 84], ["thrombotic and bleeding complications", "PROBLEM", 88, 125], ["Unfractionated Heparin", "TREATMENT", 126, 148], ["Low-Molecular-Weight Heparins", "TREATMENT", 153, 182], ["unfractionated heparin", "TREATMENT", 220, 242], ["the activated partial thromboplastin time", "TREATMENT", 261, 302], ["aPTT", "TEST", 304, 308], ["heparin", "TREATMENT", 325, 332], ["thrombotic", "OBSERVATION", 88, 98], ["Low-Molecular", "OBSERVATION_MODIFIER", 153, 166]]], ["In patients with COVID-19, besides the intensity of heparin-based regimens, substantial heterogeneity in the aPTT response may be driven by high levels of factor VIII and fibrinogen, or the presence of a lupus anticoagulant.", [["heparin", "CHEMICAL", 52, 59], ["lupus", "DISEASE", 204, 209], ["COVID-19", "CHEMICAL", 17, 25], ["patients", "ORGANISM", 3, 11], ["heparin", "SIMPLE_CHEMICAL", 52, 59], ["aPTT", "GENE_OR_GENE_PRODUCT", 109, 113], ["factor VIII", "GENE_OR_GENE_PRODUCT", 155, 166], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 171, 181], ["aPTT", "PROTEIN", 109, 113], ["factor VIII", "PROTEIN", 155, 166], ["fibrinogen", "PROTEIN", 171, 181], ["patients", "SPECIES", 3, 11], ["COVID", "TEST", 17, 22], ["heparin-based regimens", "TREATMENT", 52, 74], ["substantial heterogeneity in the aPTT response", "PROBLEM", 76, 122], ["factor VIII", "PROBLEM", 155, 166], ["fibrinogen", "TEST", 171, 181], ["a lupus anticoagulant", "TREATMENT", 202, 223], ["substantial", "OBSERVATION_MODIFIER", 76, 87], ["heterogeneity", "OBSERVATION", 88, 101], ["lupus anticoagulant", "OBSERVATION", 204, 223]]], ["29, 30 Consequently, anti-factor Xa levels may need to be measured to ensure that a therapeutic heparin level is achieved.", [["heparin", "CHEMICAL", 96, 103], ["anti-factor Xa", "GENE_OR_GENE_PRODUCT", 21, 35], ["heparin", "SIMPLE_CHEMICAL", 96, 103], ["anti-factor Xa", "PROTEIN", 21, 35], ["anti-factor Xa levels", "TEST", 21, 42], ["a therapeutic heparin level", "TEST", 82, 109]]], ["31 Trials of inhaled heparin for treatment of COVID-19 are being planned to disrupt SARS-CoV-2 and its ACE2 receptor interaction.", [["heparin", "CHEMICAL", 21, 28], ["COVID-19", "CHEMICAL", 46, 54], ["COVID-19", "CHEMICAL", 46, 54], ["heparin", "SIMPLE_CHEMICAL", 21, 28], ["COVID-19", "SIMPLE_CHEMICAL", 46, 54], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 84, 94], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 103, 116], ["ACE2", "PROTEIN", 103, 107], ["inhaled heparin", "TREATMENT", 13, 28], ["treatment of COVID", "TREATMENT", 33, 51], ["CoV", "TEST", 89, 92]]], ["Docking of the virus to host cells is mediated by the interaction between the spike (S) protein and heparan sulfate chains of proteoglycans.", [["cells", "ANATOMY", 29, 34], ["heparan sulfate", "CHEMICAL", 100, 115], ["sulfate", "CHEMICAL", 108, 115], ["host cells", "CELL", 24, 34], ["heparan sulfate chains", "GENE_OR_GENE_PRODUCT", 100, 122], ["proteoglycans", "GENE_OR_GENE_PRODUCT", 126, 139], ["host cells", "CELL_TYPE", 24, 34], ["spike (S) protein", "PROTEIN", 78, 95], ["heparan sulfate chains", "PROTEIN", 100, 122], ["the virus to host cells", "PROBLEM", 11, 34], ["heparan sulfate chains of proteoglycans", "TREATMENT", 100, 139], ["virus", "OBSERVATION", 15, 20]]], ["This facilitates further binding of SARS-CoV-2 to its cell-surface receptor, ACE2, via the surface unit (S1) of its S protein.", [["cell", "ANATOMY", 54, 58], ["surface", "ANATOMY", 59, 66], ["surface", "ANATOMY", 91, 98], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 36, 46], ["cell", "CELL", 54, 58], ["ACE2", "GENE_OR_GENE_PRODUCT", 77, 81], ["S protein", "GENE_OR_GENE_PRODUCT", 116, 125], ["cell-surface receptor", "PROTEIN", 54, 75], ["ACE2", "PROTEIN", 77, 81], ["surface unit", "PROTEIN", 91, 103], ["S1", "PROTEIN", 105, 107], ["S protein", "PROTEIN", 116, 125], ["SARS", "TEST", 36, 40], ["CoV", "TEST", 41, 44], ["ACE2", "TEST", 77, 81]]], ["[32] [33] [34] It is known that heparin can displace surface proteoglycans, and prevent SARS-CoV-2 entry into human cells.", [["surface", "ANATOMY", 53, 60], ["cells", "ANATOMY", 116, 121], ["heparin", "CHEMICAL", 32, 39], ["[32] [33] [34", "SIMPLE_CHEMICAL", 0, 13], ["heparin", "SIMPLE_CHEMICAL", 32, 39], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 88, 98], ["human", "ORGANISM", 110, 115], ["cells", "CELL", 116, 121], ["human cells", "CELL_TYPE", 110, 121], ["human", "SPECIES", 110, 115], ["human", "SPECIES", 110, 115], ["heparin", "TREATMENT", 32, 39], ["surface proteoglycans", "TREATMENT", 53, 74], ["SARS", "PROBLEM", 88, 92], ["CoV", "TEST", 93, 96]]], ["21, 35 Drug-drug interactions between COVD-19 investigational therapies and antithrombotic agents should be also considered. \u25baFig. 3 provides a graphical summary of potential interactions.DanaparoidDanaparoid (a mixture of sulfated glycosaminoglycans including heparan sulfate, dermatan sulfate, and chondroitin sulfate) attenuates thrombin generation by catalyzing the inhibition of factor Xa by antithrombin and by inhibition of thrombin by antithrombin and heparin cofactor II.", [["COVD-19", "CHEMICAL", 38, 45], ["DanaparoidDanaparoid", "CHEMICAL", 188, 208], ["heparan sulfate", "CHEMICAL", 261, 276], ["dermatan sulfate", "CHEMICAL", 278, 294], ["chondroitin sulfate", "CHEMICAL", 300, 319], ["heparin", "CHEMICAL", 460, 467], ["DanaparoidDanaparoid", "CHEMICAL", 188, 208], ["dermatan sulfate", "CHEMICAL", 278, 294], ["chondroitin sulfate", "CHEMICAL", 300, 319], ["DanaparoidDanaparoid", "SIMPLE_CHEMICAL", 188, 208], ["sulfated glycosaminoglycans", "SIMPLE_CHEMICAL", 223, 250], ["heparan sulfate", "SIMPLE_CHEMICAL", 261, 276], ["dermatan sulfate", "SIMPLE_CHEMICAL", 278, 294], ["chondroitin sulfate", "SIMPLE_CHEMICAL", 300, 319], ["thrombin", "GENE_OR_GENE_PRODUCT", 332, 340], ["factor Xa", "GENE_OR_GENE_PRODUCT", 384, 393], ["antithrombin", "GENE_OR_GENE_PRODUCT", 397, 409], ["thrombin", "GENE_OR_GENE_PRODUCT", 431, 439], ["antithrombin", "GENE_OR_GENE_PRODUCT", 443, 455], ["heparin cofactor II", "GENE_OR_GENE_PRODUCT", 460, 479], ["thrombin", "PROTEIN", 332, 340], ["factor Xa", "PROTEIN", 384, 393], ["antithrombin", "PROTEIN", 397, 409], ["thrombin", "PROTEIN", 431, 439], ["antithrombin", "PROTEIN", 443, 455], ["heparin cofactor II", "PROTEIN", 460, 479], ["COVD", "TREATMENT", 38, 42], ["investigational therapies", "TREATMENT", 46, 71], ["antithrombotic agents", "TREATMENT", 76, 97], ["DanaparoidDanaparoid", "TREATMENT", 188, 208], ["a mixture of sulfated glycosaminoglycans", "TREATMENT", 210, 250], ["heparan sulfate", "TREATMENT", 261, 276], ["dermatan sulfate", "TREATMENT", 278, 294], ["chondroitin sulfate)", "TREATMENT", 300, 320], ["thrombin generation", "TREATMENT", 332, 351], ["factor Xa", "TREATMENT", 384, 393], ["antithrombin", "TREATMENT", 397, 409], ["thrombin", "TREATMENT", 431, 439], ["antithrombin", "TREATMENT", 443, 455], ["heparin cofactor II", "TREATMENT", 460, 479]]], ["36 Currently, danaparoid is predominantly used in patients with heparin-induced thrombocytopenia in several countries other than the United States.", [["danaparoid", "CHEMICAL", 14, 24], ["heparin", "CHEMICAL", 64, 71], ["thrombocytopenia", "DISEASE", 80, 96], ["danaparoid", "CHEMICAL", 14, 24], ["danaparoid", "SIMPLE_CHEMICAL", 14, 24], ["patients", "ORGANISM", 50, 58], ["heparin", "SIMPLE_CHEMICAL", 64, 71], ["patients", "SPECIES", 50, 58], ["danaparoid", "TREATMENT", 14, 24], ["heparin", "TREATMENT", 64, 71], ["thrombocytopenia", "PROBLEM", 80, 96], ["danaparoid", "OBSERVATION", 14, 24], ["thrombocytopenia", "OBSERVATION", 80, 96]]], ["ARDS is associated with dysregulated inflammation and coagulation.", [["ARDS", "DISEASE", 0, 4], ["inflammation", "DISEASE", 37, 49], ["ARDS", "PROBLEM", 0, 4], ["dysregulated inflammation", "PROBLEM", 24, 49], ["associated with", "UNCERTAINTY", 8, 23], ["dysregulated", "OBSERVATION_MODIFIER", 24, 36], ["inflammation", "OBSERVATION", 37, 49], ["coagulation", "OBSERVATION_MODIFIER", 54, 65]]], ["5, 20, 37 Patients with ARDS have an increased risk of venous thromboembolism (VTE) as well as thrombocytopenia, 38 renal failure, and bleeding.", [["venous", "ANATOMY", 55, 61], ["renal", "ANATOMY", 116, 121], ["ARDS", "DISEASE", 24, 28], ["venous thromboembolism", "DISEASE", 55, 77], ["VTE", "DISEASE", 79, 82], ["thrombocytopenia", "DISEASE", 95, 111], ["renal failure", "DISEASE", 116, 129], ["bleeding", "DISEASE", 135, 143], ["Patients", "ORGANISM", 10, 18], ["venous", "MULTI-TISSUE_STRUCTURE", 55, 61], ["renal", "ORGAN", 116, 121], ["Patients", "SPECIES", 10, 18], ["ARDS", "PROBLEM", 24, 28], ["venous thromboembolism", "PROBLEM", 55, 77], ["VTE", "PROBLEM", 79, 82], ["thrombocytopenia", "PROBLEM", 95, 111], ["38 renal failure", "PROBLEM", 113, 129], ["bleeding", "PROBLEM", 135, 143], ["ARDS", "OBSERVATION", 24, 28], ["increased", "OBSERVATION_MODIFIER", 37, 46], ["venous", "ANATOMY", 55, 61], ["thromboembolism", "OBSERVATION", 62, 77], ["thrombocytopenia", "OBSERVATION", 95, 111], ["renal", "ANATOMY", 116, 121], ["failure", "OBSERVATION", 122, 129], ["bleeding", "OBSERVATION", 135, 143]]], ["39 Because of its safety profile in patients with heparin-induced thrombocytopenia, its minor effects on platelet function 40 (particularly in sepsis), and potential for management of disseminated intravascular coagulation (DIC), 36 ,41 danaparoid appears to be an attractive option for research in critically ill patients with COVID-19.", [["platelet", "ANATOMY", 105, 113], ["intravascular", "ANATOMY", 197, 210], ["heparin", "CHEMICAL", 50, 57], ["thrombocytopenia", "DISEASE", 66, 82], ["sepsis", "DISEASE", 143, 149], ["disseminated intravascular coagulation", "DISEASE", 184, 222], ["DIC", "DISEASE", 224, 227], ["danaparoid", "CHEMICAL", 237, 247], ["critically ill", "DISEASE", 299, 313], ["COVID-19", "CHEMICAL", 328, 336], ["patients", "ORGANISM", 36, 44], ["heparin", "SIMPLE_CHEMICAL", 50, 57], ["platelet", "CELL", 105, 113], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 197, 210], ["patients", "ORGANISM", 314, 322], ["patients", "SPECIES", 36, 44], ["patients", "SPECIES", 314, 322], ["heparin", "TREATMENT", 50, 57], ["thrombocytopenia", "PROBLEM", 66, 82], ["platelet function", "TEST", 105, 122], ["sepsis", "PROBLEM", 143, 149], ["management", "TREATMENT", 170, 180], ["disseminated intravascular coagulation", "PROBLEM", 184, 222], ["danaparoid", "TREATMENT", 237, 247], ["COVID", "TEST", 328, 333], ["thrombocytopenia", "OBSERVATION", 66, 82], ["disseminated", "OBSERVATION_MODIFIER", 184, 196], ["intravascular coagulation", "OBSERVATION", 197, 222]]], ["Importantly, however, no reversal agent is available in the setting of bleeding complications.DanaparoidThrombi have been noted in the pulmonary arteries and vessels of other organs including the liver and kidneys in patients having died of COVID-19.", [["pulmonary arteries", "ANATOMY", 135, 153], ["vessels", "ANATOMY", 158, 165], ["organs", "ANATOMY", 175, 181], ["liver", "ANATOMY", 196, 201], ["kidneys", "ANATOMY", 206, 213], ["bleeding", "DISEASE", 71, 79], ["COVID-19", "CHEMICAL", 241, 249], ["pulmonary arteries", "MULTI-TISSUE_STRUCTURE", 135, 153], ["vessels", "MULTI-TISSUE_STRUCTURE", 158, 165], ["organs", "ORGAN", 175, 181], ["liver", "ORGAN", 196, 201], ["kidneys", "ORGAN", 206, 213], ["patients", "ORGANISM", 217, 225], ["patients", "SPECIES", 217, 225], ["reversal agent", "TREATMENT", 25, 39], ["bleeding complications", "PROBLEM", 71, 93], ["DanaparoidThrombi", "PROBLEM", 94, 111], ["COVID", "TEST", 241, 246], ["bleeding", "OBSERVATION", 71, 79], ["Thrombi", "OBSERVATION", 104, 111], ["pulmonary arteries", "ANATOMY", 135, 153], ["vessels", "ANATOMY", 158, 165], ["liver", "ANATOMY", 196, 201], ["kidneys", "ANATOMY", 206, 213]]], ["The presence of these in situ thrombi raises the possibility that widespread endothelial activation in COVID-19 triggers thrombosis.", [["endothelial", "ANATOMY", 77, 88], ["thrombi", "DISEASE", 30, 37], ["COVID-19", "CHEMICAL", 103, 111], ["thrombosis", "DISEASE", 121, 131], ["COVID-19", "CHEMICAL", 103, 111], ["endothelial", "CELL", 77, 88], ["COVID-19", "GENE_OR_GENE_PRODUCT", 103, 111], ["these in situ thrombi", "PROBLEM", 16, 37], ["widespread endothelial activation", "PROBLEM", 66, 99], ["COVID", "TEST", 103, 108], ["thrombosis", "PROBLEM", 121, 131], ["situ", "OBSERVATION_MODIFIER", 25, 29], ["thrombi", "OBSERVATION", 30, 37], ["raises the possibility that", "UNCERTAINTY", 38, 65], ["widespread", "OBSERVATION_MODIFIER", 66, 76], ["endothelial activation", "OBSERVATION", 77, 99], ["thrombosis", "OBSERVATION", 121, 131]]], ["42, 43 In animal models of sepsis, danaparoid reduces cytokine levels and attenuates thrombosis.", [["sepsis", "DISEASE", 27, 33], ["danaparoid", "CHEMICAL", 35, 45], ["thrombosis", "DISEASE", 85, 95], ["danaparoid", "CHEMICAL", 35, 45], ["danaparoid", "SIMPLE_CHEMICAL", 35, 45], ["cytokine", "PROTEIN", 54, 62], ["sepsis", "PROBLEM", 27, 33], ["danaparoid", "TREATMENT", 35, 45], ["cytokine levels", "TEST", 54, 69], ["attenuates thrombosis", "PROBLEM", 74, 95], ["sepsis", "OBSERVATION", 27, 33], ["danaparoid", "OBSERVATION", 35, 45], ["attenuates", "OBSERVATION_MODIFIER", 74, 84], ["thrombosis", "OBSERVATION", 85, 95]]], ["44, 45 Intra-alveolar deposits of fibrin and activated leukocytes also contribute to the respiratory failure in patients with COVID-19 pneumonia.", [["Intra-alveolar", "ANATOMY", 7, 21], ["leukocytes", "ANATOMY", 55, 65], ["respiratory", "ANATOMY", 89, 100], ["respiratory failure", "DISEASE", 89, 108], ["pneumonia", "DISEASE", 135, 144], ["fibrin", "GENE_OR_GENE_PRODUCT", 34, 40], ["leukocytes", "CELL", 55, 65], ["patients", "ORGANISM", 112, 120], ["fibrin", "PROTEIN", 34, 40], ["activated leukocytes", "CELL_TYPE", 45, 65], ["patients", "SPECIES", 112, 120], ["Intra-alveolar deposits of fibrin", "PROBLEM", 7, 40], ["activated leukocytes", "PROBLEM", 45, 65], ["the respiratory failure", "PROBLEM", 85, 108], ["COVID", "TEST", 126, 131], ["pneumonia", "PROBLEM", 135, 144], ["Intra-alveolar", "OBSERVATION_MODIFIER", 7, 21], ["deposits", "OBSERVATION", 22, 30], ["fibrin", "OBSERVATION", 34, 40], ["activated leukocytes", "OBSERVATION", 45, 65], ["respiratory failure", "OBSERVATION", 89, 108], ["pneumonia", "OBSERVATION", 135, 144]]], ["Danaparoid can be nebulized and has been shown to attenuate pulmonary coagulopathy, systemic coagulation, pulmonary inflammation, and improve survival in a lung injury model.", [["pulmonary", "ANATOMY", 60, 69], ["pulmonary", "ANATOMY", 106, 115], ["lung", "ANATOMY", 156, 160], ["Danaparoid", "CHEMICAL", 0, 10], ["pulmonary coagulopathy", "DISEASE", 60, 82], ["systemic coagulation", "DISEASE", 84, 104], ["pulmonary inflammation", "DISEASE", 106, 128], ["lung injury", "DISEASE", 156, 167], ["Danaparoid", "CHEMICAL", 0, 10], ["Danaparoid", "SIMPLE_CHEMICAL", 0, 10], ["pulmonary", "ORGAN", 60, 69], ["pulmonary", "ORGAN", 106, 115], ["lung", "ORGAN", 156, 160], ["Danaparoid", "TREATMENT", 0, 10], ["pulmonary coagulopathy", "PROBLEM", 60, 82], ["systemic coagulation", "PROBLEM", 84, 104], ["pulmonary inflammation", "PROBLEM", 106, 128], ["a lung injury model", "PROBLEM", 154, 173], ["pulmonary", "ANATOMY", 60, 69], ["coagulopathy", "OBSERVATION", 70, 82], ["pulmonary", "ANATOMY", 106, 115], ["inflammation", "OBSERVATION", 116, 128], ["lung", "ANATOMY", 156, 160], ["injury", "OBSERVATION", 161, 167]]], ["46 Nebulized danaparoid administration may concentrate its effect on the lungs and decrease the risk of systemic adverse reactions.", [["lungs", "ANATOMY", 73, 78], ["danaparoid", "CHEMICAL", 13, 23], ["lungs", "ORGAN", 73, 78], ["Nebulized danaparoid administration", "TREATMENT", 3, 38], ["systemic adverse reactions", "PROBLEM", 104, 130], ["danaparoid", "OBSERVATION", 13, 23], ["lungs", "ANATOMY", 73, 78], ["systemic", "OBSERVATION_MODIFIER", 104, 112]]], ["Although danaparoid is being empirically used in some centers, no published report or registered clinical trials exist for its use in COVID-19.Other Parenteral AnticoagulantsParenteral anticoagulants such as bivalirudin, argatroban, and fondaparinux have been studied in management of patients with acute coronary syndromes, VTE, and heparin-induced thrombocytopenia.", [["coronary", "ANATOMY", 305, 313], ["danaparoid", "CHEMICAL", 9, 19], ["bivalirudin", "CHEMICAL", 208, 219], ["argatroban", "CHEMICAL", 221, 231], ["fondaparinux", "CHEMICAL", 237, 249], ["acute coronary syndromes", "DISEASE", 299, 323], ["VTE", "DISEASE", 325, 328], ["heparin", "CHEMICAL", 334, 341], ["thrombocytopenia", "DISEASE", 350, 366], ["danaparoid", "CHEMICAL", 9, 19], ["bivalirudin", "CHEMICAL", 208, 219], ["argatroban", "CHEMICAL", 221, 231], ["fondaparinux", "CHEMICAL", 237, 249], ["danaparoid", "SIMPLE_CHEMICAL", 9, 19], ["bivalirudin", "SIMPLE_CHEMICAL", 208, 219], ["argatroban", "SIMPLE_CHEMICAL", 221, 231], ["fondaparinux", "SIMPLE_CHEMICAL", 237, 249], ["patients", "ORGANISM", 285, 293], ["coronary", "MULTI-TISSUE_STRUCTURE", 305, 313], ["heparin", "SIMPLE_CHEMICAL", 334, 341], ["patients", "SPECIES", 285, 293], ["danaparoid", "TREATMENT", 9, 19], ["COVID", "TEST", 134, 139], ["Other Parenteral AnticoagulantsParenteral anticoagulants", "TREATMENT", 143, 199], ["bivalirudin", "TREATMENT", 208, 219], ["argatroban", "TREATMENT", 221, 231], ["fondaparinux", "TREATMENT", 237, 249], ["acute coronary syndromes", "PROBLEM", 299, 323], ["VTE", "PROBLEM", 325, 328], ["heparin", "TREATMENT", 334, 341], ["thrombocytopenia", "PROBLEM", 350, 366], ["danaparoid", "OBSERVATION", 9, 19], ["acute", "OBSERVATION_MODIFIER", 299, 304], ["coronary", "ANATOMY", 305, 313], ["syndromes", "OBSERVATION", 314, 323], ["thrombocytopenia", "OBSERVATION", 350, 366]]], ["47, 48 However, these agents are more expensive than unfractionated heparin or LMWH, and there are limited data about their use in COVID-19.Vitamin-K AntagonistsVitamin-K antagonists (VKAs), including warfarin, function by inhibiting vitamin K epoxide reductase, which results in the prevention of the recycling of vitamin K epoxide back to its active form.", [["heparin", "CHEMICAL", 68, 75], ["LMWH", "CHEMICAL", 79, 83], ["Vitamin-K AntagonistsVitamin-K", "CHEMICAL", 140, 170], ["VKAs", "CHEMICAL", 184, 188], ["warfarin", "CHEMICAL", 201, 209], ["vitamin K", "CHEMICAL", 234, 243], ["vitamin K", "CHEMICAL", 315, 324], ["Vitamin-K AntagonistsVitamin-K", "CHEMICAL", 140, 170], ["warfarin", "CHEMICAL", 201, 209], ["vitamin K epoxide", "CHEMICAL", 234, 251], ["vitamin K epoxide", "CHEMICAL", 315, 332], ["heparin", "SIMPLE_CHEMICAL", 68, 75], ["LMWH", "SIMPLE_CHEMICAL", 79, 83], ["Vitamin-K AntagonistsVitamin-K antagonists", "GENE_OR_GENE_PRODUCT", 140, 182], ["VKAs", "SIMPLE_CHEMICAL", 184, 188], ["warfarin", "SIMPLE_CHEMICAL", 201, 209], ["vitamin K epoxide reductase", "GENE_OR_GENE_PRODUCT", 234, 261], ["vitamin K epoxide", "SIMPLE_CHEMICAL", 315, 332], ["vitamin K epoxide reductase", "PROTEIN", 234, 261], ["unfractionated heparin", "TREATMENT", 53, 75], ["LMWH", "TREATMENT", 79, 83], ["COVID", "TEST", 131, 136], ["Vitamin", "TREATMENT", 140, 147], ["K AntagonistsVitamin", "TREATMENT", 148, 168], ["K antagonists", "TREATMENT", 169, 182], ["VKAs", "TREATMENT", 184, 188], ["warfarin", "TREATMENT", 201, 209], ["function", "TREATMENT", 211, 219], ["vitamin K epoxide reductase", "TREATMENT", 234, 261], ["vitamin K epoxide", "TREATMENT", 315, 332], ["LMWH", "OBSERVATION", 79, 83]]], ["49 The active form of vitamin K is essential for synthesis of clotting factors in the coagulation cascade (e.g., II, VII, IX, and X) and anticoagulant factors (proteins C and S), 49 and so VKAs result in reduction of these factors.", [["vitamin K", "CHEMICAL", 22, 31], ["vitamin K", "CHEMICAL", 22, 31], ["vitamin K", "SIMPLE_CHEMICAL", 22, 31], ["clotting factors", "GENE_OR_GENE_PRODUCT", 62, 78], ["VII", "GENE_OR_GENE_PRODUCT", 117, 120], ["IX", "GENE_OR_GENE_PRODUCT", 122, 124], ["X", "GENE_OR_GENE_PRODUCT", 130, 131], ["anticoagulant factors", "GENE_OR_GENE_PRODUCT", 137, 158], ["proteins C", "GENE_OR_GENE_PRODUCT", 160, 170], ["VKAs", "GENE_OR_GENE_PRODUCT", 189, 193], ["clotting factors", "PROTEIN", 62, 78], ["VII", "PROTEIN", 117, 120], ["IX", "PROTEIN", 122, 124], ["X", "PROTEIN", 130, 131], ["anticoagulant factors", "PROTEIN", 137, 158], ["proteins C and S", "PROTEIN", 160, 176], ["VKAs", "PROTEIN", 189, 193], ["vitamin K", "TREATMENT", 22, 31], ["synthesis of clotting factors", "PROBLEM", 49, 78], ["the coagulation cascade", "TEST", 82, 105], ["anticoagulant factors", "TEST", 137, 158], ["proteins C and S)", "TEST", 160, 177], ["VKAs", "TREATMENT", 189, 193], ["these factors", "PROBLEM", 217, 230], ["active", "OBSERVATION_MODIFIER", 7, 13]]], ["These drugs are used for treatment of established thrombotic events (e.g., deep venous thrombosis or pulmonary embolism) or for prophylaxis in patients with specific indications (e.g., atrial fibrillation and prosthetic mechanical heart valves).", [["venous", "ANATOMY", 80, 86], ["pulmonary", "ANATOMY", 101, 110], ["atrial", "ANATOMY", 185, 191], ["heart", "ANATOMY", 231, 236], ["thrombotic events", "DISEASE", 50, 67], ["venous thrombosis", "DISEASE", 80, 97], ["pulmonary embolism", "DISEASE", 101, 119], ["atrial fibrillation", "DISEASE", 185, 204], ["venous", "MULTI-TISSUE_STRUCTURE", 80, 86], ["pulmonary", "ORGAN", 101, 110], ["patients", "ORGANISM", 143, 151], ["atrial", "MULTI-TISSUE_STRUCTURE", 185, 191], ["heart valves", "MULTI-TISSUE_STRUCTURE", 231, 243], ["patients", "SPECIES", 143, 151], ["These drugs", "TREATMENT", 0, 11], ["treatment", "TREATMENT", 25, 34], ["established thrombotic events", "PROBLEM", 38, 67], ["deep venous thrombosis", "PROBLEM", 75, 97], ["pulmonary embolism", "PROBLEM", 101, 119], ["prophylaxis", "TREATMENT", 128, 139], ["atrial fibrillation", "PROBLEM", 185, 204], ["prosthetic mechanical heart valves", "TREATMENT", 209, 243], ["thrombotic", "OBSERVATION", 50, 60], ["deep", "ANATOMY_MODIFIER", 75, 79], ["venous", "ANATOMY", 80, 86], ["thrombosis", "OBSERVATION", 87, 97], ["pulmonary", "ANATOMY", 101, 110], ["embolism", "OBSERVATION", 111, 119], ["atrial", "ANATOMY", 185, 191], ["fibrillation", "OBSERVATION", 192, 204], ["prosthetic mechanical heart valves", "OBSERVATION", 209, 243]]], ["However, in the course of COVID-19 there are several challenges with use of VKAs, including drugdrug interactions, and need for international normalized ratio monitoring, as described previously.", [["VKAs", "SIMPLE_CHEMICAL", 76, 80], ["COVID", "TEST", 26, 31], ["VKAs", "TREATMENT", 76, 80], ["drugdrug interactions", "TREATMENT", 92, 113], ["international normalized ratio monitoring", "TEST", 128, 169]]], ["5 There are currently no active studies evaluating the use of VKAs in COVID-19.Direct Oral AnticoagulantsBeyond their anticoagulant effects, DOACs, especially factor Xa inhibitors, may exert anti-inflammatory effects in COVID- 19.", [["DOACs", "CHEMICAL", 141, 146], ["DOACs", "SIMPLE_CHEMICAL", 141, 146], ["factor Xa", "GENE_OR_GENE_PRODUCT", 159, 168], ["active studies", "TEST", 25, 39], ["VKAs", "TREATMENT", 62, 66], ["COVID", "TEST", 70, 75], ["Direct Oral Anticoagulants", "TREATMENT", 79, 105], ["their anticoagulant effects", "TREATMENT", 112, 139], ["DOACs", "TREATMENT", 141, 146], ["factor Xa inhibitors", "TREATMENT", 159, 179], ["COVID", "TEST", 220, 225], ["no", "UNCERTAINTY", 22, 24], ["active", "OBSERVATION_MODIFIER", 25, 31], ["anticoagulant", "OBSERVATION", 118, 131]]], ["50 As has been demonstrated with rivaroxaban, DOACs can prevent arterial and venous thrombosis in patients with history of acute coronary syndrome, 51 stable atherosclerotic vascular disease, 52 or peripheral artery disease undergoing revascularization.", [["arterial", "ANATOMY", 64, 72], ["venous", "ANATOMY", 77, 83], ["coronary", "ANATOMY", 129, 137], ["vascular", "ANATOMY", 174, 182], ["peripheral artery", "ANATOMY", 198, 215], ["rivaroxaban", "CHEMICAL", 33, 44], ["DOACs", "CHEMICAL", 46, 51], ["arterial and venous thrombosis", "DISEASE", 64, 94], ["acute coronary syndrome", "DISEASE", 123, 146], ["atherosclerotic vascular disease", "DISEASE", 158, 190], ["peripheral artery disease", "DISEASE", 198, 223], ["rivaroxaban", "CHEMICAL", 33, 44], ["DOACs", "CHEMICAL", 46, 51], ["rivaroxaban", "SIMPLE_CHEMICAL", 33, 44], ["DOACs", "SIMPLE_CHEMICAL", 46, 51], ["arterial", "MULTI-TISSUE_STRUCTURE", 64, 72], ["venous", "MULTI-TISSUE_STRUCTURE", 77, 83], ["patients", "ORGANISM", 98, 106], ["vascular", "MULTI-TISSUE_STRUCTURE", 174, 182], ["peripheral artery", "MULTI-TISSUE_STRUCTURE", 198, 215], ["patients", "SPECIES", 98, 106], ["rivaroxaban", "TREATMENT", 33, 44], ["DOACs", "TREATMENT", 46, 51], ["arterial and venous thrombosis", "PROBLEM", 64, 94], ["acute coronary syndrome", "PROBLEM", 123, 146], ["stable atherosclerotic vascular disease", "PROBLEM", 151, 190], ["peripheral artery disease", "PROBLEM", 198, 223], ["revascularization", "TREATMENT", 235, 252], ["arterial", "ANATOMY", 64, 72], ["venous", "ANATOMY", 77, 83], ["thrombosis", "OBSERVATION", 84, 94], ["acute", "OBSERVATION_MODIFIER", 123, 128], ["coronary", "ANATOMY", 129, 137], ["syndrome", "OBSERVATION", 138, 146], ["stable", "OBSERVATION_MODIFIER", 151, 157], ["atherosclerotic", "OBSERVATION", 158, 173], ["vascular", "ANATOMY", 174, 182], ["disease", "OBSERVATION", 183, 190], ["peripheral artery", "ANATOMY", 198, 215], ["disease", "OBSERVATION", 216, 223], ["revascularization", "OBSERVATION", 235, 252]]], ["53 Rivaroxaban and betrixaban reduce the risk of VTE in medically ill patients.", [["Rivaroxaban", "CHEMICAL", 3, 14], ["betrixaban", "CHEMICAL", 19, 29], ["VTE", "DISEASE", 49, 52], ["medically ill", "DISEASE", 56, 69], ["Rivaroxaban", "CHEMICAL", 3, 14], ["betrixaban", "CHEMICAL", 19, 29], ["Rivaroxaban", "SIMPLE_CHEMICAL", 3, 14], ["betrixaban", "SIMPLE_CHEMICAL", 19, 29], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["Rivaroxaban", "TREATMENT", 3, 14], ["betrixaban", "TREATMENT", 19, 29], ["VTE", "PROBLEM", 49, 52]]], ["[54] [55] [56] As such, there is interest in administering DOACs to patients with severe COVID-19.", [["[54] [55] [56] As", "CHEMICAL", 0, 17], ["COVID-19", "CHEMICAL", 89, 97], ["DOACs", "SIMPLE_CHEMICAL", 59, 64], ["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["DOACs", "TREATMENT", 59, 64], ["severe COVID", "PROBLEM", 82, 94]]], ["These benefits should be weighed against the increased risk of bleeding events.", [["bleeding", "DISEASE", 63, 71], ["bleeding events", "PROBLEM", 63, 78], ["bleeding", "OBSERVATION", 63, 71]]], ["DOACs offer the potential for in-hospital and posthospital VTE prophylaxis.", [["VTE", "DISEASE", 59, 62], ["DOACs", "SIMPLE_CHEMICAL", 0, 5], ["DOACs", "TREATMENT", 0, 5], ["posthospital VTE prophylaxis", "TREATMENT", 46, 74]]], ["Results of studies with DOACs for extended prophylaxis in medically ill patients without COVID-19 have been mixed.", [["DOACs", "CHEMICAL", 24, 29], ["COVID-19", "CHEMICAL", 89, 97], ["DOACs", "SIMPLE_CHEMICAL", 24, 29], ["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["studies", "TEST", 11, 18], ["DOACs", "TREATMENT", 24, 29], ["extended prophylaxis", "TREATMENT", 34, 54], ["COVID", "TREATMENT", 89, 94]]], ["54, 57 However, recent investigations in patients who are at high risk for VTE and low risk for bleeding (including those with severe infection) have demonstrated a net clinical benefit, especially for extended thromboprophylaxis posthospital discharge with betrixaban or rivaroxaban.", [["VTE", "DISEASE", 75, 78], ["bleeding", "DISEASE", 96, 104], ["infection", "DISEASE", 134, 143], ["betrixaban", "CHEMICAL", 258, 268], ["rivaroxaban", "CHEMICAL", 272, 283], ["betrixaban", "CHEMICAL", 258, 268], ["rivaroxaban", "CHEMICAL", 272, 283], ["patients", "ORGANISM", 41, 49], ["betrixaban", "SIMPLE_CHEMICAL", 258, 268], ["rivaroxaban", "SIMPLE_CHEMICAL", 272, 283], ["patients", "SPECIES", 41, 49], ["VTE", "PROBLEM", 75, 78], ["bleeding", "PROBLEM", 96, 104], ["severe infection", "PROBLEM", 127, 143], ["betrixaban", "TREATMENT", 258, 268], ["rivaroxaban", "TREATMENT", 272, 283], ["bleeding", "OBSERVATION", 96, 104], ["infection", "OBSERVATION", 134, 143]]], ["54, 58 There is currently one registered clinical trial (C-19-ACS) assessing low-dose rivaroxaban along with dualantiplatelet therapy, statins, and a proton-pump inhibitor in patients with COVID-19 and a suspected acute coronary syndrome (NCT04333407).Direct Oral AnticoagulantsA few centers have integrated DOACs into VTE prophylaxis algorithms for both in-hospital and postdischarge care.", [["coronary", "ANATOMY", 220, 228], ["rivaroxaban", "CHEMICAL", 86, 97], ["dualantiplatelet", "CHEMICAL", 109, 125], ["statins", "CHEMICAL", 135, 142], ["COVID-19", "CHEMICAL", 189, 197], ["acute coronary syndrome", "DISEASE", 214, 237], ["VTE", "DISEASE", 319, 322], ["rivaroxaban", "CHEMICAL", 86, 97], ["statins", "CHEMICAL", 135, 142], ["rivaroxaban", "SIMPLE_CHEMICAL", 86, 97], ["dualantiplatelet", "SIMPLE_CHEMICAL", 109, 125], ["statins", "SIMPLE_CHEMICAL", 135, 142], ["patients", "ORGANISM", 175, 183], ["patients", "SPECIES", 175, 183], ["C", "TEST", 57, 58], ["low-dose rivaroxaban", "TREATMENT", 77, 97], ["dualantiplatelet therapy", "TREATMENT", 109, 133], ["statins", "TREATMENT", 135, 142], ["a proton-pump inhibitor", "TREATMENT", 148, 171], ["COVID", "TEST", 189, 194], ["a suspected acute coronary syndrome", "PROBLEM", 202, 237], ["Direct Oral AnticoagulantsA few centers", "TREATMENT", 252, 291], ["integrated DOACs", "TREATMENT", 297, 313], ["VTE prophylaxis algorithms", "TREATMENT", 319, 345], ["acute", "OBSERVATION_MODIFIER", 214, 219], ["coronary", "ANATOMY", 220, 228], ["syndrome", "OBSERVATION", 229, 237]]], ["28 However, concerns remain about DOAC use in patients with COVID-19-associated complications, including its renal clearance and acute renal insufficiency, need for invasive procedures (e.g., dialysis access), extracorporeal membrane oxygenation, and difficultly in administering reversal agents.", [["renal", "ANATOMY", 109, 114], ["renal", "ANATOMY", 135, 140], ["extracorporeal membrane", "ANATOMY", 210, 233], ["DOAC", "CHEMICAL", 34, 38], ["acute renal insufficiency", "DISEASE", 129, 154], ["DOAC", "CHEMICAL", 34, 38], ["DOAC", "SIMPLE_CHEMICAL", 34, 38], ["patients", "ORGANISM", 46, 54], ["renal", "ORGAN", 109, 114], ["renal", "ORGAN", 135, 140], ["extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 210, 233], ["patients", "SPECIES", 46, 54], ["DOAC", "TREATMENT", 34, 38], ["COVID", "TEST", 60, 65], ["associated complications", "PROBLEM", 69, 93], ["its renal clearance", "PROBLEM", 105, 124], ["acute renal insufficiency", "PROBLEM", 129, 154], ["invasive procedures", "TREATMENT", 165, 184], ["dialysis access", "TREATMENT", 192, 207], ["extracorporeal membrane oxygenation", "TREATMENT", 210, 245], ["reversal agents", "TREATMENT", 280, 295], ["complications", "OBSERVATION", 80, 93], ["renal", "ANATOMY", 109, 114], ["acute", "OBSERVATION_MODIFIER", 129, 134], ["renal", "ANATOMY", 135, 140], ["insufficiency", "OBSERVATION", 141, 154]]], ["59, 60 Finally, drug-drug interactions need to be considered when using DOACs with some investigational COVID-19 therapies (see \u25baFig. 4).", [["DOACs", "SIMPLE_CHEMICAL", 72, 77], ["DOACs", "TREATMENT", 72, 77], ["some investigational COVID", "TREATMENT", 83, 109]]], ["5 A recent small study showed increased absorption with high drug levels of DOACs in patients with COVID-19 who received antiviral agents.", [["DOACs", "SIMPLE_CHEMICAL", 76, 81], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["A recent small study", "TEST", 2, 22], ["increased absorption", "PROBLEM", 30, 50], ["DOACs", "TREATMENT", 76, 81], ["COVID", "TEST", 99, 104], ["antiviral agents", "TREATMENT", 121, 137], ["small", "OBSERVATION_MODIFIER", 11, 16], ["increased", "OBSERVATION_MODIFIER", 30, 39], ["absorption", "OBSERVATION_MODIFIER", 40, 50]]], ["61 DOACs may offer an attractive option to prevent thromboembolic events in the prehospitalization period for high-risk patient groups with COVID-19, such as those with underlying cardiovascular disease or high VTE risk factors.", [["cardiovascular", "ANATOMY", 180, 194], ["thromboembolic", "DISEASE", 51, 65], ["cardiovascular disease", "DISEASE", 180, 202], ["VTE", "DISEASE", 211, 214], ["patient", "ORGANISM", 120, 127], ["cardiovascular", "ANATOMICAL_SYSTEM", 180, 194], ["patient", "SPECIES", 120, 127], ["an attractive option", "TREATMENT", 19, 39], ["thromboembolic events", "PROBLEM", 51, 72], ["COVID", "TREATMENT", 140, 145], ["underlying cardiovascular disease", "PROBLEM", 169, 202], ["high VTE risk factors", "PROBLEM", 206, 227], ["thromboembolic", "OBSERVATION", 51, 65], ["cardiovascular", "ANATOMY", 180, 194], ["disease", "OBSERVATION", 195, 202]]], ["There is at least one planned study with rivaroxaban underway in outpatients with COVID-19 (Prevent HD).Direct Oral AnticoagulantsIn patients with high suspicious for VTE, diagnosis should be sought when possible.", [["rivaroxaban", "CHEMICAL", 41, 52], ["COVID-19", "CHEMICAL", 82, 90], ["VTE", "DISEASE", 167, 170], ["rivaroxaban", "CHEMICAL", 41, 52], ["COVID-19", "CHEMICAL", 82, 90], ["rivaroxaban", "SIMPLE_CHEMICAL", 41, 52], ["patients", "ORGANISM", 133, 141], ["patients", "SPECIES", 133, 141], ["rivaroxaban", "TREATMENT", 41, 52], ["COVID", "TEST", 82, 87], ["HD", "TREATMENT", 100, 102], ["Direct Oral Anticoagulants", "TREATMENT", 104, 130], ["VTE", "PROBLEM", 167, 170]]], ["For empiric treatment of select patients in whom presumed VTE events cannot be confirmed during the hospitalization period, for logistical reasons, use of DOACs upon hospital discharge offers additional convenience.", [["VTE", "DISEASE", 58, 61], ["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["empiric treatment", "TREATMENT", 4, 21], ["VTE events", "PROBLEM", 58, 68], ["DOACs", "TREATMENT", 155, 160]]], ["62 Challenges with this approach include the uncertainty in the diagnosis of VTE, and that delayed VTE imaging may not have sufficiently high negative predictive value to exclude an earlier event.", [["VTE", "DISEASE", 77, 80], ["VTE", "DISEASE", 99, 102], ["this approach", "TREATMENT", 19, 32], ["VTE", "PROBLEM", 77, 80], ["delayed VTE imaging", "TEST", 91, 110], ["an earlier event", "PROBLEM", 179, 195]]], ["Some COVID-19 patients will not be candidates for DOACs, such as those with severe renal dysfunction, mechanical heart valves, and antiphospholipid syndrome, or those taking antiviral or immunomodulatory medications that may be associated with drug-drug interactions, and poor medication adherence.SulodexideSulodexide is an orally administered purified glycosaminoglycan consisting of heparan sulfate (80%) and dermatan sulfate.", [["renal", "ANATOMY", 83, 88], ["heart", "ANATOMY", 113, 118], ["renal dysfunction", "DISEASE", 83, 100], ["mechanical heart valves", "DISEASE", 102, 125], ["antiphospholipid syndrome", "DISEASE", 131, 156], ["SulodexideSulodexide", "CHEMICAL", 298, 318], ["glycosaminoglycan", "CHEMICAL", 354, 371], ["heparan sulfate", "CHEMICAL", 386, 401], ["dermatan sulfate", "CHEMICAL", 412, 428], ["SulodexideSulodexide", "CHEMICAL", 298, 318], ["heparan sulfate", "CHEMICAL", 386, 401], ["dermatan sulfate", "CHEMICAL", 412, 428], ["patients", "ORGANISM", 14, 22], ["renal", "ORGAN", 83, 88], ["heart", "ORGAN", 113, 118], ["SulodexideSulodexide", "SIMPLE_CHEMICAL", 298, 318], ["glycosaminoglycan", "SIMPLE_CHEMICAL", 354, 371], ["heparan sulfate", "SIMPLE_CHEMICAL", 386, 401], ["dermatan sulfate", "SIMPLE_CHEMICAL", 412, 428], ["patients", "SPECIES", 14, 22], ["Some COVID", "TREATMENT", 0, 10], ["DOACs", "TREATMENT", 50, 55], ["severe renal dysfunction", "PROBLEM", 76, 100], ["mechanical heart valves", "PROBLEM", 102, 125], ["antiphospholipid syndrome", "PROBLEM", 131, 156], ["antiviral", "TREATMENT", 174, 183], ["immunomodulatory medications", "TREATMENT", 187, 215], ["poor medication adherence", "PROBLEM", 272, 297], ["SulodexideSulodexide", "TREATMENT", 298, 318], ["an orally administered purified glycosaminoglycan", "TREATMENT", 322, 371], ["heparan sulfate", "TREATMENT", 386, 401], ["dermatan sulfate", "TREATMENT", 412, 428], ["renal", "ANATOMY", 83, 88], ["dysfunction", "OBSERVATION", 89, 100], ["mechanical", "OBSERVATION", 102, 112], ["heart valves", "ANATOMY", 113, 125], ["antiphospholipid syndrome", "OBSERVATION", 131, 156]]], ["63 It exerts antithrombotic properties through reduction of fibrinogen 64,65 and plasminogen activator inhibitor-1 (PAI-1) 64,66 and is thought to have anti-inflammatory properties.", [["fibrinogen 64,65", "GENE_OR_GENE_PRODUCT", 60, 76], ["plasminogen activator inhibitor-1", "GENE_OR_GENE_PRODUCT", 81, 114], ["PAI-1", "GENE_OR_GENE_PRODUCT", 116, 121], ["fibrinogen 64,65", "PROTEIN", 60, 76], ["antithrombotic properties", "TREATMENT", 13, 38], ["fibrinogen", "TEST", 60, 70], ["plasminogen activator inhibitor", "TREATMENT", 81, 112], ["PAI", "TEST", 116, 119], ["anti-inflammatory properties", "TREATMENT", 152, 180], ["antithrombotic properties", "OBSERVATION_MODIFIER", 13, 38], ["anti-inflammatory properties", "OBSERVATION", 152, 180]]], ["65, 67, 68 In a recent systematic review of randomized trials across a variety of cardiovascular indications, use of sulodexide compared with control was associated with reduced risk of VTE, myocardial infarction, cardiovascular mortality, and all-cause mortality.", [["cardiovascular", "ANATOMY", 82, 96], ["myocardial", "ANATOMY", 191, 201], ["cardiovascular", "ANATOMY", 214, 228], ["sulodexide", "CHEMICAL", 117, 127], ["VTE", "DISEASE", 186, 189], ["myocardial infarction", "DISEASE", 191, 212], ["cardiovascular mortality", "DISEASE", 214, 238], ["sulodexide", "CHEMICAL", 117, 127], ["cardiovascular", "ANATOMICAL_SYSTEM", 82, 96], ["sulodexide", "SIMPLE_CHEMICAL", 117, 127], ["myocardial", "MULTI-TISSUE_STRUCTURE", 191, 201], ["randomized trials", "TREATMENT", 44, 61], ["sulodexide", "TREATMENT", 117, 127], ["VTE", "PROBLEM", 186, 189], ["myocardial infarction", "PROBLEM", 191, 212], ["cardiovascular mortality", "PROBLEM", 214, 238], ["VTE", "OBSERVATION", 186, 189], ["myocardial", "ANATOMY", 191, 201], ["infarction", "OBSERVATION", 202, 212]]], ["69 Despite the potential interest, limited data exist about the safety and efficacy of sulodexide in patients with COVID-19 and there are currently no registered trials for sulodexide in these patients.Systemic Fibrinolytic TherapySystemic fibrinolytic (thrombolytic) therapy is approved for management of ST-segment elevation myocardial infarction, ischemic stroke, and high-risk pulmonary embolism.", [["myocardial", "ANATOMY", 327, 337], ["pulmonary", "ANATOMY", 381, 390], ["sulodexide", "CHEMICAL", 87, 97], ["sulodexide", "CHEMICAL", 173, 183], ["ST-segment elevation myocardial infarction", "DISEASE", 306, 348], ["ischemic stroke", "DISEASE", 350, 365], ["high-risk pulmonary embolism", "DISEASE", 371, 399], ["sulodexide", "CHEMICAL", 87, 97], ["sulodexide", "CHEMICAL", 173, 183], ["sulodexide", "SIMPLE_CHEMICAL", 87, 97], ["patients", "ORGANISM", 101, 109], ["sulodexide", "SIMPLE_CHEMICAL", 173, 183], ["patients", "ORGANISM", 193, 201], ["myocardial", "MULTI-TISSUE_STRUCTURE", 327, 337], ["pulmonary", "ORGAN", 381, 390], ["patients", "SPECIES", 101, 109], ["patients", "SPECIES", 193, 201], ["sulodexide", "TREATMENT", 87, 97], ["COVID", "TEST", 115, 120], ["sulodexide", "TREATMENT", 173, 183], ["Systemic Fibrinolytic TherapySystemic fibrinolytic (thrombolytic) therapy", "TREATMENT", 202, 275], ["management", "TREATMENT", 292, 302], ["ST-segment elevation myocardial infarction", "PROBLEM", 306, 348], ["ischemic stroke", "PROBLEM", 350, 365], ["high-risk pulmonary embolism", "PROBLEM", 371, 399], ["segment", "ANATOMY_MODIFIER", 309, 316], ["elevation myocardial", "ANATOMY", 317, 337], ["infarction", "OBSERVATION", 338, 348], ["ischemic", "OBSERVATION_MODIFIER", 350, 358], ["stroke", "OBSERVATION", 359, 365], ["high", "OBSERVATION_MODIFIER", 371, 375], ["risk", "OBSERVATION_MODIFIER", 376, 380], ["pulmonary", "ANATOMY", 381, 390], ["embolism", "OBSERVATION", 391, 399]]], ["Off-label use has been reported for the treatment of a small number of severely ill patients with ARDS secondary to COVID-19.", [["ill", "DISEASE", 80, 83], ["ARDS", "DISEASE", 98, 102], ["COVID-19", "CHEMICAL", 116, 124], ["COVID-19", "CHEMICAL", 116, 124], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["ARDS", "PROBLEM", 98, 102], ["COVID", "TEST", 116, 121], ["small", "OBSERVATION_MODIFIER", 55, 60], ["severely", "OBSERVATION_MODIFIER", 71, 79], ["ill", "OBSERVATION_MODIFIER", 80, 83], ["ARDS", "OBSERVATION", 98, 102]]], ["[70] [71] [72] While empiric use of fibrinolytic agents is not based on solid clinical evidence and confers significant bleeding risk, there is precedent for its use in ARDS.", [["bleeding", "DISEASE", 120, 128], ["ARDS", "DISEASE", 169, 173], ["fibrinolytic agents", "TREATMENT", 36, 55], ["significant bleeding risk", "PROBLEM", 108, 133], ["ARDS", "PROBLEM", 169, 173], ["significant", "OBSERVATION_MODIFIER", 108, 119], ["bleeding", "OBSERVATION", 120, 128], ["ARDS", "OBSERVATION", 169, 173]]], ["As with other causes of ARDS, fibrin-rich hyaline membranes have been reported in lung biopsy specimens from patients with COVID-19.", [["hyaline membranes", "ANATOMY", 42, 59], ["lung biopsy specimens", "ANATOMY", 82, 103], ["ARDS", "DISEASE", 24, 28], ["fibrin", "GENE_OR_GENE_PRODUCT", 30, 36], ["hyaline membranes", "CELLULAR_COMPONENT", 42, 59], ["lung biopsy specimens", "CANCER", 82, 103], ["patients", "ORGANISM", 109, 117], ["fibrin", "PROTEIN", 30, 36], ["patients", "SPECIES", 109, 117], ["ARDS", "PROBLEM", 24, 28], ["fibrin-rich hyaline membranes", "PROBLEM", 30, 59], ["lung biopsy specimens", "TEST", 82, 103], ["COVID", "TEST", 123, 128], ["ARDS", "OBSERVATION", 24, 28], ["fibrin", "OBSERVATION", 30, 36], ["rich", "OBSERVATION_MODIFIER", 37, 41], ["hyaline membranes", "OBSERVATION", 42, 59], ["lung", "ANATOMY", 82, 86], ["biopsy", "OBSERVATION", 87, 93]]], ["73 Additionally, D-dimer, prothrombin time, and fibrinogen levels may all be increased in COVID-19 patients with significant lung involvement, 74 suggesting derangement of coagulation.", [["lung", "ANATOMY", 125, 129], ["derangement of coagulation", "DISEASE", 157, 183], ["D-dimer", "SIMPLE_CHEMICAL", 17, 24], ["prothrombin", "GENE_OR_GENE_PRODUCT", 26, 37], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 48, 58], ["patients", "ORGANISM", 99, 107], ["lung", "ORGAN", 125, 129], ["prothrombin", "PROTEIN", 26, 37], ["fibrinogen", "PROTEIN", 48, 58], ["patients", "SPECIES", 99, 107], ["D-dimer", "TEST", 17, 24], ["prothrombin time", "TEST", 26, 42], ["fibrinogen levels", "TEST", 48, 65], ["COVID", "TEST", 90, 95], ["significant lung involvement", "PROBLEM", 113, 141], ["derangement of coagulation", "PROBLEM", 157, 183], ["increased", "OBSERVATION_MODIFIER", 77, 86], ["significant", "OBSERVATION_MODIFIER", 113, 124], ["lung", "ANATOMY", 125, 129], ["involvement", "OBSERVATION", 130, 141]]], ["The presence of microthrombi in the pulmonary microcirculation has been implicated as a possible mechanism for clinical deterioration.", [["pulmonary", "ANATOMY", 36, 45], ["pulmonary", "ORGAN", 36, 45], ["microthrombi in the pulmonary microcirculation", "PROBLEM", 16, 62], ["clinical deterioration", "PROBLEM", 111, 133], ["microthrombi", "OBSERVATION", 16, 28], ["pulmonary microcirculation", "ANATOMY", 36, 62]]], ["75 Fibrinolytic agents such as urokinase and tissue-type plasminogen activator have reduced the risk of ARDS in porcine models.", [["Fibrinolytic", "ANATOMY", 3, 15], ["ARDS", "DISEASE", 104, 108], ["urokinase", "GENE_OR_GENE_PRODUCT", 31, 40], ["tissue-type plasminogen activator", "GENE_OR_GENE_PRODUCT", 45, 78], ["porcine", "ORGANISM", 112, 119], ["urokinase", "PROTEIN", 31, 40], ["Fibrinolytic agents", "TREATMENT", 3, 22], ["urokinase and tissue-type plasminogen activator", "TREATMENT", 31, 78], ["ARDS in porcine models", "PROBLEM", 104, 126], ["ARDS", "OBSERVATION", 104, 108]]], ["76 Similarly, lung-protective findings have Therapeutic Targets for COVID-19-Associated Thrombosis Bikdeli et al.Systemic Fibrinolytic Therapybeen noted in murine models.", [["lung", "ANATOMY", 14, 18], ["Thrombosis", "DISEASE", 88, 98], ["COVID-19", "CHEMICAL", 68, 76], ["lung", "ORGAN", 14, 18], ["COVID-19", "SIMPLE_CHEMICAL", 68, 76], ["murine", "ORGANISM", 156, 162], ["murine", "SPECIES", 156, 162], ["COVID", "TEST", 68, 73], ["Thrombosis Bikdeli", "PROBLEM", 88, 106], ["Systemic Fibrinolytic Therapybeen", "TEST", 113, 146], ["lung", "ANATOMY", 14, 18], ["Thrombosis", "OBSERVATION", 88, 98], ["Fibrinolytic", "OBSERVATION", 122, 134]]], ["77 A meta-analysis of preclinical studies corroborated these findings in various animal models.", [["preclinical studies", "TEST", 22, 41]]], ["78 Anecdotal reports have noted improvement in oxygenation and ventilation parameters.", [["oxygenation", "TEST", 47, 58], ["ventilation parameters", "TEST", 63, 85], ["improvement", "OBSERVATION_MODIFIER", 32, 43], ["oxygenation", "OBSERVATION_MODIFIER", 47, 58]]], ["79 A recent small study (n \u00bc 60) study found improvement in surrogate parameters of ventilation and a reduction in ICU mortality in patients with severe non-COVID-19-related ARDS treated with inhaled streptokinase.", [["ARDS", "DISEASE", 174, 178], ["streptokinase", "CHEMICAL", 200, 213], ["patients", "ORGANISM", 132, 140], ["inhaled streptokinase", "SIMPLE_CHEMICAL", 192, 213], ["patients", "SPECIES", 132, 140], ["A recent small study", "TEST", 3, 23], ["study", "TEST", 33, 38], ["ventilation", "TREATMENT", 84, 95], ["a reduction", "TREATMENT", 100, 111], ["severe non-COVID-19", "PROBLEM", 146, 165], ["ARDS", "PROBLEM", 174, 178], ["inhaled streptokinase", "TREATMENT", 192, 213], ["small", "OBSERVATION_MODIFIER", 12, 17], ["improvement", "OBSERVATION_MODIFIER", 45, 56], ["ARDS", "OBSERVATION", 174, 178]]], ["80 The bleeding risks of fibrinolysis must be balanced against these preclinical data and small human series.", [["bleeding", "DISEASE", 7, 15], ["human", "ORGANISM", 96, 101], ["human", "SPECIES", 96, 101], ["human", "SPECIES", 96, 101], ["The bleeding risks of fibrinolysis", "PROBLEM", 3, 37], ["these preclinical data", "TEST", 63, 85], ["small human series", "TEST", 90, 108], ["bleeding", "OBSERVATION", 7, 15], ["fibrinolysis", "OBSERVATION", 25, 37]]], ["Systemic fibrinolysis has been associated with a 1 to 3% rate of intracranial hemorrhage and notable risk of other forms of major bleeding across a wide span of acute diseases.", [["intracranial", "ANATOMY", 65, 77], ["intracranial hemorrhage", "DISEASE", 65, 88], ["bleeding", "DISEASE", 130, 138], ["intracranial", "IMMATERIAL_ANATOMICAL_ENTITY", 65, 77], ["Systemic fibrinolysis", "PROBLEM", 0, 21], ["intracranial hemorrhage", "PROBLEM", 65, 88], ["major bleeding", "PROBLEM", 124, 138], ["acute diseases", "PROBLEM", 161, 175], ["fibrinolysis", "OBSERVATION", 9, 21], ["intracranial", "ANATOMY", 65, 77], ["hemorrhage", "OBSERVATION", 78, 88], ["notable", "OBSERVATION_MODIFIER", 93, 100], ["major", "OBSERVATION_MODIFIER", 124, 129], ["bleeding", "OBSERVATION", 130, 138], ["wide", "OBSERVATION_MODIFIER", 148, 152], ["span", "OBSERVATION_MODIFIER", 153, 157], ["acute", "OBSERVATION_MODIFIER", 161, 166], ["diseases", "OBSERVATION", 167, 175]]], ["[81] [82] [83] Additionally, there is concern for diffuse alveolar hemorrhage after fibrinolysis, though reports of this complication have yet to be reported.", [["alveolar", "ANATOMY", 58, 66], ["alveolar hemorrhage", "DISEASE", 58, 77], ["alveolar", "MULTI-TISSUE_STRUCTURE", 58, 66], ["diffuse alveolar hemorrhage", "PROBLEM", 50, 77], ["fibrinolysis", "PROBLEM", 84, 96], ["this complication", "PROBLEM", 116, 133], ["concern for", "UNCERTAINTY", 38, 49], ["diffuse", "OBSERVATION_MODIFIER", 50, 57], ["alveolar", "ANATOMY_MODIFIER", 58, 66], ["hemorrhage", "OBSERVATION", 67, 77], ["fibrinolysis", "OBSERVATION", 84, 96]]], ["Prior studies have suggested fibrinolytic agents such as alteplase can be associated with prolonged hypofibrinogenemia.", [["alteplase", "CHEMICAL", 57, 66], ["hypofibrinogenemia", "DISEASE", 100, 118], ["alteplase", "SIMPLE_CHEMICAL", 57, 66], ["Prior studies", "TEST", 0, 13], ["fibrinolytic agents", "TREATMENT", 29, 48], ["alteplase", "TREATMENT", 57, 66], ["prolonged hypofibrinogenemia", "PROBLEM", 90, 118], ["hypofibrinogenemia", "OBSERVATION", 100, 118]]], ["84 Based on the present evidence utilization of fibrinolysis for COVID-19-associated ARDS, even when severe, cannot uniformly be recommended given its unknown risk-benefit ratio.", [["COVID-19", "CHEMICAL", 65, 73], ["ARDS", "DISEASE", 85, 89], ["COVID-19", "SIMPLE_CHEMICAL", 65, 73], ["fibrinolysis", "PROBLEM", 48, 60], ["COVID", "TEST", 65, 70], ["ARDS", "PROBLEM", 85, 89], ["fibrinolysis", "OBSERVATION", 48, 60], ["ARDS", "OBSERVATION", 85, 89]]], ["However, investigational use of fibrinolytic agents in carefully selected patients may be considered.", [["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["fibrinolytic agents", "TREATMENT", 32, 51]]], ["A phase 2a randomized trial is underway to test the hypothesis whether systemic tissue-type plasminogen activator results in an improvement of respiratory function/oxygenation and reduction in mortality (NCT04357730).", [["respiratory", "ANATOMY", 143, 154], ["tissue-type plasminogen activator", "GENE_OR_GENE_PRODUCT", 80, 113], ["A phase 2a randomized trial", "TREATMENT", 0, 27], ["systemic tissue", "TEST", 71, 86], ["type plasminogen activator", "PROBLEM", 87, 113], ["respiratory function", "OBSERVATION", 143, 163], ["oxygenation", "OBSERVATION_MODIFIER", 164, 175], ["reduction", "OBSERVATION_MODIFIER", 180, 189]]], ["Further, inhaled fibrinolytic agents are an interesting option, potentially limiting systemic complications.", [["inhaled fibrinolytic agents", "TREATMENT", 9, 36], ["an interesting option", "TREATMENT", 41, 62], ["systemic complications", "PROBLEM", 85, 107]]], ["85 Assessment of their safety and efficacy requires further investigation (NCT04356833).Antiplatelet AgentsAspirin Dysregulated immune response and abnormal coagulation are common occurrences in the pathophysiology of viral sepsis, ARDS, and organ failure in COVID-19.", [["organ", "ANATOMY", 242, 247], ["AgentsAspirin", "CHEMICAL", 101, 114], ["abnormal coagulation", "DISEASE", 148, 168], ["viral sepsis", "DISEASE", 218, 230], ["ARDS", "DISEASE", 232, 236], ["organ failure", "DISEASE", 242, 255], ["AgentsAspirin", "SIMPLE_CHEMICAL", 101, 114], ["organ", "ORGAN", 242, 247], ["further investigation", "TEST", 52, 73], ["Antiplatelet AgentsAspirin", "TREATMENT", 88, 114], ["abnormal coagulation", "PROBLEM", 148, 168], ["viral sepsis", "PROBLEM", 218, 230], ["ARDS", "PROBLEM", 232, 236], ["organ failure", "PROBLEM", 242, 255], ["COVID", "TEST", 259, 264], ["viral", "OBSERVATION_MODIFIER", 218, 223], ["sepsis", "OBSERVATION", 224, 230], ["ARDS", "OBSERVATION", 232, 236], ["organ", "ANATOMY", 242, 247], ["failure", "OBSERVATION", 248, 255]]], ["86 Platelets play a key role in the pathogenesis of sepsis and thrombosis, and are a potential target for prevention of the complications.", [["Platelets", "ANATOMY", 3, 12], ["sepsis", "DISEASE", 52, 58], ["thrombosis", "DISEASE", 63, 73], ["Platelets", "CELL", 3, 12], ["sepsis", "PROBLEM", 52, 58], ["thrombosis", "PROBLEM", 63, 73], ["the complications", "PROBLEM", 120, 137], ["sepsis", "OBSERVATION", 52, 58], ["thrombosis", "OBSERVATION", 63, 73], ["complications", "OBSERVATION", 124, 137]]], ["87 In addition to thrombosis and hemostasis, platelets have immunomodulatory activity, including both inflammatory and anti-inflammatory responses, as well as an effect on antimicrobial host defense.", [["platelets", "ANATOMY", 45, 54], ["thrombosis", "DISEASE", 18, 28], ["platelets", "CELL", 45, 54], ["platelets", "CELL_TYPE", 45, 54], ["thrombosis", "PROBLEM", 18, 28], ["hemostasis", "TREATMENT", 33, 43], ["platelets", "TEST", 45, 54], ["immunomodulatory activity", "PROBLEM", 60, 85], ["thrombosis", "OBSERVATION", 18, 28], ["hemostasis", "OBSERVATION", 33, 43], ["inflammatory", "OBSERVATION_MODIFIER", 102, 114], ["anti-inflammatory responses", "OBSERVATION", 119, 146]]], ["88, 89 There is evidence that the initial intrinsic defense against infections is mediated by platelet-neutrophil cross-communication that tightly regulates immune and complement responses.", [["platelet", "ANATOMY", 94, 102], ["neutrophil", "ANATOMY", 103, 113], ["infections", "DISEASE", 68, 78], ["platelet", "CELL", 94, 102], ["neutrophil", "CELL", 103, 113], ["infections", "PROBLEM", 68, 78], ["platelet-neutrophil cross-communication", "TREATMENT", 94, 133], ["infections", "OBSERVATION", 68, 78]]], ["88 These interactions can facilitate a variety of proinflammatory effects such as cytokine release, endothelial cell activation, platelet-leukocyte interaction, formation of neutrophil extracellular traps, and fibrin/microthrombus formation that while potentially harmful 90, 91 can also inhibit macrophage-dependent inflammation and thus may on balance be protective.", [["endothelial cell", "ANATOMY", 100, 116], ["platelet", "ANATOMY", 129, 137], ["leukocyte", "ANATOMY", 138, 147], ["neutrophil extracellular", "ANATOMY", 174, 198], ["microthrombus", "ANATOMY", 217, 230], ["macrophage", "ANATOMY", 296, 306], ["inflammation", "DISEASE", 317, 329], ["endothelial cell", "CELL", 100, 116], ["platelet", "CELL", 129, 137], ["leukocyte", "CELL", 138, 147], ["neutrophil", "CELL", 174, 184], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 185, 198], ["fibrin", "GENE_OR_GENE_PRODUCT", 210, 216], ["microthrombus", "CELLULAR_COMPONENT", 217, 230], ["macrophage", "CELL", 296, 306], ["cytokine", "PROTEIN", 82, 90], ["proinflammatory effects", "TREATMENT", 50, 73], ["cytokine release", "TREATMENT", 82, 98], ["endothelial cell activation", "TEST", 100, 127], ["platelet", "TEST", 129, 137], ["leukocyte interaction", "PROBLEM", 138, 159], ["neutrophil extracellular traps", "TEST", 174, 204], ["fibrin/microthrombus formation", "PROBLEM", 210, 240], ["macrophage", "PROBLEM", 296, 306], ["dependent inflammation", "PROBLEM", 307, 329], ["endothelial cell", "OBSERVATION", 100, 116], ["neutrophil extracellular traps", "OBSERVATION", 174, 204], ["fibrin", "OBSERVATION", 210, 216], ["dependent", "OBSERVATION_MODIFIER", 307, 316], ["inflammation", "OBSERVATION", 317, 329]]], ["87, 92, 93 Acetylsalicylic acid (aspirin) has been extensively studied in ARDS.", [["Acetylsalicylic acid", "CHEMICAL", 11, 31], ["aspirin", "CHEMICAL", 33, 40], ["ARDS", "DISEASE", 74, 78], ["Acetylsalicylic acid", "CHEMICAL", 11, 31], ["aspirin", "CHEMICAL", 33, 40], ["Acetylsalicylic acid", "SIMPLE_CHEMICAL", 11, 31], ["aspirin", "SIMPLE_CHEMICAL", 33, 40], ["Acetylsalicylic acid (aspirin", "TREATMENT", 11, 40], ["ARDS", "PROBLEM", 74, 78], ["ARDS", "OBSERVATION", 74, 78]]], ["Aspirin has been associated with ARDS prevention and higher survival rates from acute lung injury in animal models and observational human studies.", [["lung", "ANATOMY", 86, 90], ["Aspirin", "CHEMICAL", 0, 7], ["ARDS", "DISEASE", 33, 37], ["acute lung injury", "DISEASE", 80, 97], ["Aspirin", "CHEMICAL", 0, 7], ["Aspirin", "SIMPLE_CHEMICAL", 0, 7], ["lung", "ORGAN", 86, 90], ["human", "ORGANISM", 133, 138], ["human", "SPECIES", 133, 138], ["human", "SPECIES", 133, 138], ["Aspirin", "TREATMENT", 0, 7], ["ARDS prevention", "TREATMENT", 33, 48], ["higher survival rates", "PROBLEM", 53, 74], ["acute lung injury", "PROBLEM", 80, 97], ["observational human studies", "TEST", 119, 146], ["associated with", "UNCERTAINTY", 17, 32], ["ARDS", "OBSERVATION", 33, 37], ["higher", "OBSERVATION_MODIFIER", 53, 59], ["survival", "OBSERVATION_MODIFIER", 60, 68], ["acute", "OBSERVATION_MODIFIER", 80, 85], ["lung", "ANATOMY", 86, 90], ["injury", "OBSERVATION", 91, 97]]], ["[94] [95] [96] [97] [98] [99] Aspirin has been associated with reduced mortality in the setting of both prehospital use and use in ICU.", [["[94] [95] [96] [97] [98", "CHEMICAL", 0, 23], ["Aspirin", "CHEMICAL", 30, 37], ["[94] [95] [96] [97] [98] [99] Aspirin", "CHEMICAL", 0, 37], ["[94] [95] [96] [97] [98] [99] Aspirin", "SIMPLE_CHEMICAL", 0, 37], ["Aspirin", "TREATMENT", 30, 37], ["reduced mortality", "PROBLEM", 63, 80]]], ["100 Some investigators have hypothesized that higher maintenance doses of aspirin (325-650 mg/d) may be required toP2Y 12 Receptor AntagonistsThe role of P2Y 12 receptor inhibitors has also been described in ARDS and sepsis.", [["aspirin", "CHEMICAL", 74, 81], ["ARDS", "DISEASE", 208, 212], ["sepsis", "DISEASE", 217, 223], ["aspirin", "CHEMICAL", 74, 81], ["aspirin", "SIMPLE_CHEMICAL", 74, 81], ["toP2Y 12 Receptor", "GENE_OR_GENE_PRODUCT", 113, 130], ["P2Y 12 receptor", "GENE_OR_GENE_PRODUCT", 154, 169], ["P2Y 12 receptor", "PROTEIN", 154, 169], ["aspirin", "TREATMENT", 74, 81], ["toP2Y", "TREATMENT", 113, 118], ["Receptor Antagonists", "TREATMENT", 122, 142], ["P2Y 12 receptor inhibitors", "TREATMENT", 154, 180], ["ARDS", "PROBLEM", 208, 212], ["sepsis", "PROBLEM", 217, 223], ["ARDS", "OBSERVATION", 208, 212], ["sepsis", "OBSERVATION", 217, 223]]], ["Adenosine diphosphate-mediated activation of the P2Y 12 receptor may occur in many inflammatory and immune cell types including platelets, leukocytes, and dendritic cells.", [["immune cell", "ANATOMY", 100, 111], ["platelets", "ANATOMY", 128, 137], ["leukocytes", "ANATOMY", 139, 149], ["dendritic cells", "ANATOMY", 155, 170], ["Adenosine diphosphate", "CHEMICAL", 0, 21], ["Adenosine diphosphate", "CHEMICAL", 0, 21], ["Adenosine diphosphate", "SIMPLE_CHEMICAL", 0, 21], ["P2Y 12 receptor", "GENE_OR_GENE_PRODUCT", 49, 64], ["immune cell", "CELL", 100, 111], ["platelets", "CELL", 128, 137], ["leukocytes", "CELL", 139, 149], ["dendritic cells", "CELL", 155, 170], ["P2Y 12 receptor", "PROTEIN", 49, 64], ["inflammatory and immune cell types", "CELL_TYPE", 83, 117], ["platelets", "CELL_TYPE", 128, 137], ["leukocytes", "CELL_TYPE", 139, 149], ["dendritic cells", "CELL_TYPE", 155, 170], ["Adenosine diphosphate", "TREATMENT", 0, 21], ["the P2Y 12 receptor", "TREATMENT", 45, 64], ["many inflammatory and immune cell types", "PROBLEM", 78, 117], ["platelets", "TEST", 128, 137], ["leukocytes", "TEST", 139, 149], ["dendritic cells", "PROBLEM", 155, 170], ["inflammatory", "OBSERVATION", 83, 95], ["immune cell types", "OBSERVATION", 100, 117], ["leukocytes", "ANATOMY", 139, 149], ["dendritic cells", "OBSERVATION", 155, 170]]], ["Among 224 consecutive patients admitted for community-acquired pneumonia, those receiving antiplatelet agents (aspirin and/or thienopyridines) for at least 6 months had lower use of the ICU and shorter stay in the hospital compared with age-matched controls.", [["pneumonia", "DISEASE", 63, 72], ["aspirin", "CHEMICAL", 111, 118], ["thienopyridines", "CHEMICAL", 126, 141], ["aspirin", "CHEMICAL", 111, 118], ["thienopyridines", "CHEMICAL", 126, 141], ["patients", "ORGANISM", 22, 30], ["aspirin", "SIMPLE_CHEMICAL", 111, 118], ["thienopyridines", "SIMPLE_CHEMICAL", 126, 141], ["patients", "SPECIES", 22, 30], ["community-acquired pneumonia", "PROBLEM", 44, 72], ["antiplatelet agents", "TREATMENT", 90, 109], ["aspirin", "TREATMENT", 111, 118], ["thienopyridines", "TREATMENT", 126, 141], ["pneumonia", "OBSERVATION", 63, 72]]], ["103 In a post hoc analysis from the PLATO trial, patients with acute coronary syndromes treated with the potent P2Y 12 inhibitor ticagrelor and aspirin had fewer adverse pulmonary events and sepsis and lower mortality with those events compared with patients treated with the less potent P2Y 12 inhibitor clopidogrel and aspirin.", [["coronary", "ANATOMY", 69, 77], ["pulmonary", "ANATOMY", 170, 179], ["acute coronary syndromes", "DISEASE", 63, 87], ["P2Y 12 inhibitor", "CHEMICAL", 112, 128], ["ticagrelor", "CHEMICAL", 129, 139], ["aspirin", "CHEMICAL", 144, 151], ["adverse pulmonary events", "DISEASE", 162, 186], ["sepsis", "DISEASE", 191, 197], ["P2Y 12 inhibitor", "CHEMICAL", 288, 304], ["clopidogrel", "CHEMICAL", 305, 316], ["aspirin", "CHEMICAL", 321, 328], ["ticagrelor", "CHEMICAL", 129, 139], ["aspirin", "CHEMICAL", 144, 151], ["clopidogrel", "CHEMICAL", 305, 316], ["aspirin", "CHEMICAL", 321, 328], ["patients", "ORGANISM", 49, 57], ["P2Y 12", "GENE_OR_GENE_PRODUCT", 112, 118], ["ticagrelor", "SIMPLE_CHEMICAL", 129, 139], ["aspirin", "SIMPLE_CHEMICAL", 144, 151], ["pulmonary", "ORGAN", 170, 179], ["patients", "ORGANISM", 250, 258], ["P2Y 12", "GENE_OR_GENE_PRODUCT", 288, 294], ["clopidogrel", "SIMPLE_CHEMICAL", 305, 316], ["aspirin", "SIMPLE_CHEMICAL", 321, 328], ["patients", "SPECIES", 49, 57], ["patients", "SPECIES", 250, 258], ["a post hoc analysis", "TEST", 7, 26], ["acute coronary syndromes", "PROBLEM", 63, 87], ["the potent P2Y 12 inhibitor ticagrelor", "TREATMENT", 101, 139], ["aspirin", "TREATMENT", 144, 151], ["fewer adverse pulmonary events", "PROBLEM", 156, 186], ["sepsis", "PROBLEM", 191, 197], ["lower mortality", "PROBLEM", 202, 217], ["the less potent P2Y", "TREATMENT", 272, 291], ["clopidogrel", "TREATMENT", 305, 316], ["aspirin", "TREATMENT", 321, 328], ["acute", "OBSERVATION_MODIFIER", 63, 68], ["coronary", "ANATOMY", 69, 77], ["syndromes", "OBSERVATION", 78, 87], ["pulmonary", "ANATOMY", 170, 179], ["sepsis", "OBSERVATION", 191, 197]]], ["104 The XANTHIPPE trial (Examining the Effect of Ticagrelor on Platelet Activation, Platelet-Leukocyte Aggregates, and Acute Lung Injury in Pneumonia) was the first double-blind, placebo-controlled, randomized study to evaluate the effect of ticagrelor on inflammation, platelet activation, and lung function in patients with community-or hospital-acquired pneumonia.", [["Platelet", "ANATOMY", 63, 71], ["Lung", "ANATOMY", 125, 129], ["platelet", "ANATOMY", 270, 278], ["lung", "ANATOMY", 295, 299], ["Ticagrelor", "CHEMICAL", 49, 59], ["Lung Injury", "DISEASE", 125, 136], ["Pneumonia", "DISEASE", 140, 149], ["ticagrelor", "CHEMICAL", 242, 252], ["inflammation", "DISEASE", 256, 268], ["pneumonia", "DISEASE", 357, 366], ["Ticagrelor", "CHEMICAL", 49, 59], ["ticagrelor", "CHEMICAL", 242, 252], ["Ticagrelor", "SIMPLE_CHEMICAL", 49, 59], ["Platelet", "CELL", 63, 71], ["Platelet", "CELL", 84, 92], ["Lung", "ORGAN", 125, 129], ["ticagrelor", "SIMPLE_CHEMICAL", 242, 252], ["platelet", "CELL", 270, 278], ["lung", "ORGAN", 295, 299], ["patients", "ORGANISM", 312, 320], ["patients", "SPECIES", 312, 320], ["The XANTHIPPE trial", "TREATMENT", 4, 23], ["Ticagrelor", "TREATMENT", 49, 59], ["Platelet Activation", "TEST", 63, 82], ["Platelet", "TEST", 84, 92], ["Leukocyte Aggregates", "TEST", 93, 113], ["Acute Lung Injury", "PROBLEM", 119, 136], ["Pneumonia", "PROBLEM", 140, 149], ["placebo", "TREATMENT", 179, 186], ["randomized study", "TEST", 199, 215], ["ticagrelor", "TREATMENT", 242, 252], ["inflammation", "PROBLEM", 256, 268], ["platelet activation", "TEST", 270, 289], ["lung function", "TEST", 295, 308], ["hospital-acquired pneumonia", "PROBLEM", 339, 366], ["Acute", "OBSERVATION_MODIFIER", 119, 124], ["Lung", "ANATOMY", 125, 129], ["Injury", "OBSERVATION", 130, 136], ["Pneumonia", "OBSERVATION", 140, 149], ["inflammation", "OBSERVATION", 256, 268], ["lung", "ANATOMY", 295, 299], ["pneumonia", "OBSERVATION", 357, 366]]], ["105 Among 60 randomized patients, ticagrelor administration within 48 hours of pneumonia diagnosis was associated with an anti-inflammatory effect evidenced by reduced platelet-leukocyte aggregates in the circulation, lowered interleukin (IL)-6 levels, and improved lung function with a decrease in supplemental oxygen requirements.", [["platelet", "ANATOMY", 168, 176], ["leukocyte", "ANATOMY", 177, 186], ["lung", "ANATOMY", 266, 270], ["ticagrelor", "CHEMICAL", 34, 44], ["pneumonia", "DISEASE", 79, 88], ["oxygen", "CHEMICAL", 312, 318], ["ticagrelor", "CHEMICAL", 34, 44], ["oxygen", "CHEMICAL", 312, 318], ["patients", "ORGANISM", 24, 32], ["ticagrelor", "SIMPLE_CHEMICAL", 34, 44], ["platelet", "CELL", 168, 176], ["leukocyte", "CELL", 177, 186], ["interleukin (IL)-6", "GENE_OR_GENE_PRODUCT", 226, 244], ["lung", "ORGAN", 266, 270], ["oxygen", "SIMPLE_CHEMICAL", 312, 318], ["platelet", "CELL_TYPE", 168, 176], ["interleukin (IL)-6", "PROTEIN", 226, 244], ["patients", "SPECIES", 24, 32], ["ticagrelor administration", "TREATMENT", 34, 59], ["pneumonia", "PROBLEM", 79, 88], ["an anti-inflammatory effect", "PROBLEM", 119, 146], ["reduced platelet-leukocyte aggregates", "PROBLEM", 160, 197], ["lowered interleukin (IL)", "TREATMENT", 218, 242], ["supplemental oxygen requirements", "TREATMENT", 299, 331], ["pneumonia", "OBSERVATION", 79, 88], ["anti-inflammatory effect", "OBSERVATION", 122, 146], ["reduced", "OBSERVATION_MODIFIER", 160, 167], ["platelet", "OBSERVATION", 168, 176], ["leukocyte aggregates", "OBSERVATION", 177, 197], ["circulation", "ANATOMY_MODIFIER", 205, 216], ["improved", "OBSERVATION_MODIFIER", 257, 265], ["lung", "ANATOMY", 266, 270], ["decrease", "OBSERVATION_MODIFIER", 287, 295], ["supplemental oxygen requirements", "OBSERVATION", 299, 331]]], ["However, given the potential bleeding risks, in the absence of phase III trials demonstrating favorable clinical outcomes, these research findings have not translated into routine clinical practice.P2Y 12 Receptor AntagonistsWith respect to COVID-19 and antiplatelet agents, there are many unknowns as regards their use and utility.", [["bleeding", "DISEASE", 29, 37], ["COVID-19", "CHEMICAL", 241, 249], ["COVID-19", "CHEMICAL", 241, 249], ["P2Y 12 Receptor", "GENE_OR_GENE_PRODUCT", 198, 213], ["COVID-19", "SIMPLE_CHEMICAL", 241, 249], ["antiplatelet agents", "SIMPLE_CHEMICAL", 254, 273], ["the potential bleeding risks", "PROBLEM", 15, 43], ["phase III trials", "TREATMENT", 63, 79], ["P2Y", "TEST", 198, 201], ["COVID", "TEST", 241, 246], ["antiplatelet agents", "TREATMENT", 254, 273]]], ["First, it is not clear which phase of the disease might best respond.", [["the disease", "PROBLEM", 38, 49], ["not", "UNCERTAINTY", 13, 16], ["clear", "OBSERVATION", 17, 22], ["disease", "OBSERVATION", 42, 49]]], ["Second, the optimal agent and dose to maximize efficacy while minimizing bleeding risks are unknown.", [["bleeding", "DISEASE", 73, 81], ["bleeding risks", "PROBLEM", 73, 87]]], ["Due to its pleiotropic effects, ticagrelor may have more potent antiinflammatory and even bactericidal characteristics than other agents.", [["ticagrelor", "CHEMICAL", 32, 42], ["ticagrelor", "CHEMICAL", 32, 42], ["ticagrelor", "SIMPLE_CHEMICAL", 32, 42], ["ticagrelor", "TREATMENT", 32, 42], ["other agents", "TREATMENT", 124, 136]]], ["106, 107 Randomized trials evaluating role of aspirin and clopidogrel in COVID-19 patients at increased cardiovascular risk are underway (NCT04333407).", [["cardiovascular", "ANATOMY", 104, 118], ["aspirin", "CHEMICAL", 46, 53], ["clopidogrel", "CHEMICAL", 58, 69], ["aspirin", "CHEMICAL", 46, 53], ["clopidogrel", "CHEMICAL", 58, 69], ["aspirin", "SIMPLE_CHEMICAL", 46, 53], ["clopidogrel", "SIMPLE_CHEMICAL", 58, 69], ["patients", "ORGANISM", 82, 90], ["cardiovascular", "ANATOMICAL_SYSTEM", 104, 118], ["patients", "SPECIES", 82, 90], ["aspirin", "TREATMENT", 46, 53], ["clopidogrel", "TREATMENT", 58, 69], ["COVID", "TREATMENT", 73, 78], ["increased cardiovascular risk", "PROBLEM", 94, 123]]], ["Third, antiplatelet therapies may have adverse drug-drug interactions with some investigational COVID-19 therapies such as lopinavir/ritonavir and remdesivir.", [["antiplatelet", "ANATOMY", 7, 19], ["lopinavir/ritonavir", "CHEMICAL", 123, 142], ["remdesivir", "CHEMICAL", 147, 157], ["COVID-19", "CHEMICAL", 96, 104], ["lopinavir", "CHEMICAL", 123, 132], ["ritonavir", "CHEMICAL", 133, 142], ["remdesivir", "CHEMICAL", 147, 157], ["antiplatelet", "CELL", 7, 19], ["COVID-19", "SIMPLE_CHEMICAL", 96, 104], ["lopinavir", "SIMPLE_CHEMICAL", 123, 132], ["ritonavir", "SIMPLE_CHEMICAL", 133, 142], ["remdesivir", "SIMPLE_CHEMICAL", 147, 157], ["antiplatelet therapies", "TREATMENT", 7, 29], ["some investigational COVID", "TREATMENT", 75, 101], ["therapies", "TREATMENT", 105, 114], ["lopinavir", "TREATMENT", 123, 132], ["ritonavir", "TREATMENT", 133, 142], ["remdesivir", "TREATMENT", 147, 157]]], ["5, 108, 109 Fourth, thrombocytopenia (immune-mediated or consumption-related) is associated with increased risk for worse clinical outcomes with COVID-19.", [["thrombocytopenia", "DISEASE", 20, 36], ["COVID-19", "CHEMICAL", 145, 153], ["thrombocytopenia", "PROBLEM", 20, 36], ["COVID", "TEST", 145, 150], ["thrombocytopenia", "OBSERVATION", 20, 36]]], ["110, 111 Finally, the extent to which bleeding risks are increased, particularly in patients with DIC, is unknown.DipyridamoleDipyridamole is a phosphodiesterase inhibitor that inhibits platelet aggregation by increasing intracellular concentrations of cyclic adenosine monophosphate.", [["platelet", "ANATOMY", 186, 194], ["intracellular", "ANATOMY", 221, 234], ["bleeding", "DISEASE", 38, 46], ["DIC", "DISEASE", 98, 101], ["DipyridamoleDipyridamole", "CHEMICAL", 114, 138], ["platelet aggregation", "DISEASE", 186, 206], ["cyclic adenosine monophosphate", "CHEMICAL", 253, 283], ["DipyridamoleDipyridamole", "CHEMICAL", 114, 138], ["cyclic adenosine monophosphate", "CHEMICAL", 253, 283], ["patients", "ORGANISM", 84, 92], ["DipyridamoleDipyridamole", "SIMPLE_CHEMICAL", 114, 138], ["platelet", "CELL", 186, 194], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 221, 234], ["cyclic adenosine monophosphate", "SIMPLE_CHEMICAL", 253, 283], ["platelet", "CELL_TYPE", 186, 194], ["patients", "SPECIES", 84, 92], ["bleeding risks", "PROBLEM", 38, 52], ["DIC", "PROBLEM", 98, 101], ["DipyridamoleDipyridamole", "TREATMENT", 114, 138], ["a phosphodiesterase inhibitor", "TREATMENT", 142, 171], ["platelet aggregation", "PROBLEM", 186, 206], ["increasing intracellular concentrations", "TREATMENT", 210, 249], ["cyclic adenosine monophosphate", "TREATMENT", 253, 283], ["bleeding", "OBSERVATION", 38, 46], ["increased", "OBSERVATION_MODIFIER", 57, 66], ["platelet aggregation", "OBSERVATION", 186, 206]]], ["112 In addition to its well-known antithrombotic properties, dipyridamole may have antiviral effects with proposed activity against influenza in animal models.", [["dipyridamole", "CHEMICAL", 61, 73], ["influenza", "DISEASE", 132, 141], ["dipyridamole", "CHEMICAL", 61, 73], ["dipyridamole", "SIMPLE_CHEMICAL", 61, 73], ["antithrombotic properties", "TREATMENT", 34, 59], ["dipyridamole", "TREATMENT", 61, 73], ["antiviral effects", "TREATMENT", 83, 100], ["influenza", "PROBLEM", 132, 141]]], ["113 In mouse models of viral pneumonia, dipyridamole administration promoted interferon response and prolonged survival in infected mice.", [["viral pneumonia", "DISEASE", 23, 38], ["dipyridamole", "CHEMICAL", 40, 52], ["dipyridamole", "CHEMICAL", 40, 52], ["mouse", "ORGANISM", 7, 12], ["dipyridamole", "SIMPLE_CHEMICAL", 40, 52], ["mice", "ORGANISM", 132, 136], ["interferon", "PROTEIN", 77, 87], ["mouse", "SPECIES", 7, 12], ["mice", "SPECIES", 132, 136], ["mouse", "SPECIES", 7, 12], ["mice", "SPECIES", 132, 136], ["viral pneumonia", "PROBLEM", 23, 38], ["dipyridamole administration", "TREATMENT", 40, 67], ["interferon response", "TREATMENT", 77, 96], ["viral", "OBSERVATION_MODIFIER", 23, 28], ["pneumonia", "OBSERVATION", 29, 38], ["infected mice", "OBSERVATION", 123, 136]]], ["Dipyridamole has antiviral effects in vitro, specifically confirming the affinity of dipyridamole for a SARS-CoV-2 main protease (M pro ).", [["Dipyridamole", "CHEMICAL", 0, 12], ["dipyridamole", "CHEMICAL", 85, 97], ["Dipyridamole", "CHEMICAL", 0, 12], ["dipyridamole", "CHEMICAL", 85, 97], ["Dipyridamole", "SIMPLE_CHEMICAL", 0, 12], ["dipyridamole", "SIMPLE_CHEMICAL", 85, 97], ["SARS-CoV-2 main protease", "PROTEIN", 104, 128], ["M pro", "PROTEIN", 130, 135], ["Dipyridamole", "TREATMENT", 0, 12], ["antiviral effects", "TREATMENT", 17, 34], ["dipyridamole", "TREATMENT", 85, 97], ["a SARS", "TEST", 102, 108], ["CoV-2 main protease (M pro", "TREATMENT", 109, 135], ["antiviral effects", "OBSERVATION", 17, 34]]], ["114 To date, one study has examined dipyridamole in the treatment of COVID-19; 31 patients with COVID-19 were randomized to dipyridamole (150 mg three times a day for 7 days) versus control.", [["dipyridamole", "CHEMICAL", 36, 48], ["dipyridamole", "CHEMICAL", 124, 136], ["dipyridamole", "CHEMICAL", 36, 48], ["dipyridamole", "CHEMICAL", 124, 136], ["dipyridamole", "SIMPLE_CHEMICAL", 36, 48], ["patients", "ORGANISM", 82, 90], ["dipyridamole", "SIMPLE_CHEMICAL", 124, 136], ["patients", "SPECIES", 82, 90], ["one study", "TEST", 13, 22], ["dipyridamole", "TREATMENT", 36, 48], ["COVID", "TEST", 69, 74], ["COVID", "TREATMENT", 96, 101], ["dipyridamole", "TREATMENT", 124, 136]]], ["In this small study, those treated with dipyridamole showed trends toward higher cure and hospital discharge rates.", [["dipyridamole", "CHEMICAL", 40, 52], ["dipyridamole", "CHEMICAL", 40, 52], ["dipyridamole", "SIMPLE_CHEMICAL", 40, 52], ["this small study", "TEST", 3, 19], ["dipyridamole", "TREATMENT", 40, 52], ["small", "OBSERVATION_MODIFIER", 8, 13]]], ["Increased platelet counts and decreased D-dimer levels were also noted with dipyridamole treatment, attributed to infection resolution.", [["platelet", "ANATOMY", 10, 18], ["dipyridamole", "CHEMICAL", 76, 88], ["infection", "DISEASE", 114, 123], ["dipyridamole", "CHEMICAL", 76, 88], ["platelet", "CELL", 10, 18], ["D-dimer", "GENE_OR_GENE_PRODUCT", 40, 47], ["dipyridamole", "SIMPLE_CHEMICAL", 76, 88], ["Increased platelet counts", "PROBLEM", 0, 25], ["decreased D-dimer levels", "PROBLEM", 30, 54], ["dipyridamole treatment", "TREATMENT", 76, 98], ["infection resolution", "PROBLEM", 114, 134], ["platelet counts", "OBSERVATION", 10, 25], ["decreased", "OBSERVATION_MODIFIER", 30, 39], ["D-dimer", "OBSERVATION_MODIFIER", 40, 47], ["infection", "OBSERVATION", 114, 123]]], ["115 Further high-quality data are needed to evaluate the anti-SARS-CoV-2 therapeutic potential of dipyridamole.VorapaxarVorapaxar is an antiplatelet agent that exerts its antiplatelet activity through antagonism of the protease-activated receptor 1 (PAR-1) and inhibition of thrombin-induced platelet aggregation.", [["antiplatelet", "ANATOMY", 136, 148], ["antiplatelet", "ANATOMY", 171, 183], ["platelet", "ANATOMY", 292, 300], ["dipyridamole", "CHEMICAL", 98, 110], ["VorapaxarVorapaxar", "CHEMICAL", 111, 129], ["platelet aggregation", "DISEASE", 292, 312], ["dipyridamole", "CHEMICAL", 98, 110], ["VorapaxarVorapaxar", "CHEMICAL", 111, 129], ["dipyridamole", "SIMPLE_CHEMICAL", 98, 110], ["VorapaxarVorapaxar", "SIMPLE_CHEMICAL", 111, 129], ["protease-activated receptor 1", "GENE_OR_GENE_PRODUCT", 219, 248], ["PAR-1", "GENE_OR_GENE_PRODUCT", 250, 255], ["thrombin", "GENE_OR_GENE_PRODUCT", 275, 283], ["platelet", "CELL", 292, 300], ["protease-activated receptor 1", "PROTEIN", 219, 248], ["PAR-1", "PROTEIN", 250, 255], ["thrombin", "PROTEIN", 275, 283], ["the anti-SARS", "TEST", 53, 66], ["dipyridamole", "TREATMENT", 98, 110], ["VorapaxarVorapaxar", "TREATMENT", 111, 129], ["an antiplatelet agent", "TREATMENT", 133, 154], ["its antiplatelet activity", "TREATMENT", 167, 192], ["the protease", "TREATMENT", 215, 227], ["activated receptor", "TREATMENT", 228, 246], ["thrombin", "TREATMENT", 275, 283], ["platelet aggregation", "PROBLEM", 292, 312], ["platelet aggregation", "OBSERVATION", 292, 312]]], ["116 In patients with history of myocardial infarction, or peripheral arterial disease, vorapaxar has been shown to reduce thrombotic cardiovascular events.", [["myocardial", "ANATOMY", 32, 42], ["peripheral arterial", "ANATOMY", 58, 77], ["cardiovascular", "ANATOMY", 133, 147], ["myocardial infarction", "DISEASE", 32, 53], ["peripheral arterial disease", "DISEASE", 58, 85], ["vorapaxar", "CHEMICAL", 87, 96], ["thrombotic cardiovascular events", "DISEASE", 122, 154], ["vorapaxar", "CHEMICAL", 87, 96], ["patients", "ORGANISM", 7, 15], ["myocardial", "MULTI-TISSUE_STRUCTURE", 32, 42], ["peripheral arterial", "MULTI-TISSUE_STRUCTURE", 58, 77], ["vorapaxar", "SIMPLE_CHEMICAL", 87, 96], ["cardiovascular", "ANATOMICAL_SYSTEM", 133, 147], ["patients", "SPECIES", 7, 15], ["myocardial infarction", "PROBLEM", 32, 53], ["peripheral arterial disease", "PROBLEM", 58, 85], ["vorapaxar", "TREATMENT", 87, 96], ["thrombotic cardiovascular events", "PROBLEM", 122, 154], ["myocardial", "ANATOMY", 32, 42], ["infarction", "OBSERVATION", 43, 53], ["peripheral", "ANATOMY_MODIFIER", 58, 68], ["arterial", "ANATOMY", 69, 77], ["disease", "OBSERVATION", 78, 85]]], ["117 The main concern associated with vorapaxar is its increased risk of bleeding events and reports of intracranial hemorrhage in patients with a previous history of stroke.", [["intracranial", "ANATOMY", 103, 115], ["vorapaxar", "CHEMICAL", 37, 46], ["bleeding", "DISEASE", 72, 80], ["intracranial hemorrhage", "DISEASE", 103, 126], ["stroke", "DISEASE", 166, 172], ["vorapaxar", "CHEMICAL", 37, 46], ["vorapaxar", "SIMPLE_CHEMICAL", 37, 46], ["intracranial", "IMMATERIAL_ANATOMICAL_ENTITY", 103, 115], ["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 130, 138], ["vorapaxar", "TREATMENT", 37, 46], ["bleeding events", "PROBLEM", 72, 87], ["intracranial hemorrhage", "PROBLEM", 103, 126], ["stroke", "PROBLEM", 166, 172], ["main", "OBSERVATION_MODIFIER", 8, 12], ["vorapaxar", "OBSERVATION", 37, 46], ["increased", "OBSERVATION_MODIFIER", 54, 63], ["bleeding", "OBSERVATION", 72, 80], ["intracranial", "ANATOMY", 103, 115], ["hemorrhage", "OBSERVATION", 116, 126], ["stroke", "OBSERVATION", 166, 172]]], ["PAR-1 is thought to have an important role in thrombin-induced platelet aggregation, and the link between coagulation, inflammation, and the fibrotic response.", [["platelet", "ANATOMY", 63, 71], ["platelet aggregation", "DISEASE", 63, 83], ["inflammation", "DISEASE", 119, 131], ["PAR-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["thrombin", "GENE_OR_GENE_PRODUCT", 46, 54], ["platelet", "CELL", 63, 71], ["PAR", "PROTEIN", 0, 3], ["thrombin", "PROTEIN", 46, 54], ["thrombin", "TEST", 46, 54], ["platelet aggregation", "PROBLEM", 63, 83], ["inflammation", "PROBLEM", 119, 131], ["the fibrotic response", "PROBLEM", 137, 158], ["thrombin", "OBSERVATION", 46, 54], ["platelet aggregation", "OBSERVATION", 63, 83], ["inflammation", "OBSERVATION", 119, 131], ["fibrotic response", "OBSERVATION", 141, 158]]], ["As such, investigating vorapaxar in patients with COVID-19 has received some attention.", [["vorapaxar", "CHEMICAL", 23, 32], ["COVID-19", "CHEMICAL", 50, 58], ["vorapaxar", "CHEMICAL", 23, 32], ["COVID-19", "CHEMICAL", 50, 58], ["vorapaxar", "SIMPLE_CHEMICAL", 23, 32], ["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["vorapaxar", "TREATMENT", 23, 32], ["COVID", "TREATMENT", 50, 55]]], ["50 However, its terminal half-life of 8 days renders it difficult to use in patients with severe COVID-19.", [["COVID-19", "CHEMICAL", 97, 105], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["severe COVID", "PROBLEM", 90, 102]]], ["To date, there are no registered randomized trials for use of vorapaxar in patients with COVID-19.AntithrombinThe single-chain glycosaminoglycan antithrombin, which is produced in the liver, is modestly decreased in patients hospitalized with COVID-19.", [["liver", "ANATOMY", 184, 189], ["vorapaxar", "CHEMICAL", 62, 71], ["glycosaminoglycan", "CHEMICAL", 127, 144], ["vorapaxar", "CHEMICAL", 62, 71], ["COVID-19", "CHEMICAL", 243, 251], ["vorapaxar", "SIMPLE_CHEMICAL", 62, 71], ["patients", "ORGANISM", 75, 83], ["Antithrombin", "GENE_OR_GENE_PRODUCT", 98, 110], ["single-chain glycosaminoglycan antithrombin", "GENE_OR_GENE_PRODUCT", 114, 157], ["liver", "ORGAN", 184, 189], ["patients", "ORGANISM", 216, 224], ["Antithrombin", "PROTEIN", 98, 110], ["single-chain glycosaminoglycan antithrombin", "PROTEIN", 114, 157], ["patients", "SPECIES", 75, 83], ["patients", "SPECIES", 216, 224], ["vorapaxar", "TREATMENT", 62, 71], ["COVID", "TEST", 89, 94], ["AntithrombinThe single-chain glycosaminoglycan antithrombin", "TREATMENT", 98, 157], ["COVID", "TEST", 243, 248], ["no", "UNCERTAINTY", 19, 21], ["chain glycosaminoglycan", "OBSERVATION_MODIFIER", 121, 144], ["antithrombin", "OBSERVATION", 145, 157], ["liver", "ANATOMY", 184, 189], ["modestly", "OBSERVATION_MODIFIER", 194, 202], ["decreased", "OBSERVATION_MODIFIER", 203, 212]]], ["118,119 Thus, reduced antithrombin may be a potential therapeutic target for patients with COVID-19.", [["COVID-19", "CHEMICAL", 91, 99], ["antithrombin", "GENE_OR_GENE_PRODUCT", 22, 34], ["patients", "ORGANISM", 77, 85], ["antithrombin", "PROTEIN", 22, 34], ["patients", "SPECIES", 77, 85], ["reduced antithrombin", "PROBLEM", 14, 34], ["COVID", "TEST", 91, 96]]], ["Furthermore, the \u03b2-isoform of antithrombin binds preferentially to vascular heparin sulfate proteoglycans and initiates prostacyclin production and inhibition of nuclear factor kappa B (NF-\u03baB), resulting in anti-inflammatory effects, which might be further pronounced by the binding of \u03b2-antithrombin to receptors on monocytes.", [["monocytes", "ANATOMY", 317, 326], ["heparin sulfate", "CHEMICAL", 76, 91], ["prostacyclin", "CHEMICAL", 120, 132], ["prostacyclin", "CHEMICAL", 120, 132], ["antithrombin", "GENE_OR_GENE_PRODUCT", 30, 42], ["vascular heparin sulfate proteoglycans", "GENE_OR_GENE_PRODUCT", 67, 105], ["prostacyclin", "SIMPLE_CHEMICAL", 120, 132], ["nuclear factor kappa B", "GENE_OR_GENE_PRODUCT", 162, 184], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 186, 191], ["\u03b2-antithrombin", "GENE_OR_GENE_PRODUCT", 286, 300], ["monocytes", "CELL", 317, 326], ["antithrombin", "PROTEIN", 30, 42], ["nuclear factor kappa B", "PROTEIN", 162, 184], ["NF-\u03baB", "PROTEIN", 186, 191], ["\u03b2-antithrombin", "PROTEIN", 286, 300], ["monocytes", "CELL_TYPE", 317, 326], ["antithrombin binds", "TREATMENT", 30, 48], ["vascular heparin sulfate proteoglycans", "TREATMENT", 67, 105], ["prostacyclin production", "TREATMENT", 120, 143], ["nuclear factor kappa", "TEST", 162, 182], ["monocytes", "TEST", 317, 326], ["vascular", "ANATOMY", 67, 75], ["anti-inflammatory effects", "OBSERVATION", 207, 232]]], ["120 Limited supporting data exist from patients with severe acute respiratory syndrome (SARS).", [["acute respiratory syndrome", "DISEASE", 60, 86], ["SARS", "DISEASE", 88, 92], ["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["severe acute respiratory syndrome", "PROBLEM", 53, 86], ["severe", "OBSERVATION_MODIFIER", 53, 59], ["acute", "OBSERVATION_MODIFIER", 60, 65], ["respiratory syndrome", "OBSERVATION", 66, 86]]], ["Compared with healthy individuals such patients had lower levels of the natural inhibitors of coagulation and higher levels of PAI-1.AntithrombinBlood coagulation parameters were investigated in 94 patients with COVID-19 pneumonia, of whom 49 had \"ordinary,\" 35 had severe, and 10 had critical forms of COVID-19.", [["pneumonia", "DISEASE", 221, 230], ["patients", "ORGANISM", 39, 47], ["PAI-1", "GENE_OR_GENE_PRODUCT", 127, 132], ["patients", "ORGANISM", 198, 206], ["PAI-1", "PROTEIN", 127, 132], ["patients", "SPECIES", 39, 47], ["patients", "SPECIES", 198, 206], ["the natural inhibitors", "TREATMENT", 68, 90], ["PAI", "TEST", 127, 130], ["AntithrombinBlood coagulation parameters", "TEST", 133, 173], ["COVID", "TEST", 212, 217], ["pneumonia", "PROBLEM", 221, 230], ["COVID", "TEST", 303, 308], ["pneumonia", "OBSERVATION", 221, 230]]], ["121 When compared with 40 healthy controls, patients in Thrombosis and Haemostasis Vol.", [["Thrombosis", "DISEASE", 56, 66], ["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["Thrombosis", "PROBLEM", 56, 66], ["Haemostasis Vol", "TREATMENT", 71, 86], ["Thrombosis", "OBSERVATION", 56, 66], ["Haemostasis Vol", "OBSERVATION", 71, 86]]], ["120 No. 7/2020 Therapeutic Targets for COVID-19-Associated Thrombosis Bikdeli et al.Antithrombinall three categories of COVID-19 had significantly lower levels of antithrombin, and the three subsets of patients had similar levels (86.0, 85.6, and 82.4%).", [["Thrombosis", "DISEASE", 59, 69], ["COVID-19", "CHEMICAL", 39, 47], ["COVID-19", "CHEMICAL", 120, 128], ["antithrombin", "GENE_OR_GENE_PRODUCT", 163, 175], ["patients", "ORGANISM", 202, 210], ["antithrombin", "PROTEIN", 163, 175], ["patients", "SPECIES", 202, 210], ["COVID", "TEST", 39, 44], ["Thrombosis Bikdeli", "PROBLEM", 59, 77], ["COVID", "TEST", 120, 125], ["significantly lower levels of antithrombin", "PROBLEM", 133, 175], ["similar levels", "TEST", 215, 229], ["Thrombosis", "OBSERVATION", 59, 69], ["antithrombin", "OBSERVATION", 163, 175]]], ["Nebulized antithrombin has resulted in decreased coagulopathy and inflammation in animal models of lung injury.", [["lung", "ANATOMY", 99, 103], ["coagulopathy", "DISEASE", 49, 61], ["inflammation", "DISEASE", 66, 78], ["lung injury", "DISEASE", 99, 110], ["antithrombin", "GENE_OR_GENE_PRODUCT", 10, 22], ["lung", "ORGAN", 99, 103], ["antithrombin", "PROTEIN", 10, 22], ["Nebulized antithrombin", "TREATMENT", 0, 22], ["decreased coagulopathy", "PROBLEM", 39, 61], ["inflammation", "PROBLEM", 66, 78], ["lung injury", "PROBLEM", 99, 110], ["decreased", "OBSERVATION_MODIFIER", 39, 48], ["coagulopathy", "OBSERVATION", 49, 61], ["inflammation", "OBSERVATION", 66, 78], ["animal models", "OBSERVATION_MODIFIER", 82, 95], ["lung", "ANATOMY", 99, 103], ["injury", "OBSERVATION", 104, 110]]], ["[122] [123] [124] Despite these promising findings, there is to date no clinical evidence to support antithrombin provision to critically ill patients or in those with DIC and COVID-19.", [["critically ill", "DISEASE", 127, 141], ["DIC", "DISEASE", 168, 171], ["COVID-19", "CHEMICAL", 176, 184], ["antithrombin", "GENE_OR_GENE_PRODUCT", 101, 113], ["patients", "ORGANISM", 142, 150], ["antithrombin", "PROTEIN", 101, 113], ["patients", "SPECIES", 142, 150], ["antithrombin provision", "TREATMENT", 101, 123], ["DIC", "TEST", 168, 171], ["COVID", "TEST", 176, 181]]], ["In a randomized controlled trial of 2,314 patients with severe sepsis, there was no effect of antithrombin therapy on 28-day mortality.", [["sepsis", "DISEASE", 63, 69], ["patients", "ORGANISM", 42, 50], ["antithrombin", "GENE_OR_GENE_PRODUCT", 94, 106], ["antithrombin", "PROTEIN", 94, 106], ["patients", "SPECIES", 42, 50], ["severe sepsis", "PROBLEM", 56, 69], ["antithrombin therapy", "TREATMENT", 94, 114], ["severe", "OBSERVATION_MODIFIER", 56, 62], ["sepsis", "OBSERVATION", 63, 69], ["no", "UNCERTAINTY", 81, 83]]], ["125 Moreover, in a meta-analysis of 3,019 patients included in 11 trials, antithrombin administration in critically ill patients was associated with more bleeding events (relative risk [RR]: 1.58; 95% confidence interval [CI] 1.35-1.84).", [["critically ill", "DISEASE", 105, 119], ["bleeding", "DISEASE", 154, 162], ["patients", "ORGANISM", 42, 50], ["antithrombin", "GENE_OR_GENE_PRODUCT", 74, 86], ["patients", "ORGANISM", 120, 128], ["antithrombin", "PROTEIN", 74, 86], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 120, 128], ["a meta-analysis", "TEST", 17, 32], ["antithrombin administration", "TREATMENT", 74, 101], ["more bleeding events", "PROBLEM", 149, 169], ["RR", "TEST", 186, 188], ["CI", "TEST", 222, 224]]], ["126ThrombomodulinThrombomodulin is an endothelial cell glycoprotein with potent anticoagulant and anti-inflammatory effects mediated through activated protein C (APC)-dependent and APCindependent protein C mechanisms.", [["endothelial cell", "ANATOMY", 38, 54], ["126ThrombomodulinThrombomodulin", "CHEMICAL", 0, 31], ["126ThrombomodulinThrombomodulin", "SIMPLE_CHEMICAL", 0, 31], ["endothelial cell", "CELL", 38, 54], ["protein C", "GENE_OR_GENE_PRODUCT", 151, 160], ["APC", "GENE_OR_GENE_PRODUCT", 162, 165], ["APCindependent protein C", "GENE_OR_GENE_PRODUCT", 181, 205], ["126ThrombomodulinThrombomodulin", "PROTEIN", 0, 31], ["endothelial cell glycoprotein", "PROTEIN", 38, 67], ["protein C", "PROTEIN", 151, 160], ["APC", "PROTEIN", 162, 165], ["APCindependent protein C", "PROTEIN", 181, 205], ["an endothelial cell glycoprotein", "TREATMENT", 35, 67], ["potent anticoagulant", "TREATMENT", 73, 93], ["anti-inflammatory effects", "TREATMENT", 98, 123], ["activated protein C (APC)", "TREATMENT", 141, 166], ["dependent and APCindependent protein C mechanisms", "TREATMENT", 167, 216], ["endothelial cell glycoprotein", "OBSERVATION", 38, 67], ["potent anticoagulant", "OBSERVATION", 73, 93]]], ["In inflammatory states, thrombomodulin production is downregulated and surface thrombomodulin is cleaved so that there is reduced activation of protein C. 127 The role of recombinant thrombomodulin as a potential modifier of clinical outcomes in patients with sepsis has been evaluated in clinical trials.ThrombomodulinThe SCARLET study (Sepsis Coagulopathy Asahi Recombinant LE Thrombomodulin) was a randomized placebocontrolled double-blind study of recombinant human soluble thrombomodulin in 800 patients with objective evidence of bacterial infection, sepsis-induced systemic inflammatory response syndrome, and concurrent cardiovascular and/or respiratory dysfunction.", [["surface", "ANATOMY", 71, 78], ["cardiovascular", "ANATOMY", 628, 642], ["respiratory", "ANATOMY", 650, 661], ["sepsis", "DISEASE", 260, 266], ["Sepsis", "DISEASE", 338, 344], ["bacterial infection", "DISEASE", 536, 555], ["sepsis", "DISEASE", 557, 563], ["systemic inflammatory response syndrome", "DISEASE", 572, 611], ["cardiovascular and/or respiratory dysfunction", "DISEASE", 628, 673], ["thrombomodulin", "GENE_OR_GENE_PRODUCT", 24, 38], ["surface", "CELLULAR_COMPONENT", 71, 78], ["thrombomodulin", "GENE_OR_GENE_PRODUCT", 79, 93], ["thrombomodulin", "GENE_OR_GENE_PRODUCT", 183, 197], ["patients", "ORGANISM", 246, 254], ["Thrombomodulin", "SIMPLE_CHEMICAL", 305, 319], ["human", "ORGANISM", 464, 469], ["thrombomodulin", "GENE_OR_GENE_PRODUCT", 478, 492], ["patients", "ORGANISM", 500, 508], ["thrombomodulin", "PROTEIN", 24, 38], ["surface thrombomodulin", "PROTEIN", 71, 93], ["recombinant thrombomodulin", "PROTEIN", 171, 197], ["recombinant human soluble thrombomodulin", "PROTEIN", 452, 492], ["patients", "SPECIES", 246, 254], ["human", "SPECIES", 464, 469], ["patients", "SPECIES", 500, 508], ["human", "SPECIES", 464, 469], ["inflammatory states", "PROBLEM", 3, 22], ["thrombomodulin production", "PROBLEM", 24, 49], ["surface thrombomodulin", "PROBLEM", 71, 93], ["reduced activation of protein C.", "PROBLEM", 122, 154], ["recombinant thrombomodulin", "TREATMENT", 171, 197], ["sepsis", "PROBLEM", 260, 266], ["ThrombomodulinThe SCARLET study", "TEST", 305, 336], ["Sepsis Coagulopathy", "PROBLEM", 338, 357], ["Asahi Recombinant LE Thrombomodulin", "TREATMENT", 358, 393], ["a randomized placebocontrolled double", "TREATMENT", 399, 436], ["recombinant human soluble thrombomodulin", "TREATMENT", 452, 492], ["bacterial infection", "PROBLEM", 536, 555], ["sepsis", "PROBLEM", 557, 563], ["systemic inflammatory response syndrome", "PROBLEM", 572, 611], ["concurrent cardiovascular", "PROBLEM", 617, 642], ["respiratory dysfunction", "PROBLEM", 650, 673], ["inflammatory", "OBSERVATION", 3, 15], ["thrombomodulin", "OBSERVATION", 24, 38], ["surface", "OBSERVATION_MODIFIER", 71, 78], ["thrombomodulin", "OBSERVATION", 79, 93], ["thrombomodulin", "OBSERVATION", 183, 197], ["sepsis", "OBSERVATION", 260, 266], ["SCARLET", "OBSERVATION", 323, 330], ["evidence of", "UNCERTAINTY", 524, 535], ["bacterial", "OBSERVATION_MODIFIER", 536, 545], ["infection", "OBSERVATION", 546, 555], ["sepsis", "OBSERVATION", 557, 563], ["systemic", "OBSERVATION_MODIFIER", 572, 580], ["inflammatory response syndrome", "OBSERVATION", 581, 611], ["respiratory dysfunction", "OBSERVATION", 650, 673]]], ["128 There was no significant between-group differences in the 28-day primary mortality outcome or other secondary endpoints.", [["no", "UNCERTAINTY", 14, 16], ["significant", "OBSERVATION_MODIFIER", 17, 28]]], ["A post hoc subgroup analysis in patients with coagulopathy reported a trend for reduced mortality compared with placebo (risk difference -5.40%; 95% CI \u00c01.68% to 12.48%).", [["coagulopathy", "DISEASE", 46, 58], ["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["A post hoc subgroup analysis", "TEST", 0, 28], ["coagulopathy", "PROBLEM", 46, 58], ["reduced mortality", "PROBLEM", 80, 97], ["CI", "TEST", 149, 151], ["coagulopathy", "OBSERVATION", 46, 58]]], ["A subsequent systematic review and meta-analysis suggested lower mortality among patients with (but not in those without) sepsis-induced coagulopathy treated with thrombomodulin (RR: 0.80; 95% CI, 0.65-0.98).", [["sepsis", "DISEASE", 122, 128], ["coagulopathy", "DISEASE", 137, 149], ["patients", "ORGANISM", 81, 89], ["thrombomodulin", "GENE_OR_GENE_PRODUCT", 163, 177], ["thrombomodulin", "PROTEIN", 163, 177], ["patients", "SPECIES", 81, 89], ["A subsequent systematic review", "TEST", 0, 30], ["meta-analysis", "TEST", 35, 48], ["sepsis", "PROBLEM", 122, 128], ["induced coagulopathy", "PROBLEM", 129, 149], ["thrombomodulin", "TEST", 163, 177], ["RR", "TEST", 179, 181], ["CI", "TEST", 193, 195], ["sepsis", "OBSERVATION", 122, 128], ["coagulopathy", "OBSERVATION", 137, 149]]], ["129 Currently, there is insufficient evidence to recommend the routine use of thrombomodulin in patients with severe COVID-19.", [["COVID-19", "CHEMICAL", 117, 125], ["thrombomodulin", "GENE_OR_GENE_PRODUCT", 78, 92], ["patients", "ORGANISM", 96, 104], ["thrombomodulin", "PROTEIN", 78, 92], ["patients", "SPECIES", 96, 104], ["thrombomodulin", "TREATMENT", 78, 92], ["severe COVID", "PROBLEM", 110, 122], ["thrombomodulin", "OBSERVATION", 78, 92]]], ["However, investigational use is warranted in selected subgroups with evidence of coagulopathy.Activated Protein CAPC can play a key role in reducing the damage caused by wide variety of triggers, including ischemia/reperfusion injury, gastrointestinal inflammation, sepsis, and Ebola virus infection.", [["gastrointestinal", "ANATOMY", 235, 251], ["coagulopathy", "DISEASE", 81, 93], ["ischemia/reperfusion injury", "DISEASE", 206, 233], ["gastrointestinal inflammation", "DISEASE", 235, 264], ["sepsis", "DISEASE", 266, 272], ["Ebola virus infection", "DISEASE", 278, 299], ["CAPC", "GENE_OR_GENE_PRODUCT", 112, 116], ["gastrointestinal", "ORGANISM_SUBDIVISION", 235, 251], ["Ebola virus", "ORGANISM", 278, 289], ["CAPC", "PROTEIN", 112, 116], ["Ebola virus", "SPECIES", 278, 289], ["Ebola virus", "SPECIES", 278, 289], ["coagulopathy", "PROBLEM", 81, 93], ["Activated Protein CAPC", "TREATMENT", 94, 116], ["the damage", "PROBLEM", 149, 159], ["ischemia", "PROBLEM", 206, 214], ["reperfusion injury", "PROBLEM", 215, 233], ["gastrointestinal inflammation", "PROBLEM", 235, 264], ["sepsis", "PROBLEM", 266, 272], ["Ebola virus infection", "PROBLEM", 278, 299], ["coagulopathy", "OBSERVATION", 81, 93], ["reperfusion injury", "OBSERVATION", 215, 233], ["gastrointestinal", "ANATOMY", 235, 251], ["inflammation", "OBSERVATION", 252, 264], ["sepsis", "OBSERVATION", 266, 272], ["Ebola virus", "OBSERVATION", 278, 289]]], ["130 In 2002, recombinant human protein C was approved by the U.S. Food and Drug Administration (FDA) for the clinical treatment of severe sepsis and ARDS.", [["sepsis", "DISEASE", 138, 144], ["ARDS", "DISEASE", 149, 153], ["human", "ORGANISM", 25, 30], ["protein C", "GENE_OR_GENE_PRODUCT", 31, 40], ["recombinant human protein C", "PROTEIN", 13, 40], ["human", "SPECIES", 25, 30], ["human", "SPECIES", 25, 30], ["recombinant human protein C", "TREATMENT", 13, 40], ["the clinical treatment", "TREATMENT", 105, 127], ["severe sepsis", "PROBLEM", 131, 144], ["ARDS", "PROBLEM", 149, 153], ["severe", "OBSERVATION_MODIFIER", 131, 137], ["sepsis", "OBSERVATION", 138, 144], ["ARDS", "OBSERVATION", 149, 153]]], ["Protein C concentrates reduced the risk of mortality in early studies of sepsis and septic shock.", [["sepsis", "DISEASE", 73, 79], ["septic shock", "DISEASE", 84, 96], ["Protein C", "GENE_OR_GENE_PRODUCT", 0, 9], ["Protein C concentrates", "PROBLEM", 0, 22], ["sepsis", "PROBLEM", 73, 79], ["septic shock", "PROBLEM", 84, 96], ["concentrates reduced", "OBSERVATION_MODIFIER", 10, 30], ["sepsis", "OBSERVATION", 73, 79], ["septic shock", "OBSERVATION", 84, 96]]], ["19 Specifically, a randomized trial of 1,697 patients did not demonstrate a reduction in mortality at 28 or 90 days after APC was administered in the setting of septic shock, 131 and subsequent concerns emerged regarding the risk of serious bleeding and death in individuals with bleeding precautions.", [["septic shock", "DISEASE", 161, 173], ["bleeding", "DISEASE", 241, 249], ["death", "DISEASE", 254, 259], ["bleeding", "DISEASE", 280, 288], ["APC", "CHEMICAL", 122, 125], ["patients", "ORGANISM", 45, 53], ["APC", "GENE_OR_GENE_PRODUCT", 122, 125], ["APC", "CELL_TYPE", 122, 125], ["patients", "SPECIES", 45, 53], ["a reduction in mortality", "PROBLEM", 74, 98], ["APC", "TREATMENT", 122, 125], ["septic shock", "PROBLEM", 161, 173], ["serious bleeding", "PROBLEM", 233, 249], ["death in individuals", "PROBLEM", 254, 274], ["bleeding precautions", "TREATMENT", 280, 300], ["reduction", "OBSERVATION_MODIFIER", 76, 85], ["septic shock", "OBSERVATION", 161, 173], ["serious", "OBSERVATION_MODIFIER", 233, 240], ["bleeding", "OBSERVATION", 241, 249]]], ["132 A possible explanation is that APC may only benefit septic patients complicated by DIC, which was a minority of patients in these trials.Activated Protein CIn a study of 27 patients with ARDS (16 treated with recombinant APC and 11 with placebo), the infusion of recombinant APC increased APC levels in the pulmonary compartment and attenuated systemic coagulopathy and pulmonary coagulopathy, providing faster resolution of pulmonary dysfunction without bleeding complications.", [["pulmonary compartment", "ANATOMY", 311, 332], ["pulmonary", "ANATOMY", 374, 383], ["pulmonary", "ANATOMY", 429, 438], ["septic", "DISEASE", 56, 62], ["DIC", "DISEASE", 87, 90], ["ARDS", "DISEASE", 191, 195], ["coagulopathy", "DISEASE", 357, 369], ["pulmonary coagulopathy", "DISEASE", 374, 396], ["pulmonary dysfunction", "DISEASE", 429, 450], ["bleeding", "DISEASE", 459, 467], ["APC", "CHEMICAL", 35, 38], ["APC", "CHEMICAL", 225, 228], ["APC", "GENE_OR_GENE_PRODUCT", 35, 38], ["patients", "ORGANISM", 63, 71], ["patients", "ORGANISM", 116, 124], ["patients", "ORGANISM", 177, 185], ["APC", "GENE_OR_GENE_PRODUCT", 225, 228], ["APC", "GENE_OR_GENE_PRODUCT", 279, 282], ["APC", "GENE_OR_GENE_PRODUCT", 293, 296], ["pulmonary compartment", "MULTI-TISSUE_STRUCTURE", 311, 332], ["pulmonary", "ORGAN", 374, 383], ["pulmonary", "ORGAN", 429, 438], ["APC", "CELL_TYPE", 35, 38], ["recombinant APC", "PROTEIN", 213, 228], ["recombinant APC", "PROTEIN", 267, 282], ["APC", "CELL_TYPE", 293, 296], ["patients", "SPECIES", 63, 71], ["patients", "SPECIES", 116, 124], ["patients", "SPECIES", 177, 185], ["APC", "PROBLEM", 35, 38], ["DIC", "PROBLEM", 87, 90], ["a study", "TEST", 163, 170], ["ARDS", "PROBLEM", 191, 195], ["recombinant APC", "TREATMENT", 213, 228], ["placebo", "TREATMENT", 241, 248], ["the infusion", "TREATMENT", 251, 263], ["recombinant APC increased APC levels", "TREATMENT", 267, 303], ["attenuated systemic coagulopathy", "PROBLEM", 337, 369], ["pulmonary coagulopathy", "PROBLEM", 374, 396], ["pulmonary dysfunction", "PROBLEM", 429, 450], ["bleeding complications", "PROBLEM", 459, 481], ["possible explanation", "UNCERTAINTY", 6, 26], ["pulmonary compartment", "ANATOMY", 311, 332], ["attenuated", "OBSERVATION_MODIFIER", 337, 347], ["systemic", "OBSERVATION_MODIFIER", 348, 356], ["coagulopathy", "OBSERVATION", 357, 369], ["pulmonary", "ANATOMY", 374, 383], ["coagulopathy", "OBSERVATION", 384, 396], ["pulmonary", "ANATOMY", 429, 438], ["dysfunction", "OBSERVATION", 439, 450], ["without", "UNCERTAINTY", 451, 458], ["bleeding", "OBSERVATION", 459, 467]]], ["133 However, in a subsequent randomized controlled trial of 71 patients, infusion of recombinant APC for infectious or inflammatory ARDS did not improve alveolocapillary permeability nor the clinical course of ARDS patients.", [["alveolocapillary", "ANATOMY", 153, 169], ["ARDS", "DISEASE", 132, 136], ["ARDS", "DISEASE", 210, 214], ["patients", "ORGANISM", 63, 71], ["APC", "GENE_OR_GENE_PRODUCT", 97, 100], ["alveolocapillary", "TISSUE", 153, 169], ["patients", "ORGANISM", 215, 223], ["recombinant APC", "PROTEIN", 85, 100], ["patients", "SPECIES", 63, 71], ["patients", "SPECIES", 215, 223], ["infusion of recombinant APC", "TREATMENT", 73, 100], ["infectious", "PROBLEM", 105, 115], ["inflammatory ARDS", "PROBLEM", 119, 136], ["alveolocapillary permeability", "PROBLEM", 153, 182], ["ARDS patients", "PROBLEM", 210, 223], ["infectious", "OBSERVATION", 105, 115], ["inflammatory", "OBSERVATION", 119, 131]]], ["134 It is intuitive that protein C concentrates may be more beneficial in patients with significant protein C reduction.", [["protein C", "GENE_OR_GENE_PRODUCT", 25, 34], ["patients", "ORGANISM", 74, 82], ["protein C", "GENE_OR_GENE_PRODUCT", 100, 109], ["protein C", "PROTEIN", 25, 34], ["protein C", "PROTEIN", 100, 109], ["patients", "SPECIES", 74, 82], ["protein C concentrates", "TREATMENT", 25, 47], ["significant protein C reduction", "TREATMENT", 88, 119], ["reduction", "OBSERVATION_MODIFIER", 110, 119]]], ["However, in a small study of 11 critically ill COVID-19 patients, protein C levels were overall increased, with only 4 patients having a protein C level lower than normal.", [["critically ill", "DISEASE", 32, 46], ["patients", "ORGANISM", 56, 64], ["protein C", "GENE_OR_GENE_PRODUCT", 66, 75], ["patients", "ORGANISM", 119, 127], ["protein C", "GENE_OR_GENE_PRODUCT", 137, 146], ["protein C", "PROTEIN", 66, 75], ["protein C", "PROTEIN", 137, 146], ["patients", "SPECIES", 56, 64], ["patients", "SPECIES", 119, 127], ["a small study", "TEST", 12, 25], ["critically ill COVID", "TEST", 32, 52], ["protein C levels", "TEST", 66, 82], ["a protein C level", "TEST", 135, 152], ["small", "OBSERVATION_MODIFIER", 14, 19], ["increased", "OBSERVATION_MODIFIER", 96, 105]]], ["119 The protein C mutant, 3K3A-APC, being developed for acute stroke treatment, was engineered to have low anticoagulant activity (so low bleeding risk) while retaining APCs' antiinflammatory and cytoprotective cell signaling properties that may be important in pneumonia.", [["APCs", "ANATOMY", 169, 173], ["cell", "ANATOMY", 211, 215], ["acute stroke", "DISEASE", 56, 68], ["bleeding", "DISEASE", 138, 146], ["pneumonia", "DISEASE", 262, 271], ["C", "GENE_OR_GENE_PRODUCT", 16, 17], ["3K3A-APC", "GENE_OR_GENE_PRODUCT", 26, 34], ["APCs", "CELL", 169, 173], ["cell", "CELL", 211, 215], ["protein C mutant", "PROTEIN", 8, 24], ["3K3A", "PROTEIN", 26, 30], ["APC", "CELL_TYPE", 31, 34], ["APCs", "CELL_TYPE", 169, 173], ["The protein C mutant", "PROBLEM", 4, 24], ["APC", "PROBLEM", 31, 34], ["acute stroke treatment", "TREATMENT", 56, 78], ["low anticoagulant activity", "PROBLEM", 103, 129], ["low bleeding risk", "PROBLEM", 134, 151], ["APCs' antiinflammatory", "TREATMENT", 169, 191], ["cytoprotective cell signaling properties", "TREATMENT", 196, 236], ["pneumonia", "PROBLEM", 262, 271], ["acute", "OBSERVATION_MODIFIER", 56, 61], ["stroke", "OBSERVATION", 62, 68], ["cytoprotective cell signaling", "OBSERVATION", 196, 225], ["may be important", "UNCERTAINTY", 242, 258], ["pneumonia", "OBSERVATION", 262, 271]]], ["The potential utility of recombinant APC or 3K3A-APC in patients with COVID-19, including those with DIC, is worthy of prospective investigation.", [["DIC", "DISEASE", 101, 104], ["APC", "GENE_OR_GENE_PRODUCT", 37, 40], ["3K3A-APC", "GENE_OR_GENE_PRODUCT", 44, 52], ["patients", "ORGANISM", 56, 64], ["recombinant APC", "PROTEIN", 25, 40], ["3K3A", "PROTEIN", 44, 48], ["APC", "CELL_TYPE", 49, 52], ["patients", "SPECIES", 56, 64], ["recombinant APC", "TREATMENT", 25, 40], ["APC", "PROBLEM", 49, 52], ["COVID", "TEST", 70, 75], ["prospective investigation", "TEST", 119, 144]]], ["135Contact Activation SystemDysregulation of inflammation and coagulation are hallmarks of COVID-19.", [["inflammation", "DISEASE", 45, 57], ["COVID-19", "CHEMICAL", 91, 99], ["inflammation", "PROBLEM", 45, 57], ["COVID", "TEST", 91, 96], ["inflammation", "OBSERVATION", 45, 57]]], ["The contact activation system, which includes factor XII, factor XI, high-molecular-weight kininogen, and prekallikrein, links inflammation and coagulation by triggering the generation of thrombin and bradykinin.", [["inflammation", "DISEASE", 127, 139], ["bradykinin", "CHEMICAL", 201, 211], ["bradykinin", "CHEMICAL", 201, 211], ["factor XII", "GENE_OR_GENE_PRODUCT", 46, 56], ["factor XI", "GENE_OR_GENE_PRODUCT", 58, 67], ["high-molecular-weight kininogen", "GENE_OR_GENE_PRODUCT", 69, 100], ["prekallikrein", "GENE_OR_GENE_PRODUCT", 106, 119], ["thrombin", "GENE_OR_GENE_PRODUCT", 188, 196], ["bradykinin", "SIMPLE_CHEMICAL", 201, 211], ["factor XII", "PROTEIN", 46, 56], ["factor XI", "PROTEIN", 58, 67], ["high-molecular-weight kininogen", "PROTEIN", 69, 100], ["prekallikrein", "PROTEIN", 106, 119], ["thrombin", "PROTEIN", 188, 196], ["The contact activation system", "TEST", 0, 29], ["factor XII", "PROBLEM", 46, 56], ["factor XI", "TEST", 58, 67], ["prekallikrein", "PROBLEM", 106, 119], ["links inflammation", "PROBLEM", 121, 139], ["thrombin", "TREATMENT", 188, 196], ["bradykinin", "TREATMENT", 201, 211], ["inflammation", "OBSERVATION", 127, 139]]], ["Thrombin promotes clot formation and platelet activation, whereas bradykinin induces the release of proinflammatory cytokines.Contact Activation SystemIn nonhuman primate models of bacterial sepsis, inhibition of factor XIIa or blockade of reciprocal factor XI and factor XII activation reduced the levels of inflammatory cytokines, attenuated microvascular thrombosis, and improved survival.", [["clot", "ANATOMY", 18, 22], ["platelet", "ANATOMY", 37, 45], ["microvascular", "ANATOMY", 344, 357], ["bradykinin", "CHEMICAL", 66, 76], ["bacterial sepsis", "DISEASE", 181, 197], ["microvascular thrombosis", "DISEASE", 344, 368], ["bradykinin", "CHEMICAL", 66, 76], ["Thrombin", "GENE_OR_GENE_PRODUCT", 0, 8], ["clot", "ORGANISM_SUBSTANCE", 18, 22], ["platelet", "CELL", 37, 45], ["bradykinin", "SIMPLE_CHEMICAL", 66, 76], ["factor XIIa", "GENE_OR_GENE_PRODUCT", 213, 224], ["factor XI", "GENE_OR_GENE_PRODUCT", 251, 260], ["factor XII", "GENE_OR_GENE_PRODUCT", 265, 275], ["microvascular", "MULTI-TISSUE_STRUCTURE", 344, 357], ["Thrombin", "PROTEIN", 0, 8], ["proinflammatory cytokines", "PROTEIN", 100, 125], ["factor XIIa", "PROTEIN", 213, 224], ["reciprocal factor XI", "PROTEIN", 240, 260], ["factor XII", "PROTEIN", 265, 275], ["inflammatory cytokines", "PROTEIN", 309, 331], ["Thrombin", "TREATMENT", 0, 8], ["clot formation", "PROBLEM", 18, 32], ["platelet activation", "PROBLEM", 37, 56], ["bradykinin", "PROBLEM", 66, 76], ["proinflammatory cytokines", "PROBLEM", 100, 125], ["bacterial sepsis", "PROBLEM", 181, 197], ["factor XIIa", "PROBLEM", 213, 224], ["reciprocal factor XI", "PROBLEM", 240, 260], ["factor XII activation", "PROBLEM", 265, 286], ["inflammatory cytokines", "PROBLEM", 309, 331], ["attenuated microvascular thrombosis", "PROBLEM", 333, 368], ["clot", "OBSERVATION", 18, 22], ["platelet activation", "OBSERVATION", 37, 56], ["proinflammatory cytokines", "OBSERVATION", 100, 125], ["bacterial", "OBSERVATION_MODIFIER", 181, 190], ["sepsis", "OBSERVATION", 191, 197], ["inflammatory cytokines", "OBSERVATION", 309, 331], ["attenuated", "OBSERVATION_MODIFIER", 333, 343], ["microvascular thrombosis", "OBSERVATION", 344, 368], ["improved", "OBSERVATION_MODIFIER", 374, 382], ["survival", "OBSERVATION_MODIFIER", 383, 391]]], ["[136] [137] [138] [139] Likewise, in murine models of bacterial sepsis, inflammation and coagulation were attenuated, and survival was enhanced in factor XI-deficient mice compared with their wild-type counterparts.", [["bacterial sepsis", "DISEASE", 54, 70], ["inflammation", "DISEASE", 72, 84], ["murine", "ORGANISM", 37, 43], ["XI", "GENE_OR_GENE_PRODUCT", 154, 156], ["mice", "ORGANISM", 167, 171], ["XI", "PROTEIN", 154, 156], ["murine", "SPECIES", 37, 43], ["mice", "SPECIES", 167, 171], ["mice", "SPECIES", 167, 171], ["bacterial sepsis", "PROBLEM", 54, 70], ["inflammation", "PROBLEM", 72, 84], ["coagulation", "TEST", 89, 100], ["bacterial", "OBSERVATION_MODIFIER", 54, 63], ["sepsis", "OBSERVATION", 64, 70], ["inflammation", "OBSERVATION", 72, 84]]], ["140, 141 Several inhibitors of factor XII and factor XI are currently under investigation.", [["factor XII", "GENE_OR_GENE_PRODUCT", 31, 41], ["factor XI", "GENE_OR_GENE_PRODUCT", 46, 55], ["factor XII", "PROTEIN", 31, 41], ["factor XI", "PROTEIN", 46, 55], ["factor XII", "PROBLEM", 31, 41], ["factor XI", "PROBLEM", 46, 55]]], ["Studies evaluating the efficacy and safety of these agents in COVID-19 are warranted.", [["Studies evaluating", "TEST", 0, 18], ["these agents", "TREATMENT", 46, 58], ["COVID", "TEST", 62, 67]]], ["142CorticosteroidsThere is conflicting evidence for the use of corticosteroids in COVID-19-related ARDS.", [["142Corticosteroids", "CHEMICAL", 0, 18], ["COVID-19", "CHEMICAL", 82, 90], ["ARDS", "DISEASE", 99, 103], ["142Corticosteroids", "CHEMICAL", 0, 18], ["corticosteroids", "CHEMICAL", 63, 78], ["142Corticosteroids", "SIMPLE_CHEMICAL", 0, 18], ["corticosteroids", "SIMPLE_CHEMICAL", 63, 78], ["corticosteroids", "TREATMENT", 63, 78], ["COVID", "TEST", 82, 87], ["ARDS", "PROBLEM", 99, 103], ["conflicting evidence for", "UNCERTAINTY", 27, 51], ["ARDS", "OBSERVATION", 99, 103]]], ["143 Postulated benefits, including reduction in inflammation and lung injury, must be weighed against the potential risks of delayed viral clearance and increased susceptibility to secondary infections.", [["lung", "ANATOMY", 65, 69], ["inflammation", "DISEASE", 48, 60], ["lung injury", "DISEASE", 65, 76], ["infections", "DISEASE", 191, 201], ["lung", "ORGAN", 65, 69], ["inflammation", "PROBLEM", 48, 60], ["lung injury", "PROBLEM", 65, 76], ["delayed viral clearance", "PROBLEM", 125, 148], ["increased susceptibility", "PROBLEM", 153, 177], ["secondary infections", "PROBLEM", 181, 201], ["reduction", "OBSERVATION_MODIFIER", 35, 44], ["inflammation", "OBSERVATION", 48, 60], ["lung", "ANATOMY", 65, 69], ["injury", "OBSERVATION", 70, 76], ["viral clearance", "OBSERVATION", 133, 148], ["secondary", "OBSERVATION_MODIFIER", 181, 190], ["infections", "OBSERVATION", 191, 201]]], ["[144] [145] [146] [147] Thrombosis and Haemostasis Vol.", [["Thrombosis", "DISEASE", 24, 34], ["[144] [145] [146] [147]", "CHEMICAL", 0, 23], ["[144] [145] [146] [147] Thrombosis", "SIMPLE_CHEMICAL", 0, 34], ["Thrombosis", "PROBLEM", 24, 34], ["Haemostasis Vol", "TEST", 39, 54], ["Thrombosis", "OBSERVATION", 24, 34]]], ["120 No. 7/2020 Therapeutic Targets for COVID-19-Associated Thrombosis Bikdeli et al. 1017 This document was downloaded for personal use only.", [["Thrombosis", "DISEASE", 59, 69], ["COVID-19", "CHEMICAL", 39, 47], ["COVID", "TEST", 39, 44], ["Thrombosis", "PROBLEM", 59, 69], ["Thrombosis", "OBSERVATION", 59, 69]]], ["Unauthorized distribution is strictly prohibited.CorticosteroidsMechanisms as to whether corticosteroids may modulate thrombotic risk in this patient population are not well-established.", [["corticosteroids", "CHEMICAL", 89, 104], ["thrombotic", "DISEASE", 118, 128], ["corticosteroids", "CHEMICAL", 89, 104], ["corticosteroids", "SIMPLE_CHEMICAL", 89, 104], ["patient", "ORGANISM", 142, 149], ["patient", "SPECIES", 142, 149], ["CorticosteroidsMechanisms", "TREATMENT", 49, 74], ["corticosteroids", "TREATMENT", 89, 104], ["thrombotic risk", "PROBLEM", 118, 133], ["strictly prohibited", "OBSERVATION_MODIFIER", 29, 48], ["thrombotic", "OBSERVATION_MODIFIER", 118, 128]]], ["As the microvascular and macrovascular thrombotic complications observed in COVID-19 may in part be attributable to the inflammatory environment precipitated by the infection, corticosteroids may reduce thrombotic risk through anti-inflammatory activity.", [["microvascular", "ANATOMY", 7, 20], ["macrovascular", "ANATOMY", 25, 38], ["macrovascular thrombotic complications", "DISEASE", 25, 63], ["COVID-19", "CHEMICAL", 76, 84], ["infection", "DISEASE", 165, 174], ["corticosteroids", "CHEMICAL", 176, 191], ["thrombotic", "DISEASE", 203, 213], ["COVID-19", "CHEMICAL", 76, 84], ["corticosteroids", "CHEMICAL", 176, 191], ["microvascular", "MULTI-TISSUE_STRUCTURE", 7, 20], ["macrovascular thrombotic", "PATHOLOGICAL_FORMATION", 25, 49], ["COVID-19", "GENE_OR_GENE_PRODUCT", 76, 84], ["corticosteroids", "SIMPLE_CHEMICAL", 176, 191], ["the microvascular and macrovascular thrombotic complications", "PROBLEM", 3, 63], ["COVID", "TEST", 76, 81], ["the inflammatory environment", "PROBLEM", 116, 144], ["the infection", "PROBLEM", 161, 174], ["corticosteroids", "TREATMENT", 176, 191], ["thrombotic risk", "PROBLEM", 203, 218], ["anti-inflammatory activity", "TREATMENT", 227, 253], ["microvascular", "ANATOMY", 7, 20], ["macrovascular", "OBSERVATION_MODIFIER", 25, 38], ["thrombotic", "OBSERVATION_MODIFIER", 39, 49], ["complications", "OBSERVATION", 50, 63], ["inflammatory", "OBSERVATION", 120, 132], ["infection", "OBSERVATION", 165, 174], ["anti-inflammatory activity", "OBSERVATION", 227, 253]]], ["Studies of inflammatory states, particularly rheumatologic conditions, have shown a proportional relationship between inflammatory activity, coagulability, and the risk of VTE.", [["VTE", "DISEASE", 172, 175], ["inflammatory states", "PROBLEM", 11, 30], ["rheumatologic conditions", "PROBLEM", 45, 69], ["inflammatory activity", "PROBLEM", 118, 139], ["coagulability", "PROBLEM", 141, 154], ["VTE", "PROBLEM", 172, 175], ["inflammatory", "OBSERVATION", 11, 23], ["inflammatory", "OBSERVATION_MODIFIER", 118, 130], ["VTE", "OBSERVATION", 172, 175]]], ["Results regarding frequency of thrombosis with disease-modifying therapies, including corticosteroids, are mixed.", [["thrombosis", "DISEASE", 31, 41], ["corticosteroids", "CHEMICAL", 86, 101], ["thrombosis", "PROBLEM", 31, 41], ["disease", "PROBLEM", 47, 54], ["modifying therapies", "TREATMENT", 55, 74], ["corticosteroids", "TREATMENT", 86, 101], ["thrombosis", "OBSERVATION", 31, 41], ["mixed", "OBSERVATION_MODIFIER", 107, 112]]], ["148, 149 Possible beneficial 150 mechanisms include reductions in levels of procoagulant factors, including fibrinogen and von Willebrand factor.", [["procoagulant factors", "GENE_OR_GENE_PRODUCT", 76, 96], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 108, 118], ["von Willebrand factor", "GENE_OR_GENE_PRODUCT", 123, 144], ["procoagulant factors", "PROTEIN", 76, 96], ["fibrinogen", "PROTEIN", 108, 118], ["von Willebrand factor", "PROTEIN", 123, 144], ["procoagulant factors", "TREATMENT", 76, 96], ["fibrinogen", "TEST", 108, 118]]], ["151 However, experimental studies have also linked steroid use to increased levels of various clotting factors, and several large-scale studies have shown exogenous glucocorticoids to be a risk factor for thrombosis.", [["steroid", "CHEMICAL", 51, 58], ["thrombosis", "DISEASE", 205, 215], ["steroid", "CHEMICAL", 51, 58], ["steroid", "SIMPLE_CHEMICAL", 51, 58], ["clotting factors", "PROTEIN", 94, 110], ["experimental studies", "TEST", 13, 33], ["various clotting factors", "PROBLEM", 86, 110], ["several large-scale studies", "TEST", 116, 143], ["exogenous glucocorticoids", "PROBLEM", 155, 180], ["thrombosis", "PROBLEM", 205, 215], ["exogenous glucocorticoids", "OBSERVATION", 155, 180], ["thrombosis", "OBSERVATION", 205, 215]]], ["[150] [151] [152] Prior studies of corticosteroids in patients with non-COVID-19-related ARDS have shown mixed results with potential benefit limited to only certain subgroups of patients.", [["corticosteroids", "CHEMICAL", 35, 50], ["non-COVID-19", "CHEMICAL", 68, 80], ["ARDS", "DISEASE", 89, 93], ["corticosteroids", "CHEMICAL", 35, 50], ["patients", "ORGANISM", 54, 62], ["patients", "ORGANISM", 179, 187], ["patients", "SPECIES", 54, 62], ["patients", "SPECIES", 179, 187], ["Prior studies", "TEST", 18, 31], ["corticosteroids", "TREATMENT", 35, 50], ["non-COVID", "TEST", 68, 77], ["ARDS", "PROBLEM", 89, 93], ["ARDS", "OBSERVATION", 89, 93]]], ["153 Further experience and research, including results from a series of ongoing randomized trials, are needed to better understand the balance of pro-and anticoagulant properties of glucocorticoids in the setting of COVID-19.HydroxychloroquineHydroxychloroquine is a 4-aminoquinoline that has an immunomodulatory effect and antithrombotic activity that have been demonstrated in animal models and in patients with systemic lupus erythematosus, rheumatoid arthritis, and antiphospholipid syndrome.", [["glucocorticoids", "CHEMICAL", 182, 197], ["HydroxychloroquineHydroxychloroquine", "CHEMICAL", 225, 261], ["4-aminoquinoline", "CHEMICAL", 267, 283], ["systemic lupus erythematosus", "DISEASE", 414, 442], ["rheumatoid arthritis", "DISEASE", 444, 464], ["antiphospholipid syndrome", "DISEASE", 470, 495], ["HydroxychloroquineHydroxychloroquine", "CHEMICAL", 225, 261], ["4-aminoquinoline", "CHEMICAL", 267, 283], ["glucocorticoids", "SIMPLE_CHEMICAL", 182, 197], ["HydroxychloroquineHydroxychloroquine", "SIMPLE_CHEMICAL", 225, 261], ["4-aminoquinoline", "SIMPLE_CHEMICAL", 267, 283], ["patients", "ORGANISM", 400, 408], ["patients", "SPECIES", 400, 408], ["ongoing randomized trials", "TREATMENT", 72, 97], ["pro-and anticoagulant properties", "TREATMENT", 146, 178], ["glucocorticoids", "TREATMENT", 182, 197], ["COVID", "TEST", 216, 221], ["HydroxychloroquineHydroxychloroquine", "TREATMENT", 225, 261], ["aminoquinoline", "TREATMENT", 269, 283], ["an immunomodulatory effect", "TREATMENT", 293, 319], ["antithrombotic activity", "TREATMENT", 324, 347], ["systemic lupus erythematosus", "PROBLEM", 414, 442], ["rheumatoid arthritis", "PROBLEM", 444, 464], ["antiphospholipid syndrome", "PROBLEM", 470, 495], ["antithrombotic activity", "OBSERVATION", 324, 347], ["systemic", "OBSERVATION_MODIFIER", 414, 422], ["lupus erythematosus", "OBSERVATION", 423, 442], ["rheumatoid arthritis", "OBSERVATION", 444, 464], ["antiphospholipid syndrome", "OBSERVATION", 470, 495]]], ["[154] [155] [156] [157] In a mouse model, hydroxychloroquine reversed the thrombogenic properties of antiphospholipid antibodies.", [["hydroxychloroquine", "CHEMICAL", 42, 60], ["antiphospholipid antibodies", "DISEASE", 101, 128], ["hydroxychloroquine", "CHEMICAL", 42, 60], ["[154] [155] [156] [157", "SIMPLE_CHEMICAL", 0, 22], ["mouse", "ORGANISM", 29, 34], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 42, 60], ["antiphospholipid antibodies", "GENE_OR_GENE_PRODUCT", 101, 128], ["antiphospholipid antibodies", "PROTEIN", 101, 128], ["mouse", "SPECIES", 29, 34], ["mouse", "SPECIES", 29, 34], ["a mouse model", "TREATMENT", 27, 40], ["hydroxychloroquine", "TREATMENT", 42, 60], ["antiphospholipid antibodies", "PROBLEM", 101, 128], ["antiphospholipid antibodies", "OBSERVATION", 101, 128]]], ["158 Hydroxychloroquine may also have mild antiplatelet effects in patients with antiphospholipid antibodies, and may reduce blood viscosity.", [["blood", "ANATOMY", 124, 129], ["Hydroxychloroquine", "CHEMICAL", 4, 22], ["antiphospholipid antibodies", "DISEASE", 80, 107], ["Hydroxychloroquine", "CHEMICAL", 4, 22], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 4, 22], ["patients", "ORGANISM", 66, 74], ["antiphospholipid antibodies", "GENE_OR_GENE_PRODUCT", 80, 107], ["blood", "ORGANISM_SUBSTANCE", 124, 129], ["antiphospholipid antibodies", "PROTEIN", 80, 107], ["patients", "SPECIES", 66, 74], ["Hydroxychloroquine", "TREATMENT", 4, 22], ["mild antiplatelet effects", "PROBLEM", 37, 62], ["antiphospholipid antibodies", "PROBLEM", 80, 107], ["blood viscosity", "TEST", 124, 139], ["mild", "OBSERVATION_MODIFIER", 37, 41], ["antiplatelet", "OBSERVATION", 42, 54]]], ["154 An observational prospective study of patients with antiphospholipid antibody syndrome treated with hydroxychloroquine 200 mg daily demonstrated significant reduction in soluble tissue factor levels at 3 months compared with baseline.", [["antiphospholipid antibody syndrome", "DISEASE", 56, 90], ["hydroxychloroquine", "CHEMICAL", 104, 122], ["hydroxychloroquine", "CHEMICAL", 104, 122], ["patients", "ORGANISM", 42, 50], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 104, 122], ["tissue factor", "GENE_OR_GENE_PRODUCT", 182, 195], ["antiphospholipid antibody", "PROTEIN", 56, 81], ["soluble tissue factor", "PROTEIN", 174, 195], ["patients", "SPECIES", 42, 50], ["An observational prospective study", "TEST", 4, 38], ["antiphospholipid antibody syndrome", "PROBLEM", 56, 90], ["hydroxychloroquine", "TREATMENT", 104, 122], ["significant reduction in soluble tissue factor levels", "PROBLEM", 149, 202], ["antiphospholipid antibody syndrome", "OBSERVATION", 56, 90], ["significant", "OBSERVATION_MODIFIER", 149, 160], ["reduction", "OBSERVATION_MODIFIER", 161, 170], ["soluble tissue", "OBSERVATION_MODIFIER", 174, 188]]], ["159 Other potential antithrombotic mechanisms have led to its limited evaluation as a thromboprophylaxis modality in postoperative patients more than three decades ago.", [["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 131, 139], ["its limited evaluation", "TEST", 58, 80], ["a thromboprophylaxis modality", "TREATMENT", 84, 113], ["antithrombotic", "OBSERVATION", 20, 34]]], ["160, 161 However, the exact mechanisms by which it exerts it antithrombotic effect remain largely unknown.", [["antithrombotic", "OBSERVATION", 61, 75]]], ["Given the known adverse effects with hydroxychloroquine, including QTc prolongation and risk of arrhythmias, 162 its routine use as an antithrombotic therapy in patients with COVID-19 cannot be recommend until further prospective data emerge.StatinsHMG-CoA reductase inhibitors (statins) are widely used as cholesterol-lowering medications in patients with or at increased risk of atherosclerotic cardiovascular disease.", [["cardiovascular", "ANATOMY", 397, 411], ["hydroxychloroquine", "CHEMICAL", 37, 55], ["QTc prolongation", "DISEASE", 67, 83], ["arrhythmias", "DISEASE", 96, 107], ["StatinsHMG", "CHEMICAL", 242, 252], ["statins", "CHEMICAL", 279, 286], ["cholesterol", "CHEMICAL", 307, 318], ["atherosclerotic cardiovascular disease", "DISEASE", 381, 419], ["hydroxychloroquine", "CHEMICAL", 37, 55], ["StatinsHMG-CoA", "CHEMICAL", 242, 256], ["statins", "CHEMICAL", 279, 286], ["cholesterol", "CHEMICAL", 307, 318], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 37, 55], ["QTc", "SIMPLE_CHEMICAL", 67, 70], ["patients", "ORGANISM", 161, 169], ["StatinsHMG-CoA reductase", "GENE_OR_GENE_PRODUCT", 242, 266], ["statins", "SIMPLE_CHEMICAL", 279, 286], ["cholesterol", "SIMPLE_CHEMICAL", 307, 318], ["patients", "ORGANISM", 343, 351], ["atherosclerotic", "PATHOLOGICAL_FORMATION", 381, 396], ["cardiovascular", "ANATOMICAL_SYSTEM", 397, 411], ["patients", "SPECIES", 161, 169], ["patients", "SPECIES", 343, 351], ["hydroxychloroquine", "TREATMENT", 37, 55], ["QTc prolongation", "TREATMENT", 67, 83], ["arrhythmias", "PROBLEM", 96, 107], ["an antithrombotic therapy", "TREATMENT", 132, 157], ["COVID", "TREATMENT", 175, 180], ["StatinsHMG-CoA reductase inhibitors", "TREATMENT", 242, 277], ["statins", "TREATMENT", 279, 286], ["cholesterol-lowering medications", "TREATMENT", 307, 339], ["atherosclerotic cardiovascular disease", "PROBLEM", 381, 419], ["arrhythmias", "OBSERVATION", 96, 107], ["atherosclerotic", "OBSERVATION_MODIFIER", 381, 396], ["cardiovascular disease", "OBSERVATION", 397, 419]]], ["163 The pleiotropic effects of statins include improving endothelial function, decreasing inflammatory markers, and inhibiting thrombogenicity.", [["endothelial", "ANATOMY", 57, 68], ["statins", "CHEMICAL", 31, 38], ["statins", "CHEMICAL", 31, 38], ["statins", "SIMPLE_CHEMICAL", 31, 38], ["endothelial", "CELL", 57, 68], ["inflammatory markers", "PROTEIN", 90, 110], ["statins", "TREATMENT", 31, 38], ["improving endothelial function", "PROBLEM", 47, 77], ["decreasing inflammatory markers", "PROBLEM", 79, 110], ["inhibiting thrombogenicity", "PROBLEM", 116, 142], ["improving", "OBSERVATION_MODIFIER", 47, 56], ["endothelial function", "OBSERVATION", 57, 77], ["decreasing", "OBSERVATION_MODIFIER", 79, 89], ["inflammatory", "OBSERVATION_MODIFIER", 90, 102], ["thrombogenicity", "OBSERVATION_MODIFIER", 127, 142]]], ["164 Because patients with COVID-19 may exhibit increased activation of the inflammatory cascade and are prone to venous and arterial thrombosis, leveraging statins as a component of treatment has been proposed.", [["venous", "ANATOMY", 113, 119], ["arterial", "ANATOMY", 124, 132], ["COVID-19", "CHEMICAL", 26, 34], ["venous and arterial thrombosis", "DISEASE", 113, 143], ["statins", "CHEMICAL", 156, 163], ["statins", "CHEMICAL", 156, 163], ["patients", "ORGANISM", 12, 20], ["venous", "MULTI-TISSUE_STRUCTURE", 113, 119], ["arterial", "MULTI-TISSUE_STRUCTURE", 124, 132], ["patients", "SPECIES", 12, 20], ["COVID", "TEST", 26, 31], ["increased activation of the inflammatory cascade", "PROBLEM", 47, 95], ["venous and arterial thrombosis", "PROBLEM", 113, 143], ["leveraging statins", "TREATMENT", 145, 163], ["treatment", "TREATMENT", 182, 191], ["increased", "OBSERVATION_MODIFIER", 47, 56], ["activation", "OBSERVATION", 57, 67], ["inflammatory cascade", "OBSERVATION", 75, 95], ["venous", "ANATOMY", 113, 119], ["arterial", "ANATOMY", 124, 132], ["thrombosis", "OBSERVATION", 133, 143]]], ["5, 165, 166 While no clinical studies have evaluated statin therapy in the management of COVID-19, there is biological plausibility and precedent for such investigation.", [["statin", "CHEMICAL", 53, 59], ["statin", "CHEMICAL", 53, 59], ["clinical studies", "TEST", 21, 37], ["statin therapy", "TREATMENT", 53, 67], ["COVID", "TEST", 89, 94], ["such investigation", "TEST", 150, 168]]], ["Through inhibition of the MYD88 stress-response pathway, statins suppress NF-kB-induced proinflammatory cytokines.", [["statins", "CHEMICAL", 57, 64], ["statins", "CHEMICAL", 57, 64], ["MYD88", "GENE_OR_GENE_PRODUCT", 26, 31], ["statins", "SIMPLE_CHEMICAL", 57, 64], ["NF-kB", "GENE_OR_GENE_PRODUCT", 74, 79], ["MYD88", "PROTEIN", 26, 31], ["NF-kB", "PROTEIN", 74, 79], ["proinflammatory cytokines", "PROTEIN", 88, 113], ["statins", "TREATMENT", 57, 64], ["proinflammatory cytokines", "PROBLEM", 88, 113], ["proinflammatory cytokines", "OBSERVATION", 88, 113]]], ["167 This may underlie their proposed utility in other viral pneumonias, including those caused by related coronaviruses.", [["pneumonias", "DISEASE", 60, 70], ["coronaviruses", "ORGANISM", 106, 119], ["other viral pneumonias", "PROBLEM", 48, 70], ["coronaviruses", "PROBLEM", 106, 119], ["viral", "OBSERVATION_MODIFIER", 54, 59], ["pneumonias", "OBSERVATION", 60, 70], ["coronaviruses", "OBSERVATION", 106, 119]]], ["[168] [169] [170] Besides mitigating inflammation, antiplatelet and anticoagulant properties can occur via downregulation of tissue factor, upregulation of thrombomodulin, and inhibition of thromboxane A 2 .", [["inflammation", "DISEASE", 37, 49], ["thromboxane", "CHEMICAL", 190, 201], ["thromboxane A 2", "CHEMICAL", 190, 205], ["antiplatelet", "CELL", 51, 63], ["tissue factor", "GENE_OR_GENE_PRODUCT", 125, 138], ["thrombomodulin", "GENE_OR_GENE_PRODUCT", 156, 170], ["thromboxane A 2", "GENE_OR_GENE_PRODUCT", 190, 205], ["tissue factor", "PROTEIN", 125, 138], ["thrombomodulin", "PROTEIN", 156, 170], ["mitigating inflammation", "PROBLEM", 26, 49], ["antiplatelet", "TREATMENT", 51, 63], ["anticoagulant properties", "TREATMENT", 68, 92], ["tissue factor", "PROBLEM", 125, 138], ["upregulation of thrombomodulin", "TREATMENT", 140, 170], ["thromboxane A", "TREATMENT", 190, 203], ["inflammation", "OBSERVATION", 37, 49], ["thrombomodulin", "OBSERVATION", 156, 170]]], ["171 Prior reports have shown that use of statins is associated with reduced rates of VTE, and statins have stabilizing effects on atherosclerotic plaques.", [["atherosclerotic plaques", "ANATOMY", 130, 153], ["statins", "CHEMICAL", 41, 48], ["VTE", "DISEASE", 85, 88], ["statins", "CHEMICAL", 94, 101], ["atherosclerotic plaques", "DISEASE", 130, 153], ["statins", "CHEMICAL", 41, 48], ["statins", "CHEMICAL", 94, 101], ["statins", "SIMPLE_CHEMICAL", 94, 101], ["atherosclerotic plaques", "PATHOLOGICAL_FORMATION", 130, 153], ["statins", "TREATMENT", 41, 48], ["reduced rates of VTE", "PROBLEM", 68, 88], ["statins", "TREATMENT", 94, 101], ["atherosclerotic plaques", "PROBLEM", 130, 153], ["atherosclerotic", "OBSERVATION_MODIFIER", 130, 145], ["plaques", "OBSERVATION", 146, 153]]], ["172, 173 At least three clinical trials (NCT04348695, NCT04333407, and NCT04343001) are recruiting COVID-19 patients in randomized statin investigations.Targeted Immunomodulatory TherapiesSARS-CoV-2 infection is associated with an inflammatory response marked by increased cytokine levels (e.g., IL-2, IL6, IL-10, tumor necrosis factor-\u03b1).", [["statin", "CHEMICAL", 131, 137], ["infection", "DISEASE", 199, 208], ["necrosis", "DISEASE", 320, 328], ["patients", "ORGANISM", 108, 116], ["CoV-2", "ORGANISM", 193, 198], ["IL-2", "GENE_OR_GENE_PRODUCT", 296, 300], ["IL6", "GENE_OR_GENE_PRODUCT", 302, 305], ["IL-10", "GENE_OR_GENE_PRODUCT", 307, 312], ["tumor necrosis factor-\u03b1", "GENE_OR_GENE_PRODUCT", 314, 337], ["cytokine", "PROTEIN", 273, 281], ["IL6", "PROTEIN", 302, 305], ["IL-10", "PROTEIN", 307, 312], ["tumor necrosis factor-\u03b1", "PROTEIN", 314, 337], ["patients", "SPECIES", 108, 116], ["randomized statin investigations", "TREATMENT", 120, 152], ["Targeted Immunomodulatory TherapiesSARS", "TEST", 153, 192], ["CoV-2 infection", "PROBLEM", 193, 208], ["an inflammatory response", "PROBLEM", 228, 252], ["increased cytokine levels", "PROBLEM", 263, 288], ["IL", "TEST", 296, 298], ["IL6", "TEST", 302, 305], ["IL", "TEST", 307, 309], ["tumor necrosis factor", "PROBLEM", 314, 335], ["infection", "OBSERVATION", 199, 208], ["inflammatory", "OBSERVATION", 231, 243], ["marked", "OBSERVATION_MODIFIER", 253, 259], ["increased", "OBSERVATION_MODIFIER", 263, 272], ["cytokine levels", "OBSERVATION", 273, 288]]], ["174 To treat the inflammatory response generated by severe COVID-19, some have proposed to repurpose immunomodulatory medications approved for other diseases.Targeted Immunomodulatory TherapiesOne potential target is the complement cascade.", [["COVID-19", "CHEMICAL", 59, 67], ["the inflammatory response", "PROBLEM", 13, 38], ["severe COVID", "PROBLEM", 52, 64], ["immunomodulatory medications", "TREATMENT", 101, 129], ["other diseases", "PROBLEM", 143, 157], ["Targeted Immunomodulatory Therapies", "TREATMENT", 158, 193], ["inflammatory", "OBSERVATION", 17, 29], ["severe", "OBSERVATION_MODIFIER", 52, 58]]], ["A major component of innate immunity, the complement cascade has three independent pathways for activation (classical, lectin, and alternative), each culminating with formation of the lytic membrane attack complex.", [["membrane", "ANATOMY", 190, 198], ["lectin", "GENE_OR_GENE_PRODUCT", 119, 125], ["membrane", "CELLULAR_COMPONENT", 190, 198], ["lectin", "PROTEIN", 119, 125], ["lytic membrane attack complex", "PROTEIN", 184, 213], ["activation (classical, lectin", "TREATMENT", 96, 125], ["the lytic membrane attack complex", "PROBLEM", 180, 213], ["major", "OBSERVATION_MODIFIER", 2, 7], ["component", "OBSERVATION_MODIFIER", 8, 17], ["innate immunity", "OBSERVATION", 21, 36], ["lytic", "OBSERVATION_MODIFIER", 184, 189]]], ["Eculizumab is an anti-C5 monoclonal antibody that blocks terminal complement activity.", [["Eculizumab", "CHEMICAL", 0, 10], ["Eculizumab", "CHEMICAL", 0, 10], ["Eculizumab", "SIMPLE_CHEMICAL", 0, 10], ["anti-C5 monoclonal antibody", "PROTEIN", 17, 44], ["Eculizumab", "TREATMENT", 0, 10], ["an anti-C5 monoclonal antibody", "TREATMENT", 14, 44], ["monoclonal antibody", "OBSERVATION", 25, 44], ["terminal", "OBSERVATION_MODIFIER", 57, 65], ["complement", "OBSERVATION_MODIFIER", 66, 76], ["activity", "OBSERVATION_MODIFIER", 77, 85]]], ["One of its clinical applications is complement-mediated thrombotic microangiopathy, namely atypical hemolytic uremic syndrome, which is thought to occur in some patients with 175 In one study of five COVID-19 nonsurvivors, there was evidence of systemic activation of the alternative and lectin-based complement pathways and deposition of the membrane attack complex in both lung and skin.", [["membrane", "ANATOMY", 343, 351], ["lung", "ANATOMY", 375, 379], ["skin", "ANATOMY", 384, 388], ["thrombotic microangiopathy", "DISEASE", 56, 82], ["hemolytic uremic syndrome", "DISEASE", 100, 125], ["patients", "ORGANISM", 161, 169], ["lectin", "GENE_OR_GENE_PRODUCT", 288, 294], ["membrane", "CELLULAR_COMPONENT", 343, 351], ["lung", "ORGAN", 375, 379], ["skin", "ORGAN", 384, 388], ["lectin", "PROTEIN", 288, 294], ["membrane attack complex", "PROTEIN", 343, 366], ["patients", "SPECIES", 161, 169], ["thrombotic microangiopathy", "PROBLEM", 56, 82], ["atypical hemolytic uremic syndrome", "PROBLEM", 91, 125], ["systemic activation of the alternative and lectin-based complement pathways", "PROBLEM", 245, 320], ["the membrane attack complex", "PROBLEM", 339, 366], ["thrombotic", "OBSERVATION_MODIFIER", 56, 66], ["microangiopathy", "OBSERVATION", 67, 82], ["atypical", "OBSERVATION_MODIFIER", 91, 99], ["hemolytic", "OBSERVATION_MODIFIER", 100, 109], ["uremic syndrome", "OBSERVATION", 110, 125], ["thought to occur", "UNCERTAINTY", 136, 152], ["evidence of", "UNCERTAINTY", 233, 244], ["systemic activation", "OBSERVATION", 245, 264], ["deposition", "OBSERVATION_MODIFIER", 325, 335], ["membrane attack", "OBSERVATION", 343, 358], ["both", "ANATOMY_MODIFIER", 370, 374], ["lung", "ANATOMY", 375, 379], ["skin", "ANATOMY", 384, 388]]], ["175 Based on these data and evidence of efficacy of complement inhibition in murine models of SARS-CoV and MERS-CoV, the use of eculizumab in COVID-19 has been proposed.", [["SARS-CoV", "DISEASE", 94, 102], ["eculizumab", "CHEMICAL", 128, 138], ["COVID-19", "CHEMICAL", 142, 150], ["eculizumab", "CHEMICAL", 128, 138], ["murine", "ORGANISM", 77, 83], ["SARS-CoV", "ORGANISM", 94, 102], ["MERS-CoV", "ORGANISM", 107, 115], ["eculizumab", "SIMPLE_CHEMICAL", 128, 138], ["murine", "SPECIES", 77, 83], ["SARS-CoV", "SPECIES", 94, 102], ["MERS-CoV", "SPECIES", 107, 115], ["these data", "TEST", 13, 23], ["complement inhibition", "PROBLEM", 52, 73], ["SARS", "PROBLEM", 94, 98], ["eculizumab in COVID", "TREATMENT", 128, 147]]], ["20,175 Potential barriers include a 1,000 to 2,000 times increased risk of meningococcal disease (requiring prior vaccination or antibiotic prophylaxis) and cost ($20,000-$25,000 per dose).Targeted Immunomodulatory TherapiesThe Janus kinase (JAK)-signal transducer and activator of transcription pathway is another potential therapeutic target.", [["meningococcal disease", "DISEASE", 75, 96], ["Janus kinase", "GENE_OR_GENE_PRODUCT", 228, 240], ["JAK", "GENE_OR_GENE_PRODUCT", 242, 245], ["Janus kinase", "PROTEIN", 228, 240], ["JAK", "PROTEIN", 242, 245], ["meningococcal", "SPECIES", 75, 88], ["meningococcal disease", "PROBLEM", 75, 96], ["prior vaccination", "TREATMENT", 108, 125], ["antibiotic prophylaxis", "TREATMENT", 129, 151], ["Targeted Immunomodulatory Therapies", "TREATMENT", 189, 224], ["The Janus kinase (JAK)", "TREATMENT", 224, 246], ["meningococcal disease", "OBSERVATION", 75, 96]]], ["JAK inhibitors target cytokine signaling pathways and have thus been proposed as a candidate to treat COVID-19.", [["COVID-19", "CHEMICAL", 102, 110], ["JAK", "GENE_OR_GENE_PRODUCT", 0, 3], ["JAK", "PROTEIN", 0, 3], ["cytokine", "PROTEIN", 22, 30], ["JAK inhibitors", "TREATMENT", 0, 14], ["cytokine signaling pathways", "TEST", 22, 49], ["COVID", "TEST", 102, 107]]], ["Baricitinib, a JAK1/JAK2 inhibitor approved for the treatment of rheumatoid arthritis, mitigates the systemic inflammatory response and has in vitro activity against SARS-CoV-2 through its numb-associated kinase inhibition that has a high affinity for AAK1, a regulator of clathrin-mediated endocytosis.", [["Baricitinib", "CHEMICAL", 0, 11], ["rheumatoid arthritis", "DISEASE", 65, 85], ["Baricitinib", "CHEMICAL", 0, 11], ["Baricitinib", "SIMPLE_CHEMICAL", 0, 11], ["JAK1", "GENE_OR_GENE_PRODUCT", 15, 19], ["JAK2", "GENE_OR_GENE_PRODUCT", 20, 24], ["SARS-CoV-2", "ORGANISM", 166, 176], ["AAK1", "GENE_OR_GENE_PRODUCT", 252, 256], ["clathrin", "GENE_OR_GENE_PRODUCT", 273, 281], ["JAK1", "PROTEIN", 15, 19], ["JAK2", "PROTEIN", 20, 24], ["AAK1", "PROTEIN", 252, 256], ["clathrin", "PROTEIN", 273, 281], ["SARS-CoV", "SPECIES", 166, 174], ["Baricitinib", "TREATMENT", 0, 11], ["a JAK1/JAK2 inhibitor", "TREATMENT", 13, 34], ["rheumatoid arthritis", "PROBLEM", 65, 85], ["the systemic inflammatory response", "PROBLEM", 97, 131], ["SARS", "PROBLEM", 166, 170], ["CoV", "TEST", 171, 174], ["associated kinase inhibition", "PROBLEM", 194, 222], ["a high affinity", "PROBLEM", 232, 247], ["clathrin-mediated endocytosis", "PROBLEM", 273, 302], ["rheumatoid arthritis", "OBSERVATION", 65, 85], ["systemic", "OBSERVATION_MODIFIER", 101, 109], ["inflammatory", "OBSERVATION", 110, 122]]], ["176 Notably, this therapy does carry a FDA warning for an increased incidence of VTE (6/997 patients with baricitinib vs. 0/1,070 controls), 177 and recent National Institutes of Health (NIH) COVID-19 Treatment Guidelines recommends against the use of baricitinib outside of a clinical trial, such as the NIHsponsored ACTT-2 trial comparing remdesivir AE baricitinib.", [["VTE", "DISEASE", 81, 84], ["baricitinib", "CHEMICAL", 106, 117], ["baricitinib", "CHEMICAL", 252, 263], ["baricitinib", "CHEMICAL", 355, 366], ["baricitinib", "CHEMICAL", 106, 117], ["baricitinib", "CHEMICAL", 252, 263], ["patients", "ORGANISM", 92, 100], ["baricitinib", "SIMPLE_CHEMICAL", 252, 263], ["remdesivir", "SIMPLE_CHEMICAL", 341, 351], ["baricitinib", "SIMPLE_CHEMICAL", 355, 366], ["patients", "SPECIES", 92, 100], ["this therapy", "TREATMENT", 13, 25], ["VTE", "PROBLEM", 81, 84], ["baricitinib", "TREATMENT", 106, 117], ["Treatment Guidelines", "TREATMENT", 201, 221], ["baricitinib", "TREATMENT", 252, 263], ["the NIHsponsored ACTT", "TREATMENT", 301, 322], ["remdesivir AE baricitinib", "TREATMENT", 341, 366], ["increased", "OBSERVATION_MODIFIER", 58, 67]]], ["178 Ruxolitinib is a JAK2 inhibitor approved for patients with myelofibrosis and polycythemia vera.", [["Ruxolitinib", "CHEMICAL", 4, 15], ["myelofibrosis", "DISEASE", 63, 76], ["polycythemia vera", "DISEASE", 81, 98], ["Ruxolitinib", "CHEMICAL", 4, 15], ["Ruxolitinib", "SIMPLE_CHEMICAL", 4, 15], ["JAK2", "GENE_OR_GENE_PRODUCT", 21, 25], ["patients", "ORGANISM", 49, 57], ["JAK2", "PROTEIN", 21, 25], ["patients", "SPECIES", 49, 57], ["Ruxolitinib", "TREATMENT", 4, 15], ["a JAK2 inhibitor", "TREATMENT", 19, 35], ["myelofibrosis", "PROBLEM", 63, 76], ["polycythemia vera", "PROBLEM", 81, 98], ["myelofibrosis", "OBSERVATION", 63, 76], ["polycythemia vera", "OBSERVATION", 81, 98]]], ["Similar to baricitinib (NCT04340232, NCT04320277, and NCT04346147), ruxolitinib is presently under investigation as a treatment for COVID- 19 (NCT04334044, NCT04348071, NCT04337359, NCT04331665, NCT04348695, and NCT04338958).Targeted Immunomodulatory TherapiesTocilizumab, an IL-6 receptor antagonist approved for the treatment of rheumatoid arthritis and cytokine release syndrome associated with chimeric antigen receptor-T cell therapy, is included in the Chinese National Health commission guidelines for treating COVID-19.", [["cell", "ANATOMY", 426, 430], ["baricitinib", "CHEMICAL", 11, 22], ["ruxolitinib", "CHEMICAL", 68, 79], ["Tocilizumab", "CHEMICAL", 260, 271], ["rheumatoid arthritis", "DISEASE", 331, 351], ["baricitinib", "CHEMICAL", 11, 22], ["NCT04340232", "CHEMICAL", 24, 35], ["NCT04320277", "CHEMICAL", 37, 48], ["NCT04346147", "CHEMICAL", 54, 65], ["ruxolitinib", "CHEMICAL", 68, 79], ["COVID- 19", "CHEMICAL", 132, 141], ["NCT04334044", "CHEMICAL", 143, 154], ["Tocilizumab", "CHEMICAL", 260, 271], ["baricitinib", "SIMPLE_CHEMICAL", 11, 22], ["ruxolitinib", "SIMPLE_CHEMICAL", 68, 79], ["Tocilizumab", "SIMPLE_CHEMICAL", 260, 271], ["IL-6 receptor", "GENE_OR_GENE_PRODUCT", 276, 289], ["cytokine", "PROTEIN", 356, 364], ["chimeric antigen receptor", "PROTEIN", 398, 423], ["baricitinib", "TEST", 11, 22], ["ruxolitinib", "TREATMENT", 68, 79], ["COVID", "TEST", 132, 137], ["Targeted Immunomodulatory TherapiesTocilizumab", "TREATMENT", 225, 271], ["an IL-6 receptor antagonist", "TREATMENT", 273, 300], ["rheumatoid arthritis", "PROBLEM", 331, 351], ["cytokine release syndrome", "PROBLEM", 356, 381], ["chimeric antigen receptor-T cell therapy", "TREATMENT", 398, 438], ["COVID", "TEST", 518, 523], ["Immunomodulatory Therapies", "OBSERVATION", 234, 260], ["rheumatoid arthritis", "OBSERVATION", 331, 351], ["cell therapy", "OBSERVATION", 426, 438]]], ["While findings are yet to be published, a randomized trial of 129 hospitalized patients with moderate-to-severe COVID-19 pneumonia suggested that tocilizumab administration may significantly reduce rates of death or life support interventions.", [["COVID", "DISEASE", 112, 117], ["pneumonia", "DISEASE", 121, 130], ["tocilizumab", "CHEMICAL", 146, 157], ["death", "DISEASE", 207, 212], ["patients", "ORGANISM", 79, 87], ["tocilizumab", "SIMPLE_CHEMICAL", 146, 157], ["patients", "SPECIES", 79, 87], ["moderate-to-severe COVID", "PROBLEM", 93, 117], ["pneumonia", "PROBLEM", 121, 130], ["tocilizumab administration", "TREATMENT", 146, 172], ["death", "PROBLEM", 207, 212], ["life support interventions", "TREATMENT", 216, 242], ["pneumonia", "OBSERVATION", 121, 130], ["tocilizumab", "OBSERVATION", 146, 157]]], ["179 It is thought that tocilizumab may mitigate the proatherothrombotic profile associated with rheumatoid arthritis.", [["tocilizumab", "CHEMICAL", 23, 34], ["rheumatoid arthritis", "DISEASE", 96, 116], ["tocilizumab", "SIMPLE_CHEMICAL", 23, 34], ["tocilizumab", "TREATMENT", 23, 34], ["the proatherothrombotic profile", "PROBLEM", 48, 79], ["rheumatoid arthritis", "PROBLEM", 96, 116], ["tocilizumab", "OBSERVATION", 23, 34], ["rheumatoid arthritis", "OBSERVATION", 96, 116]]], ["However, no specific data related to use of tocilizumab and VTE events in patients with COVID-19 have been published.Future Directions and ConclusionDespite the efforts of the international medical and scientific communities and recent declines in hospitalizations, COVID-19 continues to pose an unprecedented challenge.", [["tocilizumab", "CHEMICAL", 44, 55], ["VTE", "DISEASE", 60, 63], ["tocilizumab", "SIMPLE_CHEMICAL", 44, 55], ["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["tocilizumab", "TREATMENT", 44, 55], ["VTE events", "PROBLEM", 60, 70], ["COVID", "TEST", 88, 93], ["COVID", "TREATMENT", 266, 271], ["an unprecedented challenge", "TREATMENT", 293, 319]]], ["The prognosis for hospitalized patients with COVID-19, especially in the setting of critical illness, continues to be poor.", [["COVID-19", "CHEMICAL", 45, 53], ["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["COVID", "TEST", 45, 50], ["critical illness", "PROBLEM", 84, 100], ["illness", "OBSERVATION", 93, 100]]], ["180, 181 While contributing factors to poor outcomes in patients with COVID-19 are likely multifactorial, thrombotic complications play a major role in the prognosis of these patients.", [["thrombotic complications", "DISEASE", 106, 130], ["COVID-19", "CHEMICAL", 70, 78], ["patients", "ORGANISM", 56, 64], ["patients", "ORGANISM", 175, 183], ["patients", "SPECIES", 56, 64], ["patients", "SPECIES", 175, 183], ["COVID", "TEST", 70, 75], ["thrombotic complications", "PROBLEM", 106, 130], ["likely", "UNCERTAINTY", 83, 89], ["multifactorial", "OBSERVATION_MODIFIER", 90, 104], ["thrombotic", "OBSERVATION", 106, 116]]], ["5 The development of safe and effective thromboprophylaxis and treatment strategies for thrombotic disease is contingent on an improved understanding of the mechanistic and pathophysiologic basis for such complications in COVID-19 patients.", [["thrombotic disease", "DISEASE", 88, 106], ["patients", "ORGANISM", 231, 239], ["patients", "SPECIES", 231, 239], ["safe and effective thromboprophylaxis", "TREATMENT", 21, 58], ["treatment strategies", "TREATMENT", 63, 83], ["thrombotic disease", "PROBLEM", 88, 106], ["such complications", "PROBLEM", 200, 218], ["effective", "OBSERVATION_MODIFIER", 30, 39], ["thromboprophylaxis", "OBSERVATION", 40, 58]]], ["In this document, we have outlined several agents and mechanisms of action for potential for use as antithrombotic agents in the setting of COVID-19.", [["COVID-19", "CHEMICAL", 140, 148], ["antithrombotic agents", "TREATMENT", 100, 121], ["COVID", "TEST", 140, 145]]], ["Survey results from group of authors may be helpful for research priority settings for various agents and patient subgroups with COVID-19 (\u25baTable 3).", [["patient", "ORGANISM", 106, 113], ["patient", "SPECIES", 106, 113], ["various agents", "TREATMENT", 87, 101], ["COVID", "TEST", 129, 134]]], ["High-quality research investigations into the optimal drug, dose, and duration of therapies to prevent and treat thrombotic complications of COVID-19 offer the potential to improve outcomes of infected patients.Conflict of InterestNo specific funding was sought or received for this manuscript.", [["thrombotic", "DISEASE", 113, 123], ["COVID-19", "CHEMICAL", 141, 149], ["COVID-19", "CHEMICAL", 141, 149], ["patients", "ORGANISM", 202, 210], ["patients", "SPECIES", 202, 210], ["therapies", "TREATMENT", 82, 91], ["thrombotic complications", "PROBLEM", 113, 137], ["COVID", "TREATMENT", 141, 146], ["infected", "OBSERVATION", 193, 201]]]], "PMC7434367": [["Rationale ::: BACKGROUNDThe current coronavirus disease 2019 (COVID-19), caused by a novel beta coronavirus (SARS-CoV-2), has been declared a pandemic affecting 213 countries as of 12th June 2020 [1].Rationale ::: BACKGROUNDUnlike SARS-CoV, SARS-CoV-2 seems to replicate efficiently in the upper airways during the incubation period, which is estimated to last up to 14 days [2,3].", [["upper airways", "ANATOMY", 290, 303], ["coronavirus disease", "DISEASE", 36, 55], ["COVID-19", "CHEMICAL", 62, 70], ["beta coronavirus", "DISEASE", 91, 107], ["SARS", "DISEASE", 109, 113], ["SARS", "DISEASE", 241, 245], ["coronavirus", "ORGANISM", 36, 47], ["COVID-19", "ORGANISM", 62, 70], ["beta coronavirus", "ORGANISM", 91, 107], ["SARS-CoV-2", "ORGANISM", 109, 119], ["SARS-CoV", "ORGANISM", 231, 239], ["SARS-CoV-2", "ORGANISM", 241, 251], ["upper airways", "ORGANISM_SUBDIVISION", 290, 303], ["beta coronavirus", "SPECIES", 91, 107], ["coronavirus disease 2019 (COVID-19", "SPECIES", 36, 70], ["beta coronavirus", "SPECIES", 91, 107], ["SARS-CoV", "SPECIES", 231, 239], ["SARS-CoV", "SPECIES", 241, 249], ["current coronavirus disease", "PROBLEM", 28, 55], ["COVID", "TEST", 62, 67], ["a novel beta coronavirus", "PROBLEM", 83, 107], ["BACKGROUNDUnlike SARS", "PROBLEM", 214, 235], ["SARS", "PROBLEM", 241, 245], ["coronavirus disease", "OBSERVATION", 36, 55], ["upper", "ANATOMY_MODIFIER", 290, 295], ["airways", "ANATOMY", 296, 303]]], ["During this prodromal stage, asymptomatic and pre-symptomatic individuals release large amounts of viruses from infected cells [3].", [["cells", "ANATOMY", 121, 126], ["cells", "CELL", 121, 126], ["infected cells", "CELL_TYPE", 112, 126], ["this prodromal stage", "PROBLEM", 7, 27], ["asymptomatic", "PROBLEM", 29, 41], ["pre-symptomatic individuals", "PROBLEM", 46, 73], ["large amounts of viruses", "PROBLEM", 82, 106], ["infected cells", "PROBLEM", 112, 126], ["large", "OBSERVATION_MODIFIER", 82, 87], ["amounts", "OBSERVATION_MODIFIER", 88, 95], ["viruses", "OBSERVATION", 99, 106], ["infected cells", "OBSERVATION", 112, 126]]], ["As a result, viral transmission is more effective with SARS-CoV-2 than with SARS-CoV, which conversely was contagious only during the active/critical phase of the disease [3].", [["SARS-CoV-2", "ORGANISM", 55, 65], ["SARS-CoV", "ORGANISM", 76, 84], ["SARS-CoV", "SPECIES", 55, 63], ["SARS-CoV", "SPECIES", 76, 84], ["viral transmission", "TEST", 13, 31], ["SARS", "PROBLEM", 55, 59], ["CoV", "TEST", 60, 63], ["SARS", "PROBLEM", 76, 80], ["CoV", "PROBLEM", 81, 84], ["the disease", "PROBLEM", 159, 170]]], ["Furthermore, human coronaviruses which may cause common cold are known to cause re-infection regardless of pre-existing humoral immunity [4,5].", [["human", "ORGANISM", 13, 18], ["coronaviruses", "ORGANISM", 19, 32], ["human", "SPECIES", 13, 18], ["human coronaviruses", "SPECIES", 13, 32], ["human coronaviruses", "PROBLEM", 13, 32], ["common cold", "PROBLEM", 49, 60], ["re-infection", "PROBLEM", 80, 92]]], ["Therefore, there are two issues with COVID-19: high transmissibility of the virus and variable clinical pattern of the disease, which can range from pre-symptomatic/asymptomatic condition to life threatening pneumonia featured by severe acute respiratory syndrome (SARS) and hypercoagulable state [3,5].Rationale ::: BACKGROUNDThe high risk of contagion from SARS-CoV-2 has been tackled so far by infection prevention and control (IPC) measures such as self-isolation, social distancing, quarantine of contacts, use of personal protective equipment (PPE), travel restrictions and other limitations to the freedom of movement of individuals.", [["pneumonia", "DISEASE", 208, 217], ["acute respiratory syndrome", "DISEASE", 237, 263], ["SARS", "DISEASE", 265, 269], ["SARS", "DISEASE", 359, 363], ["infection", "DISEASE", 397, 406], ["SARS-CoV", "SPECIES", 359, 367], ["COVID", "TEST", 37, 42], ["the virus", "PROBLEM", 72, 81], ["the disease", "PROBLEM", 115, 126], ["pre-symptomatic/asymptomatic condition", "PROBLEM", 149, 187], ["life threatening pneumonia", "PROBLEM", 191, 217], ["severe acute respiratory syndrome", "PROBLEM", 230, 263], ["SARS", "PROBLEM", 265, 269], ["hypercoagulable state", "PROBLEM", 275, 296], ["SARS", "PROBLEM", 359, 363], ["infection prevention", "TREATMENT", 397, 417], ["control (IPC) measures", "TREATMENT", 422, 444], ["personal protective equipment", "TREATMENT", 519, 548], ["travel restrictions", "TREATMENT", 556, 575], ["virus", "OBSERVATION", 76, 81], ["disease", "OBSERVATION", 119, 126], ["pneumonia", "OBSERVATION", 208, 217], ["severe", "OBSERVATION_MODIFIER", 230, 236], ["acute", "OBSERVATION_MODIFIER", 237, 242], ["respiratory syndrome", "OBSERVATION", 243, 263], ["high risk", "OBSERVATION_MODIFIER", 331, 340], ["infection", "OBSERVATION", 397, 406]]], ["However, the effect of each intervention in containing the spread of SARS-CoV-2 has not been evaluated yet [6].Rationale ::: BACKGROUNDCurrently, the World Health Organization and the European Centre for Disease Prevention and Control guidelines recommend testing only symptomatic individuals and close contacts of a confirmed COVID-19 case [7,8].", [["SARS", "DISEASE", 69, 73], ["SARS-CoV-2", "ORGANISM", 69, 79], ["SARS-CoV", "SPECIES", 69, 77], ["each intervention", "TREATMENT", 23, 40], ["SARS", "PROBLEM", 69, 73], ["CoV", "TEST", 74, 77], ["Disease Prevention", "TREATMENT", 204, 222], ["testing", "TEST", 256, 263], ["symptomatic individuals", "PROBLEM", 269, 292]]], ["Whilst in the initial stage of the epidemic a symptom-based screening strategy was useful with the aim to treat and isolate infected cases, COVID-19 outbreaks in care homes and hospitals suggest that the current IPC measures are inadequate and have failed [9,10].", [["the epidemic a symptom", "PROBLEM", 31, 53], ["the current IPC measures", "TREATMENT", 200, 224]]], ["Furthermore, the above IPC measures are not sustainable in the long run, as they would severely ruin the economies of countries heavily affected by COVID-19.", [["COVID-19", "CHEMICAL", 148, 156], ["the above IPC measures", "TREATMENT", 13, 35], ["COVID", "TEST", 148, 153], ["economies", "OBSERVATION_MODIFIER", 105, 114]]], ["The clear need to relax/avoid the lock down measures enforced in many countries prompts for a revised approach to reduce the transmission of SARS-CoV-2 from asymptomatic/pre-symptomatic individuals, until a pharmacological intervention (ideally a vaccine or a chemoprophylaxis) will hopefully become available [9].", [["SARS", "DISEASE", 141, 145], ["SARS-CoV-2", "ORGANISM", 141, 151], ["individuals", "ORGANISM", 186, 197], ["SARS-CoV", "SPECIES", 141, 149], ["the lock down measures", "TREATMENT", 30, 52], ["a revised approach", "TREATMENT", 92, 110], ["SARS", "PROBLEM", 141, 145], ["CoV", "TEST", 146, 149], ["asymptomatic", "PROBLEM", 157, 169], ["symptomatic individuals", "PROBLEM", 174, 197], ["a pharmacological intervention", "TREATMENT", 205, 235], ["a vaccine", "TREATMENT", 245, 254], ["a chemoprophylaxis", "TREATMENT", 258, 276], ["clear", "OBSERVATION", 4, 9]]], ["As explained above, the problem with COVID-19 is transmission from asymptomatic/pre-symptomatic individuals, a phenomenon particularly critical in care homes and hospitals, where more than half residents testing positive might not develop symptoms [2,9].", [["COVID", "TEST", 37, 42], ["asymptomatic/pre-symptomatic individuals", "PROBLEM", 67, 107], ["a phenomenon", "PROBLEM", 109, 121], ["symptoms", "PROBLEM", 239, 247]]], ["In Los Angeles families have been advised by the Public Health Department to remove their relatives from care homes to reduce health risk of community outbreaks of COVID-19 [11].Rationale ::: BACKGROUNDMass testing has been considered in various countries as a possible strategy to reduce the transmission of SARS-CoV-2 from asymptomatic individuals [9].", [["COVID", "DISEASE", 164, 169], ["SARS", "DISEASE", 309, 313], ["COVID-19", "CHEMICAL", 164, 172], ["SARS-CoV-2", "ORGANISM", 309, 319], ["SARS-CoV", "SPECIES", 309, 317], ["BACKGROUNDMass testing", "TEST", 192, 214], ["SARS", "PROBLEM", 309, 313], ["CoV", "TEST", 314, 317], ["asymptomatic individuals", "PROBLEM", 325, 349]]], ["Nonetheless, mass testing on defined and contained outbreak clusters (as done in South Korea) may be sensible, not in the current global scenario though, with an ongoing pandemic [12].", [["mass testing", "TEST", 13, 25], ["outbreak clusters", "PROBLEM", 51, 68], ["mass", "OBSERVATION", 13, 17]]], ["Not to mention that mass testing is probably far beyond the capacity of microbiology laboratories even in high-income countries.", [["mass testing", "TEST", 20, 32], ["microbiology laboratories", "TEST", 72, 97], ["mass", "OBSERVATION", 20, 24]]], ["However, restricting mass testing to high risk congregate settings, such as care homes, hospitals, mental health facilities and prisons may be appropriate [9].", [["restricting mass testing", "PROBLEM", 9, 33], ["mass", "OBSERVATION", 21, 25]]], ["In an outbreak reported from a care home in Washington State, hosting a total of 76 residents, 27 of the 48 residents testing positive for COVID-19 at real time PCR were asymptomatic during the 14 days preceding the test [10].Rationale ::: BACKGROUNDHigh loads of SARS-CoV-2 are shed from the nasal cavity into the environment also before symptoms onset [2,9] and transmission of SARS-CoV-2 from asymptomatic individuals has been described [13, 14, 15].", [["nasal cavity", "ANATOMY", 293, 305], ["SARS", "DISEASE", 264, 268], ["SARS", "DISEASE", 380, 384], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 264, 274], ["nasal cavity", "MULTI-TISSUE_STRUCTURE", 293, 305], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 380, 390], ["SARS-CoV", "SPECIES", 264, 272], ["SARS-CoV", "SPECIES", 380, 388], ["COVID", "TEST", 139, 144], ["SARS", "PROBLEM", 264, 268], ["symptoms onset", "PROBLEM", 339, 353], ["SARS", "PROBLEM", 380, 384], ["CoV", "TEST", 385, 388], ["asymptomatic individuals", "PROBLEM", 396, 420], ["nasal cavity", "ANATOMY", 293, 305]]], ["Unnoticed, asymptomatic cases of COVID-19 might therefore constitute an important source of contagion, as endorsed by recent evidence from the China\u2019s National Health Commission, reporting that the vast majority of infections (four out of five) were totally asymptomatic.", [["COVID", "DISEASE", 33, 38], ["infections", "DISEASE", 215, 225], ["COVID", "TEST", 33, 38], ["infections", "PROBLEM", 215, 225], ["totally asymptomatic", "PROBLEM", 250, 270], ["infections", "OBSERVATION", 215, 225]]], ["In particular, 130 out of the total 166 new infections identified in China on 1st April 2020 had no symptoms whatsoever [16]Rationale ::: BACKGROUNDAlthough asymptomatic individuals testing positive for SARS-CoV-2 are enforced to quarantine for 14 days, mass testing would yet not resolve the endemic presence of the virus in the general population, a condition posing the risk of repeated resurgences of outbreaks, especially with cold weather conditions [17].", [["infections", "DISEASE", 44, 54], ["SARS", "DISEASE", 203, 207], ["individuals", "ORGANISM", 170, 181], ["SARS-CoV-2", "ORGANISM", 203, 213], ["SARS-CoV", "SPECIES", 203, 211], ["new infections", "PROBLEM", 40, 54], ["symptoms", "PROBLEM", 100, 108], ["individuals testing", "TEST", 170, 189], ["SARS", "PROBLEM", 203, 207], ["CoV", "TEST", 208, 211], ["mass testing", "TEST", 254, 266], ["the virus", "PROBLEM", 313, 322], ["outbreaks", "PROBLEM", 405, 414], ["new", "OBSERVATION_MODIFIER", 40, 43], ["infections", "OBSERVATION", 44, 54], ["virus", "OBSERVATION", 317, 322]]], ["There is in fact evidence that the transmissibility and viability of SARS-CoV-2 reduces importantly with hot and humid climate [5,18,19], as confirmed by the diminished spread of the novel coronavirus with increasing relative humidity from 23.33% to 82.67% (p-value = 0.002) and with increased weather temperature from \u221213.17\u00b0C to 19 \u00b0C (p-value = 0.003) observed for Chinese cities during January-March 2020 [20].Rationale ::: BACKGROUNDHumoral immunity seems not protective against human coronaviruses, and some evidence even points out a potential Antibody Dependent Enhancement (ADE) triggered by re-infections featuring the severe/critical forms of COVID-19, as with other viral diseases such as Dengue, SARS-CoV, MERS-CoV and the West Nile Virus.", [["SARS", "DISEASE", 69, 73], ["coronavirus", "DISEASE", 189, 200], ["COVID-19", "CHEMICAL", 654, 662], ["viral diseases", "DISEASE", 678, 692], ["Dengue", "DISEASE", 701, 707], ["SARS-CoV", "DISEASE", 709, 717], ["SARS-CoV-2", "ORGANISM", 69, 79], ["coronavirus", "ORGANISM", 189, 200], ["human", "ORGANISM", 484, 489], ["SARS-CoV", "ORGANISM", 709, 717], ["MERS-CoV", "ORGANISM", 719, 727], ["West Nile Virus", "ORGANISM", 736, 751], ["human", "SPECIES", 484, 489], ["Nile Virus", "SPECIES", 741, 751], ["SARS-CoV", "SPECIES", 69, 77], ["human", "SPECIES", 484, 489], ["SARS-CoV", "SPECIES", 709, 717], ["MERS-CoV", "SPECIES", 719, 727], ["West Nile Virus", "SPECIES", 736, 751], ["the transmissibility", "PROBLEM", 31, 51], ["SARS", "PROBLEM", 69, 73], ["the novel coronavirus", "PROBLEM", 179, 200], ["increasing relative humidity", "PROBLEM", 206, 234], ["p-value", "TEST", 258, 265], ["increased weather temperature", "PROBLEM", 284, 313], ["\u2212", "TEST", 319, 320], ["p-value", "TEST", 338, 345], ["BACKGROUNDHumoral immunity", "TREATMENT", 428, 454], ["human coronaviruses", "PROBLEM", 484, 503], ["a potential Antibody Dependent Enhancement", "PROBLEM", 539, 581], ["the severe/critical forms of COVID", "PROBLEM", 625, 659], ["other viral diseases", "PROBLEM", 672, 692], ["Dengue", "PROBLEM", 701, 707], ["SARS", "PROBLEM", 709, 713], ["CoV", "PROBLEM", 714, 717], ["MERS", "PROBLEM", 719, 723], ["CoV", "PROBLEM", 724, 727], ["the West Nile Virus", "PROBLEM", 732, 751], ["diminished", "OBSERVATION", 158, 168], ["humidity", "OBSERVATION_MODIFIER", 226, 234], ["increased", "OBSERVATION_MODIFIER", 284, 293], ["severe", "OBSERVATION_MODIFIER", 629, 635], ["viral diseases", "OBSERVATION", 678, 692]]], ["Given the potential of reversed and untoward consequences following relaxation of the above IPC measures, especially during cold months, and in absence of a specific registered treatment or vaccine against SARS-CoV-2, there is a clear and urgent need to find alternative solutions to prevent and control the replication of the virus and the spread of COVID-19 among humans [14].Rationale ::: BACKGROUNDCOVID-19 is a rapidly evolving pandemic.", [["SARS", "DISEASE", 206, 210], ["COVID-19", "CHEMICAL", 351, 359], ["SARS-CoV-2", "ORGANISM", 206, 216], ["humans", "ORGANISM", 366, 372], ["humans", "SPECIES", 366, 372], ["SARS-CoV", "SPECIES", 206, 214], ["humans", "SPECIES", 366, 372], ["the above IPC measures", "TREATMENT", 82, 104], ["a specific registered treatment", "TREATMENT", 155, 186], ["vaccine", "TREATMENT", 190, 197], ["SARS", "PROBLEM", 206, 210], ["alternative solutions", "TREATMENT", 259, 280], ["the virus", "PROBLEM", 323, 332], ["COVID", "TEST", 351, 356], ["BACKGROUNDCOVID", "TEST", 392, 407], ["pandemic", "PROBLEM", 433, 441], ["above IPC", "OBSERVATION_MODIFIER", 86, 95], ["clear", "OBSERVATION", 229, 234], ["pandemic", "OBSERVATION", 433, 441]]], ["Asymptomatic individuals testing positive for SARS-CoV-2 and asked to self-isolate at home were in Italy about 40% of all positive individuals at the beginning of the epidemic, then becoming >80% following the end of full lockdown [21].", [["SARS", "DISEASE", 46, 50], ["individuals", "ORGANISM", 13, 24], ["SARS-CoV-2", "ORGANISM", 46, 56], ["SARS-CoV", "SPECIES", 46, 54], ["Asymptomatic individuals testing", "TEST", 0, 32], ["SARS", "PROBLEM", 46, 50], ["CoV", "TEST", 51, 54], ["all positive individuals", "PROBLEM", 118, 142]]], ["Figure 1reports the corresponding changes as percentage or odds; the latter detects the improvement of the index score better than the former because it is able to overcome the ceiling effectsRationale ::: BACKGROUNDTherefore, in addition to an effective treatment for symptomatic patients, there is an urgent need to abate the carriage of SARS-CoV-2 in the human nasal cavity of asymptomatic/pre-symptomatic individuals, in order to contain the transmission of the novel coronavirus within the community.Objectives ::: BACKGROUNDTo find tolerable topical nasal disinfectants featured by encouraging efficacy against SARS-CoV-2, e.g. drugs effective against at least two different viruses beyond SARS-CoV-2, with similar viral/molecular structure.METHODSPubMed was investigated using \u201cAnti-Infective Agents, Local\u201d and \u201cAnti-Infective Agents, Nasal\u201d as key words and applying the filters \u201cAge: 19+ years\u201d, \u201cHumans\u201d and \u201cEnglish\u201d to identify papers published during 2010\u20132020.", [["nasal cavity", "ANATOMY", 364, 376], ["nasal", "ANATOMY", 556, 561], ["SARS", "DISEASE", 340, 344], ["coronavirus", "DISEASE", 472, 483], ["SARS", "DISEASE", 617, 621], ["SARS", "DISEASE", 696, 700], ["patients", "ORGANISM", 281, 289], ["SARS-CoV-2", "ORGANISM", 340, 350], ["human", "ORGANISM", 358, 363], ["nasal cavity", "MULTI-TISSUE_STRUCTURE", 364, 376], ["coronavirus", "ORGANISM", 472, 483], ["SARS-CoV-2", "ORGANISM", 617, 627], ["SARS-CoV-2", "ORGANISM", 696, 706], ["patients", "SPECIES", 281, 289], ["human", "SPECIES", 358, 363], ["SARS-CoV", "SPECIES", 340, 348], ["human", "SPECIES", 358, 363], ["SARS-CoV", "SPECIES", 617, 625], ["SARS-CoV", "SPECIES", 696, 704], ["the index score", "PROBLEM", 103, 118], ["BACKGROUNDTherefore", "TREATMENT", 206, 225], ["an effective treatment", "TREATMENT", 242, 264], ["SARS", "PROBLEM", 340, 344], ["CoV", "TEST", 345, 348], ["asymptomatic/pre-symptomatic individuals", "PROBLEM", 380, 420], ["topical nasal disinfectants", "TREATMENT", 548, 575], ["SARS", "PROBLEM", 617, 621], ["drugs", "TREATMENT", 634, 639], ["similar viral/molecular structure", "PROBLEM", 713, 746], ["METHODSPubMed", "TREATMENT", 747, 760], ["Anti-Infective Agents", "TREATMENT", 785, 806], ["Local\u201d", "TREATMENT", 808, 814], ["Anti-Infective Agents", "TREATMENT", 820, 841], ["improvement", "OBSERVATION_MODIFIER", 88, 99], ["nasal cavity", "ANATOMY", 364, 376], ["viruses", "OBSERVATION", 681, 688], ["viral", "OBSERVATION", 721, 726], ["molecular structure", "OBSERVATION", 727, 746]]], ["The majority of papers dealt with drugs against methicillin resistant Staphylococcus aureus (generally, mupirocin in nose associated with either chlorhexidine or hexachlorophene body wash).", [["body", "ANATOMY", 178, 182], ["methicillin", "CHEMICAL", 48, 59], ["Staphylococcus aureus", "DISEASE", 70, 91], ["mupirocin", "CHEMICAL", 104, 113], ["chlorhexidine", "CHEMICAL", 145, 158], ["hexachlorophene", "CHEMICAL", 162, 177], ["methicillin", "CHEMICAL", 48, 59], ["mupirocin", "CHEMICAL", 104, 113], ["chlorhexidine", "CHEMICAL", 145, 158], ["hexachlorophene", "CHEMICAL", 162, 177], ["methicillin resistant Staphylococcus aureus", "ORGANISM", 48, 91], ["mupirocin", "SIMPLE_CHEMICAL", 104, 113], ["nose", "ORGANISM_SUBDIVISION", 117, 121], ["chlorhexidine", "SIMPLE_CHEMICAL", 145, 158], ["hexachlorophene", "SIMPLE_CHEMICAL", 162, 177], ["Staphylococcus aureus", "SPECIES", 70, 91], ["Staphylococcus aureus", "SPECIES", 70, 91], ["drugs", "TREATMENT", 34, 39], ["methicillin resistant Staphylococcus aureus", "PROBLEM", 48, 91], ["mupirocin", "TREATMENT", 104, 113], ["chlorhexidine", "TREATMENT", 145, 158], ["hexachlorophene body wash", "TREATMENT", 162, 187], ["Staphylococcus aureus", "OBSERVATION", 70, 91]]], ["The pharmacological agents relevant for the present scoping review were: povidone-iodine solution (reported by 7 papers), alcohol-based nasal antiseptics (2 papers), quaternary ammonium compounds (1 paper) and N-chlorotaurine (1 paper).", [["nasal", "ANATOMY", 136, 141], ["povidone-iodine", "CHEMICAL", 73, 88], ["alcohol", "CHEMICAL", 122, 129], ["quaternary ammonium", "CHEMICAL", 166, 185], ["N-chlorotaurine", "CHEMICAL", 210, 225], ["povidone-iodine", "CHEMICAL", 73, 88], ["alcohol", "CHEMICAL", 122, 129], ["quaternary ammonium", "CHEMICAL", 166, 185], ["N-chlorotaurine", "CHEMICAL", 210, 225], ["povidone-iodine", "SIMPLE_CHEMICAL", 73, 88], ["alcohol", "SIMPLE_CHEMICAL", 122, 129], ["quaternary ammonium compounds", "SIMPLE_CHEMICAL", 166, 195], ["N-chlorotaurine", "SIMPLE_CHEMICAL", 210, 225], ["povidone-iodine solution", "TREATMENT", 73, 97], ["nasal antiseptics", "TREATMENT", 136, 153], ["quaternary ammonium compounds", "TREATMENT", 166, 195], ["N-chlorotaurine", "TREATMENT", 210, 225], ["nasal", "ANATOMY", 136, 141]]], ["Furthermore, \u201cnasal disinfection\u201d was used as search term in three online repositories of preliminary not peer-reviewed reports.", [["nasal", "ANATOMY", 14, 19], ["nasal disinfection", "TREATMENT", 14, 32], ["nasal", "ANATOMY", 14, 19], ["disinfection", "OBSERVATION", 20, 32]]], ["The treatments found were: povidone-iodine solution and interferon-alpha (2 papers from MedRxiv), hypothiocyanite (2 papers, of which 1 from SSRN) and alcohol-based nasal antiseptics (1 paper from arXiv).METHODSEvery cited treatment was used as key term to find additional information from different electronic databases.", [["nasal", "ANATOMY", 165, 170], ["povidone-iodine", "CHEMICAL", 27, 42], ["interferon-alpha", "CHEMICAL", 56, 72], ["hypothiocyanite", "CHEMICAL", 98, 113], ["alcohol", "CHEMICAL", 151, 158], ["povidone-iodine", "CHEMICAL", 27, 42], ["hypothiocyanite", "CHEMICAL", 98, 113], ["alcohol", "CHEMICAL", 151, 158], ["povidone-iodine", "SIMPLE_CHEMICAL", 27, 42], ["interferon-alpha", "GENE_OR_GENE_PRODUCT", 56, 72], ["MedRxiv", "SIMPLE_CHEMICAL", 88, 95], ["hypothiocyanite", "SIMPLE_CHEMICAL", 98, 113], ["alcohol", "SIMPLE_CHEMICAL", 151, 158], ["interferon", "PROTEIN", 56, 66], ["The treatments", "TREATMENT", 0, 14], ["povidone", "TREATMENT", 27, 35], ["iodine solution", "TREATMENT", 36, 51], ["interferon", "TREATMENT", 56, 66], ["alpha", "TREATMENT", 67, 72], ["MedRxiv", "TREATMENT", 88, 95], ["hypothiocyanite", "TREATMENT", 98, 113], ["nasal antiseptics", "TREATMENT", 165, 182], ["METHODSEvery cited treatment", "TREATMENT", 204, 232], ["nasal", "ANATOMY", 165, 170]]], ["The abstracts of the original articles were explored for the following terms: mechanism(s) of action, tolerability and any evidence of toxic effects or selection of resistant strains, whether the treatment was tested in vitro (in particular against SARS-CoV-2), or reached the clinical trials stage, or is currently marketed/promoted/sold.HYPOTHIOCYANITE ::: RESULTSThe lactoperoxidase (LPO) is a heme peroxidase present in several exocrine secretions, including the interface of human airways epithelium, which produces different anti-infectious agents in presence of hydrogen peroxide (H2O2), principally from halide (the iodide anion I\u2212) and pseudo-halide (thiocyanate, also known as anion SCN\u2212) substrates [22].", [["exocrine secretions", "ANATOMY", 432, 451], ["airways epithelium", "ANATOMY", 486, 504], ["hydrogen peroxide", "CHEMICAL", 569, 586], ["H2O2", "CHEMICAL", 588, 592], ["pseudo-halide", "CHEMICAL", 645, 658], ["thiocyanate", "CHEMICAL", 660, 671], ["heme", "CHEMICAL", 397, 401], ["hydrogen peroxide", "CHEMICAL", 569, 586], ["H2O2", "CHEMICAL", 588, 592], ["halide", "CHEMICAL", 612, 618], ["iodide", "CHEMICAL", 624, 630], ["pseudo-halide", "CHEMICAL", 645, 658], ["thiocyanate", "CHEMICAL", 660, 671], ["SCN\u2212", "CHEMICAL", 693, 697], ["lactoperoxidase", "GENE_OR_GENE_PRODUCT", 370, 385], ["LPO", "SIMPLE_CHEMICAL", 387, 390], ["heme peroxidase", "GENE_OR_GENE_PRODUCT", 397, 412], ["exocrine secretions", "MULTI-TISSUE_STRUCTURE", 432, 451], ["human", "ORGANISM", 480, 485], ["airways epithelium", "TISSUE", 486, 504], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 569, 586], ["H2O2", "SIMPLE_CHEMICAL", 588, 592], ["halide", "SIMPLE_CHEMICAL", 612, 618], ["iodide anion I\u2212", "SIMPLE_CHEMICAL", 624, 639], ["pseudo-halide", "SIMPLE_CHEMICAL", 645, 658], ["thiocyanate", "SIMPLE_CHEMICAL", 660, 671], ["anion SCN\u2212", "SIMPLE_CHEMICAL", 687, 697], ["lactoperoxidase", "PROTEIN", 370, 385], ["LPO", "PROTEIN", 387, 390], ["heme peroxidase", "PROTEIN", 397, 412], ["human", "SPECIES", 480, 485], ["SARS-CoV", "SPECIES", 249, 257], ["human", "SPECIES", 480, 485], ["toxic effects", "PROBLEM", 135, 148], ["resistant strains", "PROBLEM", 165, 182], ["the treatment", "TREATMENT", 192, 205], ["SARS", "PROBLEM", 249, 253], ["lactoperoxidase (LPO)", "TREATMENT", 370, 391], ["a heme peroxidase", "TREATMENT", 395, 412], ["several exocrine secretions", "PROBLEM", 424, 451], ["human airways epithelium", "PROBLEM", 480, 504], ["different anti-infectious agents", "TREATMENT", 521, 553], ["hydrogen peroxide (H2O2)", "TREATMENT", 569, 593], ["the iodide anion I\u2212", "TREATMENT", 620, 639], ["pseudo-halide (thiocyanate", "TREATMENT", 645, 671], ["secretions", "OBSERVATION", 441, 451], ["human", "ANATOMY_MODIFIER", 480, 485], ["airways epithelium", "ANATOMY", 486, 504], ["anti-infectious agents", "OBSERVATION", 531, 553]]], ["Both SCN\u2212 and I\u2212 act as a one-electron donors, H2O2 works as a relatively specific electron acceptor, whereas LPO is the catalyzing enzyme.", [["H2O2", "CHEMICAL", 47, 51], ["H2O2", "CHEMICAL", 47, 51], ["SCN\u2212", "SIMPLE_CHEMICAL", 5, 9], ["I\u2212", "SIMPLE_CHEMICAL", 14, 16], ["H2O2", "SIMPLE_CHEMICAL", 47, 51], ["electron", "SIMPLE_CHEMICAL", 83, 91], ["LPO", "SIMPLE_CHEMICAL", 110, 113], ["catalyzing enzyme", "PROTEIN", 121, 138], ["the catalyzing enzyme", "TEST", 117, 138]]], ["By undergoing two oxidations, the native LPO donates two electrons to H2O2, which is reduced to water.", [["H2O2", "CHEMICAL", 70, 74], ["H2O2", "CHEMICAL", 70, 74], ["LPO", "SIMPLE_CHEMICAL", 41, 44], ["H2O2", "SIMPLE_CHEMICAL", 70, 74], ["two oxidations", "TREATMENT", 14, 28], ["H2O2", "TREATMENT", 70, 74], ["reduced", "OBSERVATION_MODIFIER", 85, 92]]], ["At that point, LPO is reduced back to the native enzyme.", [["LPO", "SIMPLE_CHEMICAL", 15, 18], ["native enzyme", "PROTEIN", 42, 55], ["LPO", "TEST", 15, 18], ["reduced", "OBSERVATION_MODIFIER", 22, 29]]], ["Whether the required biochemical/environmental conditions are satisfied, LPO produces the active antimicrobial molecules OSCN\u2212 (hypothiocyanite) or OI\u2212 (hypoiodite) in presence of SCN\u2212 or I\u2212 respectively [22].HYPOTHIOCYANITE ::: RESULTSIn Figure 2, R-SH is a peptide or protein with a thiol moiety essential for the activity of numerous enzymes and proteins.", [["hypothiocyanite", "CHEMICAL", 128, 143], ["OI\u2212", "CHEMICAL", 148, 151], ["thiol", "CHEMICAL", 285, 290], ["OSCN", "CHEMICAL", 121, 125], ["hypothiocyanite", "CHEMICAL", 128, 143], ["OI\u2212", "CHEMICAL", 148, 151], ["hypoiodite", "CHEMICAL", 153, 163], ["thiol", "CHEMICAL", 285, 290], ["LPO", "SIMPLE_CHEMICAL", 73, 76], ["OSCN\u2212", "SIMPLE_CHEMICAL", 121, 126], ["hypothiocyanite", "SIMPLE_CHEMICAL", 128, 143], ["OI\u2212", "SIMPLE_CHEMICAL", 148, 151], ["hypoiodite", "SIMPLE_CHEMICAL", 153, 163], ["R-SH", "SIMPLE_CHEMICAL", 249, 253], ["enzymes", "PROTEIN", 337, 344], ["biochemical/environmental conditions", "TREATMENT", 21, 57], ["OI\u2212", "PROBLEM", 148, 151], ["HYPOTHIOCYANITE", "TEST", 209, 224], ["Figure", "TEST", 239, 245], ["a thiol moiety", "TREATMENT", 283, 297], ["numerous enzymes", "TEST", 328, 344], ["active", "OBSERVATION_MODIFIER", 90, 96]]], ["Sulphydryl oxidation of R-SH by OSCN\u2212 or OI\u2212 generates sulfenyl thiocyanate (R-S-SCN) or sulfenyl iodide (R-S-I), determining inhibition of bacterial glycolysis, respiration and glucose transport.", [["Sulphydryl", "CHEMICAL", 0, 10], ["R-SH", "CHEMICAL", 24, 28], ["OSCN", "CHEMICAL", 32, 36], ["sulfenyl thiocyanate", "CHEMICAL", 55, 75], ["R-S-SCN", "CHEMICAL", 77, 84], ["sulfenyl iodide", "CHEMICAL", 89, 104], ["R-S-I", "CHEMICAL", 106, 111], ["glucose", "CHEMICAL", 178, 185], ["Sulphydryl", "CHEMICAL", 0, 10], ["R-SH", "CHEMICAL", 24, 28], ["OSCN", "CHEMICAL", 32, 36], ["sulfenyl thiocyanate", "CHEMICAL", 55, 75], ["R-S-SCN", "CHEMICAL", 77, 84], ["sulfenyl iodide", "CHEMICAL", 89, 104], ["R-S-I", "CHEMICAL", 106, 111], ["glucose", "CHEMICAL", 178, 185], ["Sulphydryl", "SIMPLE_CHEMICAL", 0, 10], ["R-SH", "SIMPLE_CHEMICAL", 24, 28], ["OSCN\u2212", "SIMPLE_CHEMICAL", 32, 37], ["OI\u2212", "SIMPLE_CHEMICAL", 41, 44], ["sulfenyl thiocyanate", "SIMPLE_CHEMICAL", 55, 75], ["R-S-SCN", "SIMPLE_CHEMICAL", 77, 84], ["sulfenyl iodide", "SIMPLE_CHEMICAL", 89, 104], ["R-S-I", "SIMPLE_CHEMICAL", 106, 111], ["glucose", "SIMPLE_CHEMICAL", 178, 185], ["Sulphydryl oxidation", "TEST", 0, 20], ["OSCN", "TEST", 32, 36], ["OI", "PROBLEM", 41, 43], ["sulfenyl thiocyanate", "TREATMENT", 55, 75], ["sulfenyl iodide", "TREATMENT", 89, 104], ["bacterial glycolysis", "PROBLEM", 140, 160], ["glucose transport", "TEST", 178, 195]]], ["Inhibition of the pentose phosphate pathway was also observed only for OI\u2212, with sulfenic acid (R-S-OH) as well as SCN\u2212 or I\u2212 formed at the end of the cycle.", [["pentose phosphate", "CHEMICAL", 18, 35], ["OI\u2212", "CHEMICAL", 71, 74], ["sulfenic acid", "CHEMICAL", 81, 94], ["R-S-OH", "CHEMICAL", 96, 102], ["pentose phosphate", "CHEMICAL", 18, 35], ["OI\u2212", "CHEMICAL", 71, 74], ["sulfenic acid", "CHEMICAL", 81, 94], ["R-S-OH", "CHEMICAL", 96, 102], ["pentose", "SIMPLE_CHEMICAL", 18, 25], ["OI\u2212", "SIMPLE_CHEMICAL", 71, 74], ["sulfenic acid", "SIMPLE_CHEMICAL", 81, 94], ["R-S-OH", "SIMPLE_CHEMICAL", 96, 102], ["SCN\u2212", "SIMPLE_CHEMICAL", 115, 119], ["I\u2212", "SIMPLE_CHEMICAL", 123, 125], ["the pentose phosphate pathway", "TREATMENT", 14, 43], ["OI\u2212", "TEST", 71, 74], ["sulfenic acid", "TEST", 81, 94]]], ["Either SCN\u2212 or I\u2212 reacts with native LPO and the cycle restarts.", [["SCN\u2212", "SIMPLE_CHEMICAL", 7, 11], ["I\u2212", "SIMPLE_CHEMICAL", 15, 17], ["LPO", "SIMPLE_CHEMICAL", 37, 40], ["SCN\u2212 or I\u2212", "PROTEIN", 7, 17], ["native LPO", "TREATMENT", 30, 40], ["the cycle restarts", "TREATMENT", 45, 63]]], ["The anti-microbial activity of the entire system (enzyme plus substrates) is known to be more effective than hypothiocyanite or hypoiodite alone and has been explained by the production of short-lived, highly reactive intermediates [22].", [["hypothiocyanite", "CHEMICAL", 109, 124], ["hypoiodite", "CHEMICAL", 128, 138], ["hypothiocyanite", "CHEMICAL", 109, 124], ["hypoiodite", "CHEMICAL", 128, 138], ["hypothiocyanite", "SIMPLE_CHEMICAL", 109, 124], ["hypoiodite", "SIMPLE_CHEMICAL", 128, 138], ["enzyme", "PROTEIN", 50, 56], ["hypoiodite", "PROBLEM", 128, 138], ["anti-microbial activity", "OBSERVATION", 4, 27], ["reactive", "OBSERVATION_MODIFIER", 209, 217]]], ["Furthermore, the activity of the I\u2212 peroxidase system is more effective against E. coli than the SCN\u2212 system, in that lower I\u2212 concentrations are necessary.", [["I\u2212 peroxidase", "GENE_OR_GENE_PRODUCT", 33, 46], ["E. coli", "ORGANISM", 80, 87], ["I\u2212 peroxidase", "PROTEIN", 33, 46], ["E. coli", "SPECIES", 80, 87], ["E. coli", "SPECIES", 80, 87], ["the I\u2212 peroxidase system", "TEST", 29, 53], ["E. coli", "PROBLEM", 80, 87], ["coli", "OBSERVATION", 83, 87], ["lower", "ANATOMY_MODIFIER", 118, 123]]], ["The I\u2212 peroxidase system deserves to be tested in vitro against the new coronavirus [22].HYPOTHIOCYANITE ::: RESULTSAdditionally, OSCN\u2212 seems able to alter the surface proteins of different respiratory viruses, probably by oxidizing free thiol radicals and creating disulfide bonds [23], thus contrasting the binding of viruses with the human airways mucosae.", [["surface", "ANATOMY", 160, 167], ["airways mucosae", "ANATOMY", 343, 358], ["thiol", "CHEMICAL", 238, 243], ["thiol", "CHEMICAL", 238, 243], ["disulfide", "CHEMICAL", 266, 275], ["I\u2212 peroxidase", "GENE_OR_GENE_PRODUCT", 4, 17], ["coronavirus", "ORGANISM", 72, 83], ["OSCN", "GENE_OR_GENE_PRODUCT", 130, 134], ["free thiol radicals", "SIMPLE_CHEMICAL", 233, 252], ["human", "ORGANISM", 337, 342], ["airways mucosae", "MULTI-TISSUE_STRUCTURE", 343, 358], ["I\u2212 peroxidase", "PROTEIN", 4, 17], ["OSCN", "PROTEIN", 130, 134], ["surface proteins", "PROTEIN", 160, 176], ["human", "SPECIES", 337, 342], ["human", "SPECIES", 337, 342], ["The I\u2212 peroxidase system", "TREATMENT", 0, 24], ["the new coronavirus", "PROBLEM", 64, 83], ["different respiratory viruses", "PROBLEM", 180, 209], ["creating disulfide bonds", "TEST", 257, 281], ["respiratory viruses", "OBSERVATION", 190, 209], ["viruses", "OBSERVATION", 320, 327], ["airways mucosae", "ANATOMY", 343, 358]]], ["OSCN\u2212 may also arguably hamper the synthesis and assemblance of viral proteins and nucleic acids, thus interfering with the release of viruses from infected cells [16,24,25].HYPOTHIOCYANITE ::: RESULTSThe products of LPO extracellular oxidative complex is part of the human natural protective system of central airways against pathogen threats [16,23, 24, 25].", [["cells", "ANATOMY", 157, 162], ["extracellular", "ANATOMY", 221, 234], ["central airways", "ANATOMY", 303, 318], ["OSCN", "CHEMICAL", 0, 4], ["nucleic acids", "CHEMICAL", 83, 96], ["OSCN", "SIMPLE_CHEMICAL", 0, 4], ["nucleic acids", "SIMPLE_CHEMICAL", 83, 96], ["cells", "CELL", 157, 162], ["LPO", "SIMPLE_CHEMICAL", 217, 220], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 221, 234], ["human", "ORGANISM", 268, 273], ["central airways", "MULTI-TISSUE_STRUCTURE", 303, 318], ["OSCN", "PROTEIN", 0, 4], ["viral proteins", "PROTEIN", 64, 78], ["infected cells", "CELL_TYPE", 148, 162], ["LPO extracellular oxidative complex", "PROTEIN", 217, 252], ["human", "SPECIES", 268, 273], ["human", "SPECIES", 268, 273], ["the synthesis", "PROBLEM", 31, 44], ["viral proteins", "PROBLEM", 64, 78], ["nucleic acids", "PROBLEM", 83, 96], ["viruses", "PROBLEM", 135, 142], ["infected cells", "PROBLEM", 148, 162], ["LPO extracellular oxidative complex", "TREATMENT", 217, 252], ["oxidative complex", "OBSERVATION", 235, 252], ["central", "ANATOMY_MODIFIER", 303, 310], ["airways", "ANATOMY", 311, 318]]], ["Due to the need of maximizing gas exchange, alveolar epithelial cells cannot contain strong protective structures.", [["alveolar epithelial cells", "ANATOMY", 44, 69], ["alveolar epithelial cells", "CELL", 44, 69], ["alveolar epithelial cells", "CELL_TYPE", 44, 69], ["maximizing gas exchange", "TREATMENT", 19, 42], ["alveolar epithelial cells", "PROBLEM", 44, 69], ["gas exchange", "OBSERVATION", 30, 42], ["alveolar", "ANATOMY_MODIFIER", 44, 52], ["epithelial cells", "OBSERVATION", 53, 69], ["strong", "OBSERVATION_MODIFIER", 85, 91]]], ["The latter cells are fragile and vulnerable to infectious agents, as shown by the diffuse alveolar damage discovered in two patients undergoing surgical resections for lung adenocarcinoma, later discovered to be affected also by COVID-19 pneumonia [26].", [["cells", "ANATOMY", 11, 16], ["alveolar", "ANATOMY", 90, 98], ["lung adenocarcinoma", "ANATOMY", 168, 187], ["alveolar damage", "DISEASE", 90, 105], ["lung adenocarcinoma", "DISEASE", 168, 187], ["pneumonia", "DISEASE", 238, 247], ["cells", "CELL", 11, 16], ["alveolar", "TISSUE", 90, 98], ["patients", "ORGANISM", 124, 132], ["lung adenocarcinoma", "CANCER", 168, 187], ["patients", "SPECIES", 124, 132], ["fragile", "PROBLEM", 21, 28], ["infectious agents", "TREATMENT", 47, 64], ["the diffuse alveolar damage", "PROBLEM", 78, 105], ["surgical resections", "TREATMENT", 144, 163], ["lung adenocarcinoma", "PROBLEM", 168, 187], ["COVID", "TEST", 229, 234], ["pneumonia", "PROBLEM", 238, 247], ["fragile", "OBSERVATION_MODIFIER", 21, 28], ["infectious", "OBSERVATION", 47, 57], ["diffuse", "OBSERVATION_MODIFIER", 82, 89], ["alveolar damage", "OBSERVATION", 90, 105], ["resections", "OBSERVATION", 153, 163], ["lung", "ANATOMY", 168, 172], ["adenocarcinoma", "OBSERVATION", 173, 187], ["pneumonia", "OBSERVATION", 238, 247]]], ["Bronchi were not reported to be as vulnerable as alveoli in the same study [26].HYPOTHIOCYANITE ::: RESULTSThe lack of LPO/H2O2/SCN\u2212 system in nasal and eye secretions of humans may explain the survival and proliferation of bacteria and respiratory viruses in the mucosae of conjunctiva and nose and their subsequent shedding in the environment [27, 28, 29, 30, 31, 32].", [["alveoli", "ANATOMY", 49, 56], ["nasal", "ANATOMY", 143, 148], ["eye secretions", "ANATOMY", 153, 167], ["mucosae", "ANATOMY", 264, 271], ["conjunctiva", "ANATOMY", 275, 286], ["nose", "ANATOMY", 291, 295], ["H2O2", "CHEMICAL", 123, 127], ["H2O2", "CHEMICAL", 123, 127], ["alveoli", "MULTI-TISSUE_STRUCTURE", 49, 56], ["LPO", "SIMPLE_CHEMICAL", 119, 122], ["H2O2", "SIMPLE_CHEMICAL", 123, 127], ["SCN\u2212", "GENE_OR_GENE_PRODUCT", 128, 132], ["nasal", "ORGAN", 143, 148], ["eye secretions", "ORGAN", 153, 167], ["humans", "ORGANISM", 171, 177], ["mucosae", "MULTI-TISSUE_STRUCTURE", 264, 271], ["conjunctiva", "ORGAN", 275, 286], ["nose", "ORGAN", 291, 295], ["humans", "SPECIES", 171, 177], ["humans", "SPECIES", 171, 177], ["LPO/H2O2", "TREATMENT", 119, 127], ["SCN\u2212 system", "TREATMENT", 128, 139], ["the survival", "PROBLEM", 190, 202], ["proliferation of bacteria", "PROBLEM", 207, 232], ["respiratory viruses in the mucosae of conjunctiva and nose", "PROBLEM", 237, 295], ["nasal", "ANATOMY", 143, 148], ["eye", "ANATOMY", 153, 156], ["respiratory viruses", "OBSERVATION", 237, 256], ["mucosae", "ANATOMY", 264, 271], ["conjunctiva", "ANATOMY", 275, 286], ["nose", "ANATOMY", 291, 295]]], ["At micromolar concentration, the reactive mixture LPO/H2O2/OSCN\u2212 proved cidal activity against a range of bacteria (Gram positive and negative), fungi (Candida albicans and Candida krusei) and viruses as HIV, herpes-simplex virus (HSV-1), adenovirus, echovirus, respiratory syncytial virus (RSV) and influenza virus [33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43].HYPOTHIOCYANITE ::: RESULTSIn a recent experiment in-vitro, OSCN\u2212 produced by the oxidase/LPO/ H2O2/thiocyanate system rapidly and effectively inactivated A/swine/Illinois/02860/09 (swH1N2) influenza A virions, successfully preventing the infection of both primary human and male Sprague-Dawley rat trachea-bronchial epithelial cells [43].HYPOTHIOCYANITE ::: RESULTSIn a more recent in-vitro cell-free experiment, all 12 different strains of influenza A and B viruses (the major circulating serotypes and species causing epidemics) were effectively inactivated by the LPO/H2O2/(SCN\u2212/I\u2212) system [39].", [["trachea-bronchial epithelial cells", "ANATOMY", 660, 694], ["cell", "ANATOMY", 753, 757], ["H2O2", "CHEMICAL", 54, 58], ["OSCN", "CHEMICAL", 59, 63], ["Candida albicans", "DISEASE", 152, 168], ["HIV, herpes-simplex virus", "DISEASE", 204, 229], ["echovirus", "DISEASE", 251, 260], ["respiratory syncytial virus (RSV) and influenza virus", "DISEASE", 262, 315], ["OSCN", "CHEMICAL", 421, 425], ["H2O2", "CHEMICAL", 456, 460], ["thiocyanate", "CHEMICAL", 461, 472], ["infection", "DISEASE", 600, 609], ["influenza A and B viruses", "DISEASE", 803, 828], ["H2O2", "CHEMICAL", 933, 937], ["H2O2", "CHEMICAL", 54, 58], ["OSCN", "CHEMICAL", 59, 63], ["OSCN", "CHEMICAL", 421, 425], ["H2O2", "CHEMICAL", 456, 460], ["thiocyanate", "CHEMICAL", 461, 472], ["H2O2", "CHEMICAL", 933, 937], ["LPO", "SIMPLE_CHEMICAL", 50, 53], ["H2O2", "SIMPLE_CHEMICAL", 54, 58], ["OSCN", "SIMPLE_CHEMICAL", 59, 63], ["cidal", "SIMPLE_CHEMICAL", 72, 77], ["Gram positive", "GENE_OR_GENE_PRODUCT", 116, 129], ["Candida albicans", "ORGANISM", 152, 168], ["Candida krusei", "ORGANISM", 173, 187], ["HIV,", "ORGANISM", 204, 208], ["herpes-simplex virus", "ORGANISM", 209, 229], ["HSV-1", "ORGANISM", 231, 236], ["adenovirus", "ORGANISM", 239, 249], ["echovirus,", "ORGANISM", 251, 261], ["respiratory syncytial virus", "ORGANISM", 262, 289], ["RSV", "ORGANISM", 291, 294], ["influenza virus", "ORGANISM", 300, 315], ["OSCN", "SIMPLE_CHEMICAL", 421, 425], ["oxidase", "GENE_OR_GENE_PRODUCT", 443, 450], ["LPO", "SIMPLE_CHEMICAL", 451, 454], ["H2O2", "SIMPLE_CHEMICAL", 456, 460], ["thiocyanate", "SIMPLE_CHEMICAL", 461, 472], ["A/swine", "ORGANISM", 516, 523], ["Illinois/02860/09 (swH1N2) influenza A virions", "ORGANISM", 524, 570], ["human", "ORGANISM", 626, 631], ["Sprague-Dawley rat", "ORGANISM", 641, 659], ["trachea-bronchial epithelial cells", "CELL", 660, 694], ["cell", "CELL", 753, 757], ["influenza A and B viruses", "ORGANISM", 803, 828], ["LPO", "SIMPLE_CHEMICAL", 929, 932], ["H2O2", "SIMPLE_CHEMICAL", 933, 937], ["oxidase", "PROTEIN", 443, 450], ["primary human and male Sprague-Dawley rat trachea-bronchial epithelial cells", "CELL_TYPE", 618, 694], ["Candida albicans", "SPECIES", 152, 168], ["Candida krusei", "SPECIES", 173, 187], ["HIV", "SPECIES", 204, 207], ["herpes-simplex virus", "SPECIES", 209, 229], ["HSV-1", "SPECIES", 231, 236], ["respiratory syncytial virus", "SPECIES", 262, 289], ["RSV", "SPECIES", 291, 294], ["influenza virus", "SPECIES", 300, 315], ["swine", "SPECIES", 518, 523], ["H1N2) influenza", "SPECIES", 545, 560], ["human", "SPECIES", 626, 631], ["Sprague-Dawley rat", "SPECIES", 641, 659], ["Candida albicans", "SPECIES", 152, 168], ["Candida krusei", "SPECIES", 173, 187], ["HIV", "SPECIES", 204, 207], ["herpes-simplex virus", "SPECIES", 209, 229], ["HSV-1", "SPECIES", 231, 236], ["adenovirus", "SPECIES", 239, 249], ["respiratory syncytial virus", "SPECIES", 262, 289], ["RSV", "SPECIES", 291, 294], ["A/swine/Illinois/02860/09 (swH1N2) influenza A", "SPECIES", 516, 562], ["human", "SPECIES", 626, 631], ["Sprague-Dawley rat", "SPECIES", 641, 659], ["influenza A", "SPECIES", 803, 814], ["B viruses", "SPECIES", 819, 828], ["micromolar concentration", "TEST", 3, 27], ["the reactive mixture LPO", "TEST", 29, 53], ["OSCN", "TREATMENT", 59, 63], ["bacteria", "PROBLEM", 106, 114], ["Gram", "TEST", 116, 120], ["fungi", "TEST", 145, 150], ["Candida albicans", "TEST", 152, 168], ["Candida krusei", "TEST", 173, 187], ["viruses", "PROBLEM", 193, 200], ["HIV", "TEST", 204, 207], ["herpes-simplex virus", "TEST", 209, 229], ["HSV", "TEST", 231, 234], ["adenovirus", "PROBLEM", 239, 249], ["echovirus", "PROBLEM", 251, 260], ["respiratory syncytial virus", "PROBLEM", 262, 289], ["influenza virus", "PROBLEM", 300, 315], ["H2O2/thiocyanate system", "TREATMENT", 456, 479], ["influenza A virions", "PROBLEM", 551, 570], ["the infection", "PROBLEM", 596, 609], ["bronchial epithelial cells", "PROBLEM", 668, 694], ["influenza A", "PROBLEM", 803, 814], ["B viruses", "PROBLEM", 819, 828], ["the major circulating serotypes", "PROBLEM", 830, 861], ["epidemics", "PROBLEM", 882, 891], ["reactive", "OBSERVATION_MODIFIER", 33, 41], ["Candida krusei", "OBSERVATION", 173, 187], ["respiratory syncytial", "ANATOMY", 262, 283], ["infection", "OBSERVATION", 600, 609], ["trachea", "ANATOMY", 660, 667], ["bronchial", "ANATOMY", 668, 677], ["epithelial cells", "OBSERVATION", 678, 694], ["influenza", "OBSERVATION", 803, 812]]], ["Considering the strain-independent effect, the authors of the latter study encouraged a pharmaceutical application of the LPO/H2O2/(SCN\u2212/I\u2212) system in vivo to contribute to the clearance of influenza virus [39].HYPOTHIOCYANITE ::: RESULTSAnother laboratory experiment also challenged enzyme free OSCN\u2212 against A/H1N1 2009 pandemic influenza virus in-vitro, showing an evident dose-dependent viricidal activity, without cell toxicity [24].", [["cell", "ANATOMY", 419, 423], ["H2O2", "CHEMICAL", 126, 130], ["influenza", "DISEASE", 190, 199], ["OSCN", "CHEMICAL", 296, 300], ["influenza virus", "DISEASE", 331, 346], ["toxicity", "DISEASE", 424, 432], ["H2O2", "CHEMICAL", 126, 130], ["LPO", "SIMPLE_CHEMICAL", 122, 125], ["H2O2", "SIMPLE_CHEMICAL", 126, 130], ["SCN\u2212", "SIMPLE_CHEMICAL", 132, 136], ["influenza virus", "ORGANISM", 190, 205], ["OSCN", "SIMPLE_CHEMICAL", 296, 300], ["A/H1N1 2009 pandemic influenza virus", "ORGANISM", 310, 346], ["cell", "CELL", 419, 423], ["influenza virus", "SPECIES", 190, 205], ["pandemic influenza virus", "SPECIES", 322, 346], ["A/H1N1 2009 pandemic influenza virus", "SPECIES", 310, 346], ["the latter study", "TEST", 58, 74], ["the LPO/H2O2", "TREATMENT", 118, 130], ["SCN\u2212/I\u2212) system", "TREATMENT", 132, 147], ["influenza virus", "PROBLEM", 190, 205], ["enzyme", "TEST", 284, 290], ["A/H1N1 2009 pandemic influenza virus", "PROBLEM", 310, 346], ["dependent viricidal activity", "PROBLEM", 381, 409], ["cell toxicity", "PROBLEM", 419, 432], ["viricidal activity", "OBSERVATION", 391, 409], ["without", "UNCERTAINTY", 411, 418], ["cell toxicity", "OBSERVATION", 419, 432]]], ["Considering a demonstrated wide spectrum cidal effect [17,39], not targeting specific proteins, it could be reasonably argued that OSCN\u2212 may be effective also against SARS-CoV-2 and would therefore deserved to be tested in vitro [24,25].", [["OSCN", "CHEMICAL", 131, 135], ["OSCN", "CHEMICAL", 131, 135], ["OSCN", "SIMPLE_CHEMICAL", 131, 135], ["SARS-CoV-2", "ORGANISM", 167, 177], ["SARS-CoV", "SPECIES", 167, 175], ["SARS", "PROBLEM", 167, 171]]], ["Since it is already naturally present in human airways secretion and considering its large spectrum of action, a low level of resistance due to viral mutations and limited adverse reactions can be predicted with OSCN\u2212 [17,24,25].", [["airways", "ANATOMY", 47, 54], ["OSCN\u2212 [17,24,25", "CHEMICAL", 212, 227], ["OSCN", "CHEMICAL", 212, 216], ["human", "ORGANISM", 41, 46], ["airways", "MULTI-TISSUE_STRUCTURE", 47, 54], ["OSCN", "SIMPLE_CHEMICAL", 212, 216], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 41, 46], ["human airways secretion", "PROBLEM", 41, 64], ["a low level of resistance", "PROBLEM", 111, 136], ["viral mutations", "PROBLEM", 144, 159], ["limited adverse reactions", "PROBLEM", 164, 189], ["airways", "ANATOMY", 47, 54], ["secretion", "OBSERVATION", 55, 64], ["large", "OBSERVATION_MODIFIER", 85, 90], ["viral mutations", "OBSERVATION", 144, 159]]], ["If effective in vitro against SARS-CoV-2, in vivo aerosol trials with enzyme free OSCN\u2212 could be subsequently undertaken with the aim of providing a short term-prophylaxis for the transmissibility of SARS-CoV-2, by clearing any individual COVID-19 positive at real time PCR.HYPOTHIOCYANITE ::: RESULTSOSCN\u2212, alone or in combination with lactoferrin (LF), is already being tested in a phase 1 clinical trial (RCT02598999) on healthy volunteers and patients affected by cystic fibrosis and bronchiectasis [23].HYPOTHIOCYANITE ::: RESULTSThe LPO/H2O2/SCN\u2212 system is also a commercially available non-prescription product (Zendium) used as toothpaste and mouthwash.LACTOFERRIN ::: RESULTSLactoferrin (LF) is a natural multifunctional protein belonging to the family of transferrin.", [["cystic", "ANATOMY", 468, 474], ["SARS", "DISEASE", 30, 34], ["OSCN", "CHEMICAL", 82, 86], ["SARS", "DISEASE", 200, 204], ["cystic fibrosis", "DISEASE", 468, 483], ["bronchiectasis", "DISEASE", 488, 502], ["H2O2", "CHEMICAL", 543, 547], ["Zendium", "CHEMICAL", 619, 626], ["RESULTSLactoferrin", "CHEMICAL", 677, 695], ["H2O2", "CHEMICAL", 543, 547], ["SARS-CoV-2", "ORGANISM", 30, 40], ["OSCN", "SIMPLE_CHEMICAL", 82, 86], ["SARS-CoV-2", "ORGANISM", 200, 210], ["lactoferrin", "GENE_OR_GENE_PRODUCT", 337, 348], ["volunteers", "ORGANISM", 432, 442], ["patients", "ORGANISM", 447, 455], ["LPO", "SIMPLE_CHEMICAL", 539, 542], ["H2O2", "SIMPLE_CHEMICAL", 543, 547], ["Zendium", "SIMPLE_CHEMICAL", 619, 626], ["RESULTSLactoferrin", "GENE_OR_GENE_PRODUCT", 677, 695], ["transferrin", "GENE_OR_GENE_PRODUCT", 765, 776], ["COVID-19", "DNA", 239, 247], ["lactoferrin", "PROTEIN", 337, 348], ["LF", "PROTEIN", 697, 699], ["natural multifunctional protein", "PROTEIN", 706, 737], ["transferrin", "PROTEIN", 765, 776], ["patients", "SPECIES", 447, 455], ["SARS-CoV", "SPECIES", 30, 38], ["SARS-CoV", "SPECIES", 200, 208], ["SARS", "PROBLEM", 30, 34], ["CoV", "TEST", 35, 38], ["vivo aerosol trials", "TREATMENT", 45, 64], ["enzyme free OSCN", "TREATMENT", 70, 86], ["a short term-prophylaxis", "TREATMENT", 147, 171], ["SARS", "PROBLEM", 200, 204], ["CoV", "TEST", 205, 208], ["any individual COVID", "TEST", 224, 244], ["lactoferrin", "TREATMENT", 337, 348], ["cystic fibrosis", "PROBLEM", 468, 483], ["bronchiectasis", "PROBLEM", 488, 502], ["HYPOTHIOCYANITE", "TEST", 508, 523], ["non-prescription product (Zendium)", "TREATMENT", 593, 627], ["mouthwash", "TREATMENT", 651, 660], ["LACTOFERRIN", "TREATMENT", 661, 672], ["RESULTSLactoferrin (LF)", "TREATMENT", 677, 700], ["a natural multifunctional protein", "TREATMENT", 704, 737], ["cystic", "OBSERVATION_MODIFIER", 468, 474], ["fibrosis", "OBSERVATION", 475, 483], ["bronchiectasis", "OBSERVATION", 488, 502]]], ["It is present in the human milk and can be found in external secretions such as saliva, tears, milk, nasal and bronchial secretions, gastrointestinal fluids and urine mucosal secretions.", [["milk", "ANATOMY", 27, 31], ["secretions", "ANATOMY", 61, 71], ["saliva", "ANATOMY", 80, 86], ["tears", "ANATOMY", 88, 93], ["milk", "ANATOMY", 95, 99], ["nasal", "ANATOMY", 101, 106], ["bronchial secretions", "ANATOMY", 111, 131], ["gastrointestinal fluids", "ANATOMY", 133, 156], ["urine mucosal secretions", "ANATOMY", 161, 185], ["human", "ORGANISM", 21, 26], ["milk", "ORGANISM_SUBSTANCE", 27, 31], ["secretions", "ORGANISM_SUBSTANCE", 61, 71], ["saliva", "ORGANISM_SUBSTANCE", 80, 86], ["tears", "TISSUE", 88, 93], ["milk", "ORGANISM_SUBSTANCE", 95, 99], ["nasal", "ORGANISM_SUBDIVISION", 101, 106], ["bronchial secretions", "ORGANISM_SUBSTANCE", 111, 131], ["gastrointestinal fluids", "ORGANISM_SUBSTANCE", 133, 156], ["urine mucosal secretions", "ORGANISM_SUBSTANCE", 161, 185], ["human", "SPECIES", 21, 26], ["milk", "SPECIES", 27, 31], ["human", "SPECIES", 21, 26], ["external secretions", "PROBLEM", 52, 71], ["tears", "PROBLEM", 88, 93], ["milk", "TREATMENT", 95, 99], ["nasal and bronchial secretions", "PROBLEM", 101, 131], ["gastrointestinal fluids", "TREATMENT", 133, 156], ["urine mucosal secretions", "TEST", 161, 185], ["secretions", "OBSERVATION", 61, 71], ["nasal", "ANATOMY", 101, 106], ["bronchial", "ANATOMY", 111, 120], ["secretions", "OBSERVATION", 121, 131], ["gastrointestinal", "ANATOMY", 133, 149], ["mucosal", "ANATOMY", 167, 174], ["secretions", "OBSERVATION", 175, 185]]], ["LF is an important constituent of the neutrophilic granules of leukocytes [44].LACTOFERRIN ::: RESULTSDue to its similarities to transferrin, LF possesses iron binding capabilities; its iron is not released even at pH 3.5.", [["neutrophilic granules", "ANATOMY", 38, 59], ["leukocytes", "ANATOMY", 63, 73], ["iron", "CHEMICAL", 155, 159], ["iron", "CHEMICAL", 186, 190], ["iron", "CHEMICAL", 155, 159], ["iron", "CHEMICAL", 186, 190], ["neutrophilic granules", "CELLULAR_COMPONENT", 38, 59], ["leukocytes", "CELL", 63, 73], ["transferrin", "GENE_OR_GENE_PRODUCT", 129, 140], ["LF", "SIMPLE_CHEMICAL", 142, 144], ["iron", "SIMPLE_CHEMICAL", 155, 159], ["iron", "SIMPLE_CHEMICAL", 186, 190], ["LF", "PROTEIN", 0, 2], ["leukocytes", "CELL_TYPE", 63, 73], ["transferrin", "PROTEIN", 129, 140], ["LF", "PROTEIN", 142, 144], ["the neutrophilic granules of leukocytes", "PROBLEM", 34, 73], ["transferrin", "TEST", 129, 140], ["iron binding capabilities", "TEST", 155, 180], ["its iron", "TEST", 182, 190], ["important constituent", "OBSERVATION_MODIFIER", 9, 30], ["neutrophilic granules", "OBSERVATION", 38, 59], ["leukocytes", "OBSERVATION", 63, 73]]], ["This property ensures iron sequestration in infected tissues where the pH is typically acidic, preventing the utilization of iron by pathogenic bacteria [45].LACTOFERRIN ::: RESULTSLF is a constituent of the innate immune response and during viral infections the expression of genes encoding LF was elevated by approximately 150 fold in SARS-CoV patients compared with healthy controls [46].", [["tissues", "ANATOMY", 53, 60], ["iron", "CHEMICAL", 22, 26], ["iron", "CHEMICAL", 125, 129], ["viral infections", "DISEASE", 242, 258], ["iron", "CHEMICAL", 22, 26], ["iron", "CHEMICAL", 125, 129], ["iron", "SIMPLE_CHEMICAL", 22, 26], ["tissues", "TISSUE", 53, 60], ["iron", "SIMPLE_CHEMICAL", 125, 129], ["LF", "GENE_OR_GENE_PRODUCT", 292, 294], ["SARS-CoV", "ORGANISM", 337, 345], ["patients", "ORGANISM", 346, 354], ["LF", "PROTEIN", 292, 294], ["patients", "SPECIES", 346, 354], ["SARS-CoV", "SPECIES", 337, 345], ["iron sequestration", "PROBLEM", 22, 40], ["infected tissues", "PROBLEM", 44, 60], ["pathogenic bacteria", "PROBLEM", 133, 152], ["viral infections", "PROBLEM", 242, 258], ["genes encoding LF", "PROBLEM", 277, 294], ["elevated", "PROBLEM", 299, 307], ["SARS", "PROBLEM", 337, 341], ["iron sequestration", "OBSERVATION", 22, 40], ["infected tissues", "OBSERVATION", 44, 60], ["typically", "OBSERVATION_MODIFIER", 77, 86], ["acidic", "OBSERVATION_MODIFIER", 87, 93]]], ["LF possesses strong antiviral activity against a broad spectrum of RNA and DNA viruses, such as HIV, Zika virus, Chikungunya, hepatitis C virus, cytomegalovirus, rotavirus, among others [47, 48, 49, 50, 51, 52, 53, 54].LACTOFERRIN ::: RESULTSThe antiviral activity of LF takes place particularly when the virus attacks the host cell, since LF prevents the virus from anchoring and then entering the host cell [56].", [["cell", "ANATOMY", 328, 332], ["cell", "ANATOMY", 404, 408], ["HIV, Zika virus", "DISEASE", 96, 111], ["Chikungunya, hepatitis C virus", "DISEASE", 113, 143], ["cytomegalovirus", "DISEASE", 145, 160], ["rotavirus", "DISEASE", 162, 171], ["DNA", "CELLULAR_COMPONENT", 75, 78], ["HIV", "ORGANISM", 96, 99], ["Zika virus", "ORGANISM", 101, 111], ["Chikungunya,", "ORGANISM", 113, 125], ["hepatitis C virus", "ORGANISM", 126, 143], ["cytomegalovirus", "ORGANISM", 145, 160], ["host cell", "CELL", 323, 332], ["cell", "CELL", 404, 408], ["LF", "PROTEIN", 268, 270], ["LF", "PROTEIN", 340, 342], ["HIV", "SPECIES", 96, 99], ["Zika virus", "SPECIES", 101, 111], ["Chikungunya", "SPECIES", 113, 124], ["hepatitis C virus", "SPECIES", 126, 143], ["HIV", "SPECIES", 96, 99], ["Zika virus", "SPECIES", 101, 111], ["hepatitis C virus", "SPECIES", 126, 143], ["a broad spectrum of RNA", "PROBLEM", 47, 70], ["DNA viruses", "PROBLEM", 75, 86], ["HIV", "PROBLEM", 96, 99], ["Zika virus", "PROBLEM", 101, 111], ["Chikungunya", "PROBLEM", 113, 124], ["hepatitis C virus", "PROBLEM", 126, 143], ["cytomegalovirus", "PROBLEM", 145, 160], ["rotavirus", "PROBLEM", 162, 171], ["LACTOFERRIN", "TREATMENT", 219, 230], ["RESULTSThe antiviral activity of LF", "TREATMENT", 235, 270], ["the virus attacks the host cell", "PROBLEM", 301, 332], ["the virus", "PROBLEM", 352, 361], ["strong", "OBSERVATION_MODIFIER", 13, 19], ["antiviral activity", "OBSERVATION", 20, 38], ["host cell", "OBSERVATION", 323, 332], ["virus", "OBSERVATION", 356, 361], ["host cell", "OBSERVATION", 399, 408]]], ["It has been reported that LF binds to heparan sulfate proteoglycans (HSPGs), which are cell-surface and extracellular matrix macromolecules that are composed of a core protein decorated with covalently linked glycosaminoglycan chains [45].", [["cell", "ANATOMY", 87, 91], ["surface", "ANATOMY", 92, 99], ["extracellular matrix macromolecules", "ANATOMY", 104, 139], ["heparan sulfate", "CHEMICAL", 38, 53], ["heparan sulfate proteoglycans", "GENE_OR_GENE_PRODUCT", 38, 67], ["HSPGs", "GENE_OR_GENE_PRODUCT", 69, 74], ["cell-surface", "CELLULAR_COMPONENT", 87, 99], ["extracellular", "CELLULAR_COMPONENT", 104, 117], ["matrix macromolecules", "CELLULAR_COMPONENT", 118, 139], ["glycosaminoglycan", "SIMPLE_CHEMICAL", 209, 226], ["LF", "PROTEIN", 26, 28], ["heparan sulfate proteoglycans", "PROTEIN", 38, 67], ["HSPGs", "PROTEIN", 69, 74], ["core protein", "PROTEIN", 163, 175], ["heparan sulfate proteoglycans (HSPGs", "TREATMENT", 38, 74], ["extracellular matrix macromolecules", "TREATMENT", 104, 139], ["a core protein decorated with covalently linked glycosaminoglycan chains", "TREATMENT", 161, 233]]], ["HSPGs could be the preliminary docking sites on the host cell membrane and play an important role in the process of entry of SARS-CoV into the cell [56].", [["cell membrane", "ANATOMY", 57, 70], ["cell", "ANATOMY", 143, 147], ["SARS", "DISEASE", 125, 129], ["HSPGs", "GENE_OR_GENE_PRODUCT", 0, 5], ["cell membrane", "CELLULAR_COMPONENT", 57, 70], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 125, 133], ["cell", "CELL", 143, 147], ["HSPGs", "PROTEIN", 0, 5], ["SARS-CoV", "PROTEIN", 125, 133], ["SARS-CoV", "SPECIES", 125, 133], ["host cell membrane", "OBSERVATION", 52, 70]]], ["As shown in figure 3, LF blocks the infection of SARS-CoV by competing with the virus for HSPGs [56].", [["infection", "DISEASE", 36, 45], ["SARS", "DISEASE", 49, 53], ["SARS-CoV", "ORGANISM", 49, 57], ["HSPGs", "GENE_OR_GENE_PRODUCT", 90, 95], ["LF", "PROTEIN", 22, 24], ["HSPGs", "PROTEIN", 90, 95], ["SARS-CoV", "SPECIES", 49, 57], ["LF blocks the infection of SARS", "PROBLEM", 22, 53], ["CoV", "PROBLEM", 54, 57], ["infection", "OBSERVATION", 36, 45]]], ["This mechanism could prevent the viral concentration on the cell surface, as well as to the specific entry receptors (ACE2).", [["cell surface", "ANATOMY", 60, 72], ["cell surface", "CELLULAR_COMPONENT", 60, 72], ["ACE2", "GENE_OR_GENE_PRODUCT", 118, 122], ["entry receptors", "PROTEIN", 101, 116], ["ACE2", "PROTEIN", 118, 122], ["the viral concentration", "PROBLEM", 29, 52], ["viral concentration", "OBSERVATION", 33, 52], ["cell surface", "OBSERVATION_MODIFIER", 60, 72]]], ["It is not presently known whether LF binds to ACE2 [56].", [["ACE2", "GENE_OR_GENE_PRODUCT", 46, 50], ["LF", "PROTEIN", 34, 36], ["ACE2", "PROTEIN", 46, 50]]], ["It is likely that LF can inhibit SARS-CoV-2 invasion at micromolar concentrations and in a dose dependent fashion, just as for SARS-CoV [56].", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 127, 135], ["SARS-CoV", "SPECIES", 127, 135], ["SARS", "PROBLEM", 33, 37], ["CoV", "PROBLEM", 38, 41], ["invasion at micromolar concentrations", "TREATMENT", 44, 81], ["a dose dependent fashion", "TREATMENT", 89, 113], ["SARS", "PROBLEM", 127, 131], ["is likely", "UNCERTAINTY", 3, 12]]], ["However, there is no current confirmed information that SARS-CoV-2 binds to HSPGs.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 56, 66], ["HSPGs", "GENE_OR_GENE_PRODUCT", 76, 81], ["HSPGs", "PROTEIN", 76, 81], ["no", "UNCERTAINTY", 18, 20]]], ["Whether SARS-CoV-2 also enters host cells via HPSGs in the same way clearly warrants further investigation.LACTOFERRIN ::: RESULTSLF is available as an oral supplement and is widely used as a nutritional additive for infants at doses ranging from 100 mg to 4.5g a day for various indications without apparent toxicities [55].", [["cells", "ANATOMY", 36, 41], ["oral", "ANATOMY", 152, 156], ["SARS", "DISEASE", 8, 12], ["toxicities", "DISEASE", 309, 319], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 8, 18], ["host cells", "CELL", 31, 41], ["HPSGs", "GENE_OR_GENE_PRODUCT", 46, 51], ["oral", "ORGANISM_SUBDIVISION", 152, 156], ["infants", "ORGANISM", 217, 224], ["host cells", "CELL_TYPE", 31, 41], ["infants", "SPECIES", 217, 224], ["SARS", "PROBLEM", 8, 12], ["CoV", "TEST", 13, 16], ["HPSGs", "TEST", 46, 51], ["further investigation", "TEST", 85, 106], ["an oral supplement", "TREATMENT", 149, 167], ["a nutritional additive", "TREATMENT", 190, 212], ["apparent toxicities", "PROBLEM", 300, 319], ["host cells", "OBSERVATION", 31, 41]]], ["There is a list of 24 commercial products available by the American corporation Amazon.LACTOFERRIN ::: RESULTSA randomized, open-label, parallel-group clinical trial was conducted to examine the effectiveness of sucking tablets containing LF and LPO (LF+LPO) in alleviating symptoms of the common cold and/or influenza infection.", [["influenza infection", "DISEASE", 309, 328], ["LF", "SIMPLE_CHEMICAL", 239, 241], ["LPO", "SIMPLE_CHEMICAL", 246, 249], ["LPO", "SIMPLE_CHEMICAL", 254, 257], ["sucking tablets", "TREATMENT", 212, 227], ["alleviating symptoms", "PROBLEM", 262, 282], ["the common cold", "PROBLEM", 286, 301], ["influenza infection", "PROBLEM", 309, 328], ["common cold", "ANATOMY", 290, 301], ["infection", "OBSERVATION", 319, 328]]], ["Treatment and non-treatment groups (overall 407 subjects) were further classified into subgroups habitually wearing a face mask, washing their hands, or gargling [58].", [["face", "ANATOMY", 118, 122], ["Treatment and non-treatment groups", "TREATMENT", 0, 34], ["a face mask", "TREATMENT", 116, 127]]], ["The incidence and duration of common cold, influenza infection and gastrointestinal symptoms were not statistically different between treatment and non-treatment groups.", [["gastrointestinal", "ANATOMY", 67, 83], ["influenza infection", "DISEASE", 43, 62], ["gastrointestinal symptoms", "DISEASE", 67, 92], ["gastrointestinal", "ORGAN", 67, 83], ["common cold", "PROBLEM", 30, 41], ["influenza infection", "PROBLEM", 43, 62], ["gastrointestinal symptoms", "PROBLEM", 67, 92], ["treatment and non-treatment groups", "TREATMENT", 134, 168], ["influenza", "OBSERVATION_MODIFIER", 43, 52], ["infection", "OBSERVATION", 53, 62], ["gastrointestinal", "ANATOMY", 67, 83]]], ["(LF+LPO) tablets were moderately effective in significantly reducing the duration of fever higher than 38\u00b0C in the subgroup that did not wear a protective face mask [58].LACTOFERRIN ::: RESULTSLF in its free form is degraded within the stomach by the action of hydrochloric acid and hydrolytic enzymes.", [["stomach", "ANATOMY", 236, 243], ["fever", "DISEASE", 85, 90], ["hydrochloric acid", "CHEMICAL", 261, 278], ["hydrochloric acid", "CHEMICAL", 261, 278], ["LF+LPO", "SIMPLE_CHEMICAL", 1, 7], ["stomach", "ORGAN", 236, 243], ["hydrochloric acid", "SIMPLE_CHEMICAL", 261, 278], ["hydrolytic enzymes", "PROTEIN", 283, 301], ["(LF+LPO) tablets", "TREATMENT", 0, 16], ["fever", "PROBLEM", 85, 90], ["a protective face mask", "TREATMENT", 142, 164], ["LACTOFERRIN", "TREATMENT", 170, 181], ["hydrochloric acid", "TREATMENT", 261, 278], ["hydrolytic enzymes", "TEST", 283, 301], ["stomach", "ANATOMY", 236, 243]]], ["Newer formulations of LF including encapsulation and liposomalization have been explored.", [["encapsulation", "TREATMENT", 35, 48], ["liposomalization", "TREATMENT", 53, 69]]], ["Another interesting observation is that zinc saturated lactoferrin can apparently exert a more potent antiviral effect.", [["zinc", "CHEMICAL", 40, 44], ["zinc", "CHEMICAL", 40, 44], ["zinc", "SIMPLE_CHEMICAL", 40, 44], ["lactoferrin", "GENE_OR_GENE_PRODUCT", 55, 66], ["zinc saturated lactoferrin", "TREATMENT", 40, 66], ["more potent", "OBSERVATION_MODIFIER", 90, 101], ["antiviral effect", "OBSERVATION", 102, 118]]], ["This is of particular relevance in COVID-19 as zinc supplementation has been proposed as a possible intervention for the disease [58].", [["COVID-19", "CHEMICAL", 35, 43], ["zinc", "CHEMICAL", 47, 51], ["COVID-19", "CHEMICAL", 35, 43], ["zinc", "CHEMICAL", 47, 51], ["zinc", "SIMPLE_CHEMICAL", 47, 51], ["COVID", "TEST", 35, 40], ["zinc supplementation", "TREATMENT", 47, 67], ["the disease", "PROBLEM", 117, 128]]], ["An oral supplement combining a liposomal bovine lactoferrin (LLF) syrup (32 mg of LF/10 ml plus 12 mg of ascorbic acid) and a Zinc solution 10 mg/10 ml 2-3 times a day and 4-6 times/day was administered for 10 days to 75 symptomatic COVID-19 patients tested positive for IgM/IgG rapid test and self-isolated at home.", [["oral", "ANATOMY", 3, 7], ["ascorbic acid", "CHEMICAL", 105, 118], ["Zinc", "CHEMICAL", 126, 130], ["ascorbic acid", "CHEMICAL", 105, 118], ["Zinc", "CHEMICAL", 126, 130], ["oral", "ORGANISM_SUBDIVISION", 3, 7], ["bovine", "ORGANISM", 41, 47], ["lactoferrin", "GENE_OR_GENE_PRODUCT", 48, 59], ["ascorbic acid", "SIMPLE_CHEMICAL", 105, 118], ["Zinc", "SIMPLE_CHEMICAL", 126, 130], ["patients", "ORGANISM", 242, 250], ["IgM", "GENE_OR_GENE_PRODUCT", 271, 274], ["IgG", "GENE_OR_GENE_PRODUCT", 275, 278], ["IgM", "PROTEIN", 271, 274], ["IgG", "PROTEIN", 275, 278], ["bovine", "SPECIES", 41, 47], ["patients", "SPECIES", 242, 250], ["An oral supplement", "TREATMENT", 0, 18], ["a liposomal bovine lactoferrin (LLF) syrup", "TREATMENT", 29, 71], ["ascorbic acid)", "TREATMENT", 105, 119], ["a Zinc solution", "TREATMENT", 124, 139], ["symptomatic COVID", "TEST", 221, 238], ["IgM", "TEST", 271, 274], ["IgG rapid test", "TEST", 275, 289]]], ["All patients, who were followed up for one month, resolved their symptoms within 4-5- days since treatment inception and a half dose of LLF on 256 household contacts was effective to prevent the infection [48].", [["LLF", "CHEMICAL", 136, 139], ["infection", "DISEASE", 195, 204], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["their symptoms", "PROBLEM", 59, 73], ["treatment", "TREATMENT", 97, 106], ["the infection", "PROBLEM", 191, 204], ["infection", "OBSERVATION", 195, 204]]], ["Last but not least, out of seven authors, six worked for Sesderma Laboratories, the producer of all treatments used in the trial [48].LACTOFERRIN ::: RESULTSAs mentioned above, LF, alone or in combination with OSCN\u2212, is already being tested in a phase 1 clinical trial (RCT02598999) on healthy volunteers and patients affected by cystic fibrosis [23,25].N-CHLOROTAURINE ::: RESULTSN-chlorotaurine (NCT) is a natural oxidant part of the human defense system which is produced in the body (HOCl + taurine \u2192 NCT + H2O) by the strongly toxic hypochlorous acid and the amino-acid taurine [59].", [["cystic", "ANATOMY", 330, 336], ["body", "ANATOMY", 482, 486], ["OSCN\u2212", "CHEMICAL", 210, 215], ["cystic fibrosis", "DISEASE", 330, 345], ["RESULTSN-chlorotaurine", "CHEMICAL", 374, 396], ["NCT", "CHEMICAL", 398, 401], ["HOCl", "CHEMICAL", 488, 492], ["taurine", "CHEMICAL", 495, 502], ["H2O", "CHEMICAL", 511, 514], ["hypochlorous acid", "CHEMICAL", 538, 555], ["amino-acid", "CHEMICAL", 564, 574], ["taurine", "CHEMICAL", 575, 582], ["RESULTSN-chlorotaurine", "CHEMICAL", 374, 396], ["NCT", "CHEMICAL", 398, 401], ["HOCl", "CHEMICAL", 488, 492], ["taurine", "CHEMICAL", 495, 502], ["NCT", "CHEMICAL", 505, 508], ["H2O", "CHEMICAL", 511, 514], ["hypochlorous acid", "CHEMICAL", 538, 555], ["amino-acid taurine", "CHEMICAL", 564, 582], ["OSCN\u2212", "SIMPLE_CHEMICAL", 210, 215], ["volunteers", "ORGANISM", 294, 304], ["patients", "ORGANISM", 309, 317], ["RESULTSN-chlorotaurine", "SIMPLE_CHEMICAL", 374, 396], ["NCT", "SIMPLE_CHEMICAL", 398, 401], ["human", "ORGANISM", 436, 441], ["body", "ORGANISM_SUBDIVISION", 482, 486], ["HOCl", "SIMPLE_CHEMICAL", 488, 492], ["taurine", "SIMPLE_CHEMICAL", 495, 502], ["NCT + H2O", "SIMPLE_CHEMICAL", 505, 514], ["hypochlorous acid", "SIMPLE_CHEMICAL", 538, 555], ["amino-acid taurine", "SIMPLE_CHEMICAL", 564, 582], ["patients", "SPECIES", 309, 317], ["human", "SPECIES", 436, 441], ["human", "SPECIES", 436, 441], ["all treatments", "TREATMENT", 96, 110], ["LACTOFERRIN", "TREATMENT", 134, 145], ["cystic fibrosis", "PROBLEM", 330, 345], ["N-CHLOROTAURINE", "TREATMENT", 354, 369], ["RESULTSN-chlorotaurine (NCT)", "TREATMENT", 374, 402], ["a natural oxidant", "TREATMENT", 406, 423], ["the human defense system", "TREATMENT", 432, 456], ["taurine \u2192 NCT + H2O)", "TREATMENT", 495, 515], ["the strongly toxic hypochlorous acid", "TREATMENT", 519, 555], ["the amino-acid taurine", "TREATMENT", 560, 582], ["cystic", "OBSERVATION_MODIFIER", 330, 336], ["fibrosis", "OBSERVATION", 337, 345], ["body", "ANATOMY", 482, 486]]], ["Recently NCT was obtained by synthesis and large quantities were available.", [["NCT", "GENE_OR_GENE_PRODUCT", 9, 12], ["NCT", "PROTEIN", 9, 12], ["Recently NCT", "TEST", 0, 12]]], ["This compound revealed an optimal compromise between sufficient disinfecting power and good tissue tolerability.", [["tissue", "ANATOMY", 92, 98], ["tissue", "TISSUE", 92, 98], ["This compound", "PROBLEM", 0, 13], ["an optimal compromise", "PROBLEM", 23, 44], ["optimal", "OBSERVATION_MODIFIER", 26, 33], ["compromise", "OBSERVATION", 34, 44], ["good tissue tolerability", "OBSERVATION", 87, 111]]], ["NCT can be stored long-term at low temperatures, and has killing activity against bacteria, fungi, parasites and viruses (Herpes simplex virus type 1; Herpes simplex virus type 2; Adenovirus; Influenza virus A and HIV-1).", [["Herpes simplex virus", "DISEASE", 122, 142], ["Herpes simplex virus", "DISEASE", 151, 171], ["Influenza virus A", "DISEASE", 192, 209], ["NCT", "SIMPLE_CHEMICAL", 0, 3], ["Herpes simplex virus type 1", "ORGANISM", 122, 149], ["Herpes simplex virus type 2", "ORGANISM", 151, 178], ["Adenovirus;", "ORGANISM", 180, 191], ["Influenza virus A", "ORGANISM", 192, 209], ["HIV-1", "ORGANISM", 214, 219], ["Herpes simplex virus", "SPECIES", 122, 142], ["type 1", "SPECIES", 143, 149], ["Herpes simplex virus", "SPECIES", 151, 171], ["Influenza virus", "SPECIES", 192, 207], ["HIV-1", "SPECIES", 214, 219], ["Herpes simplex virus type 1", "SPECIES", 122, 149], ["Herpes simplex virus type 2", "SPECIES", 151, 178], ["Influenza virus A", "SPECIES", 192, 209], ["HIV-1", "SPECIES", 214, 219], ["low temperatures", "PROBLEM", 31, 47], ["bacteria", "PROBLEM", 82, 90], ["fungi", "PROBLEM", 92, 97], ["parasites", "PROBLEM", 99, 108], ["viruses", "TEST", 113, 120], ["Herpes simplex virus type", "TEST", 122, 147], ["Herpes simplex virus type", "TEST", 151, 176], ["Adenovirus", "PROBLEM", 180, 190], ["Influenza virus A", "PROBLEM", 192, 209]]], ["NCT can be applied to sensitive body regions as an endogenous antiseptic.", [["body", "ANATOMY", 32, 36], ["NCT", "SIMPLE_CHEMICAL", 0, 3], ["body", "ORGANISM_SUBDIVISION", 32, 36], ["NCT", "PROTEIN", 0, 3], ["NCT", "TREATMENT", 0, 3], ["an endogenous antiseptic", "TREATMENT", 48, 72], ["endogenous antiseptic", "OBSERVATION", 51, 72]]], ["Tolerability was very good in the eye, skin, mucous membranes and paranasal sinuses.", [["eye", "ANATOMY", 34, 37], ["skin", "ANATOMY", 39, 43], ["mucous membranes", "ANATOMY", 45, 61], ["paranasal sinuses", "ANATOMY", 66, 83], ["eye", "ORGAN", 34, 37], ["skin", "ORGAN", 39, 43], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 45, 61], ["paranasal sinuses", "MULTI-TISSUE_STRUCTURE", 66, 83], ["good", "OBSERVATION", 22, 26], ["eye", "ANATOMY", 34, 37], ["skin", "ANATOMY", 39, 43], ["mucous membranes", "ANATOMY", 45, 61], ["paranasal sinuses", "ANATOMY", 66, 83]]], ["The ciliary beat frequency of epithelial cells of the nasal mucosa, a very sensitive parameter for toxicity, was decreased only moderately and reversibly by 1% NCT [60].", [["ciliary", "ANATOMY", 4, 11], ["epithelial cells", "ANATOMY", 30, 46], ["nasal mucosa", "ANATOMY", 54, 66], ["toxicity", "DISEASE", 99, 107], ["epithelial cells", "CELL", 30, 46], ["nasal mucosa", "MULTI-TISSUE_STRUCTURE", 54, 66], ["epithelial cells", "CELL_TYPE", 30, 46], ["epithelial cells of the nasal mucosa", "PROBLEM", 30, 66], ["toxicity", "PROBLEM", 99, 107], ["ciliary beat", "OBSERVATION", 4, 16], ["epithelial cells", "OBSERVATION", 30, 46], ["nasal mucosa", "ANATOMY", 54, 66], ["very", "OBSERVATION_MODIFIER", 70, 74], ["sensitive", "OBSERVATION", 75, 84]]], ["A special field of application of NCT is inhalation for treatment of various infections.", [["infections", "DISEASE", 77, 87], ["NCT", "SIMPLE_CHEMICAL", 34, 37], ["NCT is inhalation", "TREATMENT", 34, 51], ["treatment", "TREATMENT", 56, 65], ["various infections", "PROBLEM", 69, 87], ["various", "OBSERVATION_MODIFIER", 69, 76], ["infections", "OBSERVATION", 77, 87]]], ["A phase I double-blind randomized clinical study with test group (inhalation of 1% NCT) and a parallel control group (0.9% NaCl as placebo) was carried out in two Austrian centers.", [["NaCl", "CHEMICAL", 123, 127], ["NaCl", "CHEMICAL", 123, 127], ["blind randomized clinical study", "TEST", 17, 48], ["test group (inhalation", "TREATMENT", 54, 76], ["1% NCT", "TREATMENT", 80, 86], ["a parallel control group (0.9% NaCl as placebo", "TREATMENT", 92, 138]]], ["The forced expiratory volume in the first second (FEV1), was not reduced and blood analyses showed no abnormalities compared to the baseline and compared to the control arm [60].", [["blood", "ANATOMY", 77, 82], ["blood", "ORGANISM_SUBSTANCE", 77, 82], ["The forced expiratory volume", "TEST", 0, 28], ["blood analyses", "TEST", 77, 91], ["abnormalities", "PROBLEM", 102, 115], ["forced", "OBSERVATION_MODIFIER", 4, 10], ["expiratory volume", "OBSERVATION", 11, 28]]], ["Overall, there is no evidence of efficacy of NCT to clear the nasopharynx from SARS-CoV-2.INTERFERON-alpha ::: RESULTSThe interferon, discovered by virologists in 1957, is part of the human anti-viral innate defenses and plays a critical role in anti-viral immunity, interfering with the viral replication and spread with different mechanisms, including inhibition of the cell metabolism and downregulating the secretion of cytokines which stimulate the adaptive immunity [61].", [["nasopharynx", "ANATOMY", 62, 73], ["cell", "ANATOMY", 372, 376], ["SARS", "DISEASE", 79, 83], ["NCT", "SIMPLE_CHEMICAL", 45, 48], ["nasopharynx", "ORGAN", 62, 73], ["interferon", "GENE_OR_GENE_PRODUCT", 122, 132], ["human", "ORGANISM", 184, 189], ["cell", "CELL", 372, 376], ["interferon", "PROTEIN", 122, 132], ["cytokines", "PROTEIN", 424, 433], ["human", "SPECIES", 184, 189], ["SARS-CoV", "SPECIES", 79, 87], ["human", "SPECIES", 184, 189], ["NCT", "PROBLEM", 45, 48], ["anti-viral immunity", "TREATMENT", 246, 265], ["the viral replication", "TREATMENT", 284, 305], ["the cell metabolism", "TREATMENT", 368, 387], ["downregulating the secretion of cytokines", "TREATMENT", 392, 433], ["no evidence of", "UNCERTAINTY", 18, 32], ["nasopharynx", "ANATOMY", 62, 73], ["SARS", "OBSERVATION", 79, 83]]], ["An in vitro test confirmed the efficacy of IFN-\u03b1 against SARS-like coronavirus infections [62].", [["IFN-\u03b1", "CHEMICAL", 43, 48], ["SARS-like coronavirus infections", "DISEASE", 57, 89], ["IFN-\u03b1", "SIMPLE_CHEMICAL", 43, 48], ["SARS-like coronavirus", "ORGANISM", 57, 78], ["IFN", "PROTEIN", 43, 46], ["An in vitro test", "TEST", 0, 16], ["IFN", "TEST", 43, 46], ["SARS", "PROBLEM", 57, 61], ["coronavirus infections", "PROBLEM", 67, 89]]], ["Animal tests have confirmed that IFN-\u03b1 nasal spray can effectively block or reduce SARS-CoV infection-related damage in monkeys [63,64].INTERFERON-alpha ::: RESULTSSARS-CoV-2 can inhibit the endogenous secretion of IFN by host cells, thus in turn reducing their ability to suppress viral infections.", [["nasal", "ANATOMY", 39, 44], ["cells", "ANATOMY", 227, 232], ["IFN", "CHEMICAL", 33, 36], ["SARS-CoV infection", "DISEASE", 83, 101], ["viral infections", "DISEASE", 282, 298], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 33, 38], ["SARS-CoV", "ORGANISM", 83, 91], ["monkeys", "ORGANISM", 120, 127], ["RESULTSSARS-CoV-2", "GENE_OR_GENE_PRODUCT", 157, 174], ["IFN", "GENE_OR_GENE_PRODUCT", 215, 218], ["host cells", "CELL", 222, 232], ["IFN", "PROTEIN", 33, 36], ["IFN", "PROTEIN", 215, 218], ["host cells", "CELL_TYPE", 222, 232], ["SARS-CoV", "SPECIES", 83, 91], ["Animal tests", "TEST", 0, 12], ["IFN", "TREATMENT", 33, 36], ["nasal spray", "TREATMENT", 39, 50], ["SARS", "PROBLEM", 83, 87], ["CoV infection", "PROBLEM", 88, 101], ["damage in monkeys", "PROBLEM", 110, 127], ["INTERFERON", "TEST", 136, 146], ["alpha", "TEST", 147, 152], ["RESULTSSARS", "TEST", 157, 168], ["CoV", "TEST", 169, 172], ["the endogenous secretion of IFN", "PROBLEM", 187, 218], ["host cells", "PROBLEM", 222, 232], ["viral infections", "PROBLEM", 282, 298], ["infections", "OBSERVATION", 288, 298]]], ["Therefore, the use of exogenous IFN is critical with the severe form of COVID-19 [65].", [["COVID-19", "CHEMICAL", 72, 80], ["IFN", "GENE_OR_GENE_PRODUCT", 32, 35], ["IFN", "PROTEIN", 32, 35], ["exogenous IFN", "TREATMENT", 22, 35], ["COVID", "TEST", 72, 77]]], ["A recent open-label prospective study tested nasal drops of recombinant human interferon alpha (rhIFN-\u03b1) on 2,944 health care workers in China during SARS-CoV-2 epidemics as follows [66]:\u20222,415 subjects (997 doctors and 1,418 nurses with average ages of 37.38 and 33.56 years respectively) included in a \u201clow-risk group\u201d were administered 2-3 drops/nostril/time of rhIFN-\u03b1, 4 times/day for 28 days.\u2022529 subjects (122 doctors and 407 nurses with average ages of 35.24 and 32.16 years respectively) were included in a \u201chigh-risk group\u201d and administered 2-3 drops/nostril/time of rhIFN-\u03b1, 4 times/day for 28 days, in addition to thymosin-\u03b1 11.6 mg hypodermic injection once a week.", [["nasal", "ANATOMY", 45, 50], ["rhIFN-\u03b1", "CHEMICAL", 96, 103], ["SARS-CoV-2 epidemics", "DISEASE", 150, 170], ["rhIFN-\u03b1", "CHEMICAL", 365, 372], ["rhIFN-\u03b1", "CHEMICAL", 577, 584], ["thymosin-\u03b1", "CHEMICAL", 626, 636], ["nasal", "ORGANISM_SUBDIVISION", 45, 50], ["human", "ORGANISM", 72, 77], ["interferon alpha", "GENE_OR_GENE_PRODUCT", 78, 94], ["rhIFN-\u03b1", "SIMPLE_CHEMICAL", 96, 103], ["subjects", "ORGANISM", 194, 202], ["rhIFN-\u03b1", "SIMPLE_CHEMICAL", 365, 372], ["rhIFN-\u03b1", "SIMPLE_CHEMICAL", 577, 584], ["thymosin-\u03b1", "SIMPLE_CHEMICAL", 626, 636], ["recombinant human interferon alpha", "PROTEIN", 60, 94], ["rhIFN-\u03b1", "PROTEIN", 96, 103], ["rhIFN", "PROTEIN", 365, 370], ["human", "SPECIES", 72, 77], ["human", "SPECIES", 72, 77], ["SARS-CoV", "SPECIES", 150, 158], ["label prospective study", "TEST", 14, 37], ["nasal drops", "TREATMENT", 45, 56], ["recombinant human interferon alpha", "TREATMENT", 60, 94], ["a \u201clow-risk group\u201d", "TREATMENT", 302, 320], ["rhIFN", "TREATMENT", 365, 370], ["rhIFN", "TREATMENT", 577, 582], ["thymosin", "TREATMENT", 626, 634], ["nasal", "ANATOMY", 45, 50]]]], "4f83f4d99a6f16380d33bf4dd8d8952d859397ae": [["Maternal and infant morbidity and mortality are obvious consequences of many intrapartum and peripartum infections, but even infections that produce few observable maternal symptoms can dramatically affect fetal intra-uterine growth and development.", [["fetal intra-uterine", "ANATOMY", 206, 225], ["peripartum infections", "DISEASE", 93, 114], ["infections", "DISEASE", 125, 135], ["fetal intra-uterine", "MULTI-TISSUE_STRUCTURE", 206, 225], ["infant", "SPECIES", 13, 19], ["Maternal and infant morbidity", "PROBLEM", 0, 29], ["obvious consequences", "PROBLEM", 48, 68], ["many intrapartum and peripartum infections", "PROBLEM", 72, 114], ["even infections", "PROBLEM", 120, 135], ["few observable maternal symptoms", "PROBLEM", 149, 181], ["fetal intra-uterine growth", "PROBLEM", 206, 232], ["morbidity", "OBSERVATION", 20, 29], ["infections", "OBSERVATION", 104, 114]]]], "PMC7267325": [["AcknowledgementsThe patient in this manuscript has given written informed consent to the publication of their case details.Funding sourcesNone reported.", [["patient", "ORGANISM", 20, 27], ["patient", "SPECIES", 20, 27]]]], "21b8b82cdba8a71fabe15ecfb856547258d41f22": [["Letter: Epidemiological variations in neuro-oncological patients' presentation during the Coronavirus 1 crisis in the Clinical Department of Neurosurgery of Ancona 2 3", [["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64]]]], "8d9944bec81f21703b870f91be857b941872a508": [["Cytomegalovirus; Glycoprotein complex; Inhibitor, glycoprotein processing enzyme; Castanospermine; Deoxynojirimycin Introduction A number of viral glycoproteins with a range from 52 to 250 kDa are synthesized in cytomegalovirus (CMV) infected cells and are major components of the outer envelope (Stinski, 1976 (Stinski, , 1977 Farrar and Oram, 1984) .", [["cells", "ANATOMY", 243, 248], ["outer envelope", "ANATOMY", 281, 295], ["Castanospermine", "CHEMICAL", 82, 97], ["Deoxynojirimycin", "CHEMICAL", 99, 115], ["cytomegalovirus (CMV) infected", "DISEASE", 212, 242], ["Castanospermine", "CHEMICAL", 82, 97], ["Deoxynojirimycin", "CHEMICAL", 99, 115], ["Cytomegalovirus", "ORGANISM", 0, 15], ["Glycoprotein complex", "GENE_OR_GENE_PRODUCT", 17, 37], ["Castanospermine", "SIMPLE_CHEMICAL", 82, 97], ["Deoxynojirimycin", "SIMPLE_CHEMICAL", 99, 115], ["cytomegalovirus", "ORGANISM", 212, 227], ["CMV", "ORGANISM", 229, 232], ["cells", "CELL", 243, 248], ["Glycoprotein complex", "PROTEIN", 17, 37], ["glycoprotein processing enzyme", "PROTEIN", 50, 80], ["viral glycoproteins", "PROTEIN", 141, 160], ["cytomegalovirus (CMV) infected cells", "CELL_TYPE", 212, 248], ["CMV", "SPECIES", 229, 232], ["Cytomegalovirus", "PROBLEM", 0, 15], ["Glycoprotein complex", "TREATMENT", 17, 37], ["Inhibitor", "TREATMENT", 39, 48], ["glycoprotein processing enzyme", "TREATMENT", 50, 80], ["Castanospermine", "TREATMENT", 82, 97], ["Deoxynojirimycin", "TREATMENT", 99, 115], ["viral glycoproteins", "TREATMENT", 141, 160], ["cytomegalovirus (CMV) infected cells", "PROBLEM", 212, 248], ["cytomegalovirus", "OBSERVATION", 212, 227], ["infected cells", "OBSERVATION", 234, 248]]], ["The envelope glycoproteins of CMV are considered to be important in virus infectivity and are known to induce the production of antibodies that neutralise the virus in vitro (Pereira et al., 1982; Britt, 1984; Rasmussen et al., 1985) .", [["CMV", "ORGANISM", 30, 33], ["envelope glycoproteins", "PROTEIN", 4, 26], ["antibodies", "PROTEIN", 128, 138], ["CMV", "SPECIES", 30, 33], ["The envelope glycoproteins", "TREATMENT", 0, 26], ["CMV", "PROBLEM", 30, 33], ["virus infectivity", "PROBLEM", 68, 85], ["the production of antibodies", "PROBLEM", 110, 138], ["envelope", "OBSERVATION_MODIFIER", 4, 12], ["glycoproteins", "OBSERVATION_MODIFIER", 13, 26], ["CMV", "OBSERVATION", 30, 33]]], ["Distinct families of glycoprotein complexes expressed on the virion envelope have been separated by ionexchange chromatography (Kari et al., 1986) and recently designated gcI, gcII and gclII with gcI comprising a major component (Gretch et al., 1988a) .", [["gcI", "GENE_OR_GENE_PRODUCT", 171, 174], ["gcII", "GENE_OR_GENE_PRODUCT", 176, 180], ["gclII", "GENE_OR_GENE_PRODUCT", 185, 190], ["glycoprotein complexes", "PROTEIN", 21, 43], ["gcI", "PROTEIN", 171, 174], ["gcII", "PROTEIN", 176, 180], ["gclII", "PROTEIN", 185, 190], ["gcI", "PROTEIN", 196, 199], ["glycoprotein complexes", "PROBLEM", 21, 43], ["the virion envelope", "TREATMENT", 57, 76], ["glycoprotein complexes", "OBSERVATION_MODIFIER", 21, 43]]], ["Under reducing conditions, SDS-PAGE analysis showed the gcI family consisted of glycoproteins of 50--55, 93-95 and 130 kDa, respectively (Kari et al., 1986; Farrar and Greenaway, 1986; Gretch et al., 1988a,b) .", [["SDS", "CHEMICAL", 27, 30], ["gcI", "GENE_OR_GENE_PRODUCT", 56, 59], ["gcI family", "PROTEIN", 56, 66], ["glycoproteins", "PROTEIN", 80, 93], ["SDS", "TEST", 27, 30], ["PAGE analysis", "TEST", 31, 44], ["glycoproteins", "TEST", 80, 93]]], ["In one of these studies (Farrar and Greenaway, 1986) , immunoprecipitation of purified CMV envelope glycoproteins using a monoclonal antibody with specificity for a 52 kDa glycoprotein (Law et al., 1985) revealed three disulphide cross-bridged complexes of 150 kDa (52 kDa + 95 kDa), 180 kDa (52 kDa + 130 kDa) and 250 kDa, a possible multimeric form.", [["disulphide", "CHEMICAL", 219, 229], ["CMV", "ORGANISM", 87, 90], ["purified CMV envelope glycoproteins", "PROTEIN", 78, 113], ["monoclonal antibody", "PROTEIN", 122, 141], ["52 kDa glycoprotein", "PROTEIN", 165, 184], ["disulphide cross-bridged complexes", "PROTEIN", 219, 253], ["150 kDa", "PROTEIN", 257, 264], ["52 kDa", "PROTEIN", 266, 272], ["multimeric form", "PROTEIN", 335, 350], ["these studies", "TEST", 10, 23], ["immunoprecipitation", "TEST", 55, 74], ["purified CMV envelope glycoproteins", "PROBLEM", 78, 113], ["a monoclonal antibody", "TEST", 120, 141], ["kDa", "TEST", 269, 272], ["kDa", "TEST", 278, 281], ["kDa", "TEST", 288, 291], ["kDa", "TEST", 296, 299], ["kDa", "TEST", 306, 309], ["kDa", "TEST", 319, 322], ["possible", "UNCERTAINTY", 326, 334]]]], "PMC7127024": [["BackgroundThere are several reasons why transplant-related infectious diseases are important to the critical care community.", [["infectious diseases", "DISEASE", 59, 78], ["transplant", "TREATMENT", 40, 50], ["infectious diseases", "PROBLEM", 59, 78], ["infectious", "OBSERVATION", 59, 69]]], ["First, there are increasing numbers of immunocompromised patients in the intensive care unit (ICU) because of the improved survival rates of recipients of all types of solid organ transplants (SOTs).", [["solid organ", "ANATOMY", 168, 179], ["patients", "ORGANISM", 57, 65], ["recipients", "ORGANISM", 141, 151], ["solid", "CANCER", 168, 173], ["organ", "ORGAN", 174, 179], ["SOTs", "CANCER", 193, 197], ["patients", "SPECIES", 57, 65], ["solid organ transplants", "TREATMENT", 168, 191], ["increasing", "OBSERVATION_MODIFIER", 17, 27], ["numbers", "OBSERVATION_MODIFIER", 28, 35], ["immunocompromised", "OBSERVATION", 39, 56], ["solid organ transplants", "OBSERVATION", 168, 191]]], ["As the longevity of transplant recipients increases, these patients are more prone to develop chronic conditions that frequently require ICU stays.", [["recipients", "ORGANISM", 31, 41], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["transplant recipients", "TREATMENT", 20, 41], ["chronic conditions", "PROBLEM", 94, 112], ["ICU stays", "TREATMENT", 137, 146]]], ["Second, the development of novel and more potent immunosuppressive agents has the potential to increase the frequency and severity of posttransplant infections that subsequently necessitate admission to a critical care unit.", [["infections", "DISEASE", 149, 159], ["more potent immunosuppressive agents", "TREATMENT", 37, 73], ["posttransplant infections", "PROBLEM", 134, 159], ["more potent", "OBSERVATION_MODIFIER", 37, 48], ["infections", "OBSERVATION", 149, 159]]], ["Lastly, infections in transplant candidates and recipients are a major cause of morbidity, mortality, increased length of hospital stay, and increased costs.1", [["infections", "DISEASE", 8, 18], ["recipients", "ORGANISM", 48, 58], ["infections", "PROBLEM", 8, 18], ["transplant candidates", "TREATMENT", 22, 43], ["morbidity", "PROBLEM", 80, 89], ["increased costs", "PROBLEM", 141, 156], ["infections", "OBSERVATION", 8, 18], ["morbidity", "OBSERVATION", 80, 89], ["increased", "OBSERVATION_MODIFIER", 102, 111], ["length", "OBSERVATION_MODIFIER", 112, 118], ["increased", "OBSERVATION_MODIFIER", 141, 150], ["costs", "OBSERVATION", 151, 156]]]], "3a2ffa9550e2c77083bb6d824d1166e3d3e4049b": [["The emergence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its related disease (COVID-19) [1] has significantly affected the haemodialysis population [2] [3] [4] .", [["Acute Respiratory Syndrome Coronavirus", "DISEASE", 24, 62], ["[2] [3] [4]", "SIMPLE_CHEMICAL", 173, 184], ["Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2", "SPECIES", 17, 76], ["Severe Acute Respiratory Syndrome Coronavirus", "PROBLEM", 17, 62], ["SARS", "TEST", 66, 70], ["CoV", "TEST", 71, 74], ["its related disease", "PROBLEM", 82, 101], ["COVID", "TEST", 103, 108], ["significantly affected the haemodialysis population", "PROBLEM", 121, 172], ["Severe", "OBSERVATION_MODIFIER", 17, 23], ["Acute", "OBSERVATION_MODIFIER", 24, 29], ["Respiratory Syndrome", "OBSERVATION", 30, 50]]], ["Transmission is thought to be mainly by respiratory aerosols, although it is becoming evident that asymptomatic carriers also play an important role [5] and the presenting symptoms can be non-respiratory [6] .", [["respiratory aerosols", "PROBLEM", 40, 60], ["the presenting symptoms", "PROBLEM", 157, 180], ["thought to be", "UNCERTAINTY", 16, 29], ["respiratory aerosols", "OBSERVATION", 40, 60]]], ["We report our experience with the management and follow-up of contacts in a large university-associated, in-hospital dialysis centre.", [["the management", "TREATMENT", 30, 44]]]], "0971654807175d1b86d20d239cf135a4553704d3": [["Judikatur-HighlightsEUGH ZU WRRL UND AARHUS EuGH 28.05.2020, C-535/18, Land Nordrhein-Westfalen Wieder einmal wurde der EuGH mit Fragen des Verschlechterungsverbots der Wasserrahmen-RL 2000/60/EG (WRRL) sowie Beteiligungsrechten, diesmal im Zusammenhang mit einer Verschlechterung des Grundwasserzustands durch den Neubau eines Autobahnabschnitts, befasst.", [["Land Nordrhein-Westfalen Wieder einmal wurde der EuGH mit Fragen des Verschlechterungsverbots der Wasserrahmen-RL 2000/60/EG (WRRL) sowie Beteiligungsrechten, diesmal im Zusammenhang mit einer Verschlechterung des Grundwasserzustands durch den Neubau eines Autobahnabschnitts", "SPECIES", 71, 346], ["Land Nordrhein", "TREATMENT", 71, 85], ["mit Fragen des Verschlechterungsverbots der Wasserrahmen", "TREATMENT", 125, 181], ["Beteiligungsrechten", "TREATMENT", 209, 228], ["diesmal im Zusammenhang mit einer Verschlechterung des", "TREATMENT", 230, 284]]], ["Konkret war zu entscheiden, ob Eigent\u00fcmer von Hausbrunnen Verst\u00f6\u00dfe gegen Art 4 WRRL geltend machen k\u00f6nnen, und wann von einer (projektbedingten) Verschlechterung des chemischen Zustands eines Grundwasserk\u00f6rpers auszugehen ist.Judikatur-HighlightsHierzu hielt der Gerichtshof fest, dass auch Einzelpersonen befugt sein m\u00fcssen, einen Versto\u00df gegen das Verschlechterungsverbot gerichtlich geltend zu machen, wenn diese Verletzung sie unmittelbar betrifft.", [["Konkret war zu entscheiden, ob Eigent\u00fcmer von Hausbrunnen Verst\u00f6\u00dfe gegen Art 4 WRRL geltend machen k\u00f6nnen, und wann von einer (projektbedingten)", "SPECIES", 0, 144], ["Judikatur-HighlightsHierzu hielt der Gerichtshof fest, dass auch Einzelpersonen befugt sein m\u00fcssen, einen Versto\u00df gegen das Verschlechterungsverbot gerichtlich geltend zu machen, wenn diese Verletzung sie unmittelbar betrifft", "SPECIES", 226, 451], ["Verschlechterung des", "TREATMENT", 145, 165], ["Judikatur", "TEST", 226, 235]]], ["Damit", [["Damit", "CHEMICAL", 0, 5]]]], "PMC7127101": [["The worldwide outbreak of the life-threatening disease severe acute respiratory syndrome (SARS) was caused by infection with SARS-CoV as a novel coronavirus (CoV).1, 2 The genome of SARS-CoV contains 11\u201314 major annotated open reading frames including those predicted to encode for known viral proteins, including the replicase polyproteins, S (spiked protein), polymerase, M (membrane protein), N (nucleocapsid protein), and E (small envelope protein).2 The replicase polyproteins ppla and pplb encoded by the SARS-CoV are extensively processed to yield the functional subunits for successful viral propagation.3 The SARS-CoV 3CLpro, which is also called main protease (Mpro) mediates the proteolytic processing of replicase polypeptides into functional proteins, plays an important role in viral replication.", [["acute respiratory syndrome", "DISEASE", 62, 88], ["SARS", "DISEASE", 90, 94], ["infection", "DISEASE", 110, 119], ["SARS-CoV", "DISEASE", 125, 133], ["coronavirus", "DISEASE", 145, 156], ["SARS", "DISEASE", 618, 622], ["SARS-CoV", "ORGANISM", 125, 133], ["coronavirus", "ORGANISM", 145, 156], ["CoV", "ORGANISM", 158, 161], ["SARS-CoV", "ORGANISM", 182, 190], ["S (spiked protein", "GENE_OR_GENE_PRODUCT", 342, 359], ["M (membrane protein", "GENE_OR_GENE_PRODUCT", 374, 393], ["N (nucleocapsid protein", "GENE_OR_GENE_PRODUCT", 396, 419], ["E (small envelope protein", "GENE_OR_GENE_PRODUCT", 426, 451], ["ppla", "GENE_OR_GENE_PRODUCT", 482, 486], ["pplb", "GENE_OR_GENE_PRODUCT", 491, 495], ["SARS-CoV", "ORGANISM", 511, 519], ["SARS-CoV 3CLpro", "GENE_OR_GENE_PRODUCT", 618, 633], ["Mpro", "GENE_OR_GENE_PRODUCT", 671, 675], ["SARS-CoV", "DNA", 182, 190], ["open reading frames", "DNA", 222, 241], ["viral proteins", "PROTEIN", 288, 302], ["replicase polyproteins", "PROTEIN", 318, 340], ["S", "PROTEIN", 342, 343], ["spiked protein", "PROTEIN", 345, 359], ["polymerase", "PROTEIN", 362, 372], ["M (membrane protein", "PROTEIN", 374, 393], ["N", "PROTEIN", 396, 397], ["nucleocapsid protein", "PROTEIN", 399, 419], ["E", "PROTEIN", 426, 427], ["small envelope protein", "PROTEIN", 429, 451], ["replicase polyproteins", "PROTEIN", 459, 481], ["ppla", "PROTEIN", 482, 486], ["pplb", "PROTEIN", 491, 495], ["SARS-CoV", "PROTEIN", 511, 519], ["SARS-CoV 3CLpro", "DNA", 618, 633], ["protease", "PROTEIN", 661, 669], ["Mpro", "PROTEIN", 671, 675], ["replicase polypeptides", "PROTEIN", 716, 738], ["functional proteins", "PROTEIN", 744, 763], ["coronavirus", "SPECIES", 145, 156], ["SARS-CoV", "SPECIES", 125, 133], ["CoV", "SPECIES", 158, 161], ["SARS-CoV", "SPECIES", 182, 190], ["SARS-CoV", "SPECIES", 511, 519], ["SARS-CoV", "SPECIES", 618, 626], ["threatening disease severe acute respiratory syndrome", "PROBLEM", 35, 88], ["SARS", "PROBLEM", 90, 94], ["infection", "PROBLEM", 110, 119], ["SARS", "PROBLEM", 125, 129], ["CoV", "PROBLEM", 130, 133], ["a novel coronavirus", "PROBLEM", 137, 156], ["SARS", "PROBLEM", 182, 186], ["known viral proteins", "PROBLEM", 282, 302], ["the replicase polyproteins", "TEST", 314, 340], ["S (spiked protein", "TEST", 342, 359], ["polymerase", "TEST", 362, 372], ["M (membrane protein", "TEST", 374, 393], ["N (nucleocapsid protein", "TEST", 396, 419], ["The replicase polyproteins ppla", "TREATMENT", 455, 486], ["the functional subunits", "TREATMENT", 555, 578], ["successful viral propagation", "PROBLEM", 583, 611], ["The SARS", "TEST", 614, 622], ["CoV 3CLpro", "TREATMENT", 623, 633], ["the proteolytic processing of replicase polypeptides", "TREATMENT", 686, 738], ["viral replication", "TREATMENT", 792, 809], ["worldwide", "OBSERVATION_MODIFIER", 4, 13], ["outbreak", "OBSERVATION_MODIFIER", 14, 22], ["threatening", "OBSERVATION_MODIFIER", 35, 46], ["disease", "OBSERVATION_MODIFIER", 47, 54], ["severe", "OBSERVATION_MODIFIER", 55, 61], ["acute", "OBSERVATION_MODIFIER", 62, 67], ["respiratory syndrome", "OBSERVATION", 68, 88], ["infection", "OBSERVATION", 110, 119], ["viral proteins", "OBSERVATION", 288, 302], ["polyproteins ppla", "OBSERVATION", 469, 486], ["viral propagation", "OBSERVATION", 594, 611], ["viral replication", "OBSERVATION", 792, 809]]], ["The active site of SARS-CoV 3CLpro has a catalytic dyad with the sulfur of Cys145 as a nucleophile and the imidazole ring of His41 as a general base.4 Therefore, the SARS-CoV 3CLpro can be considered an attractive target for developing effective drugs against SARS.", [["SARS", "DISEASE", 19, 23], ["sulfur", "CHEMICAL", 65, 71], ["Cys145", "CHEMICAL", 75, 81], ["imidazole", "CHEMICAL", 107, 116], ["His41", "CHEMICAL", 125, 130], ["SARS", "DISEASE", 166, 170], ["SARS", "DISEASE", 260, 264], ["sulfur", "CHEMICAL", 65, 71], ["Cys145", "CHEMICAL", 75, 81], ["imidazole", "CHEMICAL", 107, 116], ["His41", "CHEMICAL", 125, 130], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 19, 27], ["sulfur", "SIMPLE_CHEMICAL", 65, 71], ["Cys145", "SIMPLE_CHEMICAL", 75, 81], ["His41", "SIMPLE_CHEMICAL", 125, 130], ["SARS-CoV 3CLpro", "ORGANISM", 166, 181], ["SARS-CoV 3CLpro", "PROTEIN", 19, 34], ["SARS-CoV", "SPECIES", 19, 27], ["SARS-CoV", "SPECIES", 166, 174], ["SARS", "PROBLEM", 19, 23], ["the sulfur of Cys145", "TREATMENT", 61, 81], ["a nucleophile", "TREATMENT", 85, 98], ["the imidazole ring of His41", "TREATMENT", 103, 130], ["SARS", "PROBLEM", 260, 264], ["active", "OBSERVATION_MODIFIER", 4, 10], ["site", "OBSERVATION_MODIFIER", 11, 15], ["SARS", "OBSERVATION", 19, 23], ["base", "ANATOMY_MODIFIER", 144, 148]]]], "PMC7075675": [["Dear editor: Coronavirus (COVID-19) is a new respiratory disease that is spreading widely throughout the world(1).", [["respiratory", "ANATOMY", 45, 56], ["respiratory disease", "DISEASE", 45, 64], ["COVID-19", "ORGANISM", 26, 34], ["Coronavirus", "PROBLEM", 13, 24], ["a new respiratory disease", "PROBLEM", 39, 64], ["Coronavirus", "OBSERVATION", 13, 24], ["new", "OBSERVATION_MODIFIER", 41, 44], ["respiratory disease", "OBSERVATION", 45, 64]]], ["There is no valid information available on pregnant women and their complications.", [["women", "ORGANISM", 52, 57], ["women", "SPECIES", 52, 57], ["their complications", "PROBLEM", 62, 81], ["no", "UNCERTAINTY", 9, 11]]], ["But given previous epidemics (SARS and MERS), as well as mental and physical changes during pregnancy (2), pregnant women are more likely to be affected by the virus.", [["SARS", "DISEASE", 30, 34], ["women", "ORGANISM", 116, 121], ["women", "SPECIES", 116, 121], ["previous epidemics (SARS and MERS)", "PROBLEM", 10, 44], ["mental and physical changes during pregnancy", "PROBLEM", 57, 101], ["the virus", "PROBLEM", 156, 165], ["virus", "OBSERVATION", 160, 165]]]]}